

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064611 A1(51) International Patent Classification⁷: C07H 21/02,
21/04San Francisco, CA 94081 (US). SUN, Yongming [US/US];
869 S. Winchester Boulevard, Apartment 260, San Jose,
CA 95128 (US). LIU, Chenghua [CN/US]; 1125 Ranchero
Way #14, San Jose, CA 95117 (US).

(21) International Application Number: PCT/US02/04197

(22) International Filing Date: 12 February 2002 (12.02.2002)

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/268,292 13 February 2001 (13.02.2001) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:US 60/268,292 (CIP)
Filed on 13 February 2001 (13.02.2001)(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): DI-
ADEXUS, INC. [US/US]; 343 Oyster Point Boulevard,
South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SALCEDA, Susana
[AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136
(US). MACINA, Roberto, A. [AR/US]; 4118 Crescendo
Avenue, San Jose, CA 95136 (US). HU, Ping [US/US]; 108
Palmer Street, San Ramon, CA 94583 (US). RECIPON,
Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA
94115 (US). KARRA, Kalpana [IN/US]; 6511 Rainbow
Drive, San Jose, CA 95129 (US). CAFFERKEY, Robert
[IE/US]; 849 West Orange Avenue, Apartment 1030, South**Published:**

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast tissue, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.



WO 02/064611 A1

-1-

COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS

This application claims the benefit of priority from U.S. Provisional Application
5 Serial No. 60/268,292 filed February 13, 2001, which is herein incorporated by reference
in its entirety.

FIELD OF THE INVENTION

The present invention relates to newly identified nucleic acid molecules and
polypeptides present in normal and neoplastic breast cells, including fragments, variants
10 and derivatives of the nucleic acids and polypeptides. The present invention also relates
to antibodies to the polypeptides of the invention, as well as agonists and antagonists of
the polypeptides of the invention. The invention also relates to compositions comprising
the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists
of the invention and methods for the use of these compositions. These uses include
15 identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-
cancerous disease states in breast tissue, identifying breast tissue and monitoring and
identifying and/or designing agonists and antagonists of polypeptides of the invention.
The uses also include gene therapy, production of transgenic animals and cells, and
production of engineered breast tissue for treatment and research.

20 BACKGROUND OF THE INVENTION

Excluding skin cancer, breast cancer, also called mammary tumor, is the most
common cancer among women, accounting for a third of the cancers diagnosed in the
United States. One in nine women will develop breast cancer in her lifetime and about
192,000 new cases of breast cancer are diagnosed annually with about 42,000 deaths.
25 Bevers, *Primary Prevention of Breast Cancer*, in BREAST CANCER, 20-54 (Kelly K Hunt
et al., ed., 2001); Kochanek et al., 49 Nat'l. Vital Statistics Reports 1, 14 (2001).

In the treatment of breast cancer, there is considerable emphasis on detection and
risk assessment because early and accurate staging of breast cancer has a significant
impact on survival. For example, breast cancer detected at an early stage (stage T0,
30 discussed below) has a five-year survival rate of 92%. Conversely, if the cancer is not
detected until a late stage (i.e., stage T4), the five-year survival rate is reduced to 13%.
AJCC Cancer Staging Handbook pp. 164-65 (Irvin D. Fleming et al. eds., 5th ed. 1998).
Some detection techniques, such as mammography and biopsy, involve increased

-2-

discomfort, expense, and/or radiation, and are only prescribed only to patients with an increased risk of breast cancer.

Current methods for predicting or detecting breast cancer risk are not optimal. One method for predicting the relative risk of breast cancer is by examining a patient's risk factors and pursuing aggressive diagnostic and treatment regiments for high risk patients. A patient's risk of breast cancer has been positively associated with increasing age, nulliparity, family history of breast cancer, personal history of breast cancer, early menarche, late menopause, late age of first full term pregnancy, prior proliferative breast disease, irradiation of the breast at an early age and a personal history of malignancy. Lifestyle factors such as fat consumption, alcohol consumption, education, and socioeconomic status have also been associated with an increased incidence of breast cancer although a direct cause and effect relationship has not been established. While these risk factors are statistically significant, their weak association with breast cancer limited their usefulness. Most women who develop breast cancer have none of the risk factors listed above, other than the risk that comes with growing older. NIH Publication No. 00-1556 (2000).

Current screening methods for detecting cancer, such as breast self exam, ultrasound, and mammography have drawbacks that reduce their effectiveness or prevent their widespread adoption. Breast self exams, while useful, are unreliable for the detection of breast cancer in the initial stages where the tumor is small and difficult to detect by palpitation. Ultrasound measurements require skilled operators at an increased expense. Mammography, while sensitive, is subject to over diagnosis in the detection of lesions that have questionable malignant potential. There is also the fear of the radiation used in mammography because prior chest radiation is a factor associated with an increase incidence of breast cancer.

At this time, there are no adequate methods of breast cancer prevention. The current methods of breast cancer prevention involve prophylactic mastectomy (mastectomy performed before cancer diagnosis) and chemoprevention (chemotherapy before cancer diagnosis) which are drastic measures that limit their adoption even among women with increased risk of breast cancer. Bevers, *supra*.

A number of genetic markers have been associated with breast cancer. Examples of these markers include carcinoembryonic antigen (CEA) (Mughal et al., 249 JAMA 1881 (1983)) MUC-1 (Frische and Liu, 22 J. Clin. Ligand 320 (2000)), HER-2/neu (Haris et al., 15 Proc.Am.Soc.Clin.Oncology. A96 (1996)), uPA, PAI-1, LPA, LPC,

RAK and BRCA (Esteva and Fritsche, *Serum and Tissue Markers for Breast Cancer*, in BREAST CANCER, 286-308 (2001)). These markers have problems with limited sensitivity, low correlation, and false negatives which limit their use for initial diagnosis. For example, while the BRCA1 gene mutation is useful as an indicator of an increased risk for breast cancer, it has limited use in cancer diagnosis because only 6.2 % of breast cancers are BRCA1 positive. Malone et al., 279 JAMA 922 (1998). See also, Mewman et al., 279 JAMA 915 (1998) (correlation of only 3.3%).

Breast cancers are diagnosed into the appropriate stage categories recognizing that different treatments are more effective for different stages of cancer. Stage TX indicates that primary tumor cannot be assessed (i.e., tumor was removed or breast tissue was removed). Stage T0 is characterized by abnormalities such as hyperplasia but with no evidence of primary tumor. Stage Tis is characterized by carcinoma in situ, intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no tumor. Stage T1 is characterized as having a tumor of 2 cm or less in the greatest dimension. Within stage T1, Tmic indicates microinvasion of 0.1 cm or less, T1a indicates a tumor of between 0.1 to 0.5 cm, T1b indicates a tumor of between 0.5 to 1 cm, and T1c indicates tumors of between 1 cm to 2 cm. Stage T2 is characterized by tumors from 2 cm to 5 cm in the greatest dimension. Tumors greater than 5 cm in size are classified as stage T4. Within stage T4, T4a indicates extension of the tumor to the chest wall, T4b indicates edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast, T4c indicates a combination of T4a and T4b, and T4d indicates inflammatory carcinoma. AJCC Cancer Staging Handbook pp. 159-70 (Irvin D. Fleming et al. eds., 5th ed. 1998). In addition to standard staging, breast tumors may be classified according to their estrogen receptor and progesterone receptor protein status. Fisher et al., 7 Breast Cancer Research and Treatment 147 (1986). Additional pathological status, such as HER2/neu status may also be useful. Thor et al., 90 J.Nat'l.Cancer Inst. 1346 (1998); Paik et al., 90 J.Nat'l.Cancer Inst. 1361 (1998); Hutchins et al., 17 Proc.Am.Soc.Clin.Oncology A2 (1998).; and Simpson et al., 18 J.Clin.Oncology 2059 (2000).

In addition to the staging of the primary tumor, breast cancer metastases to regional lymph nodes may be staged. Stage NX indicates that the lymph nodes cannot be assessed (e.g., previously removed). Stage N0 indicates no regional lymph node metastasis. Stage N1 indicates metastasis to movable ipsilateral axillary lymph nodes. Stage N2 indicates metastasis to ipsilateral axillary lymph nodes fixed to one another or

-4-

to other structures. Stage N3 indicates metastasis to ipsilateral internal mammary lymph nodes. Id.

Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Simpson et al., 18 J. Clin. Oncology 2059 (2000). Generally, pathological staging of breast cancer is preferable to clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred if it were as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of breast cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion. Progress in this field will allow more rapid and reliable method for treating breast cancer patients.

Treatment of breast cancer is generally decided after an accurate staging of the primary tumor. Primary treatment options include breast conserving therapy (lumpectomy, breast irradiation, and surgical staging of the axilla), and modified radical mastectomy. Additional treatments include chemotherapy, regional irradiation, and, in extreme cases, terminating estrogen production by ovarian ablation.

Until recently, the customary treatment for all breast cancer was mastectomy. Fonseca et al., 127 Annals of Internal Medicine 1013 (1997). However, recent data indicate that less radical procedures may be equally effective, in terms of survival, for early stage breast cancer. Fisher et al., 16 J. of Clinical Oncology 441 (1998). The treatment options for a patient with early stage breast cancer (i.e., stage Tis) may be breast-sparing surgery followed by localized radiation therapy at the breast. Alternatively, mastectomy optionally coupled with radiation or breast reconstruction may be employed. These treatment methods are equally effective in the early stages of breast cancer.

Patients with stage I and stage II breast cancer require surgery with chemotherapy and/or hormonal therapy. Surgery is of limited use in Stage III and stage IV patients. Thus, these patients are better candidates for chemotherapy and radiation therapy with surgery limited to biopsy to permit initial staging or subsequent restaging because cancer is rarely curative at this stage of the disease. AJCC Cancer Staging Handbook 84, ¶. 164-65 (Irvin D. Fleming et al. eds., 5th ed. 1998).

In an effort to provide more treatment options to patients, efforts are underway to define an earlier stage of breast cancer with low recurrence which could be treated with lumpectomy without postoperative radiation treatment. While a number of attempts have

-5-

been made to classify early stage breast cancer, no consensus recommendation on postoperative radiation treatment has been obtained from these studies. Page et al., 75 Cancer 1219 (1995); Fisher et al., 75 Cancer 1223 (1995); Silverstein et al., 77 Cancer 2267 (1996).

5 As discussed above, each of the methods for diagnosing and staging breast cancer is limited by the technology employed. Accordingly, there is need for sensitive molecular and cellular markers for the detection of breast cancer. There is a need for molecular markers for the accurate staging, including clinical and pathological staging, of breast cancers to optimize treatment methods. Finally, there is a need for sensitive
10 molecular and cellular markers to monitor the progress of cancer treatments, including markers that can detect recurrence of breast cancers following remission.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while
15 indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

20 SUMMARY OF THE INVENTION

The present invention solves these and other needs in the art by providing nucleic acid molecules and polypeptides as well as antibodies, agonists and antagonists, thereto that may be used to identify, diagnose, monitor, stage, image and treat breast cancer and non-cancerous disease states in breast; identify and monitor breast tissue; and identify
25 and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered breast tissue for treatment and research.

Accordingly, one object of the invention is to provide nucleic acid molecules that are specific to breast cells and/or breast tissue. These breast specific nucleic acids
30 (BSNAs) may be a naturally-occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. If the BSNA is genomic DNA, then the BSNA is a breast specific gene (BSG). In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast. In a more preferred embodiment, the nucleic acid molecule encodes a

-6-

polypeptide that comprises an amino acid sequence of SEQ ID NO: 172 through 295. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 171. By nucleic acid molecule, it is also meant to be inclusive of sequences that selectively hybridize or exhibit substantial sequence

5 similarity to a nucleic acid molecule encoding a BSP, or that selectively hybridize or exhibit substantial sequence similarity to a BSNA, as well as allelic variants of a nucleic acid molecule encoding a BSP, and allelic variants of a BSNA. Nucleic acid molecules comprising a part of a nucleic acid sequence that encodes a BSP or that comprises a part of a nucleic acid sequence of a BSNA are also provided.

10 A related object of the present invention is to provide a nucleic acid molecule comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of a BSNA. In a preferred embodiment, the nucleic acid molecule comprises one or more expression control sequences controlling the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment
15 of a BSP.

Another object of the invention is to provide vectors and/or host cells comprising a nucleic acid molecule of the instant invention. In a preferred embodiment, the nucleic acid molecule encodes all or a fragment of a BSP. In another preferred embodiment, the nucleic acid molecule comprises all or a part of a BSNA.

20 Another object of the invention is to provided methods for using the vectors and host cells comprising a nucleic acid molecule of the instant invention to recombinantly produce polypeptides of the invention.

Another object of the invention is to provide a polypeptide encoded by a nucleic acid molecule of the invention. In a preferred embodiment, the polypeptide is a BSP.

25 The polypeptide may comprise either a fragment or a full-length protein as well as a mutant protein (mutein), fusion protein, homologous protein or a polypeptide encoded by an allelic variant of a BSP.

Another object of the invention is to provide an antibody that specifically binds to a polypeptide of the instant invention..

30 Another object of the invention is to provide agonists and antagonists of the nucleic acid molecules and polypeptides of the instant invention.

Another object of the invention is to provide methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. In a

-7-

preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast. In another preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying and/or monitoring breast tissue. The nucleic acid molecules of the instant invention may also be used in gene therapy, for producing transgenic animals and cells, and for producing engineered breast tissue for treatment and research.

The polypeptides and/or antibodies of the instant invention may also be used to identify, diagnose, monitor, stage, image and treat breast cancer and non-cancerous disease states in breast. The invention provides methods of using the polypeptides of the invention to identify and/or monitor breast tissue, and to produce engineered breast tissue.

The agonists and antagonists of the instant invention may be used to treat breast cancer and non-cancerous disease states in breast and to produce engineered breast tissue.

Yet another object of the invention is to provide a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences.

DETAILED DESCRIPTION OF THE INVENTION

Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press (1989) and *Sambrook et al., Molecular Cloning: A Laboratory Manual*, 3d ed., Cold Spring Harbor

-8-

Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4th Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999); each of which is incorporated herein by reference in its entirety.

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally-occurring and modified nucleotides linked together by naturally-occurring and/or non-naturally occurring nucleotide linkages.

The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages

(*e.g.*, alpha anomeric nucleic acids, etc.) The term “nucleic acid molecule” also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated
5 sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A “gene” is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround
10 the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well-known in the art, eukaryotic genes usually contain both exons and introns. The term “exon” refers to a
15 nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute a contiguous sequence to a mature mRNA transcript. The term “intron” refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be “spliced out” during processing of the transcript.

20 A nucleic acid molecule or polypeptide is “derived” from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An “isolated” or “substantially pure” nucleic acid or polynucleotide (*e.g.*, an
25 RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a
30 portion of a polynucleotide in which the “isolated polynucleotide” is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term “isolated” or “substantially pure” also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized

-10-

polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant
5 vectors present as episomes or as integrated into a host cell chromosome.

A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to
10 occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression
15 or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and United States Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule,
20 or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally
25 comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35,
30 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by
5 expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as
10 those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well-known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other
15 polynucleotide(s) prior to ligation.

The term "naturally-occurring nucleotide" referred to herein includes naturally-occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotide linkages
20 such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical
25 Approach, pp. 87-108, Oxford University Press (1991); United States Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In
30 addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the

-12-

polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally-occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence.

- 5 In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998); herein incorporated by reference). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.

A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense therapy, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology"

-13-

interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term "substantial similarity" or "substantial sequence similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned
5 with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well-known algorithm of sequence identity,
10 such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists when a nucleic acid or fragment thereof hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under selective hybridization conditions. Typically, selective hybridization will occur when there is at least about 55% sequence identity,
15 preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% sequence identity, over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt
20 concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. "Stringent hybridization conditions" and "stringent wash conditions" in the context of nucleic acid hybridization experiments depend upon a number of different
25 physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, "stringent hybridization" is performed at about 25°C below the thermal melting point (T_m) for the specific DNA
30 hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the T_m for the specific DNA hybrid under a particular set of conditions. The T_m is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51, hereby incorporated by reference.

-14-

The T_m for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^\circ\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) - 0.63 (\% \text{ formamide}) - (600/l)$$

where l is the length of the hybrid in base pairs.

The T_m for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The T_m for a particular RNA-DNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

10 In general, the T_m decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C
15 would be subtracted from the calculated T_m of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well-known in the art.

20 An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without
25 formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a
30 library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (*e.g.* 42°C and 6X SSC) and varying the formamide

concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well-known in the art. *See Sambrook et al.* (1989), *supra*, pages 8.46 and 9.46-9.58, herein incorporated by reference. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

- 5 Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An
10 exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

- As defined herein, nucleic acid molecules that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode
15 polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid molecule is created synthetically or recombinantly using high codon degeneracy as permitted by the redundancy of the genetic code.

- Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (*e.g.*, for oligonucleotide probes) may be calculated by the formula:
20 $T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/N)$,
wherein N is change length and the $[\text{Na}^+]$ is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the T_m) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using
25 mismatched probes, pools of degenerate probes or “guessmers,” as well as hybridization solutions and methods for empirically determining hybridization conditions are well-known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

- The term “digestion” or “digestion of DNA” refers to catalytic cleavage of the
30 DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the

-16-

purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and they are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well-known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well-known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies.

The term "microarray" or "nucleic acid microarray" refers to a substrate-bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Microarrays or nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical

Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). These microarrays include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are
5 disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000).

The term "mutated" when applied to nucleic acid molecules means that nucleotides in the nucleic acid sequence of the nucleic acid molecule may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration
10 may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. In a preferred embodiment, the nucleic acid molecule comprises the wild type nucleic acid sequence encoding a BSP or is a BSNA. The nucleic acid molecule may be mutated by any method known in the art
15 including those mutagenesis techniques described *infra*.

The term "error-prone PCR" refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.*, Leung *et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-
20 33 (1992).

The term "oligonucleotide-directed mutagenesis" refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*, Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).

The term "assembly PCR" refers to a process which involves the assembly of a
25 PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

The term "sexual PCR mutagenesis" or "DNA shuffling" refers to a method of error-prone PCR coupled with forced homologous recombination between DNA
30 molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g.*, Stemmer, *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes ("Family shuffling").

-18-

The term “*in vivo* mutagenesis” refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

The term “cassette mutagenesis” refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term “recursive ensemble mutagenesis” refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. See, e.g., Arkin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term “exponential ensemble mutagenesis” refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. See, e.g., Delegrave *et al.*, *Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993). Each of the references mentioned above are hereby incorporated by reference in its entirety.

“Operatively linked” expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in *trans* or at a distance to control the gene of interest.

The term “expression control sequence” as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that

-19-

enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include the promoter, ribosomal binding site, and

- 5 transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

- The term "vector," as used herein, is intended to refer to a nucleic acid molecule
- 10 capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral
- 15 genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable
- 20 of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector.
- 25 However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

- The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which an expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell
- 30 but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

-20-

As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally-occurring and non-naturally-occurring proteins and polypeptides, polypeptide fragments and polypeptide mutants, derivatives and analogs. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises a BSP encoded by a nucleic acid molecule of the instant invention, as well as a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be indicated by a number of means well-known in the art, such as polyacrylamide gel electrophoresis of a protein sample,

-21-

followed by visualizing a single polypeptide band upon staining the gel with a stain well-known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well-known in the art for purification.

The term "polypeptide fragment" as used herein refers to a polypeptide of the
5 instant invention that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length polypeptide. In a preferred embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids
10 long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" refers to polypeptides or fragments thereof that are substantially similar in primary structural sequence but which include, *e.g.*, *in vivo* or *in vitro* chemical
15 and biochemical modifications that are not found in the native polypeptide. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization,
20 disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as
25 arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , and ^3H , ligands which bind to labeled
30 antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides

-22-

are well-known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*, herein incorporated by reference.

The term "fusion protein" refers to polypeptides of the instant invention comprising polypeptides or fragments coupled to heterologous amino acid sequences.

- 5 Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be
- 10 produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

- 15 The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide of the instant invention that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the
- 20 same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

- 25 The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide of the instant invention. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce
- 30 an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH₂NH--, --CH₂S--, --CH₂-CH₂--,
--CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂--, and --CH₂SO--, by methods

-23-

well-known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992), incorporated herein by reference). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

A "polypeptide mutant" or "mutein" refers to a polypeptide of the instant invention whose sequence contains substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a native or wild-type protein. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally-occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to the wild type protein. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not

-24-

substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991), each of which are incorporated herein by reference.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2nd Ed., Sinauer Associates (1991), which is incorporated herein by reference. Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as α -, α -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

A protein has "homology" or is "homologous" to a protein from another organism if the encoded amino acid sequence of the protein has a similar sequence to the encoded amino acid sequence of a protein of a different organism and has a similar biological activity or function. Alternatively, a protein may have homology or be homologous to another protein if the two proteins have similar amino acid sequences and have similar biological activities or functions. Although two proteins are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the proteins. Instead, the term "homologous" is defined to mean that the two proteins have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous protein is one that exhibits 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous proteins that exhibit 80%, 85% or 90%

-25-

sequence similarity to the wild type protein. In a yet more preferred embodiment, a homologous protein exhibits 95%, 97%, 98% or 99% sequence similarity.

When "sequence similarity" is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity" comprises conservative or moderately conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (*e.g.*, charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. *See, e.g.*, Pearson, *Methods Mol. Biol.* 24: 307-31 (1994), herein incorporated by reference.

For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992), herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from

-26-

different species of organisms or between a wild type protein and a mutein thereof. *See, e.g.*, GCG Version 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer

- 5 program BLAST, especially blastp or tblastn. *See, e.g.*, Altschul *et al.*, *J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997); herein incorporated by reference. Preferred parameters for blastp are:

- Expectation value: 10 (default)
- Filter: seg (default)
- 10 Cost to open a gap: 11 (default)
- Cost to extend a gap: 1 (default)
- Max. alignments: 100 (default)
- Word size: 11 (default)
- No. of descriptions: 100 (default)
- 15 Penalty Matrix: BLOSUM62

- The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number
- 20 of different organisms, it is preferable to compare amino acid sequences.

- Database searching using amino acid sequences can be measured by algorithms other than blastp are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best
- 25 overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1, herein incorporated by reference.

- 30 An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')₂, Fv,

-27-

dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. An Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; an F(ab')₂ fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

10 By "bind specifically" and "specific binding" is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

15 A single-chain antibody (scFv) is an antibody in which a VL and VH region are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston *et al., Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but
20 using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al., Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it
25 an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one
30 or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-

-28-

chain antibody or Fab fragment has one binding site, while a "bispecific" or "bifunctional" antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

10 A "neutralizing antibody" or "an inhibitory antibody" is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An "activating antibody" is an antibody that increases the activity of a polypeptide.

The term "epitope" includes any protein determinant capable of specifically binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than 1 μ M, preferably less than 100 nM and most preferably less than 10 nM.

The term "patient" as used herein includes human and veterinary subjects.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

25 The term "breast specific" refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the breast as compared to other tissues in the body. In a preferred embodiment, a "breast specific" nucleic acid molecule or polypeptide is expressed at a level that is 5-fold higher than any other tissue in the body. In a more preferred embodiment, the "breast specific" nucleic acid molecule or polypeptide is expressed at a level that is 10-fold higher than any other tissue in the body, more preferably at least 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide

levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

5

Nucleic Acid Molecules

One aspect of the invention provides isolated nucleic acid molecules that are specific to the breast or to breast cells or tissue or that are derived from such nucleic acid molecules. These isolated breast specific nucleic acids (BSNAs) may comprise a cDNA,
10 a genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast, a breast-specific polypeptide (BSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 172 through 295. In
15 another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 171.

A BSNA may be derived from a human or from another animal. In a preferred embodiment, the BSNA is derived from a human or other mammal. In a more preferred embodiment, the BSNA is derived from a human or other primate. In an even more
20 preferred embodiment, the BSNA is derived from a human.

By "nucleic acid molecule" for purposes of the present invention, it is also meant to be inclusive of nucleic acid sequences that selectively hybridize to a nucleic acid molecule encoding a BSNA or a complement thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may not encode a BSP. However, in a
25 preferred embodiment, the hybridizing nucleic acid molecule encodes a BSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 172 through 295. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic
30 acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 through 171.

In a preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding a BSP under low stringency conditions. In a more preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding a BSP under moderate stringency conditions. In a more preferred

-30-

embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding a BSP under high stringency conditions. In an even more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 172 through 295. In a yet more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1 through 171. In a preferred embodiment of the invention, the hybridizing nucleic acid molecule may be used to express recombinantly a polypeptide of the invention.

By "nucleic acid molecule" as used herein it is also meant to be inclusive of sequences that exhibits substantial sequence similarity to a nucleic acid encoding a BSP or a complement of the encoding nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding human BSP. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the similar nucleic acid molecule is one that has at least 60% sequence identity with a nucleic acid molecule encoding a BSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 172 through 295, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding a BSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding a BSP.

In another preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a BSNA or its complement. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 171. In a preferred embodiment, the nucleic acid molecule is one that has at least 60% sequence identity with a BSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1 through 171, more preferably at least 70%, even more preferably at least 80% and even more

preferably at least 85%. In a more preferred embodiment, the nucleic acid molecule is one that has at least 90% sequence identity with a BSNA, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid
5 molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a BSNA.

A nucleic acid molecule that exhibits substantial sequence similarity may be one that exhibits sequence identity over its entire length to a BSNA or to a nucleic acid molecule encoding a BSP, or may be one that is similar over only a part of its length. In
10 this case, the part is at least 50 nucleotides of the BSNA or the nucleic acid molecule encoding a BSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally-occurring one
15 that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 172 through 295 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1 through 171. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid
20 molecule from a human, when the BSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar
25 nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In
30 another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of a BSNA. Further, the substantially similar nucleic acid molecule may or may not be a BSNA. However, in a preferred embodiment, the substantially similar nucleic acid molecule is a BSNA.

-32-

By "nucleic acid molecule" it is also meant to be inclusive of allelic variants of a BSNA or a nucleic acid encoding a BSP. For instance, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes. In fact, more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001). Thus, the sequence determined from one individual of a species may differ from other allelic forms present within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein. Further, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the nucleic acid molecule comprising an allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes a BSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that is a BSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1 through 171. In a preferred embodiment, the allelic variant is a naturally-occurring allelic variant in the species of interest. In a more preferred embodiment, the species of interest is human.

By "nucleic acid molecule" it is also meant to be inclusive of a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is a BSP. However, in a preferred embodiment, the part encodes a BSP. In one aspect, the invention comprises a part of a BSNA. In a second aspect, the invention comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to a BSNA. In a third aspect, the invention comprises a part of a nucleic acid molecule that is an allelic variant of a BSNA. In a fourth aspect, the invention comprises a part of a nucleic acid molecule that encodes a BSP. A part comprises at least 10 nucleotides, more preferably at least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

-33-

By "nucleic acid molecule" it is also meant to be inclusive of sequence that encoding a fusion protein, a homologous protein, a polypeptide fragment, a mutein or a polypeptide analog, as described below.

Nucleotide sequences of the instantly-described nucleic acids were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (e.g., reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Molecular Dynamics, Sunnyvale, CA, USA). Further, all amino acid sequences of the polypeptides of the present invention were predicted by translation from the nucleic acid sequences so determined, unless otherwise specified.

In a preferred embodiment of the invention, the nucleic acid molecule contains modifications of the native nucleic acid molecule. These modifications include nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that can be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

In a preferred embodiment, isolated nucleic acid molecules can include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. In a more preferred embodiment, the labeled nucleic acid molecule may be used as a hybridization probe.

Common radiolabeled analogues include those labeled with ^{33}P , ^{32}P , and ^{35}S , such as α - ^{32}P -dATP, α - ^{32}P -dCTP, α - ^{32}P -dGTP, α - ^{32}P -dTTP, α - ^{32}P -3'dATP, α - ^{32}P -ATP, α - ^{32}P -CTP, α - ^{32}P -GTP, α - ^{32}P -UTP, α - ^{35}S -dATP, α - ^{35}S -GTP, α - ^{33}P -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade

-34-

Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

Nucleic acid molecules can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); see Alers *et al.*, *Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994);

Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally-coupled to the target nucleic acid using aryl azide chemistry; after reduction, a
5 free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report
10 specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. See, e.g., Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279: 1228-1229 (1998); Marras *et al.*, *Genet. Anal.* 14: 151-156 (1999); U. S. Patent 5,846,726; 5,925,517; 5,925,517;
15 5,723,591 and 5,538,848; Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the invention may be modified by altering one or more
20 native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. See Hartmann *et al.* (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science, Kluwer Law International (1999); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd
25 (1997); the disclosures of which are incorporated herein by reference in their entireties. Such altered internucleoside bonds are often desired for antisense techniques or for targeted gene correction. See Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation,
30 phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having

-36-

normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U. S. Patents 3,687,808; 5 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside 10 linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include 15 those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; 20 and others having mixed N, O, S and CH₂ component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 25 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced 30 with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S.

patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Automated PNA synthesis is readily achievable on commercial synthesizers (see, e.g., "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA).

PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The T_m of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the T_m of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the T_m by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the T_m by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in U.S. Patents 5,760,012 and 5,731,181, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acids of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly

-38-

comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001);

5 Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994), the disclosures of which are incorporated herein by reference in their entirety. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201

10 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997), the disclosures of which are incorporated herein by reference in their entirety.

Methods for Using Nucleic Acid Molecules as Probes and Primers

The isolated nucleic acid molecules of the present invention can be used as

15 hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

20 In one embodiment, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the gene of a BSNA, such as deletions, insertions, translocations, and duplications of the BSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.*, Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and

25 Clinical Applications, John Wiley & Sons (1999), the disclosure of which is incorporated herein by reference in its entirety. The isolated nucleic acids of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.*, Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that

30 include the nucleic acid molecules of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

In another embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect, characterize, and quantify BSNA in, and

isolate BSNA from, transcript-derived nucleic acid samples. In one aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A⁺-selected RNA samples. In another aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.,* Schwarczacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000), the disclosure of which is incorporated herein by reference in its entirety. In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to BSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000), the disclosures of which are incorporated herein by reference in their entirety.

Thus, in one embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In a preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a BSP. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 172 through 295. In another preferred embodiment, the probe or primer is derived from a BSNA. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer

-40-

in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well-known in the art. *See, e.g.,* Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well-known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995); the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, *e.g.,* in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995); the disclosure of which is incorporated herein by reference in its entirety.

PCR and hybridization methods may be used to identify and/or isolate allelic variants, homologous nucleic acid molecules and fragments of the nucleic acid molecules of the invention. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules that encode homologous proteins, analogs, fusion protein or muteins of the invention. The nucleic acid primers of the present invention can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.,* U.S. Patent 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.,* Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7 (2001); U.S. Patents 5,854,033 and 5,714,320; and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by

reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. See, e.g., Lizardi *et al.*, *Nature Genet.* 19(3): 225-32 (1998).

Nucleic acid molecules of the present invention may be bound to a substrate
5 either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to
10 a porous substrate, e.g., a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon. The nucleic acid molecule of the present invention can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, e.g., a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without
15 limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including
20 rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or
25 some combination thereof. The nucleic acid molecule of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, e.g. on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such
30 as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides

Another aspect of the present invention relates to vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

- 5 The vectors can be used, *inter alia*, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids
10 of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides (expression vectors). Vectors of the present invention will often be suitable for several such uses.

- Vectors are by now well-known in the art, and are described, *inter alia*, in Jones
15 *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000);
20 Sambrook (2001), *supra*; Ausubel (1999), *supra*; the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the skill in the art, only basic features need be described here.

- Nucleic acid sequences may be expressed by operatively linking them to an
25 expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part
30 of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for

example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred
5 embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their
10 derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989, λ GT10 and λ GT11, and other phages, *e.g.*, M13 and filamentous single-stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline,
15 chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous
20 recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and
25 a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEplac series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2, 2 μ plasmids and derivatives thereof, and improved shuttle vectors such as those
30 described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIp1ac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

-44-

Insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSFTM cells (Protein Sciences Corp., Meriden, CT, USA)), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors
5 are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the
10 polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

In another embodiment, the host cells may be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway.
15 Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, e.g., in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A).
20 Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in
25 mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (e.g., vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (e.g., bovine papillomavirus),
30 and retroviral vectors (e.g., murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

-45-

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, or the *araBAD* operon. Prokaryotic expression vectors may further include transcription terminators, such as the *aspA* terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the *CYC1* promoter, the *GAL1* promoter, the *GAL10* promoter, *ADH1* promoter, the promoters of the yeast α -mating system, or the *GPD* promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the *CYC1* or *ADH1* gene.

-46-

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 or the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the BSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit β -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well-known in the art. Nucleic acid vectors may also comprise stabilizing sequences (e.g., ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well-known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors include either naturally inducible promoters, such as the trc promoter, which is regulated by the lac operon, and the pL promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid Plac/ara-1 promoter and the PLtetO-1 promoter. The PLtetO-1 promoter takes advantage of the high expression levels from the PL promoter of phage lambda, but replaces the lambda repressor sites with two

-47-

copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response
5 element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one aspect of the invention, expression vectors can be designed to fuse the
10 expressed polypeptide to small protein tags that facilitate purification and/or visualization. Tags that facilitate purification include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA,
15 USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable
20 fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion protein with glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity
25 resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG®
30 antibody (Stratagene, La Jolla, CA, USA), and the HA epitope.

For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that

carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or
5 identification tags. Useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusion to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusion proteins for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, e.g., the gene III
10 protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. See Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996).
15 Vectors for yeast display, e.g. the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the α -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, e.g., the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet
20 derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring
25 proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic
30 fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. See Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of

-49-

protein fusions, are well-known in the art. See Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.* Cormack *et al.*, *Gene* 173: 33-38 (1996); United States Patent Nos. 6,090,919 and 5,804,387) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.* Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patents 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

25 Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application Nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and

-50-

cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent
5 antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-
10 293, AmphoPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA), allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally
15 well to express the nucleic acid sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must
20 be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into
25 the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide BSPs with such post-
30 translational modifications.

Polypeptides of the invention may be post-translationally modified. Post-translational modifications include phosphorylation of amino acid residues serine, threonine and/or tyrosine, N-linked and/or O-linked glycosylation, methylation, acetylation, prenylation, methylation, acetylation, arginylation, ubiquination and

racemization. One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational
5 modifications. See, e.g., www.expasy.org (accessed August 31, 2001), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-
10 anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications may be found in
15 web sites such as the Delta Mass database <http://www.abrf.org/ABRF/ResearchCommittees/deltamass/deltamass.html> (accessed October 19, 2001); "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. *Nucleic Acids Res.* 29; 332-335 (2001) and <http://www.glycosuite.com/> (accessed October 19, 2001); "O-GLYCBASE version 4.0: a
20 revised database of O-glycosylated proteins" Gupta et al. *Nucleic Acids Research*, 27: 370-372 (1999) and <http://www.cbs.dtu.dk/databases/OGLYCBASE/> (accessed October 19, 2001); "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. *Nucleic Acids Res* 27(1):237-239 (1999) and <http://www.cbs.dtu.dk/databases/PhosphoBase/> (accessed October 19, 2001); or <http://pir.georgetown.edu/pirwww/search/textresid.html> (accessed October 19, 2001).

Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from
30 normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another

-52-

common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue.

- 5 Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

- Another post-translational modification that may be altered in cancer cells is
- 10 prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signaling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).
- 15

- Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to
- 20 the corresponding polypeptides from noncancerous cells.

- Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is
- 25 cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell
- 30 compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method

known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g, p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website www.expasy.org. The nucleic acid molecule is then be introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational

-54-

modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its
5 controllability, and its compatibility with the nucleic acid sequence of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture
10 requirements, and the ease of purification from them of the products coded for by the nucleic acid sequences of this invention.

The recombinant nucleic acid molecules and more particularly, the expression vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention
15 may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid sequences according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

Vectors of the present invention will also often include elements that permit *in*
20 *vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell
25 (*e.g.*, conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well-known in the art (*See*, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an
30 expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be

-55-

able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and
5 prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces*
10 *pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO
15 cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well-known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA,
20 USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from breast are particularly preferred because they may provide a more native post-translational processing. Particularly preferred are human breast cells.

Particular details of the transfection, expression and purification of recombinant
25 proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. See, e.g., Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*, herein
30 incorporated by reference.

Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well-known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

5 Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, e.g., with CaCl_2 , or a solution of Mg^{2+} , Mn^{2+} , Ca^{2+} , Rb^+ or K^+ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent
10 strains are also available commercially (e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent, that is, competent to take up exogenous DNA by electroporation, by various pre-pulse
15 treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols (BioRad, Richmond, CA, USA) (http://www.biorad.com/LifeScience/pdf/New_Gene_Pulser.pdf).

Vectors can be introduced into yeast cells by spheroplasting, treatment with
20 lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action of hydrolytic enzymes such as snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from *Arthrobacter luteus*, to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol
25 (PEG) and Ca^{2+} . Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of
30 PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991).

- 5 The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

- Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be
10 coprecipitated with CaPO_4 or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for CaPO_4 transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN®
15 Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent, FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, CA, USA) ([http://www.bio-rad.com/LifeScience/pdf/](http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf)
20 [New_Gene_Pulser.pdf](http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf)); Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000); incorporated herein by reference in its entirety. Other transfection techniques include transfection by particle bombardment and microinjection. See, e.g., Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA*
25 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

- Purification of recombinantly expressed proteins is now well by those skilled in the art. See, e.g., Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid
30 Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.),

-58-

Protein Purification Applications, Oxford University Press (2001); the disclosures of which are incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, if purification tags have been fused through use of an expression vector that appends such tags, purification can be effected, at least in part, by means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

10 Polypeptides

Another object of the invention is to provide polypeptides encoded by the nucleic acid molecules of the instant invention. In a preferred embodiment, the polypeptide is a breast specific polypeptide (BSP). In an even more preferred embodiment, the polypeptide is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 172 through 295. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification and using methods well-known to those having ordinary skill in the art.

In another aspect, the polypeptide may comprise a fragment of a polypeptide, wherein the fragment is as defined herein. In a preferred embodiment, the polypeptide fragment is a fragment of a BSP. In a more preferred embodiment, the fragment is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 172 through 295. A polypeptide that comprises only a fragment of an entire BSP may or may not be a polypeptide that is also a BSP. For instance, a full-length polypeptide may be breast-specific, while a fragment thereof may be found in other tissues as well as in breast. A polypeptide that is not a BSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-BSP antibodies. However, in a preferred embodiment, the part or fragment is a BSP. Methods of determining whether a polypeptide is a BSP are described *infra*.

Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patents 4,708,871 and 5,595,915, the disclosures of

which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

5 Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize the proteins of the present invention. *See, e.g.,* Lerner, *Nature* 299: 592-596 (1982); Shinnick *et al., Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al., Science* 219: 660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further
10 described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic, meaning that they are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.

 Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as
15 competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Patents 5,539,084 and 5,783,674, incorporated herein by reference in their
20 entireties.

 The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the protein of the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids,
25 or 50 amino acids or more in length. Of course, larger fragments having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

 One having ordinary skill in the art can produce fragments of a polypeptide by truncating the nucleic acid molecule, *e.g.,* a BSNA, encoding the polypeptide and then
30 expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally-occurring polypeptide. Methods of producing polypeptide fragments are well-known in the art. *See, e.g.,* Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992),

-60-

supra; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment of polypeptide of the invention, preferably a BSP, may be produced by chemical or enzymatic cleavage of a polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule encoding a
5 fragment of the polypeptide, preferably a BSP, in a host cell.

By "polypeptides" as used herein it is also meant to be inclusive of mutants, fusion proteins, homologous proteins and allelic variants of the polypeptides specifically exemplified.

A mutant protein, or mutein, may have the same or different properties compared
10 to a naturally-occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native protein. Small deletions and insertions can often be found that do not alter the function of the protein. In one embodiment, the mutein may or may not be breast-specific. In a preferred embodiment, the mutein is breast-specific. In a preferred
15 embodiment, the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 172 through 295. In a more preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to
20 a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In yet a more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295.

25 A mutein may be produced by isolation from a naturally-occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical
30 techniques. In a preferred embodiment, a mutein may be produced from a host cell comprising an altered nucleic acid molecule compared to the naturally-occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid sequence of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino

-61-

acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is breast-specific, as described below. Multiple random mutations can be introduced into the

5 gene by methods well-known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well-known in the art. *See, e.g.*,

10 Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), U.S. Patent 5,223,408, and the references discussed *supra*, each herein incorporated by reference.

By "polypeptide" as used herein it is also meant to be inclusive of polypeptides homologous to those polypeptides exemplified herein. In a preferred embodiment, the

15 polypeptide is homologous to a BSP. In an even more preferred embodiment, the polypeptide is homologous to a BSP selected from the group having an amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the homologous polypeptide is one that exhibits significant sequence identity to a BSP. In a more preferred embodiment, the polypeptide is one that exhibits significant sequence identity

20 to an comprising an amino acid sequence of SEQ ID NO: 172 through 295. In an even more preferred embodiment, the homologous polypeptide is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In a yet more

25 preferred embodiment, the homologous polypeptide is one that exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In another preferred embodiment, the homologous polypeptide is one that exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%,

30 99.7%, 99.8% or 99.9% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the amino acid substitutions are conservative amino acid substitutions as discussed above.

In another embodiment, the homologous polypeptide is one that is encoded by a nucleic acid molecule that selectively hybridizes to a BSNA. In a preferred embodiment,

-62-

the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a BSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the BSNA is selected from the group consisting of SEQ ID NO: 1 through 171. In another preferred embodiment, the

- 5 homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes a BSP under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the BSP is selected from the group consisting of SEQ ID NO: 172 through 295.

- The homologous polypeptide may be a naturally-occurring one that is derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, baboon or gorilla, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 172 through 295. The homologous polypeptide may also be a naturally-occurring polypeptide from a human, when the BSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally-occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. In another embodiment, the homologous polypeptide may be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. In another embodiment, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of a BSP. Further, the homologous protein may or may not encode polypeptide that is a BSP. However, in a preferred embodiment, the homologous polypeptide encodes a polypeptide that is a BSP.

- 30 Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("cross-reactive proteins") that competitively inhibit the

-63-

binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well-known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, by "polypeptide" as used herein it is also meant to be inclusive of polypeptides encoded by an allelic variant of a nucleic acid molecule encoding a BSP. In a preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 172 through 295. In a yet more preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 171.

In another embodiment, the invention provides polypeptides which comprise derivatives of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is a BSP. In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 172 through 295, or is a mutein, allelic variant, homologous protein or fragment thereof. In a preferred embodiment, the derivative has been acetylated, carboxylated, phosphorylated, glycosylated or ubiquitinated. In another preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as ^{125}I , ^{32}P , ^{35}S , and ^3H . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well-known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

-64-

It will be appreciated, as is well-known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

-65-

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOE, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOE, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMAP, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SLA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMH, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

The polypeptides, fragments, and fusion proteins of the present invention can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to the polypeptides, fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-BSP antibodies.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half-life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999), incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

In yet another embodiment, the invention provides analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred

-66-

embodiment, the polypeptide is a BSP. In a more preferred embodiment, the analog is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the analog is one that comprises one or more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally-occurring polypeptide. In general, the non-peptide analog is structurally similar to a BSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH₂NH--, --CH₂S--, --CH₂-CH₂--,
--CH=CH--(cis and trans), --COCH₂--, --CH(OH)CH₂-- and --CH₂SO--. In another embodiment, the non-peptide analog comprises substitution of one or more amino acids of a BSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (see, e.g., Kole *et al.*, *Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, inter alia, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993); the disclosures of which are incorporated herein by reference in their entireties.

Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide. The Fmoc and tBOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during

synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyI quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS-FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from

5 Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)-TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl

10 side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially,

15 including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-

20 trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-

25 aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- β -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-

30 hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-

-68-

phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-
 5 1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed
 10 mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*,
 15 *Science* 292(5516): 498-500 (2001).

Fusion Proteins

The present invention further provides fusions of each of the polypeptides and fragments of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide is a BSP. In a more preferred embodiment, the polypeptide
 20 that is fused to the heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 172 through 295, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the nucleic acid molecule encoding the fusion protein comprises all or part of the nucleic acid sequence of SEQ ID NO: 1 through 171, or comprises all or part of a nucleic acid sequence that
 25 selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 171.

The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of
 30 the protein of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP
5 chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of
10 recombinantly-expressed proteins. *See, e.g.,* Ausubel, Chapter 16, (1992), *supra*. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so
15 included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins — into the periplasmic space or extracellular milieu for
20 prokaryotic hosts, into the culture medium for eukaryotic cells — through incorporation of secretion signals and/or leader sequences. For example, a His⁶ tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an
25 epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

30 Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. *See* Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et*

-70-

- al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); ; Colas *et al.*, (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. *Nature* 380, 548-550; Norman, T. *et al.*, (1999) Genetic selection of peptide inhibitors of biological pathways. *Science* 285, 591-595, Fabbrizio *et al.*, (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. *Oncogene* 18, 4357-4363; Xu *et al.*, (1997) Cells that register logical relationships among proteins. *Proc Natl Acad Sci U S A.* 94, 12473-12478; Yang, *et al.*, (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nuc. Acids Res.* 23, 1152-1156; Kolonin *et al.*, (1998) Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers. *Proc Natl Acad Sci U S A* 95, 14266-14271; Cohen *et al.*, (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95, 14272-14277; Uetz, P.; Giot, L.; al, e.; Fields, S.; Rothberg, J. M. (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* 403, 623-627; Ito, *et al.*, (2001) A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc Natl Acad Sci U S A* 98, 4569-4574, the disclosures of which are incorporated herein by reference in their entireties. Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

The polypeptides and fragments of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, *diphtheria* toxin, *shiga* toxin A, *anthrax* toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, *myc*, hemagglutinin (HA), GST, immunoglobulins, β -galactosidase, biotin *trpE*, protein A, β -lactamase, α -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), *lacZ*, green fluorescent protein (GFP), yeast α mating factor, GAL4 transcription activation or DNA binding domain,

-71-

luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. *See, e.g.*, Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art.

- 5 Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well-known in the art (*e.g.*, a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding
10 proteins or other molecules that bind to the BSP.

As further described below, the isolated polypeptides, muteins, fusion proteins, homologous proteins or allelic variants of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize BSPs, their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to
15 assay for the polypeptides of the present invention, particularly BSPs, *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of BSPs, as for example by immunoprecipitation, and for use
20 as specific agonists or antagonists of BSPs.

One may determine whether polypeptides including muteins, fusion proteins, homologous proteins or allelic variants are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine
25 scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are
30 available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides including fragments, homologous polypeptides, muteins, analogs, derivatives and fusion proteins is well-known and within the skill of

-72-

one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated
5 proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous or non-proteinaceous material and are well-known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated proteins of the
10 present invention are used as therapeutic agents, such as in vaccines and as replacement therapy, the isolated proteins of the present invention are also useful at lower purity. For example, partially purified proteins of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In preferred embodiments, the purified and substantially purified proteins of the
15 present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

20 For example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind
25 specifically to the immobilized protein of the present invention.

As another example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include
30 polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

-73-

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with
5 sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction there between. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the
10 surface-bound protein to indicate biological interaction there between.

Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid
15 molecules of the invention, as well as antibodies that bind to fragments, muteins, derivatives and analogs of the polypeptides. In a preferred embodiment, the antibodies are specific for a polypeptide that is a BSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 172 through 295, or a fragment, mutein,
20 derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also
25 due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a BSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or visa versa. In addition, alternative splice forms of a BSP may be indicative of cancer. Differential degradation of the C or N-terminus of a BSP may also be a marker or target for anticancer therapy. For example, a BSP may
30 be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

As is well-known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention

-74-

will discriminate over adventitious binding to non-BSP polypeptides by at least 2-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human breast.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about 1×10^{-6} molar (M), typically at least about 5×10^{-7} M, 1×10^{-7} M, with affinities and avidities of at least 1×10^{-8} M, 5×10^{-9} M, 1×10^{-10} M and up to 1×10^{-13} M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In this case, antibodies to the proteins of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the protein or protein fragments of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patents 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered

-75-

antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention can also be obtained from other species, including mammals such as rodents (typically mouse, but
5 also rat, guinea pig, and hamster) lagomorphs, typically rabbits, and also larger mammals, such as sheep, goats, cows, and horses, and other egg laying birds or reptiles such as chickens or alligators. For example, avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000, the contents of which are hereby incorporated in their entirety. In such cases, as with the transgenic human-
10 antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of the proteins of the present invention can be used effectively as immunogens when
15 conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide and fragments of the present invention to other moieties. For example, peptides of the present invention
20 can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

25 Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From
30 Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996), the disclosures of which are incorporated herein by reference. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990).

-76-

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the proteins of the present invention. Antibodies from avian species may have particular advantage in detection of the proteins of the present invention, in human serum or tissues (Viking et al., *Biosens. Bioelectron.* 13: 1257-1262 (1998)).

Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well-known in the art, Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997), incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant production of either whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein

-77-

(pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. *See, e.g.,* Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997);

5 Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994). Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. *See, e.g.,* Barbas

10 (2001), *supra*; Kay, *supra*; Abelson, *supra*, the disclosures of which are incorporated herein by reference in their entireties.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length

15 antibody in a further prokaryotic or a eukaryotic host cell.

Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. *See, e.g.,* Takahashi *et al.*, *Biosci.*

20 *Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3):1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997); Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998), the disclosures of which are incorporated herein

25 by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. *See, e.g.,* Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997);

30 and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000);

-78-

Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995), the disclosures of which are incorporated herein
5 by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.* Pollock *et al.*, *J. Immunol. Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995), the disclosures
10 of which are incorporated herein by reference in their entireties.

Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells.

Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998), herein incorporated
15 by reference, review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.

Antibodies of the present invention can also be prepared by cell free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic
20 animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999), the disclosures of which are incorporated herein by reference in their entireties.

The invention further provides antibody fragments that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present
25 invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful fragments are Fab, Fab', Fv, F(ab)'₂, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).
30

It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively

-79-

inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized
5 antibodies; such derivatives are less immunogenic in human beings, and thus more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful derivative is PEGylation to increase the serum half life of the antibodies.

Chimeric antibodies typically include heavy and/or light chain variable regions
10 (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g.,* United States Patent No. 5,807,715; Morrison *et al.*, *Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al.*, *Nature* 309(5966): 364-7 (1984); Takeda *et al.*, *Nature* 314(6010): 452-4 (1985), the disclosures of which are incorporated herein by reference in
15 their entireties. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al.*, *Nature* 332(6162): 323-7 (1988); Co *et al.*, *Nature* 351(6326): 501-2 (1991); United States Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886;
20 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties.

Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

25 It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. The present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be
30 prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco *et al.*, *Proc. Natl.*

-80-

Acad. Sci. (USA) 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to
5 provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments
10 encoded by the isolated nucleic acids of the present invention.

The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label is preferably an enzyme that catalyzes production and local deposition of a detectable product.

15 Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well-known, and include alkaline phosphatase, β -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl
20 phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodinitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue
25 tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H_2O_2), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate
30 reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe et al., *Methods Enzymol.* 133: 331-53 (1986); Kricka et al., *J. Immunoassay* 17(1): 67-83

-81-

(1996); and Lundqvist *et al.*, *J. Biolumin. Chemilumin.* 10(6): 353-9 (1995), the disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

The antibodies can also be labeled using colloidal gold.

5 As another example, when the antibodies of the present invention are used, *e.g.*, for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores.

There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

10 For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

15 Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568,
20 BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5,
25 Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for Western blotting
30 applications, they can usefully be labeled with radioisotopes, such as ³³P, ³²P, ³⁵S, ³H, and ¹²⁵I.

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be ²²⁸Th, ²²⁷Ac, ²²⁵Ac, ²²³Ra, ²¹³Bi, ²¹²Pb,

-82-

^{212}Bi , ^{211}At , ^{203}Pb , ^{194}Os , ^{188}Re , ^{186}Re , ^{153}Sm , ^{149}Tb , ^{131}I , ^{125}I , ^{111}In , ^{105}Rh , $^{99\text{m}}\text{Tc}$, ^{97}Ru , ^{90}Y , ^{90}Sr , ^{88}Y , ^{72}Se , ^{67}Cu , or ^{47}Sc .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application for which they are mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998), the disclosures of which are incorporated herein by reference in their entireties.

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

Substrates can be porous or nonporous, planar or nonplanar.

For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microspheres can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

-83-

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the
5 antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by
10 one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the
15 antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

Transgenic Animals and Cells

20

In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding a BSP. In a preferred embodiment, the BSP comprises an amino acid
25 sequence selected from SEQ ID NO: 172 through 295, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise a BSNA of the invention, preferably a BSNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 171, or a part, substantially similar nucleic acid molecule, allelic variant
30 or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human BSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric

homozygotes. Methods of producing transgenic animals are well-known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual*, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al.*, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press (2000); and Pinkert, *Transgenic Animal Technology: A Laboratory Handbook*, Academic Press (1999).

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson et al., Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11: 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent 4,873,191 (1989) retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g., Van der Putten et al., Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g., Thompson et al., Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g., Lo, 1983, Mol. Cell. Biol.* 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g., Ulmer et al., Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g., Lavitrano et al., Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g., Campbell et al., Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e.*, a nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g.*, the teaching of Lasko *et al. et al., Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to

verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well-known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas et al., *Cell* 51: 503-512 (1987); Thompson et al., *Cell* 5: 313-321 (1989).

-86-

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable
5 marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications
10 to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g., Thomas, supra* and *Thompson, supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

15 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.,* knockouts) are administered to a patient *in vivo*. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells,
20 blood cells (*e.g.,* lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.,* by transduction (using viral vectors, and preferably
25 vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve
30 expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.,* in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.,* genetically engineered fibroblasts can be implanted as part of a skin graft;

-87-

genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patents 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible
5 cells, they can be administered using well-known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

10 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

15 Computer Readable Means

A further aspect of the invention relates to a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO:
1 through 171 and SEQ ID NO: 172 through 295 as described herein, as the complete set
20 of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

25 The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be
30 reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

-88-

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence comprising the sequence of an amino acid of the invention in a computer readable

medium; and comparing said an amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence.

Diagnostic Methods for Breast Cancer

10

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by comparing expression of a BSNA or a BSP in a human patient that has or may have breast cancer, or who is at risk of developing breast cancer, with the expression of a BSNA or a BSP in a normal human control. For purposes of the present invention, “expression of a BSNA” or “BSNA expression” means the quantity of BSG mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term “expression of a BSP” or “BSP expression” means the amount of BSP that can be measured by any method known in the art or the level of translation of a BSG BSNA that can be measured by any method known in the art.

15
20

The present invention provides methods for diagnosing breast cancer in a patient, in particular squamous cell carcinoma, by analyzing for changes in levels of BSNA or BSP in cells, tissues, organs or bodily fluids compared with levels of BSNA or BSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of a BSNA or BSP in the patient versus the normal human control is associated with the presence of breast cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing breast cancer in a patient by analyzing changes in the structure of the mRNA of a BSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing breast cancer in a patient by analyzing changes in a BSP compared to a BSP from a normal control. These

25
30

-90-

changes include, *e.g.*, alterations in glycosylation and/or phosphorylation of the BSP or subcellular BSP localization.

In a preferred embodiment, the expression of a BSNA is measured by determining the amount of an mRNA that encodes an amino acid sequence selected from
5 SEQ ID NO: 172 through 295, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the BSNA expression that is measured is the level of expression of a BSNA mRNA selected from SEQ ID NO: 1 through 171, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acids. BSNA expression may be measured by any method known in
10 the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g.*, Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. BSNA transcription may be measured by any method known in the art including using a reporter
15 gene hooked up to the promoter of a BSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.*, aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, BSNA expression may be compared to a known control, such as normal breast nucleic acid, to detect a change in expression.

20 In another preferred embodiment, the expression of a BSP is measured by determining the level of a BSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 172 through 295, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for
25 instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of BSNA or BSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of breast cancer. The expression level of a BSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the BSP expression level may be
30 determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.*, Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the BSP

-91-

structure may be determined by any method known in the art, including, *e.g.*, using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

5 In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to a BSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-BSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the
10 antibody on the solid support under conditions in which the BSP will bind to the anti-BSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-BSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the BSP to the labeled antibody will occur. After
15 binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of a BSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

20 Other methods to measure BSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-BSP antibody is attached to a solid support and an allocated amount of a labeled BSP and a sample of interest are incubated with the solid support. The amount of labeled BSP detected which is attached to the solid support can be correlated to the quantity of a BSP in the sample.

25 Of the proteomic approaches, 2D PAGE is a well-known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is
30 perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of a BSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example,

5 reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

10 Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more BSNAs of interest. In this approach, all or a portion of one or more BSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the
15 RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid
20 molecule or a secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any
25 other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of blood. In a preferred embodiment, the specimen tested for expression of BSNA or BSP includes, without limitation, breast tissue, fluid obtained by bronchial alveolar lavage (BAL), sputum, breast cells grown in cell culture, blood, serum, lymph node tissue and lymphatic fluid. In another preferred embodiment,
30 especially when metastasis of a primary breast cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, adrenal glands and colon. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, *e.g.*, transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy,

-93-

bone marrow biopsy and bone marrow aspiration. *See* Scott, *supra* and Franklin, pp. 529-570, in Kane, *supra*. For early and inexpensive detection, assaying for changes in BSNAs or BSPs in cells in sputum samples may be particularly useful. Methods of obtaining and analyzing sputum samples is disclosed in Franklin, *supra*.

- 5 All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of a BSNA or BSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other BSNA or BSPs as disclosed herein.
- 10 Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular BSNA or BSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more
- 15 preferably at least ten additional cancer markers are used.

Diagnosing

- In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more BSNAs and/or BSPs in a sample from a patient suspected of having breast cancer. In general, the method comprises the steps
- 20 of obtaining the sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP and then ascertaining whether the patient has breast cancer from the expression level of the BSNA or BSP. In general, if high expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times
- 25 higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times lower, more preferably are at least
- 30 five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

-94-

The present invention also provides a method of determining whether breast cancer has metastasized in a patient. One may identify whether the breast cancer has metastasized by measuring the expression levels and/or structural alterations of one or more BSNA and/or BSPs in a variety of tissues. The presence of a BSNA or BSP in a certain tissue at levels higher than that of corresponding noncancerous tissue (*e.g.*, the same tissue from another individual) is indicative of metastasis if high level expression of a BSNA or BSP is associated with breast cancer. Similarly, the presence of a BSNA or BSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of a BSNA or BSP is associated with breast cancer. Further, the presence of a structurally altered BSNA or BSP that is associated with breast cancer is also indicative of metastasis.

In general, if high expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

The BSNA or BSP of this invention may be used as element in an array or a multi-analyte test to recognize expression patterns associated with breast cancers or other breast related disorders. In addition, the sequences of either the nucleic acids or proteins may be used as elements in a computer program for pattern recognition of breast disorders.

Staging

The invention also provides a method of staging breast cancer in a human patient. The method comprises identifying a human patient having breast cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more BSNA and/or BSPs. First, one or more tumors from a variety of patients are staged according to procedures well-known in the art, and the expression level of one or more BSNA and/or BSPs is determined for each stage to obtain a

-95-

standard expression level for each BSNA and BSP. Then, the BSNA or BSP expression levels are determined in a biological sample from a patient whose stage of cancer is not known. The BSNA or BSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the BSNA and BSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of a BSNA or BSP to determine the stage of a breast cancer.

Monitoring

Further provided is a method of monitoring breast cancer in a human patient.

One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the breast cancer. The method comprises identifying a human patient that one wants to monitor for breast cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more BSNA or BSPs, and comparing the BSNA or BSP levels over time to those BSNA or BSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in a BSNA or BSP that are associated with breast cancer.

If increased expression of a BSNA or BSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively.

One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of a BSNA or BSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an decrease in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of BSNA or BSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples.

-96-

Monitoring a patient for onset of breast cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of a BSNA and/or BSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more BSNAs and/or BSPs are detected. The presence of higher (or lower) BSNA or BSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly breast cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more BSNAs and/or BSPs of the invention can also be monitored by analyzing levels of expression of the BSNAs and/or BSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

Detection of Genetic Lesions or Mutations

The methods of the present invention can also be used to detect genetic lesions or mutations in a BSG, thereby determining if a human with the genetic lesion is susceptible to developing breast cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing breast cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the BSGs of this invention, a chromosomal rearrangement of BSG, an aberrant modification of BSG (such as of the methylation pattern of the genomic DNA), or allelic loss of a BSG. Methods to detect such lesions in the BSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

Methods of Detecting Noncancerous Breast Diseases

The invention also provides a method for determining the expression levels and/or structural alterations of one or more BSNAs and/or BSPs in a sample from a patient suspected of having or known to have a noncancerous breast disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP, comparing the

-97-

expression level or structural alteration of the BSNA or BSP to a normal breast control, and then ascertaining whether the patient has a noncancerous breast disease. In general, if high expression relative to a control of a BSNA or BSP is indicative of a particular noncancerous breast disease, a diagnostic assay is considered positive if the level of

5 expression of the BSNA or BSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of a noncancerous breast disease, a diagnostic assay is considered positive if the level of expression of the BSNA

10 or BSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether a BSNA and/or BSP

15 is associated with a particular noncancerous breast disease by obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining which BSNAs and/or BSPs are expressed in the tissue at either a higher or a lower level than in normal breast tissue. In another embodiment, one may determine whether a BSNA or BSP exhibits structural alterations in a particular noncancerous breast disease state by

20 obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining the structural alterations in one or more BSNAs and/or BSPs relative to normal breast tissue.

Methods for Identifying Breast Tissue

25 In another aspect, the invention provides methods for identifying breast tissue. These methods are particularly useful in, *e.g.*, forensic science, breast cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a

30 sample is breast tissue or has breast tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising breast tissue or having breast tissue-like characteristics, determining whether the sample expresses one or more BSNAs and/or BSPs, and, if the sample expresses one or more BSNAs and/or BSPs, concluding that the sample comprises breast tissue. In a preferred embodiment, the BSNA encodes a

35 polypeptide having an amino acid sequence selected from SEQ ID NO: 172 through 295,

-98-

or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the BSNA has a nucleotide sequence selected from SEQ ID NO: 1 through 171, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses a BSNA can be accomplished by any method known in the art.

- 5 Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether a BSP is expressed. Determining whether a sample expresses a BSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the BSP
- 10 has an amino acid sequence selected from SEQ ID NO: 172 through 295, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two BSNAs and/or BSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five BSNAs and/or BSPs are determined.

- 15 In one embodiment, the method can be used to determine whether an unknown tissue is breast tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into breast tissue.
- 20 This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new breast tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH,
- 25 aqueous:air interface and various other culture conditions.

Methods for Producing and Modifying Breast Tissue

- In another aspect, the invention provides methods for producing engineered breast tissue or cells. In one embodiment, the method comprises the steps of providing cells,
- 30 introducing a BSNA or a BSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of breast tissue cells. In a preferred embodiment, the cells are pluripotent. As is well-known in the art, normal breast tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered breast tissue or cells comprises one of these cell types. In another

-99-

embodiment, the engineered breast tissue or cells comprises more than one breast cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the breast cell tissue. Methods for manipulating culture conditions are well-known in the art.

5 Nucleic acid molecules encoding one or more BSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode BSPs having amino acid sequences selected from SEQ ID NO: 172 through 295, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected
10 from SEQ ID NO: 1 through 171, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly preferred embodiment, a BSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well-known in the art and are described in detail, *supra*.

Artificial breast tissue may be used to treat patients who have lost some or all of
15 their breast function.

Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, antibodies, antibody derivatives,
20 antibody fragments, agonists, antagonists, and inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises a BSNA or part thereof. In a more preferred embodiment, the BSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 171, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity
25 thereto. In another preferred embodiment, the pharmaceutical composition comprises a BSP or fragment thereof. In a more preferred embodiment, the BSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 172 through 295, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the
30 pharmaceutical composition comprises an anti-BSP antibody, preferably an antibody that specifically binds to a BSP having an amino acid that is selected from the group consisting of SEQ ID NO: 172 through 295, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

-100-

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art, and is further described in
5 Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed. (2000), the disclosures of which are incorporated herein by reference in their entireties,
10 and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation,
15 topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain
20 suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and
25 alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and
30 alginic acid.

Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

-101-

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

5 Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

10 Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or
15 suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral)
20 administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and
25 flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present
30 invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and
5 administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate,
10 isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the
15 suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as
20 polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

25 The pharmaceutical compositions of the present invention can be administered topically.

For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops,
30 tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid

-103-

ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases
5 as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various
10 powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for
15 reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts
20 tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the
25 intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example BSP polypeptide, fusion protein, or fragments thereof, antibodies specific for BSP, agonists, antagonists or inhibitors of BSP, which ameliorates the signs or symptoms
30 of the disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model

-104-

can also be used to determine an initial preferred concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well-known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to

-105-

the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

Therapeutic Methods

5 The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of breast function. As used herein, “treating” includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term “treating” encompasses any
10 improvement of a disease, including minor improvements. These methods are discussed below.

Gene Therapy and Vaccines

 The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be
15 driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of “naked” nucleic acid vaccination, as further
20 described in U.S. Patents 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; and 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g.*, Doronin *et al.*, *J. Virol.* 75: 3314-24 (2001).

25 In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of a BSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of a BSP are
30 administered, for example, to complement a deficiency in the native BSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g.*, Cid-Arregui, *supra*. In a preferred embodiment, the nucleic acid

-106-

molecule encodes a BSP having the amino acid sequence of SEQ ID NO: 172 through 295, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express a BSP, fusions, or fragments thereof can
5 be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in BSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode a BSP having the amino acid sequence of SEQ ID NO: 172 through 295, or a fragment, fusion protein, allelic variant or homolog thereof.

10 *Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of a BSG antisense nucleic acid, are administered to downregulate transcription and/or translation of a BSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

15 Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of a BSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of
20 sequence-specific hybridization to BSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995), the disclosures of which are incorporated herein by reference in their entireties.

25 Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the BSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000), the disclosures of which are incorporated herein by reference. Pharmaceutical
30 compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

-107-

In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding a BSP, preferably a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule
5 having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Polypeptide Administration

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a BSP, a
10 fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant BSP defect.

Protein compositions are administered, for example, to complement a deficiency in native BSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to BSP. The immune response can
15 be used to modulate activity of BSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate BSP.

In a preferred embodiment, the polypeptide is a BSP comprising an amino acid
20 sequence of SEQ ID NO: 172 through 295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Antibody, Agonist and Antagonist Administration

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well-known, antibody compositions are administered, for example,
30 to antagonize activity of BSP, or to target therapeutic agents to sites of BSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred

-108-

embodiment, the antibody specifically binds to a BSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which
5 bind to a BSP or have a modulatory effect on the expression or activity of a BSP. Modulators which decrease the expression or activity of BSP (antagonists) are believed to be useful in treating breast cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of a BSP can
10 also be designed, synthesized and tested for use in the imaging and treatment of breast cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the BSPs identified herein. Molecules identified in the library as being capable of binding to a BSP are key candidates for further evaluation for use in the treatment of breast cancer. In a preferred embodiment,
15 these molecules will downregulate expression and/or activity of a BSP in cells.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of BSP is administered. Antagonists of BSP can be produced using methods generally known in the art. In particular, purified BSP can be used to screen libraries of pharmaceutical
20 agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of a BSP.

In other embodiments a pharmaceutical composition comprising an agonist of a BSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

25 In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP encoded by a
30 nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

Targeting Breast Tissue

The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the

-109-

breast or to specific cells in the breast. In a preferred embodiment, an anti-BSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if breast tissue needs to be selectively destroyed. This would be useful for targeting and killing breast cancer cells.

- 5 In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting breast cell function.

In another embodiment, an anti-BSP antibody may be linked to an imaging agent that can be detected using, e.g., magnetic resonance imaging, CT or PET. This would be useful for determining and monitoring breast function, identifying breast cancer tumors,

- 10 and identifying noncancerous breast diseases.

EXAMPLES

Example 1: Gene Expression analysis

BSGs were identified by mRNA subtraction analysis using standard methods. The sequences were extended using GeneBank sequences, Incyte's proprietary database.

- 15 From the nucleotide sequences, predicted amino acid sequences were prepared.
DEX0306_1, DEX0306_2 correspond to SEQ ID NO.1, 2 etc. DEX0157 was the parent sequence found in the mRNA subtractions.

	DEX0306_1	DEX0157_1	DEX0306_172
	DEX0306_2	flex DEX0157_1	
20	DEX0306_3	DEX0157_2	DEX0306_173
	DEX0306_4	flex DEX0157_2	
	DEX0306_5	DEX0157_3	DEX0306_174
	DEX0306_6	flex DEX0157_3	
	DEX0306_7	DEX0157_4	DEX0306_175
25	DEX0306_8	flex DEX0157_4	
	DEX0306_9	DEX0157_5	DEX0306_176
	DEX0306_10	flex DEX0157_5	
	DEX0306_11	DEX0157_6	DEX0306_177
	DEX0306_12	flex DEX0157_6	
30	DEX0306_13	DEX0157_7	DEX0306_178
	DEX0306_14	DEX0157_8	DEX0306_179
	DEX0306_15	DEX0157_9	DEX0306_180
	DEX0306_16	flex DEX0157_9	
	DEX0306_17	DEX0157_10	DEX0306_181
35	DEX0306_18	flex DEX0157_10	DEX0306_182
	DEX0306_19	DEX0157_11	DEX0306_183
	DEX0306_20	flex DEX0157_11	
	DEX0306_21	DEX0157_12	DEX0306_184
	DEX0306_22	flex DEX0157_12	
40	DEX0306_23	DEX0157_13	DEX0306_185
	DEX0306_24	flex DEX0157_13	
	DEX0306_25	DEX0157_14	DEX0306_186
	DEX0306_26	flex DEX0157_14	
	DEX0306_27	DEX0157_15	DEX0306_187
45	DEX0306_28	flex DEX0157_15	
	DEX0306_29	DEX0157_16	DEX0306_188

-110-

DEX0306_30 DEX0157_17 DEX0306_189
DEX0306_31 flex DEX0157_17 DEX0306_190
DEX0306_32 DEX0157_18 DEX0306_191
DEX0306_33 flex DEX0157_18
5 DEX0306_34 DEX0157_19 DEX0306_192
DEX0306_35 DEX0157_20 DEX0306_193
DEX0306_36 flex DEX0157_20 DEX0306_194
DEX0306_37 DEX0157_21
DEX0306_38 DEX0157_22 DEX0306_195
10 DEX0306_39 flex DEX0157_22
DEX0306_40 DEX0157_23 DEX0306_196
DEX0306_41 flex DEX0157_23
DEX0306_42 DEX0157_24 DEX0306_197
DEX0306_43 DEX0157_25 DEX0306_198
15 DEX0306_44 flex DEX0157_25 DEX0306_199
DEX0306_45 DEX0157_26 DEX0306_200
DEX0306_46 DEX0157_27 DEX0306_201
DEX0306_47 flex DEX0157_27
DEX0306_48 DEX0157_28 DEX0306_202
20 DEX0306_49 flex DEX0157_28
DEX0306_50 DEX0157_29 DEX0306_203
DEX0306_51 flex DEX0157_29
DEX0306_52 DEX0157_30 DEX0306_204
DEX0306_53 flex DEX0157_30 DEX0306_205
25 DEX0306_54 DEX0157_31 DEX0306_206
DEX0306_55 flex DEX0157_31
DEX0306_56 DEX0157_32 DEX0306_207
DEX0306_57 flex DEX0157_32
DEX0306_58 DEX0157_33 DEX0306_208
30 DEX0306_59 flex DEX0157_33
DEX0306_60 DEX0157_34
DEX0306_61 flex DEX0157_34
DEX0306_62 DEX0157_35 DEX0306_209
DEX0306_63 DEX0157_36 DEX0306_210
35 DEX0306_64 flex DEX0157_36
DEX0306_65 DEX0157_37 DEX0306_211
DEX0306_66 flex DEX0157_37 DEX0306_212
DEX0306_67 DEX0157_38 DEX0306_213
DEX0306_68 DEX0157_39 DEX0306_214
40 DEX0306_69 flex DEX0157_39 DEX0306_215
DEX0306_70 DEX0157_40 DEX0306_216
DEX0306_71 flex DEX0157_40 DEX0306_217
DEX0306_72 DEX0157_41 DEX0306_218
DEX0306_73 flex DEX0157_41 DEX0306_219
45 DEX0306_74 DEX0157_42 DEX0306_220
DEX0306_75 flex DEX0157_42
DEX0306_76 DEX0157_43 DEX0306_221
DEX0306_77 flex DEX0157_43
DEX0306_78 DEX0157_44 DEX0306_222
50 DEX0306_79 flex DEX0157_44
DEX0306_80 DEX0157_45 DEX0306_223
DEX0306_81 flex DEX0157_45 DEX0306_224
DEX0306_82 DEX0157_46 DEX0306_225
DEX0306_83 DEX0157_47 DEX0306_226
55 DEX0306_84 DEX0157_48 DEX0306_227
DEX0306_85 DEX0157_49 DEX0306_228
DEX0306_86 flex DEX0157_49 DEX0306_229
DEX0306_87 DEX0157_50 DEX0306_230
DEX0306_88 flex DEX0157_50 DEX0306_231
60 DEX0306_89 DEX0157_51 DEX0306_232
DEX0306_90 flex DEX0157_51
DEX0306_91 DEX0157_52 DEX0306_233

-111-

DEX0306_92 DEX0157_53 DEX0306_234
DEX0306_93 flex DEX0157_53 DEX0306_235
DEX0306_94 DEX0157_54 DEX0306_236
DEX0306_95 flex DEX0157_54
5 DEX0306_96 DEX0157_55 DEX0306_237
DEX0306_97 DEX0157_56 DEX0306_238
DEX0306_98 flex DEX0157_56 DEX0306_239
DEX0306_99 DEX0157_57 DEX0306_240
DEX0306_100 DEX0157_58 DEX0306_241
10 DEX0306_101 flex DEX0157_58
DEX0306_102 DEX0157_60 DEX0306_242
DEX0306_103 flex DEX0157_60 DEX0306_243
DEX0306_104 DEX0157_61 DEX0306_244
DEX0306_105 flex DEX0157_61 DEX0306_245
15 DEX0306_106 DEX0157_62 DEX0306_246
DEX0306_107 flex DEX0157_62 DEX0306_247
DEX0306_108 DEX0157_63 DEX0306_248
DEX0306_109 flex DEX0157_63
DEX0306_110 DEX0157_64 DEX0306_249
20 DEX0306_111 flex DEX0157_64 DEX0306_250
DEX0306_112 DEX0157_65 DEX0306_251
DEX0306_113 DEX0157_66 DEX0306_252
DEX0306_114 DEX0157_67 DEX0306_253
DEX0306_115 DEX0157_68 DEX0306_254
25 DEX0306_116 flex DEX0157_68 DEX0306_255
DEX0306_117 DEX0157_69 DEX0306_256
DEX0306_118 flex DEX0157_69 DEX0306_257
DEX0306_119 DEX0157_70 DEX0306_258
DEX0306_120 flex DEX0157_70
30 DEX0306_121 DEX0157_71 DEX0306_259
DEX0306_122 flex DEX0157_71
DEX0306_123 DEX0157_72 DEX0306_260
DEX0306_124 flex DEX0157_72 DEX0306_261
DEX0306_125 DEX0157_73 DEX0306_262
35 DEX0306_126 flex DEX0157_73 DEX0306_263
DEX0306_127 DEX0157_74 DEX0306_264
DEX0306_128 flex DEX0157_74
DEX0306_129 DEX0157_75 DEX0306_265
DEX0306_130 DEX0157_76 DEX0306_266
40 DEX0306_131 flex DEX0157_76 DEX0306_267
DEX0306_132 DEX0157_77 DEX0306_268
DEX0306_133 flex DEX0157_77
DEX0306_134 DEX0157_78 DEX0306_269
DEX0306_135 flex DEX0157_78 DEX0306_270
45 DEX0306_136 DEX0157_79 DEX0306_271
DEX0306_137 flex DEX0157_79 DEX0306_272
DEX0306_138 DEX0157_80 DEX0306_273
DEX0306_139 DEX0157_81 DEX0306_274
DEX0306_140 flex DEX0157_81 DEX0306_275
50 DEX0306_141 DEX0157_82 DEX0306_276
DEX0306_142 flex DEX0157_82
DEX0306_143 DEX0157_83 DEX0306_277
DEX0306_144 flex DEX0157_83
DEX0306_145 DEX0157_85 DEX0306_278
55 DEX0306_146 flex DEX0157_85
DEX0306_147 DEX0157_86 DEX0306_279
DEX0306_148 flex DEX0157_86 DEX0306_280
DEX0306_149 DEX0157_87 DEX0306_281
DEX0306_150 flex DEX0157_87
60 DEX0306_151 DEX0157_88 DEX0306_282
DEX0306_152 flex DEX0157_88
DEX0306_153 DEX0157_89 DEX0306_283

-112-

DEX0306_154 flex DEX0157_89
 DEX0306_155 DEX0157_90 DEX0306_284
 DEX0306_156 flex DEX0157_90 DEX0306_285
 DEX0306_157 DEX0157_93 DEX0306_286
 5 DEX0306_158 DEX0157_94 DEX0306_287
 DEX0306_159 flex DEX0157_94
 DEX0306_160 DEX0157_95 DEX0306_288
 DEX0306_161 flex DEX0157_95
 DEX0306_162 DEX0157_96 DEX0306_289
 10 DEX0306_163 DEX0157_97 DEX0306_290
 DEX0306_164 flex DEX0157_97
 DEX0306_165 DEX0157_98 DEX0306_291
 DEX0306_166 DEX0157_99 DEX0306_292
 DEX0306_167 DEX0157_100 DEX0306_293
 15 DEX0306_168 flex DEX0157_100
 DEX0306_169 DEX0157_101 DEX0306_294
 DEX0306_170 DEX0157_102 DEX0306_295
 DEX0306_171 flex DEX0157_102

20 Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation
 detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The
 method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5'
 reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity
 25 of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected
 by the laser detector of the Model 7700 Sequence Detection System (PE Applied
 Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to
 standardize the amount of sample RNA added to the reaction and normalize for Reverse
 Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate
 30 dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this
 endogenous control. To calculate relative quantitation between all the samples studied,
 the target RNA levels for one sample were used as the basis for comparative results
 (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard
 curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence
 35 Detection System).

The tissue distribution and the level of the target gene are evaluated for every
 sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer
 tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently,
 first strand cDNA is prepared with reverse transcriptase and the polymerase chain
 40 reaction is done using primers and Taqman probes specific to each target gene. The
 results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute
 numbers are relative levels of expression of the target gene in a particular tissue
 compared to the calibrator tissue.

-113-

One of ordinary skill can design appropriate primers. The relative levels of expression of the BSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to a normal tissue (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the BSNA in pairs of matching samples and 1 cancer and 1 normal/normal adjacent of tissue may also be determined. All the values are compared to a normal tissue (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

In the analysis of matching samples, BSNA's show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples.

Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer stage (*e.g.* higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matching samples tested are indicative of SEQ ID NO: 1 through 171 being diagnostic markers for cancer.

Example 2B: Custom Microarray Experiment

Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were performed using Agilent-recommended protocols and reagents. Briefly, each microarray was hybridized with cRNAs synthesized from polyA⁺ RNA, isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment, the experimental sample was polyA⁺ RNA isolated from cancer tissue from

-114-

a single individual and the reference sample was a pool of polyA+ RNA isolated from normal tissues of the same organ as the cancerous tissue (*i.e.* normal breast tissue in experiments with breast cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were
5 scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition and Analysis Software (Axon). A total of 36 experiments comparing the expression patterns of breast cancer derived polyA+ RNA (9 stage 1 cancers, 23 stage 2 cancers, 4 stage 3 cancers) to polyA+ RNA isolated from a pool of 10 normal breast tissues were
10 analyzed.

Data normalization and expression profiling were done with Expressionist software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed
15 by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated negative control ± 2 Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Arrays with poor detection limits were not analyzed and the experiments were repeated. To evaluate
20 normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has
25 minimum thresholding criteria that employs user defined parameters to identify quality data. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background ± 2 SD)-(% pixels saturated)], and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low
30 expressors and saturated features were not included in analysis.

Relative expression data was collected from Expressionist based on meeting the quality parameters described above. Sensitivity data was calculated using an analysis tool. Up- and down- regulated genes were identified using criteria for percentage of valid values obtained, and the percentage of experiments in which the gene is up- or

-115-

down-regulated. These criteria were set independently for each data set, depending on the size and the nature of the data set. Results for several BSNA's are shown in the following table. The first three columns of the table contain information about the sequence itself (Oligo ID, Parent ID, and SEQ ID NO), the next 3 columns show the results obtained. '%valid' indicates the percentage of 36 unique experiments total in which a valid expression value was obtained, '%up' indicates the percentage of 20 experiments in which up-regulation of at least 2.5-fold was observed, and '%down' indicates the percentage of the 36 experiments in which down-regulation of at least 2.5-fold was observed. The last column in Table 1 describes the location of the microarray probe (oligo) relative to the sequence.

OligoID	Parent ID	Patent # SEQ ID NO	Sensitivity of up and down regulation			Oligo Seq location in original seq.	Oligo Seq location in FLEX seq
			% valid	% up	% down		
16052	8056	DEX0157_74, DEX0131_52 SEQ ID NO: 127/128	100	11.1	33.3	75-134	1928-1987
24688	5998	DEX0167_22, DEX0157_95, DEX0133_22, DEX0131_78 SEQ ID NO: 160/161	94.4	2.8	58.3	437-496	1093-1152
24689	5998	DEX0157_95, DEX0131_78 SEQ ID NO: 160/161	97.2	2.8	61.1	397-456	
27873	8713	DEX0157_74, DEX0131_52 SEQ ID NO: 127/128	100	13.9	30.6	101-160	1954-2013
33090	5973	DEX0157_73, DEX0131_56 SEQ ID NO: 125/126	97.2	2.8	44.4	408-466	2142-2200
33091	5973	DEX0157_73, DEX0131_56 SEQ ID NO: 125/126	100	2.8	41.7	368-427	1221-1280

Example 3: Protein Expression

The BSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the BSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the BSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH₂-terminus of the coding sequence of BSNA, and six histidines, flanking the

-116-

COOH-terminus of the coding sequence of BSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is
5 confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of BSP was achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that had been separated from total cell lysate were incubated with a nickle chelating resin. The column was packed and washed with five column
10 volumes of wash buffer. BSP was eluted stepwise with various concentration imidazole buffers.

Example 4: Protein Fusions

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also
15 should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a
20 polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the
25 vector can be modified to include a heterologous signal sequence. *See, e. g.*, WO 96/34891.

Example 5: Production of an Antibody from a Polypeptide

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such
30 cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The

-117-

splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies. Using the Jameson-Wolf methods the following epitopes were predicted. (Jameson and Wolf, CABIOS, 4(1), 181-186, 1988, the contents of which are incorporated by reference).

The predicted antigenicity for the amino acid sequences is as follows:

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
DEX0306_172			Myristyl 28-33; 53-58; 60-65; Pkc_Phospho_Site 67-69;	26, .882, .574
DEX0306_173			Myristyl 13-18; Pkc_Phospho_Site 19-21;	
DEX0306_174		1, i20-42o		
DEX0306_175	11-21, 1.07, 11		Pkc_Phospho_Site 4-6; 12-14;	
DEX0306_176	52-69, 1.16, 18 9-18, 1.16, 10		Asn_Glycosylation 82-85; Ck2_Phospho_Site 7-10; Myristyl 79-84;	

-118-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			Pkc_Phospho_Site 4-6;	
DEX0306_ 177			Asn_Glycosylation 7-10;55-58; Ck2_Phospho_Site 22-25;57-60; Pkc_Phospho_Site 57-59; Tyr_Phospho_Site 46-52;	
DEX0306_ 178	10-47,1.07,38 80-141, 1.03, 62		Myristyl 33- 38;129-134; Pkc_Phospho_Site 116-118;147-149;	
DEX0306_ 179			Myristyl 3-8;	
DEX0306_ 180	59-74,1.04,16		Ck2_Phospho_Site 4-7;49-52; Myristyl 45- 50;50-55;80- 85;86-91;95-100; Pkc_Phospho_Site 60-62;65-67;69- 71;	
DEX0306_ 182			Myristyl 22-27;	
DEX0306_ 184	12-36,1.22,25		Asn_Glycosylation 32-35; Camp_Phospho_Site 26-29; Ck2_Phospho_Site 9-12; Pkc_Phospho_Site 25-27;	
DEX0306_ 185	6-39,1.13,34		Asn_Glycosylation 64-67; Ck2_Phospho_Site 37-40;65-68; Glycosaminoglycan 48-51; Myristyl 14-19;49-54;51- 56; Pkc_Phospho_Site 18-20;42-44;	
DEX0306_ 187		1,α25-47i	Ck2_Phospho_Site 70-73; Myristyl 7-12; Pkc_Phospho_Site 42-44;	
DEX0306_ 188		3,i5-22α32- 54i61-83α	Myristyl 27- 32;141-146;144- 149; Pkc_Phospho_Site 17-19;55-57;90- 92;111-113;	17, .989, .91
DEX0306_			Ck2_Phospho_Site	

-119-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
190			73-76; Myristyl 12-17;17-22;66- 71; Pkc_Phospho_Site 91-93;	
DEX0306_ 192			Pkc_Phospho_Site 6-8;	
DEX0306_ 193			Myristyl 4-9;	
DEX0306_ 194	415-439, 1.14,25 242-251, 1.13,10 459-528, 1.11,70 159-197, 1.09,39 777-810, 1.09,34 632-669, 1.07,38 1034-1044, 1.04,11 1077-1103, 1.03,27		Asn_Glycosylation 12-15;19-22;23- 26;151-154;513- 516;873-876;886- 889; Camp_Phospho_ Site 107-110; Ck2_Phospho_Site 72-75;260- 263;283-286;319- 322;463-466;807- 810;975-978; Glycosaminoglycan 125-128;905- 908;913-916; Myristyl 13- 18;28-33;30- 35;52-57;53- 58;58-63;61- 66;62-67;126- 131;179-184;372- 377;529-534;699- 704;716-721;717- 722;721-726;837- 842;845-850;889- 894;906-911;910- 915; Pkc_Phospho_Site 129-131;160- 162;188-190;189- 191;356-358;613- 615;822-824;825- 827; Prokar_ Lipoprotein 44- 54;	
DEX0306_ 195			Pkc_Phospho_Site 6-8;	
DEX0306_ 196			Pkc_Phospho_Site 24-26;33-35;	
DEX0306_ 197			Pkc_Phospho_Site 7-9;	
DEX0306_ 198	39-55,1.09,17 25-34,1.05,10		Ck2_Phospho_Site 92-95; Pkc_Phospho_Site 107-109;	
DEX0306_ 199	97-113, 1.09,17		Ck2_Phospho_Site 150-153;193-	

-120-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
	83-92, 1.05, 10		196;200-203; Myristyl 11- 16;178-183; Pkc_Phospho_Site 165-167; Tyr_Phospho_Site 53-61;	
DEX0306_200		1,i12-34o	Asn_Glycosylation 20-23; Myristyl 18-23;	
DEX0306_201			Myristyl 16-21; Pkc_Phospho_Site 24-26;	24, .944, .7 79
DEX0306_202	25-37, 1.17, 13		Ck2_Phospho_Site 12-15; Myristyl 27-32;31-36;53- 58;	
DEX0306_203			Asn_Glycosylation 28-31; Myristyl 8-13;62-67;63- 68;64-69;	
DEX0306_204			Pkc_Phospho_Site 2-4;	
DEX0306_205			Ck2_Phospho_Site 60-63;77-80; Myristyl 14-19; Pkc_Phospho_Site 57-59;	
DEX0306_206		1,o5-24i	Myristyl 4-9;	
DEX0306_207			Ck2_Phospho_Site 64-67;75-78; Myristyl 71- 76;81-86;85-90;	
DEX0306_208			Asn_Glycosylation 53-56;62-65; Myristyl 72-77; Pkc_Phospho_Site 63-65;64-66;	
DEX0306_209			Asn_Glycosylation 47-50; Pkc_Phospho_Site 28-30;38-40; Tyr_Phospho_Site 29-36;30-36;	
DEX0306_211			Asn_Glycosylation 33-36; Ck2_Phospho_Site 17-20; Pkc_Phospho_Site 26-28;	
DEX0306_212	30-39, 1.06, 10		Ck2_Phospho_Site 76-79; Myristyl 19-24;31-36;92- 97; Pkc_Phospho_Site	17, .97, .82 9

-121-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			12-14;76-78; Pkc_Phospho_Site 29-31;	
DEX0306_213			Myristyl 43-48;48-53;	
DEX0306_214			Myristyl 90-95;101-106;104-109;	21,.973,.8 2
DEX0306_215	104-118, 1.16,15		Ck2_Phospho_Site 5-8;	
DEX0306_216		1,i11-33o	Myristyl 42-47;54-59;67-72; Pkc_Phospho_Site 4-6;37-39;	33,.982,.8 23
DEX0306_217			Asn_Glycosylation 12-15; Ck2_Phospho_Site 8-11; Myristyl 3-8; Pkc_Phospho_Site 23-25;	
DEX0306_218			Asn_Glycosylation 21-24; Ck2_Phospho_Site 43-46; Pkc_Phospho_Site 23-25;	
DEX0306_219			Amidation 19-22; Pkc_Phospho_Site 23-25;	
DEX0306_220	14-32,1.13,19		Pkc_Phospho_Site 18-20;	
DEX0306_221			Pkc_Phospho_Site 2-4;	
DEX0306_223			Ck2_Phospho_Site 31-34;38-41;57-60;79-82;85-88; Pkc_Phospho_Site 7-9;	
DEX0306_224		1,i17-26o	Asn_Glycosylation 34-37; Ck2_Phospho_Site 36-39;	
DEX0306_225			Pkc_Phospho_Site 34-36;	15,.918,.7 44
DEX0306_226	52-72,1.19,21	1,i73-95o	Amidation 66-69; Ck2_Phospho_Site 6-9; Myristyl 74-79;78-83;	
DEX0306_227		1,i20-42o		
DEX0306_228		1,o22-44i	Prokar_ Lipoprotein 23-33;	
DEX0306_230			Camp_Phospho_Site 3-6; Myristyl 31-	
DEX0306_231				

-122-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			36;90-95;	
DEX0306_232		1,015-32i	Myristyl 47-52; Pkc_Phospho_Site 2-4;	
DEX0306_233			Asn_Glycosylation 4-7;	
DEX0306_234	24-39,1.2,16		Myristyl 8-13; Pkc_Phospho_Site 65-67;	
DEX0306_235	560-572, 1.27,13 509-519, 1.23,11 1126-1153, 1.19,28 861-873, 1.18,13 794-804, 1.16,11 964-976, 1.16,13 880-901, 1.16,22 812-828, 1.11,17 588-612, 1.09,25 41-77, 1.07,37 461-489, 1.07,29 735-751, 1.07,17 978-1011, 1.06,34 535-558, 1.04,24 1081-1.04,17 620-644, 1.03,25 654-671, 1.01,18 354-382,1,29		Amidation 281- 284;403-406;721- 724; Asn_Glycosylation 633-636;655-658; Atp_Gtp_A 507- 514; Camp_Phospho_Site 54-57;479-482; Ck2_Phospho_Site 132-135;144- 147;181-184;209- 212;217-220;244- 247;310-313;332- 335;345-348;546- 549;558-561;560- 563;593-596;617- 620;622-625;635- 638;651-654;656- 659;697-700;739- 742;740-743;745- 748;969-972; Glycosaminoglycan 482-485;719-722; Myristyl 110- 115;130-135;142- 147;159-164;230- 235;254-259;277- 282;341-346;400- 405;510-515;572- 577;582-587;645- 650;721-726;823- 828;842-847;843- 848;846-851;872- 877;922-927;940- 945;954-959; Pkc_Phospho_Site 72-74;83-85;148- 150;155-157;156- 158;209-211;627- 629;635-637;656- 658;660-662;661- 663;736-738;739- 741;745-747;766- 768;802-804;813- 815;913-915;965- 967;973-975;	

-123-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			Tyr_Phospho_Site 55-62;426-433; Zinc_Finger_C2h2 36-56;176- 197;250-270;278- 298;337-357;517- 537;	
DEX0306_ 236	11-29,1,19	1,o32-54i		
DEX0306_ 237			Glycosaminoglycan 80-83; Myristyl 14-19;54-59;58- 63; Pkc_Phospho_Site 68-70;80-82;	
DEX0306_ 238		1,o62-84i	Asn_Glycosylation 30-33; Pkc_Phospho_Site 31-33;	
DEX0306_ 239	42-63,1.12,22		Asn_Glycosylation 145-148; Ck2_Phospho_Site 4-7;63-66;151- 154; Euk_Co2_Anhydrase 126-142; Myristyl 25-30;33-38;125- 130; Pkc_Phospho_Site 280-282;	
DEX0306_ 240	20-34,1.08,15		Asn_Glycosylation 53-56; Camp_Phospho_Site 41-44; Pkc_Phospho_Site 39-41;	
DEX0306_ 242			Myristyl 49-54; Pkc_Phospho_Site 33-35;	
DEX0306_ 243			Ck2_Phospho_Site 23-26;24-27; Pkc_Phospho_Site 9-11;23-25;	
DEX0306_ 244			Asn_Glycosylation 4-7;	
DEX0306_ 245	45-55,1.15,11		Camp_Phospho_Site 51-54; Ck2_Phospho_Site 60-63; Pkc_Phospho_Site 22-24;	
DEX0306_ 246			Pkc_Phospho_Site 7-9;35-37;	
DEX0306_ 247			Myristyl 86-91; Pkc_Phospho_Site 17-19;	22,.929,.6 52

-124-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
DEX0306_248				18,.993,.914
DEX0306_249			Asn_Glycosylation 2-5; Ck2_Phospho_Site 54-57; Pkc_Phospho_Site 54-56;	28,.911,.74
DEX0306_250	142-180, 1.03,39 9-21,1,13		Asn_Glycosylation 13-16;132-135; Ck2_Phospho_Site 97-100; Pkc_Phospho_Site 17-19;55-57;113-115;134-136;153-155;	
DEX0306_251	113-123, 1.14,11 37-60,1.09,24		Camp_Phospho_Site 50-53; Ck2_Phospho_Site 88-91; Pkc_Phospho_Site 39-41;49-51;88-90; Prokar_Lipoprotein 59-69; Tyr_Phospho_Site 87-95;	
DEX0306_252			Pkc_Phospho_Site 10-12;	
DEX0306_253		1,i12-43o	Myristyl 30-35; Prokar_Lipoprotein 12-22;	30,.996,.862
DEX0306_254			Ck2_Phospho_Site 16-19; Myristyl 31-36;36-41; Pkc_Phospho_Site 32-34; Rgd 25-27;	
DEX0306_255			Asn_Glycosylation 386-389;516-519;536-539;626-629;638-641;883-886; Camp_Phospho_Site 61-64; Ck2_Phospho_Site 147-150;201-204;205-208;252-255;394-397;435-438;462-465;491-494;511-514;524-527;552-555;632-635;646-649;756-759;839-842;867-870;887-890; Myristyl 25-30;263-268;751-	

-125-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			756;879-884; Pkc_Phospho_Site 29-31;107- 109;147-149;201- 203;506-508; Tyr_Phospho_Site 467-473;	
DEX0306_ 256	65-75,1.02,11 25-50,1.02,26		Asn_Glycosylation 56-59; Myristyl 14-19; Prokar_ Lipoprotein 8-18;	
DEX0306_ 257	179-203, 1.18,25 527-569, 1.15,43 422-464, 1.11,43 20-39,1.06,20 335-367, 1.06,33 43-117, 1.01,75		Amidation 267- 270; Asn_Glycosylation 176-179; Camp_Phospho_Site 71-74;324-327; Ck2_Phospho_Site 42-45;54-57;75- 78;99-102;109- 112;161-164;197- 200;206-209;223- 226;228-231;273- 276;283-286;336- 339;447-450;482- 485;497-500;567- 570; Glycosaminoglycan 246-249; Myristyl 24-29;38-43;86- 91;124-129;249- 254;262-267;278- 283;290-295;332- 337;410-415;430- 435; Pkc_Phospho_Site 12-14;18-20;28- 30;35-37;54- 56;69-71;296- 298;336-338;411- 413;434-436; Tyr_Phospho_Site 23-29;137- 144;310-318;	
DEX0306_ 258			Ck2_Phospho_Site 34-37;	
DEX0306_ 259			Asn_Glycosylation 31-34;	
DEX0306_ 260			Camp_Phospho_Site 6-9; Myristyl 54- 59;	
DEX0306_ 261	96-105, 1.19,10		Ck2_Phospho_Site 71-74;101-104; Glycosaminoglycan 55-58; Myristyl 52-57;54-59;58-	

-126-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			63;67-72; Pkc_Phospho_Site 17-19;137- 139;146-148;197- 199;215-217; Prokar_Lipoprotei n 164-174;	
DEX0306_ 262	30-41,1.02,12		Asn_Glycosylation 86-89; Ck2_Phospho_Site 21-24; Myristyl 96-101; Pkc_Phospho_Site 18-20;	
DEX0306_ 263	239-249, 1.13,11		Amidation 72-75; Asn_Glycosylation 119-122;120-123; Camp_Phospho_Site 107-110;216-219; Ck2_Phospho_Site 28-31;43-46;63- 66;160-163;169- 172;187-190; Myristyl 69- 74;158-163; Pkc_Phospho_Site 17-19;24-26;35- 37;52-54;59- 61;106-108;122- 124;184-186; Prokar_ Lipoprotein 248- 258;	
DEX0306_ 264			Myristyl 35-40; Pkc_Phospho_Site 21-23;22-24;	
DEX0306_ 265		1,17-290	Camp_Phospho_Site 47-50; Ck2_Phospho_Site 54-57; Myristyl 37-42; Pkc_Phospho_Site 72-74;	
DEX0306_ 266			Asn_Glycosylation 7-10;17-20; Pkc_Phospho_Site 2-4;	
DEX0306_ 267			Amidation 43-46; Ck2_Phospho_Site 79-82; Pkc_Phospho_Site 11-13;89-91;	
DEX0306_ 268			Pkc_Phospho_Site 8-10;45-47; Prokar_Lipoprotei n 32-42;	

-127-

DEX ID	ANTIGENICITY Position, AI Ave,Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
DEX0306_269			Camp_Phospho_Site 66-69; Ck2_Phospho_Site 12-15;34-37;56-59; Myristyl 30-35; Pkc_Phospho_Site 34-36;56-58;	
DEX0306_270	49-134,1,86		Asn_Glycosylation 46-49; Ck2_Phospho_Site 65-68;84-87;93-96;109-112; Myristyl 4-9;59-64; Pkc_Phospho_Site 60-62;89-91;104-106;115-117;116-118; Tyr_Phospho_Site 92-99;117-124;118-124;	
DEX0306_272	235-299,1.1,65 369-406, 1.07,38 99-109, 1.01,11		Asn_Glycosylation 37-40;69-72;284-287; Ck2_Phospho_Site 85-88;141-144;149-152;192-195;204-207; Glycosaminoglycan 433-436; Myristyl 43-48;44-49;96-101;118-123;402-407;406-411;432-437;438-443; Pkc_Phospho_Site 48-50;433-435; Rgd 278-280; Tyr_Phospho_Site 50-56;	
DEX0306_273			Pkc_Phospho_Site 6-8;15-17;	
DEX0306_274			Asn_Glycosylation 44-47;	
DEX0306_275			Asn_Glycosylation 78-81; Ck2_Phospho_Site 17-20; Myristyl 13-18;	
DEX0306_276			Ck2_Phospho_Site 58-61; Glycosaminoglycan 93-96; Myristyl 28-33;48-53;50-55;67-72;71-76; Pkc_Phospho_Site	

-128-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			5-7;18-20;44-46;57-59; Rgd 59-61;	
DEX0306_277		1,o37-59i	Ck2_Phospho_Site 22-25; Myristyl 71-76; Pkc_Phospho_Site 12-14;	
DEX0306_279			Myristyl 15-20;	
DEX0306_280			Ck2_Phospho_Site 76-79; Pkc_Phospho_Site 16-18;	27,.985,.682
DEX0306_281	17-29,1.07,13		Myristyl 5-10;9-14; Pkc_Phospho_Site 24-26;	
DEX0306_282		1,o15-32i		
DEX0306_283			Asn_Glycosylation 35-38; Ck2_Phospho_Site 37-40; Myristyl 3-8; Pkc_Phospho_Site 57-59;	
DEX0306_284	28-37,1.09,10		Ck2_Phospho_Site 46-49; Pkc_Phospho_Site 32-34;	21,.958,.821
DEX0306_285	226-245, 1.37,20 489-501, 1.22,13 1271-1284, 1.21,14 1192-1203, 1.11,12 745-755, 1.09,11 929-940, 1.08,12 1039-1051, 1.08,13 1133-1150, 1.05,18 547-576, 1.05,30 89-98,1.04,10 22-53,1.03,32 1073-1086, 1.03,14 1243-1253, 1.03,11 1418-1461,		Amidation 473-476; Asn_Glycosylation 512-515;726-729; Camp_Phospho_Site 475-478;571-574;646-649; Ck2_Phospho_Site 29-32;143-146;176-179;228-231;230-233;232-235;263-266;294-297;388-391;447-450;493-496;506-509;517-520;581-584;664-667;890-893;929-932; Gram_Pos_Anchorin g 670-675; Myristyl 49-54;56-61;125-130;152-157;185-190;214-219;677-682;708-713;840-845;921-926;	

-129-

DEX ID	ANTIGENICITY	TRANSMEMBRANE	PTM	SIGNAL
	Position, AI Ave, Length	Predicted Helix, Topology	PTM	PEPTIDE Position, Max Score, Mean Score
	1.01, 44		Pkc_Phospho_Site 21-23; 29-31; 143- 145; 388-390; 415- 417; 443-445; 530- 532; 539-541; 552- 554; 565-567; 581- 583; 748-750; 802- 804; 925-927; 931- 933; 987-989; 996- 998; Tyr_Phospho_Site 867-874; Amidation 473-476; Asn_Glycosylation 512-515; 726-729; Camp_Phospho_Site 475-478; 571- 574; 646-649; Ck2_Phospho_Site 29-32; 143- 146; 176-179; 228- 231; 230-233; 232- 235; 263-266; 294- 297; 388-391; 447- 450; 493-496; 506- 509; 517-520; 581- 584; 664-667; 890- 893; 929-932; Gram_Pos_ Anchoring 670- 675; Myristyl 49- 54; 56-61; 125- 130; 152-157; 185- 190; 214-219; 677- 682; 708-713; 840- 845; 921-926; Pkc_Phospho_Site 21-23; 29-31; 143- 145; 388-390; 415- 417; 443-445; 530- 532; 539-541; 552- 554; 565-567; 581- 583; 748-750; 802- 804; 925-927; 931- 933; 987-989; 996- 998; Tyr_Phospho_Site 867-874;	
DEX0306_286		2, i13-30o35-54i	Asn_Glycosylation 15-18; Ck2_Phospho_Site 41-44; Myristyl 2-7; Pkc_Phospho_Site 6-8;	
DEX0306			Asn_Glycosylation	

-130-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
287			43-46; 51-54; Ck2_Phospho_Site 34-37; Pkc_Phospho_Site 70-72;	
DEX0306_ 288			Asn_Glycosylation 42-45; Camp_Phospho_Site 12-15; Myristyl 4-9;	
DEX0306_ 290	20-31, 1.14, 12		Pkc_Phospho_Site 6-8; 21-23;	
DEX0306_ 291			Glycosaminoglycan 31-34; Myristyl 30-35;	
DEX0306_ 292			Camp_Phospho_Site 8-11; Ck2_Phospho_Site 11-14;	
DEX0306_ 293			Ck2_Phospho_Site 36-39; Myristyl 2-7; 94-99;	
DEX0306_ 294	31-52, 1.01, 22		Pkc_Phospho_Site 47-49;	
DEX0306_ 295			Myristyl 56-61;	

Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

- 5 RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1 through 171. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds;
- 10 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies).

- 15 The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is

-131-

cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are
5 nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium
10 iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. *Id.* Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical
15 Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological
20 Sample**

Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 µg/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells
25 are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate,
30 at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl

-132-

phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

Example 8: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 $\mu\text{g/kg/day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day , and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 $\mu\text{g/kg/hour}$ to about 50 mg/kg/hour , either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

-133-

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U. S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate,

-134-

succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, 5 aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a 10 concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e. g., 0.2 15 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation 20 for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more 25 containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the 30 present invention may be employed in conjunction with other therapeutic compounds.

Example 9: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form.

-135-

Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

- 5 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 $\mu\text{g/kg}$ of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

Example 10: Method of Treating Increased Levels of the Polypeptide

- 10 Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

- For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0
15 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

Example 11: Method of Treatment Using Gene Therapy

- One method of gene therapy transplants fibroblasts, which are capable of
20 expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room
25 temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

- At this time, fresh media is added and subsequently changed every several days.
30 After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf

-136-

intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 12: Method of Treatment Using Gene Therapy-*In Vivo*

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.

-137-

The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO 90/11092, WO 98/11779; U. S. Patent 5,693,622;

- 5 5,705,151; 5,580,859; Tabata H. et al. (1997) *Cardiovasc. Res.* 35 (3): 470-479, Chao J et al. (1997) *Pharmacol. Res.* 35 (6): 517-522, Wolff J. A. (1997) *Neuromuscul. Disord.* 7 (5): 314-318, Schwartz B. et al. (1996) *Gene Ther.* 3 (5): 405-411, Tsurumi Y. et al. (1996) *Circulation* 94 (12): 3281-3290 (incorporated herein by reference).

- The polynucleotide constructs may be delivered by any method that delivers
10 injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

- The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell,
15 including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. et al. (1995) *Ann. NY Acad. Sci.* 772: 126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85 (1): 1-7) which can be prepared by methods well known to those skilled in the art.

- 20 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target
25 cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

- The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow,
30 thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue

-138-

ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They
5 are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

10 For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 µg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of
15 injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation
20 particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for
25 polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by
30 intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about

-139-

0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e. g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

10 The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 13: Transgenic Animals

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40: 691-698 (1994); Carver et al., Biotechnology (NY) 11: 1263-1270 (1993); Wright et al., Biotechnology (NY) 9: 830-834 (1991); and Hoppe et al., U. S. Patent 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., Science 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., Cell 57: 717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115: 171-229 (1989), which is incorporated by reference herein in its entirety.

-140-

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380: 64-66 (1996); Wilmut et al., Nature 385: 810813 (1997)).

5 The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a
10 particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous
15 gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus
20 inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265: 103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant
25 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples
30 obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

-141-

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 14: Knock-Out Animals

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., *Nature* 317: 230-234 (1985); Thomas & Capecchi, *Cell* 51: 503-512 (1987); Thompson et al., *Cell* 5: 313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the

-142-

recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (I. e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e. g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent 5,399,349; and Mulligan & Wilson, U. S. Patent 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function

-143-

of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

All patents, patent publications, and other published references mentioned herein
5 are hereby incorporated by reference in their entireties as if each had been individually
and specifically incorporated by reference herein. While preferred illustrative
embodiments of the present invention are described, one skilled in the art will appreciate
that the present invention can be practiced by other than the described embodiments,
which are presented for purposes of illustration only and not by way of limitation. The
10 present invention is limited only by the claims that follow.

-144-

CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising
 - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes
5 an amino acid sequence of SEQ ID NO: 172 through 295;
 - (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID
NO: 1 through 171;
 - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid
molecule of (a) or (b); or
 - 10 (d) a nucleic acid molecule having at least 60% sequence identity to the nucleic
acid molecule of (a) or (b).
2. The nucleic acid molecule according to claim 1, wherein the nucleic acid
molecule is a cDNA.
15
3. The nucleic acid molecule according to claim 1, wherein the nucleic acid
molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid
20 molecule is a mammalian nucleic acid molecule.
5. The nucleic acid molecule according to claim 4, wherein the nucleic acid
molecule is a human nucleic acid molecule.
- 25 6. A method for determining the presence of a breast specific nucleic acid
(BSNA) in a sample, comprising the steps of:
 - (a) contacting the sample with the nucleic acid molecule according to claim 1
under conditions in which the nucleic acid molecule will selectively hybridize to a breast
specific nucleic acid; and
 - 30 (b) detecting hybridization of the nucleic acid molecule to a BSNA in the
sample, wherein the detection of the hybridization indicates the presence of a BSNA in
the sample.
7. A vector comprising the nucleic acid molecule of claim 1.

-145-

8. A host cell comprising the vector according to claim 7.

9. A method for producing a polypeptide encoded by the nucleic acid molecule
5 according to claim 1, comprising the steps of (a) providing a host cell comprising the
nucleic acid molecule operably linked to one or more expression control sequences, and
(b) incubating the host cell under conditions in which the polypeptide is produced.

10. A polypeptide encoded by the nucleic acid molecule according to claim 1.
10

11. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence with at least 60%
sequence identity to of SEQ ID NO: 172 through 295; or
(b) a polypeptide comprising an amino acid sequence encoded by a nucleic
15 acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 171.

12. An antibody or fragment thereof that specifically binds to the polypeptide
according to claim 11.

13. A method for determining the presence of a breast specific protein in a
20 sample, comprising the steps of:
(a) contacting the sample with the antibody according to claim 12 under
conditions in which the antibody will selectively bind to the breast specific protein; and
(b) detecting binding of the antibody to a breast specific protein in the sample,
25 wherein the detection of binding indicates the presence of a breast specific protein in the
sample.

14. A method for diagnosing and monitoring the presence and metastases of
breast cancer in a patient, comprising the steps of:
30 (a) determining an amount of the nucleic acid molecule of claim 1 or a
polypeptide of claim 11 in a sample of a patient; and
(b) comparing the amount of the determined nucleic acid molecule or the
polypeptide in the sample of the patient to the amount of the breast specific marker in a
normal control; wherein a difference in the amount of the nucleic acid molecule or the

-146-

polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of breast cancer.

15. A kit for detecting a risk of cancer or presence of cancer in a patient, said
5 kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 11 in a sample of a patient.

16. A method of treating a patient with breast cancer, comprising the step of
administering a composition according to claim 12 to a patient in need thereof, wherein
10 said administration induces an immune response against the breast cancer cell expressing the nucleic acid molecule or polypeptide.

17. A vaccine comprising the polypeptide or the nucleic acid encoding the
polypeptide of claim 11.

15

SEQUENCE LISTING

<110> diaDexus, Inc.
 Salceda, Susana
 Macina, Roberto
 Hu, Ping
 Recipon, Herve
 Karra, Kalpana
 Cafferkey, Robert
 Sun, Yongming
 Liu, Chenghua

<120> Compositions and Methods Relating to Breast Specific Genes and Proteins

<130> DEX-0306

<150> 60/268,292

<151> 2001-02-13

<160> 295

<170> PatentIn version 3.1

<210> 1

<211> 591

<212> DNA

<213> Homo sapien

<400> 1

```

gctcttctctg tctacaaagg ggactgctca cagtggcctc agcttggtgg ttttgagggg      60
ccgccccccg gccctccata aggggtatcct gggcctgaga attctgcacg tgccattgga      120
tggaatgtaca gcctcaaagc gaagtgcagc ccacggggaga tgggtccgag gtccaggctg      180
tggccatcca gccccctgtg gcttgtccag cctctgtgca cccctggtgt cttcactcca      240
ggggcagaca gtagccactg cagttccttt cttcgtgaga taacagtagt gatagcagct      300
ggggctaaca ggctaggctt agtgtcctgc gcatttggtc agcttctcac tcgacacctc      360
ctaaagcaat ggggaggccc ccactagccc agttttcagg aagtcaactg ggagggtaga      420
tgggggccag aggtcccaca gctactgatg gcccgagcca gggtgagctt tcctggatgt      480
ccagtccgga tcccacttgc agatctcatg ctctcagata ggtgggacaa gttcttttgt      540
cacagtgtg gctctgtcct gaggcctcat tgctggctgg tgtgctctgc t              591

```

<210> 2

<211> 2754

<212> DNA

<213> Homo sapien

<400> 2

```

gccagaagca gcctcagctt ggcaagggtg ggagatgact gctgttcctc tcgcatttgg      60

```


2

ggaaaacagg ctccctcggt agctcgatga tccctcttttg atcttgtgtg acctcctgga 120
 gagtggatga cgctggtggc cttagctttt ctacacagtg taaattgcac tgggcgatgt 180
 cccagagca gggcaaggtc tctagagcgg gtctcccaca tgactggctt cacacaggca 240
 ctccgcctcg ggttgcattg tctgtgtcat cttaccggtc cagggttgca ggtaggaaat 300
 gtttgtaccc tcttctgatt gccacctcct tcccatcgcc ccttagggac agggcttgag 360
 ggccagttag gcgctggtca ggcaccccag gcctccttgg gacctgcca ggggcaccct 420
 gagagctcct gaaacccccca cttagcttcc agacctttct gcaaaagctc ctctggctt 480
 tctccctcc cccaatctat gggtcacagc taacagatct gagggcaact gctgtgctag 540
 tggccagggc tgcacctgcc atccccggct ctgccacttt agggccttct agaggcagtg 600
 tccttaggaa gtagctctga ggcattgggtt tctgtctcct gtgcagggca gctgatggga 660
 taagggtggg aaggacggtc agtgcttggg cccagctgg ccagcctggc gatggggaaa 720
 ccaaaccatg tccccagcg aagggccaga gtgggaacct gtctcatgc ccttcgtcct 780
 gaggagccct gaggtgggca gcaggggcca ggggaagttt tcaggccttc atcaaagaga 840
 acaacatcct cagctccgca cccctcatcc tgtatcagca cttaccggtg tgtgactgcc 900
 cttgtcagct agcatacggg gggcccacct gggccactgg ctgtttatgc cactgattta 960
 tgatagggaa tattatcttt gaacccaatg aagtgttttc tccccatca caaaaaaaaa 1020
 aattcttatt tttagtagac atgtatttac caaaaatatg tactcaatta ttgtattttg 1080
 gattttatca atttaaaat tgtggaaatt tgtttgtctt tacgccaaca taatattgat 1140
 tttgcctctt ggctctgaaa gccccaaata tttaccgtct agcccgttac agaaaaagtc 1200
 tgctgactac tgagccagac ctccattacc tccatccctg ttggattatt taaagaaagc 1260
 ctacagacagt aagggtcttt ttaaaagaat aaaatgactt ggtttgcgct tgggaagcagg 1320
 ggaagcattc agatgagcgg tttctgcatt aacctgcct atcacgcac tcgtgtcctg 1380
 tgtggctggc gagccccct tgggaaggtc tgggtcttca gctggctcct gcagagtcca 1440
 cccgcctcgt tgggtgggaat gcagagccct ttgctttcct tcttgccgcc tgcttcctgt 1500
 tcctggggac ccgctgggac tttggtctgc atccccctggc caggccctc agggttgatg 1560
 cgtggagaag gactttgagc agtggtggg agcagtggcc tctggccag ctacactct 1620
 tgcctgggga ggggcagcct gatctcacct ccacctagta ccttggggac tgaggacctt 1680
 ttggcttctc tggagcctgc aagcctcttc ccatgtgtcc agctgtctct cctgctacaa 1740
 aggggactgc tcacagtggc ctacagcttg tggttttgag gggccgcccc ccggccctcc 1800
 ataagggtat cctgggcctg agaattctgc atctgccatt ggaggatgga cagcctcaaa 1860

```

tggaaggagt cccacgggag atgggtccga ggtccggtg tggccatcca gccccctgtg 1920
gcttgccag cctctgtgca ccctgggtgt cttcactcca ggggcagaca gcagccactg 1980
cagttccttt cttcgtgagt aacagtagtg atagcagctg gggctaacag gctaggcttt 2040
gtgttctgcg catttggtca gcttctcact cgatcctccc taaagcaatg gggaggcccc 2100
cactagccca gttttcagga agtcaactgg gaggttagat gggggccagg gtcccacagc 2160
tactgatggc ccgagccagg ttgagcttcc tgggtgccag tccggatccc acttgcatat 2220
ctcatgctct cagataggtg ggacaagtgc ttttgtcaca gtgctggctc tgtcctgagg 2280
cctcattgct ggctgggtgt gctctgctgg gaaaagcttt gcggggcttg cttgggtaac 2340
cacagaagag aaggggactg tttgggtgca ctctctgcag cctccccgtg ctgggtggaa 2400
gcacgggtac tgtgttctct aatgttcatt tatttaaaat gatttctttc taaagatgta 2460
acctccacac ctttctccag attgggtgac tcttttctaa aggtgggtgg agtatctgtc 2520
ggggtgggtg ggcccttggg tgggtcaggt ggggtgtgaga ggtcctgggg aggtggcggt 2580
tgagctcaaa gttgtcctac tgccatgttt ttgtacctga aataaagcat attttgcact 2640
tgttactgta ccatagtgcg gacgagaagt ctgtatgtgg gatctgtgct tgggttagaa 2700
tgcaataaaa actcacattt gtaagaaaaa aaaaaaaat aaaaagatgc ggcc 2754

```

```

<210> 3
<211> 856
<212> DNA
<213> Homo sapien

```

```

<400> 3
acgttaaaat taagaactta ggctttgggt taaaaaaca taaatgaagt gaaaaaaca 60
agccacagag taaaagaaga tacttgacgc aagtgataaa ggattagtat ccaggatata 120
taaagactgt tattgagtca atgtgaaagg gagaaaaaca cctgaagcaa agaatggatg 180
ccggcattaa ataggcactt caaagaggaa ccatgaacga ccaaaatcaa gtgagttagt 240
gaccagtacc cattagtaat taggaaatag caaattaaga ccacaaagag ggcagttagt 300
gtgggtcaca cacctctaata ctacgagggt tgggagtcca gggccagagg atcccttgag 360
gccaggaggt ggagtctagc ctgggaaaca tagcaagacc ctgtctctac aaaaaataa 420
ataaataaaa taagaaaaaa gtaaaccaca aggagatgac ttaccaccag gcaaaaatat 480
taaagtatgc taataccaag tatcaagaag aatgaagcaa gatagctcaa atatgctttt 540
gaaggaaata tactgggctt ccattcattc tgaaataccc cttatttaag atactctatt 600
atattaaata cagttccaaa acaaaagaaa tccaaagaac aaaaaactaa cccaatactt 660

```

ttatcacttg taattgtata ttacaccata ttgaaagata tatttttacga cttattagag	720
aacgattttt aaattggata tcaactctgtg catacaaata aaataaagtg attaaggttc	780
taacaaaaaa acaaaccaca acaccaaagg ctttttaagg gggggaggaa taaggaaagg	840
ggcccaaaaa agggac	856

<210> 4
 <211> 1580
 <212> DNA
 <213> Homo sapien

<400> 4	
gtcccttttt tgggccctt tccttatcc tccccctt aaaaagcctt tgggtgtgtg	60
gtttgttttt ttgttagaac cttaatcact ttattttatt ttgtatgcac aagagtata	120
tccaattaaa aatcgttctc taataagtct aaaatatatc tttcaatatg tgtaataac	180
aaattacaag tgataaaagt attgggttag tttttgttc tttgatttct tttgttttg	240
aactgtatth aatataatag agtatcttaa ataaggggta tttcagaatg aatgaagccc	300
agtatatthc cttcaaaagc atatttgagc tatcttgctt cattcttctt gatacttgg	360
attagcatac tttaatatth ttgcctggg gtaagtcac tccttggtt ttacttttt	420
cttattttat ttattttatt tttttagag acagggctt gctatgttc ccaggctaga	480
ctccacctcc tggcctcaag ggatcctctg ggcctggact cccaagccgc tgagattaga	540
gggtgtgtgag ccacctcac tgcctcttt gtggctctta tttgctatth cctaattact	600
aatgggaact ggtcacctac tcaactgatt ttggctgttc atgggtctc tttgaagtgc	660
ctatttaatg ccggcatcca ttctttgctt caggtgtttt tctcccttcc acattgactc	720
aataacagtc tttatatatc ctggatacta atcctttatc acttgctgca agtatcttct	780
tttactctgt ggcttgtht tttcacttca tttattgtt tttaaaccaa agcctaagtt	840
cttaatttht acgtacttga actgacattt tctaccttg cccctccca ccttagttc	900
ccagacacct cttatgatct ggggtcgagg agccgcctt cctggcggtc tcagctggg	960
cctggggagc gaaggcggcg ggcgctcgcg ggaggagctg cgcgattcgg atgctgggga	1020
ggtagaagtc gcggggccgc caggccgcg gggtaaggaa ggccgggagg ccgcgggggt	1080
ccacggcgcg gagggagccg caggcaccgg gcacagccct cgcctatcgc cgagaccgg	1140
caggcccagg agccagaggg cggcggcgtg agaggggaacc gcctccaaag gacgccctcg	1200
ccctcccgca ggcatagtcg caggcgccag tcccggctcg agccagctgg ggggtgctcc	1260
ggggagctga gccgggggag ggccgggccc cccaacggat caataggggg gtttctccca	1320

5

gggtgccgtt tctctggccc gcgacgccct acccgccgga gccgcccac cgcaagcccc 1380
 gccccgaagg cgggtgcagc caggaaggcg gggcctgggtg gcctctgggc gctggcgcca 1440
 agttcagagc cgcgccctgg gctggggcgt ggcggccgcg tctgcacttc cccccctgcy 1500
 cgcctctgga gagcccgga gagacgcacc ctcaggctcg ccaagaccga gaacaagcgg 1560
 gcgcgggcag cggagcccat 1580

<210> 5
 <211> 800
 <212> DNA
 <213> Homo sapien

<400> 5
 tggtcgcgcc cgaggtacaa aggctttgag gtccatggac tatacttgtc ccatttatca 60
 tcccagggtg tgctttgacc ctagggatac cctggctatt aagataaaaa gatttggtga 120
 cattaaaatt atgaatatgt cagtaataat ccagcacaca ttgaaatatt gacacagatt 180
 accataattt gtgcaacatc ttataaacia tgtcatttcc acagtagtct aaggcttcac 240
 cagcctggcc cactgtatct agactttagg ttcattttta ttaattatgc tttccttctc 300
 tgtatcattt gggaagttga taaatatcac ttccttagat accttcattc agtgatata 360
 ctggctttta caattaaatt ggaaaaggta agtttctctt tgggtgggtg agagttggac 420
 catcaattct aatctacaaa aggaaattca tgatttcact ctgacgccta ggatctagcc 480
 aaggctggtc tgcagtatca gatgtccaaa ctcactctact attagccata ttttgtagt 540
 cgtttgctca aactttgtca aaaatgcctt tgccatgatt ttgttgctat ctggatttca 600
 aacatggaca gttaggaaga tgtgcattga agtaggaaaa ttttgttcag catctgctgt 660
 tattttattt ttaccacttc aaaaatggcc actgtctttt taacaaacac caacgacaac 720
 aacacacaaa acaaaaaaaaa acacctgcy gcttaccctg gccctccttt tccctgttga 780
 attgtttccc cccaatcac 800

<210> 6
 <211> 956
 <212> DNA
 <213> Homo sapien

<400> 6
 atttataagg cccttcaaatt ttgtggcttc ctttctcata cttctcaagt ataataaag 60
 ggggagaaaa accccaccat caacacaaaa gaaggctata aagactgtgc accttttaac 120
 aagtcaattt gtagtcagtc cctgggcctg tctttttttt tttttaattt tgaagctacc 180

6

```

tgaggtttag aattccttca gccctagctg cttttattct gctttttatt taaacaaaaa 240
gagggggagg atctgaagga aactagtttt ctgtacaaag gctttgaggt ccatggacta 300
tacttgcccc atttatcatc ccagggtggtg ctttgaccct gccataccct ggctattaag 360
ataaaaagat ttgtggacat taaaattatg aatatgtcag taataatcca gcacacattg 420
aaatattgac acagattacc ataatttgtg caacatctta taaacaatgt catttccata 480
gtagtctaag gcttcaccag cctggcccac tgtatctaga ctttaggttc attttaataa 540
ttatgctttc cttctctgta tcatttggga agttgataaa tatcacttcc ttagatacct 600
tcattcagtg atatatctgg cttttacaat taaattggaa aaggtaagtt tctctttggt 660
gggttgagag ttggaccatc aattctaata taaaaagga aattcatgat ttactctga 720
cgcctaggat ctagccaagg ctggctctgca gtatcagatg tccaaactca tctactatta 780
gccatatttt gtgagtcgtt tgtctaaact ttgtcaaaaa tgcctttgcc atgattttgt 840
tgctatctgg atttcaaaca tggacagtta ggaagatgtg cattgaagta ggaaaaattt 900
gttcagattt gctgttattt attttttaaa ttaaaaatgg aaatgtaaaa aaaaaa 956

```

```

<210> 7
<211> 489
<212> DNA
<213> Homo sapien

```

```

<400> 7
actatgtggt aacataatcc caccttctta gagctttggt ccttctgaag gtgtatagat 60
acagcttgtc ttgaaatgtc tttctccaca taatgaagca tgctgaatgc tgggaatctg 120
gagcagcagc cctgggagcc ctgagttttg aagtgttttg gtttgcttca aagggttagaa 180
gaacttgata tgtatggcaa acaactttag aatactagtt actcactaac atgaggcggg 240
taatgttgct ctagattcta tattccagta aagccagctt ttcttattat tggagtaggc 300
aaatgaatgg cattagaatt agtgggtggc ttgtaagttg tagttatagg cactttacca 360
cttctgcca ttagcaggca tccttgtttt ttcttctttt ccctctttgt tccttctttt 420
ccctttctcc ttatacattt tctttctcta ctttaattct ccttcctcct tactgtagat 480
cccaagctt 489

```

```

<210> 8
<211> 3190
<212> DNA
<213> Homo sapien

```

```

<400> 8
ctctcattag cctgttcaga gtcttggggg aaattgagat ttttgagatt ttttttaaaa 60

```

actcaaatat tttactagtt tgcctgccat tttatttctt ttacaaagca gaagcatata 120
 ccaattttatc acagtatttt agtaaatact gcaacattca tccttaaagc ttcaccaaga 180
 aaagcatctt tgtagtagtg ctggaaaact attcagaata tacagataaa aatgctgttc 240
 ttttaattgct tacattgctt cttcccataa aaagcaaaaa ggaatcagtg cttgctattg 300
 ctcttttctt tgaagttgta acaattgata catatattat gagttgactg gtcgattctg 360
 tacctggccc atccttttaga atgttcttgt catgtagcag tcctacgtac tcttttcatg 420
 agcagtcctgt gatctcactc tgtgagttca gctattactc gctcgtggga gcttaatctt 480
 ttcaaaatga agttgattta aaaagtcttc aggagagta atcatgttag aggtggtatt 540
 cgatggaaga aagtttagag agttaggagt gggggtagaa ttctagaatt tataagagtc 600
 caggaagcat agcagtcagg ggcaaaaatt agcgtaatat ggagtaggca atagaggagc 660
 tactggagtc agaagtcact gcagagtga acataggaag atggactcct agcttacatg 720
 agattccctg cagctgtaat atagacaatt cccacatggc tgttctacac agaattacct 780
 gctaagattt tttgtttatt tttgtttgag tggatttttc actccaattg tataatggaa 840
 atcagtgagg aaataggggt taccttatat tcatgagttc tagtttctac tgttctgcta 900
 tgtgtttcta agcaagagca aaggatactt catacttttt tcgttatatg attgatcttc 960
 aaattgggat ttaccttttt caatatgttt taaagtagtc ttattcctct tttgatttgt 1020
 taaacaagca ttttagttca gctattgaat agccttccaa aaaattaatt cagccttgca 1080
 ggtaagtacc atactaagac ttttaaccaa tagtttttaa tcattctgcc tttattccaa 1140
 actgtaaatc tgtacacata agataaaaca tactaagtat tgcataaatt gttaacgtta 1200
 cagtaaattg ttatctgcag ggctgacaga cataatgttg gtgggcaact gtgatcctat 1260
 acatacatat atgcaaaagg ggattttaaa agtgcagatt atagagtaga ttgacaaatt 1320
 ttattttata ttcagttgtc ctctctgctt ccatctgtgt tgctctctta gttgagagag 1380
 agttagccat ttgacgattt taagtcagtg ggaacttatt tttagttact caataaaatt 1440
 aatattttat ttgtatttta acttacagag taggttggtta ataacagctg aactgtgtaa 1500
 cattgttgct tcaaattgaa gtttatatta tgaacattca gaatcaatgc tcatgtagca 1560
 gcatattatt gagctatttt gagtttgaaa tgtggagaaa cgctaaacca tgtactatgt 1620
 gttaacataa tcccaccttc tttagagcttt gttccttctg aaggtgtata gatacagctt 1680
 gtcttgaaat gtctttctcc acataatgaa gcatgctgaa tgctgggaat ctggagcagc 1740
 agccctggga gccctgagtt ttgaagtgtt ttggtttgct tcaaagggtta gaagaacttg 1800

8

atatgtatgg caaacaactt tagaatacta gttactcact aacatgaggc gggtaatgtt 1860
 gctctagatt ctatattcca gtaaagccag cttttcttat tattggagta ggcaaatgaa 1920
 tggcattaga attagtgggt ggcttgaag ttgtagtat aggcacttta ccacttcttg 1980
 ccattagcag gcacacctgt tttttcttct tttccctctt tgttccctct tttccctttc 2040
 tccttataca ttttctttct ctactttaat tctcttctct ccttactgta gatcccaagc 2100
 ttctagctta ggtttgcaag tcatattgct tggccctcca cattcactga gaggtgaaga 2160
 taggctgacc ccctgtcctc ttacatttga gggatcatag actgctgtgt gaattctgga 2220
 aagtctcagg tccctaccag ggcactgaat ggcttctcaa tggctgtaga gacagtacag 2280
 ttttccaaag cagcctaatt catctggaca gctaccaggc actttggaaa gttgggtcag 2340
 ttactactat gaggccataa tatatttgct ggtattaaaa ttcttcagaa ttggaattac 2400
 tatttgaaat aatatttttg ttgacttaag ttttgagaga caattctaaa attgatctag 2460
 agactcattc aatagcaatg tgacctttta aatacttaca ttaagtataa ctgccagtag 2520
 attaaatcat atatatatat atatatatat atatatatgt aagagcttcc tctatttact 2580
 actgttgaac ttcagtaatt tttagaggct aaataatggt cagaatgttt ttaagtgtgc 2640
 tcttttatta catgcttgtg cagggtttgt aattcagtag agaaaagttt aacctgtac 2700
 atttttgtat gtaaaaagtc ttttaagtag tcttatcctt atttaaataa acagaataaa 2760
 attaccttga gtaggtctgt tattcttatt aaaatggaaa aatgctctgt aatgacttga 2820
 tctgttttta tttagtgaa caattttgga aagtattctt tatagtacaa ctttctatac 2880
 ctggattgat taagatcaga tgtgattcga gtagtccagc catatcttgt agcccttctt 2940
 tgaatgagag ggtggctgga gtggtctggt gctgggatat cacggtgcta cagagcctga 3000
 catgttgact gtcactacat gttgagggat ggaaatagaa gtctctgaac ttcccatgta 3060
 atattaaagc tcttaacaaa atgagacaaa ctagagattc agttgagaga ttttatgtta 3120
 gagtgatctg aaaaaaagtt aatttctaaa ctgctatctt aatattatta tatttggaga 3180
 ctgatgctgt 3190

<210> 9
 <211> 672
 <212> DNA
 <213> Homo sapien

<400> 9
 ggtcgcggcc gaggtactat tgctctggct cctggccctc tccttgctat gggctctacc 60
 ctcaagtcgc tctgtgattc aaagatgaac tgccaatcaa atgttctctt aatgaaagat 120

9

```

ccaatcactc tacagcatgt gtgtattcaa agaacctatc taagactttc ttttggtcac 180
gggtgggaggc tgttgctgaa aacataccag agccatttgt ggaggtcagc tgacaggccg 240
catgaccttg gcaatggact actggtcacg tgggactgct taggactgtg caatggaact 300
tgggggcaaa actgatggag acagccaatg ggccttaaact ccagcaggca aagacagagt 360
aagttcttat ttgtgtagcc cagggcttat caaagtgtgg ttcttggacc acgtgcatca 420
gtatcagctg taagtatttg gcaaaatgca gattcccggg ccctgcacca aacagattga 480
ctttgaatct ctgggggttg ggctaaaaaa aaagaaaaaa aaaccctaca ttttaaacia 540
gctcttcaga tgacccttgt gtaagtttga gagcatctgc tggaaaacca ctagaatttg 600
caaacggcac tcaaaatact ccagccagtc cactagccaa agaccagatc tgagaccgga 660
tgggaaatta tc 672

```

```

<210> 10
<211> 997
<212> DNA
<213> Homo sapien

```

```

<400> 10
ggtcgaggcc gaggtactat tgetctggct cctggccctc tccttgctat gggtcttacc 60
ctcaagtcgc tctgtgattc aaagatgaac tgccaatcaa atgttcctct aatgaaagat 120
ccaatcactc tacagcatgt gtgtattcaa agaacctatc taagactttc ttttggtcac 180
gggtgggaggc tgttgctgaa aacataccag agccatttgt ggaggtcagc tgacaggccg 240
catgaccttg gcaatggact actggtcacg tgggactgct taggactgtg caatggaact 300
tgggggcaaa actgatggag acagccaatg ggccttaaact ccagcaggca aagacagagt 360
aagttcttat ttgtgtagcc cagggcttat caaagtgtgg ttcttggacc acgtgcatca 420
gtatcagctg taagtatttg gcaaaatgca gattcccggg ccctgcacca aacagattga 480
ctttgaatct ctgggggttg ggctaaaaaa aaagaaaaaa aaaccctaca ttttaaacia 540
gctcttcaga tgacccttgt gtaagtttga gagcatctgc tggaaaacca ctagaatttg 600
caaacggcca cctcaaaata ctccagccag tcccactaag ccaaagactt tcttttggtc 660
atgggtgggag gctgttgctg aaaacatacc agagccatt gtggaggtca gctgacaggc 720
cgcatgacct tggcaatgga ctactggta tctgggactg cttaggactg tgcaatggaa 780
cttgggggca aaactgatgg agacagccaa tgggccttaa atccagcagg caaagacaga 840
gtaagttctt atttgtgtag ccagggctt atcaaagtgt ggttcttgga ccacgtgcat 900
cagtatcagc tgtaagtatt tggcaaatg cagattcccg ggcctgcac caaacagatt 960

```


10

gactttgaat ctctgggggt tgggctaaaa aaaaaaa 997

<210> 11
 <211> 696
 <212> DNA
 <213> Homo sapien

<400> 11
 gccgccggg caggtacaaa tgggtgcccatt gccattcatt tgactgtggg tggccctcta 60
 gtctagggct ctcttagtga atgggtgtgg aaatatgatt tttctaagtt ccttcctttt 120
 ccttttgata gatgagtttg agatgatgga gtaggagtga ggccctcagg cacttctggg 180
 aaagacattc cacctgcaag cagcattttg agtaaagcac tgctgtgggt tgccgattta 240
 tgggtccattt aatgttaggc taaagcacct ttaatcattt ttgttgtttt aagataatgt 300
 atttgtgaag tggataaaca ctggaaatag ggtgcttctt ctggaaagtt cagtgtaaaa 360
 cactaacaag gctttggcgg gtttatctgg ctttataaac aagtctgaaa aatggatgaa 420
 agctaaatat ataaagcagt tggttgtcta tcttttatca ttttttactc agatctgtat 480
 ttaacactta tttatttggt agtttttaca ttcaaaagaa actacacttg gaactttggc 540
 taacattgta ggatattttt taattgttcc tacattttta agcatgattc atcatttttg 600
 taacttagat catttttaat ggtcttttct ttcaataacc agttacatca tgttttggga 660
 actctttggg tccatataag gtgaattggg gcaaaa 696

<210> 12
 <211> 3233
 <212> DNA
 <213> Homo sapien

<400> 12
 aacggtccta aggtagcgag agaatactac caggtgctag tttttccagt attgacttct 60
 gattactatt tccttttctc atcttttagtt tttcaagatt tgctttacca aaatagtaaa 120
 gcctttatca tcagcttata ttgaataatg ttgtaattgg tttcaatcaa agtttctcct 180
 caggtacttg gggggcccta gccttctaag gaactcccag gcacctactt aacaaggcca 240
 gctacacact cagtatgtga taagcccat gatggatgca ggtagaatt caaagacctg 300
 gttggagtcc tagatgtgga gacaggatca tcaggtcaca cttgttagat gactaacact 360
 atcagtagaa gctcttgaga gattttccta acgcagcaag atttctgtga gtagaggat 420
 cctgggaggt atcctgggag gcagcctatt gacttgacca agtaagctga tcagggtggc 480
 tcctctaccc actaaagaaa tgtgtaaaaa ctagcaataa ttgctttatc ttaaactcct 540
 ggacatactc agttcctcca ttccactggt ctattgcaa tacctttggt gttttcttca 600

cactcctctt ggcagcaaat gtctgaaagt atttcaattg tgtaatgtta aggagttttt 660
 tcatagcttc agaaaagagg gcagcaaata tgaagcctta agttcaaaat aagtcattct 720
 acctagaaat acagacccca gagcacattg catgaaaata cctgtactct gcagttcctc 780
 aaagcagtat tcttcctgaa aagccaaaca ccacacctat tttcctattt gctaagaatc 840
 agaataagca cgttgtaaat agtatccaaa gcagattcta aaatgacata gtaagaagcc 900
 agattcaaat tgtaacccaa gaagacaata gaaatccac tttacccac tgtcatcagt 960
 tagaacaccc ttgcaaaaac tgtaaccact taagcaattc atctgatccc agaagatcat 1020
 accttctttt gaaagtatag gacagatata agtgggaaac gtggcgcttc tgagcaacac 1080
 aggataaatg taggagggcc ttaaaaaata aatctcaatt catacactgg agcagcaaaa 1140
 aactgagcag gaaaggaaac agaataccaaa gtcatttttc atatagctgt tgtcaaatag 1200
 tataaccttg gtgtcttctt tgagttgcct ggacagtatt tatgaaacaa aaaactaaat 1260
 gccccccatt tggggacggg gggaggggtt cagacctcta acctggattc agagccttag 1320
 aggccgagag ggaatctgga atctggtatt actgagatcc taggtaaaag aaccagcctg 1380
 gcagtcttcc ccacctcatt ggtccgtgct tttattttta aacccaaaaa aaaaaaaaaa 1440
 acacaccctc ttatgtagga atttcccttt tacaataaat ttgacctggg agaaataaac 1500
 ttgcctgcct gctcttaaat gccagacagt tggaagcaaa tgccgaggga aagggtgcca 1560
 gagccatgct tgataggact ttgaatattt tctccttaat taaagtacgt tgcttgattt 1620
 tagactataa gatgctatgg aggtctatcc catgccatgc caatgtgaat tgctttgctt 1680
 cagtaacaat cagaagacca gtccaacaga aaataacttg tcataattcc accttagatt 1740
 ctagacctct catacctgca gtgtacagaa tatgtacatg ttccaatgga attcactatt 1800
 tttggcttta gtgtcaaaga gattgggtctt acaaggttca tctgatttcc cataacaagt 1860
 aaattttata atcctatgat tctaaattca atccccaata tagattctaa gcatcaaadc 1920
 aaaatcacag acaaaggga actggctgag aggggtctta gttatttcaa atccatgacc 1980
 aaagtgtcca aagacatgaa actcttatac ctgctgagca tttcacttta ctatacaaaa 2040
 tgtcagctac ccagttgcat cctgtgacat gatcagactg tcaatgtgga ccagtggcca 2100
 ggagcatatt tatgggcat ttctgttcat cattctttac agagcattga ggtttccac 2160
 tgaaacagct tctttagtca gacgtctata gattttacat aaatttacat ttaaatgcat 2220
 taagttgat ggccaattg agcatctgaa tgaatatagt gggggttggt ggtggtgcaa 2280
 attctgctgg ctttatgtta tggttttctt cgtgtttttt cttggttttg tctggcttct 2340

12

```

tctggcaagt gccctaaaag actggaacac tgtataaagt catagacata gaaccatatg 2400
ggaaagccca gatgaaaaaa tggaagaata aaatcaagtt gtcaaagttc cagcaacagc 2460
cctgacttct tcaggaatcc aagcaaattg aaagccaaga caaatgtac aaatggtgcc 2520
catgccattc atttgactgt ggggtggcct ctagtctagg gctctcttag tgaatggttg 2580
tggaaatatg atttttctaa gtcccttctt tttccttttg atagatgagt ttgagatgat 2640
ggagtaggag tggggccctc aggcacttct ggtaaagaca ttccacctgc aagcagcatt 2700
ttgagtaaag cactgctgtg gtttgccgat ttatggcca tttaatgtta ggctaaagca 2760
cctttaatca tttttgttgt tttaagataa tgtatttgtg aagtggataa aactggaaa 2820
tagggtgctt cttctggaaa gttcagtgtg aaacacaaac aaggctttgg cgggtttatc 2880
tggctttata aacaagtctg aaaaatggat gaaagctaaa tatataaagc agttggttgt 2940
ctatctttta tcatttttac tcagatctgt atttaacact tatttatttg ttagttttta 3000
cattcaaaag aaatacactt tgaacttttg ctaacattgt aggatatttt ttaattgttt 3060
ctacattttt aaagcatgat tcatcatttt tgtaaaacta gatcattttt taattgtctt 3120
ttcttttcca atagaccagt taccactcat gtgtctgcag aacctcttta ttgtattcct 3180
ataataaatg taaaatattt gtagcaaaaa aaaaaaaaaa aaaaaactcg gtc 3233

```

```

<210> 13
<211> 847
<212> DNA
<213> Homo sapien

```

```

<400> 13
actagactat gatatggact taccctcttg gtgccagccc tacaagctgc atgaccgtaa 60
tcagcctgtg acactacgac atgcgccact cagcctgtgc cactcttggc ctgagccttc 120
ggcctcttat gactgaggcg gacaactcac gctcaacaat ggcaaagact gctgcaccat 180
tgctagatca catcaatggg gccaccaact actctcttct tcacctacca acagtggact 240
gactggcttc tatgactcct atccacctca tctgctcccc tagtcacgaa ctacaagaca 300
ccacacaccc ccagccgcag cgogaatgcc aaaggttcag cacacacggg gcgcaaacaa 360
cccaatgcgc gacctatcat catccataca tatctggcgc tgctacgcgg acctacctac 420
gcatgtcgc tcctgactac tctgctccac tgatggctcc tcctaccaac acgcgcttgg 480
ctcctgccag cctgcagccc acacacctgc gccctccctt ggacgacac ccactcaccg 540
ccgactgccg aacgcaccag ctgacggaca cagctccact ccacccgcgc ccaatcacct 600
cgcgacgcc ccagcccttg ccctcccata cccacggcct acaccacag cgccacctc 660

```

13

aactgcgac cggctgcca tatctctcca cgtcccgccc tctgcccccc ctccacacac 720
 gcagcatcca cccagacaac ccacactgca cgaccctca tcacagcccc tcaaagccct 780
 ccaccaccac acaccagcag tcccccgccc caacacctaa taaacccac ccccgccgag 840
 cctcaca 847

<210> 14
 <211> 267
 <212> DNA
 <213> Homo sapien

<400> 14
 actgtagcag tgagctcaag tgttgggtgt atcagctcaa aacaccatgt gatgccaatc 60
 atctccacag gagcaatttg ttaccaga atctaagaat taaatcttag aatgtattaa 120
 tgttaaattt ctgtgagatt atattgtagt cacgtagaat gtcctgactt gtaggaatac 180
 ccactaagga aatcagaaat cacggtagag cgtcagcaat ttactctcaa atggttcaga 240
 gaaagaaagt tctttgtagt aaagctt 267

<210> 15
 <211> 824
 <212> DNA
 <213> Homo sapien

<400> 15
 tggtcgcggc cgaggtacag tgggtggaaa gggcatttgg agctcattag aatgagacat 60
 agttaagagt ccattctca tcagtgtatt ccagactgag gaagaaatgg ggcagcagtc 120
 aggagagctc gggattttga gtatagcaga atttaagtga aatggaaact acactcttta 180
 atttgttctt ccatggaatt gctttttcta tgcaagggt gagccccag gagagccctt 240
 gtgaagggaa tgctgatttg tgtgaatata ttaggtgag taggtatcta gtgaggatga 300
 gttgggagga tgagttgggt aaggcgtgcc cctctgacac tgttctgggt ataaaagaca 360
 acatcatgat gagatcttca tctgaataaa actatgccct ggccttttca gaaactgcgg 420
 gcactgcagg tcccacagtg tgatggagtc caagctggga tcactgcgag atgaggagtc 480
 agaggagtgg cttcggcagg catgggagct tcaggccctg agagagaaga cagaaattca 540
 gaaaacggag tggaaaagaa aaacgtgaag gaactgcatg aagagcacat ggctgagaag 600
 aaagagctac aggaggagaa ccagaggctc cagggcctcc ctgtctcagg atcagaagaa 660
 ggcaggctgc cagttccaag tgccagatca agcaccctcc gtgccagctg caggaacgag 720
 ctaggatcat tgcttcagg aggagagacc agccttggtc tcaaggaagg gcaccggacc 780
 aaaggggcaa gggggggaca cagagaggat ccacaggaaa aatg 824

<210> 16
 <211> 1998
 <212> DNA
 <213> Homo sapien

<400> 16
 ttacttttta ttaaagtata ggaatcaaac tggataccaa attctcagtg cagttgggta 60
 gtcattttgt taatgtatatt ttaaaaaatt ttaagggtaa aaaccagcaa gattccattt 120
 agaatgattg tgaaaaaac actgtaagac gtccattttc aaaatgcaaa aaatgattct 180
 tcctgatgtt aggaaggcca atgaaaacta tatgtatatt gaaaatatatt tttcctcaaa 240
 actttttccc tgatacagaa gtctgagagc ttactttggc tacattacct gactaaagag 300
 agaacttttag attagacctg gggtaaattg agatgccaaag ggagtgtcta gctaaatgga 360
 aataccacga aggtttgtaa tgccaagaaa gtcagctctg tgggtgtgtca taagcagcat 420
 atggaaacca ggagtgcacac attagaaccc gggagttgtg catacatctg atcaagcatt 480
 tgactctgaa aatattcagg gagtttagaa attgttaacc tttggaacca gtattgttta 540
 gcaatagttg agaagtgtta gcaagaatga tatcaagtta aacttaggca cttggagtta 600
 catccttaaa gccttaatag ggcttatgag ttttatacag tcatacagat agaaatatgt 660
 tgcttttgtt actacgacag tcatatatta taagaaataa tcaaagggtg gtggaaaggc 720
 atcctctctt tgatccaatt ttctgtacct ttttcttcag gtcacacaca ctgctagccc 780
 aggaatcact aggtattgat gactctactt caagctgtgc aaagcccttt ctggagacag 840
 ccaggatgtt ttgtagggag agaggcagga gtcctcaggg agtggcctgg ggtgagaccc 900
 tcccataggc tctaagagtc tcatttctcat cagtgtattc cagactgagg aagaaatggg 960
 gcagcagtca ggagagctcg ggatttatga gtatagcaga atttaagtga aatggaaact 1020
 aactcttta atttgttctt ccatggaatt gctttttcta tgcaagggtc gagccccag 1080
 gagagccctt gtagaaggga atgctgattt gtgtgaatat ctgtaggtga gtaggtatct 1140
 agtgaggatg agttgggagg atgagttggg taaggcgtgc ccctctgaca ctgattctgg 1200
 gataataaaa gacaacatca tgatgagatc ttcatcatga aataaaacta tgccctggcc 1260
 ttttcagaaa ctgcgggcac tgcaggtccc acagtgtgat ggagtccaag ctgggatcac 1320
 tgcgagatga ggagtgcagag gagtggcttc ggcaggcatg ggagcttcag gccctgagag 1380
 agaagacaga aattcagaaa acggagtggg aaagaaaaac gtgaagggaac tgcatgaaga 1440
 gcacatggct gagaagaaag agctacagga ggagaaccag aggtccagg gcctccctgt 1500
 ctcaggatca gaagaaggca ggctgcccag tcccagtgcc agatcagcac cctccgtgcc 1560

15

```

cagctgcagg aacaagctag gatcattgcc tcccaggagg agatgatcca gtccttgtct 1620
ctcaggaagg tggaggggat ccacaagggtg ccaaaggctg tggacacaga ggaggactct 1680
ccagaggaag agatggagga ctcccaggat gaacagcaca aggtgctggc agctctgagg 1740
cgtaacccca ctttgctgaa gcacttcaga ccaatcctgg aggacaccct ggaagagaag 1800
ctcgaaagca tggggataag gaaggatgca aagggaatct cgattcagac tctcagacac 1860
ctggaatccc tgctgagagt ccagcgggag cagaaggccc ggaagtttct tgaatttctg 1920
agtctgaggg gaaagcttgt caaggaagtc accagcagag cgaaggagag acaggagaat 1980
ggcgcgtgtg tgtcccag 1998

```

```

<210> 17
<211> 653
<212> DNA
<213> Homo sapien

```

```

<400> 17
gcgtggctgc cggcgaggta catggccgca agcagactaa cgcgttgacg ctaatttaat 60
gtattttacc tcacactaag gtcattgcttg ataaagacgt taaactcaac ttgtaaaatg 120
gtagcccagt gctatgcaca gagtgggtgc tcattagtgt tgaatgaaca catttgtaat 180
actacatgta attccatctg actgctttgt taaattttca gttagaacgt agatactgta 240
aagtccacac acacattaaa tcttgtttct ctgaaagtat ggcatcaaaa atactttag 300
aaaaaccttg tcacaactga tttgaatgtt cctattttct ttgactttga tattggcttg 360
taatgtctct tttcatcata tgtaatatca gtggaacagg cagcgtact caagtccaa 420
ggattcctca gtgatcagtg atccagggcc gttcatgaac cactgggctg gatttgactg 480
ttgagtgtgg cagttaatgc ccctcaagaa atcaaaggat gtcttataag tgtcttccaa 540
aaaaaagcaa atgctgaaat cctattggca aagtaaactg aaattggctg ctatatttta 600
tataatcatt tctgcaaata ccattttttg aatactaata ttgacatgg tta 653

```

```

<210> 18
<211> 1498
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (29)..(29)
<223> a, c, g or t

```

```

<400> 18

```

16

```

ttattcagtg catagcttta agccagtgn tggattcacta agtggacagc cagtctccca    60
gctctctgcc ttccccaaaa gggtcgtagt aggtcaccct tctacagcag ctaactagag    120
tcctaactaa tgggatccag cagggccatt tctccagagg gccagtatcc tattaggaga    180
ctcttggaat tcttaggttc tactcaagag tgggaaggacc aatcacctct gatattctgt    240
ggaaggtttg gggtaaatt ctgccctctg cattctgtgc aacttgtata aaagtcaagt    300
tagtattaca tgaattgggg tagggtagt gctttgaaaa aatggtgaac cggctgggag    360
cgggtggctca cgtctgtaat ccagcactt tgggaggccg aggcgggtgg atcatgaggt    420
caggagtctg agaccagcct ggccaacata tagttgcttt ggacctcatt tggaaaaata    480
atctgccttt ctaattgttc tgcataaggtt aaaatgataa atttacatc tttgaaccta    540
taccagattg tgggtgtcga gtgaccggca cactgtctga cacacagtca gtgtgcacgt    600
atttgtctga gtgaatgagg agacctgaga aaccgggtgac gtggcacagg gaagccagct    660
ggcccaggat tccgtacatg gccgcaagca gactaacgag ttgacgctaa tttaatgtat    720
tttacctcac actaagggtc tgcttgataa agacgttaaa ctcaacttgt aaaatggtag    780
cccagtgcta tgccaggagt ggggtgctcat tagtggtgaa tgaacacatt tgtaatacta    840
catgtaattc catctgactg ctttggttaa ttttcagtta gaacgtagat actgtaaagt    900
ccacacacac attaaatctt gttttcctga aagtatggca tcaaaaatac ttgtagaaaa    960
accttgtcac aactgatttg aatgttccta ttttcttga cttagatatt ggcttgtaat   1020
gtctcttttc atcatatgta atatcagtgg aacaggcagc gctactcaag tcctaaggat   1080
tcctcagtga tcagtgatcc agggccgttc atgaaccact gggctggatt tgactgttga   1140
gtgtggcagt taatgcccct caagaaatca aaggatgtct tataagtgtc ttccaaaaaa   1200
aagcaaatgc tgaaatccta ttggcaaagt aaactgaaat tggctgctat attttatata   1260
atcatttctg caaatcccat tttttgaata ctaatatattg acatgggttaa ttcttattaa   1320
tttggttgaa ttgtttattg ttaataatgc aaatagataa tttttaatta tccacaactg   1380
atgtgaatgt tcctattttc ttgactttg atattggctt gtaatgtctc ttttcatcat   1440
atgtaatatc agtggaaacag gcagcgtac tcaagtccca aggattcctc agtgatca    1498

```

<210> 19
<211> 171
<212> DNA
<213> Homo sapien

```

<400> 19
gccgcccggg caggtaactaa atgaaacata atatttattt ataaaagtgt gtagattgtt    60

```

17

aaatcacaaa aagagtgcta tgaccattat gtatgaggaa acaggccttt gacctctggg 120
 aaagcactgc tcaaaaagtc ttagtgccca tttttgaatt ccccaaacag a 171

<210> 20
 <211> 1820
 <212> DNA
 <213> Homo sapien

<400> 20
 gaatttcgta atccttgaaa ttgaaaaaaa aaaaattgtg tttttaaaga gtgaaaacag 60
 ttaggaaaca agtagaactg taatcagaac gctgcttcaa ttgatattaa aaataacctc 120
 aataataatg taaaggttcc tttctctgtg gtcagttata ttcttaggga tagcctagaa 180
 ggaatatatg gttagaacta agtgtgacta atcatctgag ccttgaagag aaacttcagt 240
 gcctctaaac agatcatcta caaaacaaca ggtaaacatt tatgccagtt aagtgggtca 300
 tgtttttgtt tcttgggttt ttcctaaatt taagtgaggt tgggcttacc ttgtagataa 360
 aattatgttt tctttttggt aaataactga atgtggataa cgtcaaatca gaatattttg 420
 tgaggaggtg atgatttgaa attaagctag atttctaggg aggtgttggg tccaatgaag 480
 gatgggaaga aattaaaata gtcttcaaac tcttctctta ttatatattg ttgctttgga 540
 aaagattggt cctatcctca atctaattta ttcactatta atattttaaa aacattcctg 600
 agatacttaa aaagaccac ttagcgatta tagttgctca atgaaacaag aatttattta 660
 tgcatagatt tttctctgta tcttaccaaa atccacttta cttagataac actaaattgt 720
 tottaaagac tactcatttc ccaataatcc tttatgattt caaaatttct agtggctcag 780
 aagtgaattt tattttattt gtctttcact tgaataaatg agaaccaga aattaataat 840
 gttgtttatt gcttactgtc aggactattt caaagactaa gaagagtttc ttctaacccc 900
 tccctctcaa aggaatccta aattattagt tgttagataa gttttgtatg ctaagatatt 960
 caggtttata gtttatgtat gtgtgtatat atataaatat atatgtatat ataaatatta 1020
 tgttcagttt ggagtctggc acaactccat tatgtggatt agagagtaag atattatgga 1080
 tgataaagta ctaaatgaaa cataatattt atttataaaa gtgtgtagat tgttaaatca 1140
 caaaaagagt gctatgacca ttatgtatga ggaaacaggc ctttgacctc ctggaaagca 1200
 ctgctcaaaa gtcattagtg ccatttttg aattcccaa acagaaagct tcttagaaaa 1260
 cacgctgaga ttttatttac aggaattct ttgacacatt tcaattgggtg ttagtcaag 1320
 tatagcaagt acttaataat gactgaattt catgttccta cagtcataca tattcattag 1380
 aagttttatg ttgttggctc gatctgattc tcttttgttt gtgggtggaa cggcactgag 1440

18

```

agaagtatag ttttttaaac ttgaacatgt tcagtagtta cattgcctta gaaaaccag 1500
acacatagca gtggaaatga aagaaatggc atcagaagtg acttaattta gcaattgtga 1560
ttcctcttgt aaaacaaaac aaaaaaaca tgccatattt tttggagaaa agtgggcaat 1620
atagggggtt cgttgtctgt ttcacaagaa gactcatttg ttcttttggg ggaaccagtg 1680
ccttacagat tttgtatata ctgtaattat tcaggactag ggaacaaaca attgtattgt 1740
atttgttaca gattgtatat ggctttgttt taacattccc ctaaataaaa tggcttcatt 1800
ctccccttgg aaaaaaaaaa 1820

```

```

<210> 21
<211> 611
<212> DNA
<213> Homo sapien

```

```

<400> 21
acccaagaca ggttctgaac catgcttatg cagagctttt agtattaaag agggagagta 60
aaagaagtgt cagagtocag atttatcact gaacccaata ctttcttact ccctggggca 120
tctcctaata ctgatcctaa aatgctcctg tttctgagaa gctagggcaa gacctgcctt 180
acaagacca gccatttgcc ttattcatag gatcataagc aagagaactg cattccagga 240
agaatgaagg aagaaggaag gctgctcaca gtagcagaag ggaggcaggg gccgagctgt 300
tcaagtcaca taaactctaa gaagcccagt cagcaaaata agtctatctt caattctagt 360
tgagtccagg actctgagga gctgtgattc acccagtttt tcttgcaaaa ggcacagtcg 420
ctaaactaaa ttggtgcaat tcacttcctc ttgcctctct gggttcattcc accaattgtg 480
gttgagaaac acatcttagg gaagaaacag tatctaagca ttaaagagaa aatatccac 540
tttgctcctc ttctcccta aaccgaact gctcttacat acaagataat ttttaaatca 600
taagattggg a 611

```

```

<210> 22
<211> 1885
<212> DNA
<213> Homo sapien

```

```

<400> 22
catgaacatt tgaggetgat tccctgtggg aaaaatcatt caaatctatt cactcatctg 60
atggctgttg cttgttttat tttttgtcca agagaggtgg tgttggaccg aggtagagaa 120
gacagtggta caccagaaat aacccaaagg attgccctt ctgtagaagg cccttagact 180
ccatgatgcc tttcagctgg gtgctatact tgcacctaac tctgggggct tcactttcta 240
tccctacaat tactcaaaca gataaaaggc tggatgttaa catgtagtta taaggggcgt 300

```

```

gatctaataag taaggaatat cacttcccac aagtccttca aacaagattt gtgaggagct 360
ggatttgtca gcatgtcaga tctttttgaa aaccagagag tagaatgtaa gcaataccct 420
tgtcgttaatt aaagaccaga ctccatcctt ataccactga tgcctctggt accttaatcc 480
ttaaaaatatt tagtgaccct tgccttctaa ttcttgacac aaatatataa tgaccatttt 540
agatcgggga actccctttc tttgaaggca gtttagggat tccacagatg ggctttgaac 600
ctgctaataag tgtatggaaa actgagttaa ttacaaatgt ctttttctca aaagtgcgtt 660
tctggtttct gtcagattca acaggtctgt acccaagaca ggttctgaac cactgcttat 720
gcagagcttt tagtattaaa gagggagagt aaaagaagtg tcagagtcca gatttatcac 780
tgaacccaat actttcttac tccctggggc atctcctaact actgaccta aaatgctcct 840
gtttctgaga agctagggca agacctgcct taaaaagact agccattttg ccttattcat 900
aggatcataa gcaagagaac tgcattccag gaagaatgaa ggaagaagga aggctgctca 960
cagtagcaga agggaggcag gggccaagct gttcaagtca cataaactct aagaagccca 1020
gtcagcaaaa taagtctatc ttcaattcta gttgagtcca ggactctgag gagctgtgat 1080
tcacccagtt tttcctgcaa aaggcacagt cgctaaacta aattgggtgca attcacttcc 1140
tcttgccctc ctgggttcatt ccaccaattg tgggtgagaa acacatctta gggaagaaac 1200
agtatctaag cattaaagag aaaatatccc actttgctcc tcttctccc taaccccgaa 1260
ctgctcttac atacaagata atttttaaat tataagattg gtattaacac aattattgat 1320
aaagagaaac aatgaccaac tcattagcta acgatgctag aatacttatg caagccctag 1380
agttaagggt cttagtgtgg acacctttcc agaattggaa ggaaaaccaa ccagaaagct 1440
tattaccctg catcagctga aaagctaagc cacagccatt tccctaaag ttctgtttct 1500
gggagaatga gatcttcaag aataactctt gcccttgat gaggcagtca aattcaaacc 1560
agtgatggca acaacttgca aacacgtaat tctgacctt attttccagc acttaaaaca 1620
aaatccccac tcaatacaaa gtttctatgt gcctcttgcc tgaaatcaac aagaaacagc 1680
tcacctgccc aaagactcct ctttctctgc cagggcaaaa gcaatctgca gccagagat 1740
tcaaacctag acatacacat ccacaattgt cttaatctca gcagtactgg gaaagctttg 1800
tactcaactt aacctgtcat ttaacctttt ccactagtcc tcccttaacc agactgcttc 1860
ctgtcttgaa acaaagaaaa aaccc 1885

```

<210> 23

<211> 494

<212> DNA

20

<213> Homo sapien

<400> 23

```

aagcgcgcgc attgtgatgg atctatatatt taccctgtgc tttctatatag ctgtcctcaa      60
agcgtaaaacc attccaaatt attttccaac gtagtggttat atgtgtgcag cagagctatt      120
tctgcctggg cattgccagt ccctgagcag gagggctctca cagtgaggtc tgcaggactg      180
taagtttggg gtctgactcc ctggccaccc tgtgtgggct gtgactgtct ctcagagcta      240
taccgccctt ttctctgctg gcagcccgac agagctggct caaccatcgg aggtcgcagg      300
ccaccagcca cgtggcacca ccatggcagc cttccagggt aaggtgagac acacaaggca      360
tgacctgggg gccgaccgga tccccatcac aaacgccaca aacaccataa acacaaccca      420
ccctgatcag agactaagca gagaaagcag ggagaggacc tagagttact cagtaatgac      480
tcaggaagga gacc                                     494

```

<210> 24

<211> 1692

<212> DNA

<213> Homo sapien

<400> 24

```

gtccccacc atggaagagg ccgggccac cactgcaag tcttctctga gccacgttct      60
caagtcttct ctgagccgcg ttctccagg tgtgctgctg gagtcaattg gcatttcctc      120
caagcctgaa agtgtagtca gattcagaat gggcttttct agattcccct gtaagatctt      180
tcccctgctc ctggcaggag caccacacca tgggaacccc agggcccacg cagctgcccg      240
ggactggggg accaggacgt ggcacttctc acatgggtgg aaagatgggt ttacagaatg      300
gtggcatgga gacgctgtgg cctggcaagg atcaatgggg tggcatctgg cattagccat      360
caggaagact taaggctgaa gggacattgg gcaggagct ctcagggtcg ctccaccgcg      420
cccagggtg acagcccata gtatcactta ggtgggact gagagtcacc tgggggagag      480
gagagaaggg gcccaacttc ccagcccct agtatcactt aggggtgggac tgagagtcac      540
ctgggggaga ggagagaagg gacccaactt cccagcccc tggcaccttc cctgcctttc      600
ccagtctttt accagagtca taagatggtc cttggctctg ggcaggcatg tggccctggg      660
gagctctggg gtcagaggtc aaggtgcttt gcatgtcagg caggcttgac ttttgcctgt      720
agaaagacta tagaaagatg gcaagctagg cctcttttct ggaaaagtgc caacagctga      780
taatttttagg aaataatgtt ttgaatgtga agtgtgactt tttagaataa aaagacagga      840
agctcttaga aactgcaaga ttctaaatct aagcaaaagg ctatatTTTA ccctgtgctt      900
ttctatagct gtccctaaag cgtaaaccat tccaaattat tttcaactag tgttatatgt      960

```

21

gttcagcaga gctatttctg cctgggcatt gccagtcctt gagcaggagg gtctcacagt 1020
 gaggtctgca ggactgtaag tttgggggtct gactccctgg ccaccctgtg tgggctgtga 1080
 ctgtctctca gagctatacc cggcctttct ctgctggcag cccgacagag ctggctcaac 1140
 catcgagggt cgcaggccac cagcccgtgg ccacactggc agccttccag gtgaagggtga 1200
 gacaaacaag gcatgacctg ggggccgccc ggctcccat cacaaacgcc acaaacacca 1260
 caaacacaac ccaccctgat cagagactaa gcagagaaag caggagagg acctagagtt 1320
 actcagtaat gactcaggaa ggagacccta agcttctacc acatgccaga ctctgtgccc 1380
 agtgcagcat aaacgtcctc agaaccagcc tgggccagc ctggccgagc cggacgttcc 1440
 tgggaaaggt tacaggagga gcaggccag gccacagca cttttagaag cccatgaaaa 1500
 tgtcttcatt tctcttcaaa tcacaaacaa aacgtgcaaa acccattctg gagtgcattc 1560
 tttcactggc gaccaacca gtcctaagat aaccttctta atagttctat ggaggaagct 1620
 gcaaaggcag aagtgactac aaccacaaa agtcatgatg gagccctgac gtgtgtgtac 1680
 acacacacta ca 1692

<210> 25
 <211> 430
 <212> DNA
 <213> Homo sapien

<400> 25
 acccagcgtc ccctggccag agccaccaga ggacagagct cccaatgagc ccagctgcta 60
 gaaaagaagg tggagtcca ggcagaagag ttcttcaggc tgaacggaaa tgattccaga 120
 gggaaatgca gatatgaaga aggagataaa gagctccaga aatggcaaata agcagggtga 180
 gcctacgga cttctctaac ggaagaaatt acctttaaaa cacacgtgca ggcttagagc 240
 aaaagaaacc gtgccataag gtgtgagtaa gtgaagtgcc tgtgacacct acagatcaga 300
 gaagcagagg cctccgggat ggcaaggcaa ggttgcgca tttcatatga agtgacacat 360
 catcataaaa gaatgcatta aatatacata tgtatgcatt caaattacac taacatcaca 420
 tatatccatt 430

<210> 26
 <211> 2603
 <212> DNA
 <213> Homo sapien

<400> 26
 tgtttggtcc agtgaatctg cccaccaaca cccgcctct caccatccac cagcccttgg 60

22

accctagca ctgagctcac agtgaaaggg aatatttgct tgtaaataga aatagacgct	120
ggttagaaac caactggaaa gaatctttcg ttgaatagga gttaaaaaac aaggaaatta	180
accctactct gggatatttct gaaactggca atctatgctt gtctaggacg gccagacta	240
accctaactcg ccccgctcatc aacacagcag cacagcgttt cctccaggag aaacaccaag	300
atctcacgtc ccatccacag gctgaggctg ctgctcctgc aggaacctgg tgcagtgtag	360
caattccaca tcctgaaatt gctcatcaaa actcctatta aagtgtcaaa cagtgaatag	420
ctaaaaatacc actttgcttg aacagtgaag aggttggaag gaaaacgtta actgtatcag	480
agaatatgga ctctaacaat acaggagctc aggttcattt tgaagtcaact cttcttccaa	540
cagattcaact aaggctcttt gtcaacacaa attgaaaacc gttaaaaaaa aaagtaatta	600
tgatgcttcc tgccctccat gaaaggacca catacagaca ccacgctcat atctgaggcc	660
ctggggtagc ctttaatggc ccagcagaat ggccagaacc gttagaggaa acatttaata	720
aagtctggag tcagagccct ggggtctag ctggattcct ggaggtgagg ccagaagcc	780
agcgggaggg aattggaggc cggaggtca aactgtccc acttccacca agggcccctc	840
ctccaacagc ttccaggctg ccaaagcccc tgcacacct ccagggtccc ctgggtccag	900
cctcatgctt cccataatga gtttttaaac cacaacgctg catcagggtga catctcttct	960
gcaggctgtg cgcgtctcca gggggaaggg ggctgtgtct ttgggacagt ttgtgctctc	1020
aatcacttga ctgctgacag gcacctcagc tgaatggtgt gatttatgca aagattgtgc	1080
tgaattattt aaagcattct ctatttaaag aacagagaat atttaattag cattctgctg	1140
tgtttaattg aagactcaca aatcaattaa aactgcttac cttttggcag ttcagtaact	1200
tcacagaaac ctcccaggaa atgcaccta ttacacagctg ggttcacct ataccagcg	1260
acctgtggcc agtgtggcgc tgtgattaga ggaggctcag cgccttcaga ggagcggcct	1320
ggctgtgccc acattagaga aaggcttcca tcgtcgttgg tcctctttct cacagggact	1380
ctggggtctt ggtgccggga gatgcaacc cctctggcag cccggcttca ttttagggac	1440
agtgactatg gagaaacca ggtctgacct attttctcca gaggggaggg agccacaggg	1500
aaaggcccct tgttgctctg ttggccctga gtgcctccca ggaaagggtca gagcacagac	1560
tcagccctgg gagggccgag agatcccgtt ggaccctgcc ctctcgaca ctctggacaa	1620
gatgcagaga gtggggctct ggcagcaaga tcccgaggga gtggggcctt ggagctcagg	1680
gccagaccga gggggtgctc attgctggct ctggcctaca gacacgttga cattggcacc	1740
acacgggcca actgaaacct taagagaaaa ccagcgtcc cctggccaga gccaccagag	1800
gacagagctc ccaatgagcc cagctgctag aaaagaaggt ggagtcacag gcagaagagt	1860

23

```

tcttcaggct gaatggaaat gattccagag ggaaatgcag atatgaagaa ggagataaag 1920
agctccagaa atggcaaata gcaggggtgag cctacgcgac ttctctaacg gaagaaatta 1980
cctttaaaac acacgtgcag gcttagagca aaagaaaccg tgccataagg tgtgagtaag 2040
tgaagtgcct gtgacacca cagatcagag aagcagaggc ctccgggatg gcaaggcaag 2100
gttgccgcat ttcatatgaa gtgcacaatc atcataaaag aatgcattaa atatacatat 2160
gtatgcattc aaattacact aacatcacat atatccatta gactttatca aaattaaaat 2220
cttctgttca tccacataaa acgatgtcac ttactgcaa aaatattctc aaatatttat 2280
ccaagtgtg agatccagaa taagtaacc ctaaaatttc ataataaac aacttggtga 2340
aacaacggtc aaaggatttg aacacttcgc caaatgatgg caaataaaca caagaaaaag 2400
tgctcgacag actcgagcac caggaagatg cgtcgtaa acacaacaaa accaccacac 2460
acaccacag tagccaaaat ctataaaact ggtggcacca aacgtgaggg aggatgtggc 2520
ccaccagca ctgttgctgt gcattcttgg tgagaacacc taagacgtcc cctcaatggg 2580
attagaaaac cacaaggcag gca 2603

```

```

<210> 27
<211> 614
<212> DNA
<213> Homo sapien

```

```

<400> 27
acatatattt aaaggaaga tggatacaat ttgtttttat tatataaatc taggtaagg 60
gaaatgcttt tgtcaacaaa aatacagtgt agtgaatttt atatttgcg cttgattagg 120
taaactgaaa actaacaata gaaatattat ttactgcat tgaaatacca tgaactttca 180
gacttggttag ttctacaagc agttgtgcta ccttaatttt gtgtttccag aaataaaaat 240
taaccttagt tatgctgtca tttttaacta ataaaaaag tataattcat aaaacttttg 300
gctttataag ataattataa aattatatat ttttttctgt ttttgtggg ttgggaaaac 360
atatttctat ttctattcac ttttcaaatg caggtctcat aatatgtgtc aatgatataa 420
gatgatggaa gacttctgta ataaaaacat atgtcattat cttcaatttg ttcaataaat 480
aatttaactg tgaacaaca aaaaaaaaaa ccaaaaaaaaa aaaaaaaaaa acaaaaaaacg 540
ggggggggcc accggggcaa agggggcccc gggggaaggg ttcccgggca aatccccata 600
agagcaaaaa acat 614

```

```

<210> 28
<211> 1134

```

24

<212> DNA

<213> Homo sapien

<400> 28

```

gcacgaggat tgggtcaaagt agtattctct tgaagttcta gtcaatttaa tttgatccaa      60
taagtttttc tgaatctcct ttttaagttc caagaaattc tattataaat aagtgtactt      120
ttaccaattc cattgtataa gcaaacagac accttttaga aaaggataag taatcatcaa      180
tttgtttttt ttaaaaaaaaa acaattttcca gactactaaa tttggcataa gaataattct      240
tttaaaatgc aacatacttt aattagtttt tttggatatat gcataagatg tgaactttcc      300
tattgatatc actttatatt aatagagatg tacatttctt tctatgccgt ggctagagca      360
aaagttaata atgattattht acacaattga ttttaattct taggatatgt ataattattg      420
atattatatc tgatttaaaa atactattcc atacattttt tttttcagga gataaaacat      480
agggaaaggt tttcatgtga attctttgta tcactttgaa gtacatatat ttaaaggga      540
gatggataca atttgttttt attatataaa tctaggtaag gtgaaatgct tttgtcaaca      600
aaaatacagt gtagtgaatt ttatatttgt cacttgatta ggtaaactga aaactaaca      660
tagaaatatt attttactgc attgaaatac catgaacttt cagacttggt agttctacaa      720
gcagttgtgc taccttaatt ttgtgtttcc agaaataaaa attaacctta gttatgctgt      780
catttttaac taataaaaaa agtataattc ataaaacttt tggctttata agataattat      840
aaaattatat atttttttct gtttttgtgg ggttgggaaa acattttctt atttctattc      900
actcttcaaa tgcaggtctc ataatatgtg tcaatgatat aagatgatgg aagactttgt      960
aataaaaaa tatgtcatta tcttcaattt gttcaataaa taatttaatg tgaaaaaaaa      1020
aaaaaaaaa ccaaaaaaaaa aaaaaaaaaa acaaaaaaacg gggggggggcc accgggggcaa      1080
agggggcccc gggggaaggg ttcccgggca aatccccata agagcaaaaa acat          1134

```

<210> 29

<211> 1139

<212> DNA

<213> Homo sapien

<400> 29

```

cgaggtagcc attataatta ctaaactgtg aagtcactat tattagtatc tgaccagcta      60
tacaaaacat catcaatttt acttttgaca caaaaggtag taaaaatcgc aaacgataaa      120
gaagacacta ctcatataaa gtcatgttta ctaatccagc accataattc cagtctcaga      180
acctcccatg cagattggaa agggattatg ggaacgaggt gagtatgtag gacatgtcgg      240
cgctagtaac atcaaattga cggccccata tttgctcgct tcacaagaca aaaaacacag      300

```

25

```

ggtcctccca aagtaagcag aagatgacat gacggcatgg agacgaaaaa caaaacgcta 360
gcgcgctaaa tcaatggta atagctgcaa aaccatctga tgacaactag ggtaacttcc 420
cgtgtcaacc aaaaattcac aaacaagtaa gcactacctg tagaacagac acgaagtcaac 480
gcaaacctac actttgagca cgctgacca gagatccgag cacactcccc gaccaccaa 540
cacacagcag gccacgcggt agagagaaca agaatacaaa ggacaagcga gtagctgtag 600
aagcgatgag agagagcgta cgtagagatg ggggaggaac accacgtagg agcagaactg 660
ctgcactgcg tgcacacgag acgcgaacag acgaaactac acgaagacaa aaggaaaagg 720
aaaggatggg accagagggg agagccaagc atgagagaca caccaaagg caccgcacg 780
ctgcatggcg aagcgagaag aacagcagat aaccacaaaa aaaagcacac acggtgggac 840
atacacacca gagggggagc atcagacaca gggacaaacc actaaagcag gagaactgg 900
cgcgaaagga ctgaactaaa cagcacaac acgcaacgag cagcgaacag ccgatcatag 960
gcgtgacacc cgactacagc aaaagaaacg gagaagttat cgacacaagg gatgacaagg 1020
aaacaggcta atggccaag gagaggaaca ataagatgga tgagcacagt agggcgaaca 1080
agggataacc caagtgaaga aacagtgaag aagaggaatg cacacaataa gaacgcaa 1139

```

```

<210> 30
<211> 235
<212> DNA
<213> Homo sapien

```

```

<400> 30
agtgtttgca acagcaccat ttgtcaaatt caaagatgct caaaagggtgt tccctacttt 60
gcatgagagg gagagctttg taacaggaaa ttgtataagg caaactctct attcattcct 120
aaggcctctg ttcattccta atgtttacat ggttctctac tctgaagggc accaactatg 180
acctcacctt cttaacatgg aaaatcaaaa tctaaatgaa ttaccattaa aagga 235

```

```

<210> 31
<211> 2171
<212> DNA
<213> Homo sapien

```

```

<400> 31
ctgcattttt ctgtcattct cttcatttgt ttttaagggtg aaaattttct tacagttgat 60
gcaaagtatc aackacttta ccctaccttc tcccctttta gatgggttct tcctgagttt 120
tggagtcttg tatgattatc agtattcccc tgtcaaaatc aaatctattc aggtttcttc 180
actgttgaga acacctaaat gtttttattt ttgagaagtg gggacagagt ctactatgt 240
caccagggt ggagtgaat ggcatgatct cagctcactg caaccttcgc ctctgggkt 300

```


caagcgattc tcctgcctcc gcctcctgag tagctgggat tataggcacg caccaccacg 360
cccagytwwt tttttgtatt tagtagagac agagtttcac catgttggcc aggctggctc 420
tgaactcctg accttgtgat ccaccacct cggcctcccg aggggtgctgg gattacaggc 480
atgagccacc acgcttggct aagaacacct aaatttttat gtttcttggc tcaaaaacca 540
gttccatttc taatgttgtc ctcaacaaga ggctaattgg tggtagagaca gcaggggagg 600
aggaagagct gtggtttcta acttggtcaa ctgaggaat aagcgatttt agctttatct 660
aaagtcttct gtccagcttt aagcactttg taagacatgg ctgaaagtag cttttctatc 720
agaattgcag atagtcatgt tgggctaaca gtcaattgga tatattcctt tacctcacat 780
gaccccgca actgtggagg tatctagagg tgaacaggc aagtgaatg gacacctctg 840
ctgtgaatgt tttagagaag gaaattcaaa aaatgttcta actgaaagca ctgttgaata 900
tgggtatcgg ctttcttttt cactttgact cttaacatta tcagtcaact tccacattaa 960
tgaaagttga ccatagttat ttccaaataa aaagaaacca actcttacca ggtcttggac 1020
tgtgatgtca tattattcag ttttatgctt gttcctgagc agaactcata agagtgcacat 1080
agtcagctgc tgacggcacc tcagccacgc cactcttact cagttcagtg ggtgtgcttg 1140
cgtggttaga tgtggtgcag ccctctctac gctcttctat ttttgggata tttcctatct 1200
aaccttcaaa tagcttccaa ttcttttttt cttggactgg cttcattctg aatttgtgct 1260
aaaataatct ttcataaaga gacctcagtt tatagcgtaa cagactacac aatgcactga 1320
tgttttcata atgtttaagg gaccactgc aagaagcttg ctgcctcctt ttaattgtat 1380
tcatttagat tttgattttc catgttaaga aggtgaggtc catgttgggtg cccttcagag 1440
tagagaacca tgtaaacatt aggaatgaac agaggcctta ggaatgaata gagagtttgc 1500
cttatacaat ttctgttac aaagctctcc ctctcatgca aagtagggaa caccttttga 1560
gcatctttga atttgacaaa tgggtgctgtt gcaaacactt ttttttgag atgaagtctc 1620
gcggttgtca cccgggctgg agtgagtggt cgtgatctcg gctcactgca acttccacct 1680
cctgggttcc agccagttct cctgcctcag cctcccaagt agctgagatt acaggcgcct 1740
gccacccac ctggctgatt tttgtaattt tagtagagac ggggtttcac catgttggcc 1800
aggctgatta actcctgacc tcagggtatc cacctttctc ggctcccaaa gtgcttggga 1860
ttacgggtgt gagccaccgt gccgggcctg caaacacatt ttaattgaca aactagggc 1920
tgttgtacaa aatagtaatg atagccatgg aagttttacc ttattctgtg agaagtgttc 1980
ttaaacttat taaagtgtct aaaactaagg ttagtgcttc taaaggaagt ggccggttct 2040

27

cctaagaagc aattatcact gtccctgact ttgtctgggt gggttggttc cccctgtccc 2100

cgattggctc tgggtgtcctg ctttgccgcg gttcttttaa gccagcgcgg gttatttttt 2160

gaaaacctcg g 2171

<210> 32

<211> 192

<212> DNA

<213> Homo sapien

<400> 32

gcgtggcgcg gccgaggtac tgtctctaca gccattgaga agccattcag tgccctggta 60

gggacctgag actttccaga attcacacag cagtctatga tccctcaa atgtaaggagac 120

agggggtcag cctatcttca cctctcagtg aatgtggagg gccaaagcaat atgacttgca 180

aacctaagct ag 192

<210> 33

<211> 2641

<212> DNA

<213> Homo sapien

<400> 33

tttttttttt ttcttttcca agttatttaa ttacagcat cagtctccaa atataataat 60

attaagatag cagtttagaa attaactttt ttccagatca ctctaacata aaatctctca 120

actgaatctc tagtttgtct ctttttgta agagctttta tattacatgg gaagttcaga 180

gacttctatt tccatccctc aacatgtagt gacagtcaac atgtcaggct ctgtagcacc 240

gtgatatccc agcaccagac cactccagcc accctctcat tcaaagaagg gctacaagat 300

atggctggac tactcgaatc acatctgatc ttaatcaatc caggtataga aagttgtact 360

ataaagaata ctttccaaaa ttgttctact aaataaaaac agatcaagtc attacagagc 420

atttttccat ttttaataaga ataacagacc tactcaaggt aattttattc tgtttattta 480

aataaggata agactactta aaagactttt tacatacaaa aatgtacaag gttaaacttt 540

tctgtactga attacaaaac ctgcacaagc atgtaataaa agagcacact taaaaacatt 600

ctgaccatta tttagcctct aaaaattact gaagttcaac agtagtaa atagaggaagct 660

cttacatata tatatatata tatatatata tatatgattt aatctactgg cagttttact 720

taatgtaagt atttaaaagg tcacattgct attgaatgag tctctagatc aattttagaa 780

ttgtctctca aaacttaagt caaccaa atattttcaa atagtaattc caattctgaa 840

gaattttaat accagcaa atattatggc ctcatagtag taactgaacc aactttccaa 900

agtgcctggg agctgtccag atgaattagg ctgctttgga aaactgtact gtctctacag 960

ccattgagaa gccattcagt gccctggtag ggacctgaga ctttccagaa ttcacacagc 1020
 agtctatgat ccctcaaag taagaggaca gggggtcagc ctatcttcac ctctcagtga 1080
 atgtggaggg ccaagcaata tgacttgcaa acctaagcta gaagcttggg atctacagta 1140
 aggaggaagg agaattaaag tagagaaaga aaatgtataa ggagaaaggg aaaagaagga 1200
 acaaagaggg aaaagaagaa aaaacaagga tgcctgctaa tggcaggaag tggtaaagtg 1260
 cctataacta caacttaca gccacccact aattctaag ccattcattt gcctactcca 1320
 ataataagaa aagctggctt tactggaata tagaatctag agcaacatta cccgcctcat 1380
 gttagtgagt aactagtatt ctaaagttgt ttgccatata tatcaagttc ttctaacctt 1440
 tgaagcaaac caaaacactt caaaactcag ggctcccagg gctgctgctc cagattccca 1500
 gcattcagca tgcttcatta tgtggagaaa gacatttcaa gacaagctgt atctatacac 1560
 cttcagaagg aacaaagctc taagaaggtg ggattatggt aacacatagt acatggttta 1620
 gcgtttctcc acatttcaaa ctcaaaatag ctcaataata tgctgctaca tgagcattga 1680
 ttctgaatgt tcataatata aacttcaatt tgaagcaaca atgttacaca gttcagctgt 1740
 tattaccaac ctactctgta agttaaaata caaataaaat attaatTTTA ttgagtaact 1800
 aaaaataagt tcccactgac ttaaaatcgt caaatggcta actctctctc aactaagaga 1860
 gcaacacaga tggaagcaga gaggacaact gaataataaa taaaatttgt caatctactc 1920
 tataatctgc acttttaaaa tccccttttg catatatgta tgtataggat cacagttgcc 1980
 caccaacatt atgtctgtca gccctgcaga taacaattta ctgtaacggt aacaatttat 2040
 gcaatactta gtatgtttta tcttatgtgt acagatttac agtttggaaat aaaggcagaa 2100
 tgattaaaaa ctattgggtt aaagtcttag tatggtactt acctgcaagg ctgaattaat 2160
 tttttggaag gctattcaat agctgaacta aaatgcttgt ttaacaaatc aaaagaggaa 2220
 taagactact ttaaaacata ttgaaaaagg taaatccaa tttgaagatc aatcatataa 2280
 cgaaaaaagt atgaagtatc ctttgctctt gcttagaaac acatagcaga acagtagaaa 2340
 ctagaactca tgaatataag gtaaacccta ttttccact gatttccatt atacaattgg 2400
 agtgaaaata ccactcaaac aaaaataaac aaaaaatctt agcaggtaat tctgtgtaga 2460
 acagccatgt gggaattgtc tatattacag ctgcaggga tctcatgtaa gctaggagtc 2520
 catcttccta tggtgcactc tgcagtgact tctgactccc agtagctcct ctattgccta 2580
 ctccatatta cgctaatttt tgccccctga ctgctatgct tcctgggact cttattaaat 2640
 t 2641

<210> 34
 <211> 434
 <212> DNA
 <213> Homo sapien

<400> 34
 atttccttat acacacaccg aatcagaata tactttcagt tctacaattt gacaatacac 60
 atagctgatt tatagcaagt gtgccatgaa ctgagggttt gtttagtttg tttttgcagg 120
 gctgccataa tgctgtcttc acgggacggg aaagaaagta tcacttgggc cgcatctaata 180
 atgaaatact gaaggtgggt gtagagaggg tgctagggct ttgaacagcg gcacttcctt 240
 tctgagagag agaaaacatc atgctcccc cgcgccgaac tcattttaca ggttgattgg 300
 gtgaacaatt cttggcaggc cctgagctag tctgggtatc ctgagtcaag agagaggccc 360
 tgccctctgag gtaaagtgtc tctcatctgc ctaagtttgc ttagaaaactt tggcttatga 420
 aagattaacc taag 434

<210> 35
 <211> 197
 <212> DNA
 <213> Homo sapien

<400> 35
 tctgagacaa tagggcatgg gtccctctaata tcactctgag cggcgcatgt gatggatagc 60
 ggcgcccggg cagggaaacc cctactggac cctgtgtgtc tgccagcctg gaggctttgt 120
 ctccagccct gcctttattc ctccctgcct ccacaccagc ctccccttgc ttctccttac 180
 agactatcca agaagtg 197

<210> 36
 <211> 3414
 <212> DNA
 <213> Homo sapien

<400> 36
 atgggggatt tcgcagcccc cgctgctgcc gcgaatggca gtagtatattg catcaacagt 60
 agcctgaaca gcagcctcgg cggggccggg atcgggtgtga ataatactcc caatagtact 120
 cccgctgctc cgagtagcaa tcaccgggca gccggtggat gcggcggtc cgggggcccc 180
 ggcgggcggtt cggcgccggt tcccaagcac agcaccgtgg tggagcggct ccgccagcgc 240
 atcgagggtt gccgtcggca ccacgtcaac tgcgagaaca ggtaccagca ggctcagggtg 300
 gagcagctgg agctggagcg ccgggacacc gtgagcctct accagcggac cctggagcag 360
 agggccaaga aatcggggcg cggcaccggc aaacagcagc acccgagcaa accccagcaa 420

30

gatgcggagg ctgcctcggc ggagcagagg aaccacacgc tgatcatgct acaagagact	480
gtgaaaagga agttggaagg agctcgatca ccacttaatg gagaccagca gaatgggtgct	540
tgtgatggga atttttctcc gactagcaaa cgaattcgaa aggacatttc tgcggggatg	600
gaagccatca acaatttgcc cagtaacatg ccactgcctt cagcttctcc tcttcaccaa	660
cttgacctga aaccttcttt gcccttgagc aacagtggaa ctcacactcc tgggcttcta	720
gaagatctaa gtaagaatgg taggctccct gagattaaac ttcctgtcaa cggttgagct	780
gacctggagg atagcttcac catcttgagc agcaaagacc tcaaacaaga acctctcgat	840
gaccctactt gcatagacac atcagaaaca tctctttcaa atcagaacaa gctgttctca	900
gacattaatc tgaatgatca ggagtggcaa gaattaatag atgaattggc caacacgggt	960
cctgaggatg acatacagga cctgttcaac gaagactttg aagagaagaa ggagccagaa	1020
ttctcgagc cagcaactga gacctcttc tcccaggaga gtgcgagcgt gaagagcgac	1080
ccctctcact ctcccttcgc acatgtctcc atgggatctc cccaggcgag gccttcttct	1140
tctggtcctc ccttttctac tgtctccacg gccactagtt taccttctgt tgccagcact	1200
ccgcagctc caaacctgc aagctcacca gcaaactgtg ctgtccagtc ccctcaaact	1260
ccaaaccaag ccacactcc aggccaaagct ccacctcggc ctggaaatgg ttatctcctg	1320
aatccggcag cagtgcagct ggccgggtca gcgtcagggc ctgtggctgt gccagctct	1380
gacatgtctc cagcagaaca gctcaaacag atggctgcac agcagcaaca aagggccaaa	1440
ctcatgcagc agaagcagca acagcaacag cagcagcagc agcagcagca gcagcagcag	1500
cagcaacagc agcagcagca gcagcaacag cactcaaact agacttcaa ttggtctccc	1560
ttaggacctc cctctagtcc atatggagca gcttttactg cagaaaaacc aaatagccca	1620
atgatgtacc cccaagcctt taacaaccaa aacctatag tgcctccaat ggcaacaac	1680
ctgcagaaga caacaatgaa taactacctc cctcagaatc acatgaatat gatcaatcag	1740
cagccaaata acttgggtac aaactcctta acaaacagc acaatattct gacttatggc	1800
aaactaaac ccctgaacca cttcaatgca gacctgagtc agaggatgac accaccagtg	1860
gccaacocca acaaaaacc cttgatgccg tatatccagc agcagcaaca gcagcagcaa	1920
cagcaacagc agcagcagca gcagcagcag ccgccacctc cacagctcca ggccccagg	1980
gcacacctga gcgaagacca gaaacgcctg cttctcatga agcagaaagg agtgatgaat	2040
cagcccatgg cttacgtgc acttccatcc cagggtcagg agcagcatcc agttggactt	2100
ccccgaacca caggcccat gcagtcctcc gtgccccag gctcaggtgg catggctctca	2160
ggagccagtc ccgcaggccc cggcttctctg ggagccagc cccaagcagc catcatgaag	2220

cagatgctca ttgatcagcg ggcccagttg atagagcagc agaagcaaca gttcctgcgg 2280
 gagcaaaggc agcagcagca gcagcagcag cagcagattt tggcggaaca gcagttgcag 2340
 caatcacatc taccocggca gcacctccag ccacagcgga atccataccc agtgcagcag 2400
 gtcaatcagt ttcaagggttc tcccaggat atagcagccg taagaagcca agcagccctc 2460
 cagagcatgc gaacgtcacg gctgatggca cagaacgcag gcatgatggg aataggaccc 2520
 tcccagaacc ctgggacgat ggccaccgca gctgcgcagt cggagatggg actggccctc 2580
 tatagcacca cgcctaccag ccaaccagga atgtacaata tgagcacagg catgacccaa 2640
 atgttgacgc atccaaacca aagtggcatg agcatcacac ataaccaagc ccagggaccg 2700
 aggcaacctg cctctgggca ggggggttga atgggtgagt gcttttgtca gagcatgctg 2760
 gtgaactcag ccattacca gcaacatcca cagatgaaag ggccagtagg ccaggccttg 2820
 cctaggcccc aagccctcc aaggctgcag agccttatgg gaacagtcca gcaaggagca 2880
 caaagctggc aacagaggag cttgcagggc atgcctggga ggactagtgg agaattggga 2940
 ccattcaaca atggcgccag ctacctctt caagctgggc agccgagact gaccaagcag 3000
 cacttccac agggactgag ccagtcagtc gtggatgcta acacgggcac agtgaggacc 3060
 ctcaaccag ctgccatggg tcggcagatg atgccatcgc tcccggggca gcaaggcacc 3120
 agccaggcga ggccaatggt catgtctggc ctgagccagg gagtcccagg catgccagcg 3180
 ttcagccagc cccagcaca gcagcagata cccagtggca gctttgtctc aagcagccag 3240
 agccaagcct atgagcggaa tgcccctcag gacgtgtcat acaattacag tggcgacgga 3300
 gctgggggtt ccttccctgg cctcccgac ggtgcagacc ttgtggactc catcatcaaa 3360
 ggcgggccag gggacgagtg gatgcaggag cttgatgaat tgtttggtaa cccc 3414

<210> 37
 <211> 678
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (310)..(611)
 <223> a, c, g, or t

<400> 37
 tcataatgct gtcgagcggc ccgcagtgtt gatggatcgg ccgccgggca ggtacctgct 60
 gtgtggcagg ctctgggctg ggggctttat tcagcttcct cagcctgctt cgacttcccg 120
 attagagagc taatgtgaat caccaaccct gtgatgcctc ttgagatgag agttcagatt 180

32

```

tccaagaag atctaagcag ttggtccaaa ttgtagttca ctagcaaatg acccagtgtc 240
gtccctgtgg tgtgtttatg acatgatgga agatgctgcc ttcaaaagtg tccacttgta 300
agaagatgtn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 600
nnnnnnnnnn nacacacaaa aaaaagggtgg gggaaccagg gcaagcggtc ccgggggaaa 660
tggtttccgc acattcca 678

```

```

<210> 38
<211> 461
<212> DNA
<213> Homo sapien

```

```

<400> 38
gtgcggcga ggtaccaact gacatttcag tttttctgtt tgaagtccaa tgtattagt 60
actctgtggc tgctctcttc acctgccctt tgtggcctgt ctacaattct aaatggattt 120
tgaactcaat gtcgtcgctt ctggtttctt gcatatacca atagcattac ctatgacttt 180
ttttttcttg agctattttc actgagctga gctaataaac taaaactgag ttatgtttaa 240
tatttgtatc aaatacataa aaggaatact gctttttcct tttgtggctc aaaggtagct 300
gcattttaaa atatttgtga aaataaaaac ttttgttatt agaaaaaaaa aaaaaaaaaa 360
aaaaaaaaaa ggcttggggg aaaccggggg ccaaaagcgg tgtcccgggg gggaattggg 420
ttctccggtc caaattcccc aaaaaaatcg agaagaaaag t 461

```

```

<210> 39
<211> 633
<212> DNA
<213> Homo sapien

```

```

<400> 39
caacaccatc tttttttttt tttttttttt ttgagacaga ttcttactct gcactccagc 60
ctgggtgacag agcgagattc catctcaaaa aaaaaaaaaa agtatgcacg taaaaatttc 120
ttaacctgtt atcaatgtct gagctacata attatctttc tagttggagt ttgttttagg 180
tgtgtaccaa ctgacatttc agtttttctg tttgaagtcc aatgtattag tgactctgtg 240
gctgctctct tcacctgcc cttgtggcct gtctacaatt ctaaatggat tttgaactca 300

```

33

```

atgtcgtcgc ttctggtttc ctgcatatac caatagcatt acctatgact ttttttttcc 360
tgagctatatt tctactgagct gagctaata gaactaaactg agttatgttt aatattttgta 420
tcaaatacat aaaaggaata ctgctttttc cttttgtggc tcaaaggtag ctgcatttta 480
aaatattttgt gaaaataaaa acttttggtta tttagaaaaa aaaaaaaaaa aaaaaaaaaa 540
aaggcttggg ggaaaccggg ggccaaaagc ggtgtcccg gggggaattg gtttctccgg 600
tccaaattcc ccaaaaaaat cgagaagaaa agt 633

```

<210> 40
 <211> 536
 <212> DNA
 <213> Homo sapien

```

<400> 40
ggggccgccc gggcaggtag ttgacagtgt tatctgtcac ttatttaaaa aaaaaacaca 60
aaaggaatgc tccacatttg acgtgtagtg ctataaaaca cagaatattt cattgtcttc 120
attagggtgaa atcgcaaaaa atatttcttt agaaacataa gcagaatctt aaagtatatt 180
ttcatataac ataatttgat attctgtatt actttcactg ttaaattctc agagtattat 240
ttggaacggc atgaaaaatt aaaatttcga tcatgtttta gagacagtgg agtgtaaattc 300
tgtggctaatt tctgttggtc gtttgtatta taaatgtaaa atagtattcc agctattgtg 360
caatatgtaa atagtgtaaa taaacacaag taataaatga agtgtttgtt ataaaaaaaa 420
aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gtggggggaa cccggggcca aaaggggttc 480
cgggggggaa attggtttcc ggccaaaaat ttccaacaat ttgggagaaa aaaggt 536

```

<210> 41
 <211> 1206
 <212> DNA
 <213> Homo sapien

```

<400> 41
gtactctccc aaatgcagcc taatcttagt aacctgaag tttatcattc tttaaaacta 60
aatagaatac caatggttta gatattccaa caaagaatgc tagaaacaaa tgtctaattc 120
cgattattag ctttaaccaac cctgtgaaca ctgagggttc agaactgccg gggttaattc 180
tgtggcctag actactgagg attctgatag cacatgtaag actaagcact cttcaagctg 240
taataaagca tccacatgta tctgtgatga ttttcattgc tttagcattg cagccatgta 300
acaactgcag aaagaaggta tttttaaaaa tacaatagac tacacttttt ggatcacaga 360
gaaatacaga tgactctga gactgcctat gtttataaac atgttgtgtc ccctaactga 420
agtgcagggt cttctggaat tgacattaag aagtgtggat agtcatatca cacgcaatgt 480

```


atttgttttc agcagtgagc agaccgtaca ggagcagcac accaggagcc atgagaagtg 540
 ccttggaac caacagggaa acagaactat ctttatacac atcccctcat ggacaagaga 600
 tttatttttg cagacagact cttccataag tcctttgagt tttgtatgtt gttgacagtt 660
 tgcagatata tattcgataa atcagtgtac ttgacagtgt tatctgtcac ttatttaaaa 720
 aaaaaacaca aaaggaatgc tccacatttg acgtgtagtg ctataaaaca cagaatattt 780
 cattgtcttc attaggtgaa atcgcaaaa atatttcttt agaaacataa gcagaatctt 840
 aaagtatatt ttcatataac ataatttgat attctgtatt actttcactg ttaaattctc 900
 agagtattat ttggaacggc atgaaaaatt aaaatttcga tcatgtttta gagacagtgg 960
 agtgtaaatc tgtggctaata tctgttggtc gtttgattta taaatgtaaa atagtattcc 1020
 agctattgtg caatatgtaa atagtgtaaa taaacacaag taataaatga agtgtttgtt 1080
 ataaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gtgggggggaa cccggggcca 1140
 aaaggggttc cggggggggaa attggtttcc gggccaaaat ttccaacaat ttgggagaaa 1200
 aaagggt 1206

<210> 42
 <211> 209
 <212> DNA
 <213> Homo sapien

<400> 42
 ccgggcagggt ggaacttagt gggcagcatt acgggcagcg ctaaggaacc atttaaagta 60
 agacaagtcc acacagctgt ggtgcttttc tacgagtctt gttccaactg ctgcataaca 120
 atagaatgtt ggaagcagga attagtttta aagtaagact tcagaagtgg aaacaaattt 180
 gatattttatt ttataatga tataatagc 209

<210> 43
 <211> 706
 <212> DNA
 <213> Homo sapien

<400> 43
 gaaccctcca aaacatctga aaagcaaatt tgggggggatg aggaagtgag atgatgactt 60
 gattctcctt ctaggaagaa tagaggaacc cttctggcaa aatttcaagc atctacaaga 120
 ggaggttttc cagaaaataa agacactggc tcagctctca aaggatgttc aggatgtcat 180
 gttctacagt atcctggcca tgctcagaga cagaggggct ctacaggacc tgatgaacat 240
 gctggaattg gacagctcag gtcatttga tggccctggt ggtgccatcc taaagaaact 300

35

tcaacaggat tcaaaccatg catggtttaa cccaaaggac cccattcttt atctccttga 360
agccataatg gtgctgagtg acttccaaca cgatttgctg gcctgttcca tggagaagag 420
gatcctgctt cagcaacagg agctggtaag gagcatcctg gagccaaact tcagataccc 480
ctggagcatt cccttcaccc tcaaacctga gtcctcgcc cactccaga gtgagggttt 540
ggcatcacct atggctgctg gaggagtgtg gccttaggac ggagctggat aaccccaggt 600
caacctggga tgtagaagca aagatgccct gtctgtcctc tatgggactc tctcgttgct 660
gagcagtggg tgaaggctaa gcctccctga tgggagcagt cagaaa 706

<210> 44
<211> 1298
<212> DNA
<213> Homo sapien

<400> 44
atatgaagtt aaaaccagag ctatttctga cacagcaatt tttgagcggg catttgccaa 60
aatacgaaca agttcacatc ctcccagtag gtgagtgtga gtttgctgga ggtgggggtg 120
gggatcccat cctgcacaca tggggtaagt agggcagatt gccctgcct cgcctttgcc 180
accaccgcc tagggcctgg cgtttgtgta tgtggaatgg gaagggtcca gaaagctgag 240
aacatggagg atgaatggga atgggggcag gaagaagtgt agtaagaggg aggaggtggt 300
aggagagcag aaccctccaa aacatctgaa aagcaaattt ggggggatga ggaagtgaga 360
tgatgacttg attctccttc taggaagaat agaggaaccc ttctggcaaa atttcaagca 420
tctacaagag gaggttttcc agaaaataaa gacactggct cagctctcaa aggatgttca 480
ggatgtcatg ttctacagta tcctggccat gtcagagac agaggggctc tacaggacct 540
gatgaacatg ctggaattgg acagctcagg tcatttggat ggccctggtg gtgccatcct 600
aaagaaactt caacaggatt caaaccatgc atggtttaac ccaaaggacc ccattcttta 660
tctccttgaa gccataatgg tgctgagtga ctccaacac gatttgctgg cctgttccat 720
ggagaagagg atcctgcttc agcaacagga gctggtaagg agcatcctgg agccaaactt 780
cagatacccc tggagcattc ccttcaccct caaacctgag ctctcgccc cactccagag 840
tgagggtttg gccatcacct atggcctgct ggaggagtgt ggccttagga cggagctgga 900
taacccaggg tcaacctggg atgtagaagc aaagatgccc ctgtctgccc tctatgggac 960
tctctcattg ctgcagcagc tggctgaggc ctaagccctc cctgatgggc agtcagtcca 1020
gagatgctgg ccctcgccca gtctatgctg tgagtgtcct tatgggtgca agagataggg 1080
ctgtgcctct ctgcgtttcc aggtggagta gagacagtaa tgggtagaga ctttaggaaa 1140

36

tggttttgggg tggtggaata ctctatatat tgacaagagt ttatatattg acaagagttt 1200
 atatatattgt caaaactcct caaatagtat gttaaagacg taagcgtttc actatgtata 1260
 aattttactt caaaataata aaaacaata ctgactct 1298

<210> 45
 <211> 531
 <212> DNA
 <213> Homo sapien

<400> 45
 acaacattca aacaaccagt ggtgaggttg taaatcaaat gagagaggag gaactgatcc 60
 gggtagcagg aacacatttc caagtaaaat ttgcaacaga gcatgttgag atcatggttt 120
 taatttatga atggcattat tatctttaaa ctattatttt ccaagctcat atatggcctt 180
 tttgaagggt ttccgaatgt tacatttgat ttttaagatct aatccaaaat gaaatataga 240
 atgtgcttag tttctataa aaatgccaat gactatctct taaattagtc aaggaaagac 300
 aaattaccaa aattcaaact tatttgaatt atttttaagt gattccaggc aataaataca 360
 tagaaccat ggaaagtttt agcttcaaat cacaaaattg caaaaaaaaa aaatggtaaa 420
 tggctaataca taaggggggt tatggaaaat attgggtcac ctttaattata ggtttaaatg 480
 ccacaaacaa tataataata gttttaactt acttttttcg attactaagc a 531

<210> 46
 <211> 469
 <212> DNA
 <213> Homo sapien

<400> 46
 taacgccatc agctcgctgc ttaaagccgt gtttgcgtct catTTTTctca aagaaatctg 60
 ctttagtttg agattacagt ttatcaaag ttaaggcttt gaccccaaaa tctgggtcca 120
 gaaagacagg aaggccagct aagaggaggt ttccagagtg cgtagaaagg ctgctctgtg 180
 cttcggcatt tgttctggaa gtgcttcttc gggtggcaaa gattcctagc aaaacctttg 240
 actggaggct ttacagggcc atacaccaa tatcactaat gacagtgttg taaaatagct 300
 tttgtgcacc atgcttagga ttcaaggagg ataaagtata tctttctaaa gttatacttt 360
 agaaactgtc attccatgtt gaaatgataa acattccatg tttatctttt gtgtaagaag 420
 taaaaaagca aaaattcatt gcatcaaagt aggtcaggca ctgctaaag 469

<210> 47
 <211> 483
 <212> DNA
 <213> Homo sapien

37

<400> 47
 aaaccgagtt ctggagaacg ccatcagctc gctgcttaaa gccgtgtttg ctctcatttt 60
 ctcaaagaaa tctgttttag tttagatta cagtttatca aatgttaagg ctttgacccc 120
 aaaatctggt ccagaaaaga caggaaggcc agctaagagg aggttttcag agtgcataga 180
 aaggctgctc tgtgcttcgg catctgttct ggaagtgctt cttcggttgg caaagattcc 240
 tagcaaaacc tttagactgga ggctttacag ggccatacac ccaatatcac taatgacagt 300
 gttgtaaaaat agcttttgtg caccatgctt aggattcaag gaggataaag tatactcttc 360
 taaagttata ctttagaaac tgtcattcca tgttgaaatg ataaacattc catgtttatc 420
 ttttgtgtaa gaagtaaaaa agcaaaaatt cattgcatca aagtaggtca ggcaactgcta 480
 aag 483

<210> 48
 <211> 600
 <212> DNA
 <213> Homo sapien

<400> 48
 tccattttctc atggcttgct catcttcggg cttcaggtc tgacttcato tcaggatggg 60
 atcgggtgtgt gtctgttttc atagatccac tacatcagaa gtatctttac atctctgtat 120
 ctttacatcc caaggtcaag gccctggcaa cctcagaggt tcccatagct tcagtcttcc 180
 ccaaaccatg ccacttcctc ccatttcttt gggtcaggaa tctggctttt gttttccata 240
 tttctttttc ccaagacatt gggaggcatc tggatgaaca caccaataaa acagttctct 300
 ccccaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaac aaaaaacgaa 360
 gaacaaagaa cagagaaaaa aaaaaacaag aaacacccaa aaacaaaaaa gaaaacgcgg 420
 ccgccagcgc acgcgcgagg gcgcgggagc acacctgtg gccagcccgc gagcgagaag 480
 ggagcggggc gggcggggcg gaccggagac ccaaggaggg cgcaggggagc aacgaacggg 540
 agccggaggga gcgcgacact gcacgcagga gagcagacgg gaggggagac agcgcgggga 600

<210> 49
 <211> 1098
 <212> DNA
 <213> Homo sapien

<400> 49
 aacctcttca acaataaatt gctctttggg gacattttat gcacagaact gtgcaccctc 60
 ctcagaacag caggctctta atggcccatg tgatgagaag ggcccatca aggcagcagg 120
 aatgggccac tctccacac cccatgggac aggcactgc cactcctgct gcctgcac 180

```

cccagggttta tggctgcatg gtagaagtca cttctgtaag aaattcacct ttctaaaata 240
aagtatgctc ttttttctga gacatctata gaataacttg tggcagagtg ttttaaaaac 300
tgatttggat tttttttatc ctttaaccgt gtgaaaggat ggaagggatt ttaggtggaa 360
gagaagttaa gaacagaaag atagagcagg tttttagagt gggagaatta atcccaaaga 420
aaaagagggc atggaaacaa atgtggatgc catgggctct gtgccagact tgccagtgc 480
gactggaaca ggccgggctc ctcaactcag ggctcctgcc tcagctgtgg ttcccgagc 540
ctctgggtct cacggaaccc ttccttggga gttccatttc tcatggcttt gctcatcttc 600
cggcttcagg ctctgacttc atctcaggat gggatcgggtg tgtgtctgtt ttcatagatc 660
cactacatca gaagtatctt tacatctctg tatctttaca tcccaaggtc aaggccctgg 720
caacctcaga ggttcccata gtttcagtct tcccaaacc atgccacttc ctccatttc 780
tttgggtcag gaatctggct tttgttttcc atatttcttt ttcccaagac attgggaggc 840
atctggtgaa caacaccaat aaaacagttc tctccccacg gtcattccagg tcaacttctct 900
aactcattcc tgcacacaca gcacacgtgg aatttgcttg tttagtctat gttcttgact 960
tgatcacaga cgctgtaca ataaagcccc ttttcaacaa ggtgctgcag aatgataatg 1020
ctttcccaa aatctgaaac tgatttgtat cattgaagtt ttttctgta ttaaaaataa 1080
agcaaaatta aaaataaa 1098

```

```

<210> 50
<211> 540
<212> DNA
<213> Homo sapien

```

```

<400> 50
ggtcgcgggc gaggtactcc cgcctcctgg agcggccgac ccacatgga ttctcaacag 60
gtggccggca catcttctga gcctcgctct ctcatctgaa agtggagtgt aagtccaaga 120
agattcattt agacaaagaa ggtggaaaaa aaggactttc tgggccagca agtcggatga 180
ccaccctcca aggggcagag gagggcccat tttgtgaaga agaaatcaac taccggaaa 240
acgccacagg aggacatgtt tctgcagatg tagttgccct agaaacagaa gagtatgggg 300
gtgtgaatgt cttctctttt gggggcaaac actatgtcct tttctttttc tagatacagt 360
taattcctgg aaatttttagc gagtttgttc ttgtggatat tttgaacaat aaagagtgaa 420
aatcaaaaaa aaaaaaaaaa aaaaaaaaaa accctgggag gtacccatgg cgcaagcct 480
ggtcccttgg ggggacactg gggtaccgg cccccaattc ccacaattg cggagcaacg 540

```

39

<210> 51
 <211> 1028
 <212> DNA
 <213> Homo sapien

<400> 51
 cggccgcggc atgaaaggcg gcgaggagag gcagcactgc tgctcttgac ttctgagcag 60
 ggcttagaga gcctgccccg gcttaagccg agctgctggg gctgaccctg agcgccgagt 120
 ccgcgagctc tgagtcggga gcctcccagc cgtggagccg tgggatgagg ggggcgttg 180
 gggacagggc aaagtcgac ttggtgttac agccgcccga tcctagcgcg gagctgcgag 240
 cctgaccggc cgcgtctggc atggtcagag aaagaatttt cttttcccaa ctccggcttt 300
 tggttttgtg tgtccacctt gcgcaactcc ggagccagcc gacccacat ggattctcaa 360
 caggtggccg gcacatcttc tgagcctcgc tctctcatct gaaagtggag tgtaagtcca 420
 agaagattca tttagacaaa gaaggtggaa aaaaaggact ttctgggcca gcaagtcgga 480
 tgaccaccct ccaaggggca gaggagggcc catthttgtga agaagaaatc aactaccgg 540
 aaaacgccac aggaggacat gtttctgcag atgtagtgtc cctagaaaca gaagagtatg 600
 ggggtgtgaa tgtcttctct tttgggggca aacactatgt ccttttcttt ttctagatac 660
 agttaattcc tggaaatttt agcgagtttg ttctgttgga tattttgaac aataaagagt 720
 gaaaatcact ttggagtcac ttaatcttcg ttagaagggc agtttcttcc agggccattt 780
 tctttcacca gatttgtttt tctcgttcc caaatgaggt agttttaaaa atcaaagtcc 840
 acttgctaac tcacctggga aagagactgc gacagaagga agagaagtaa atagacatca 900
 ctctcaaact aaaagtgtaa ctttcattcc tggcagctga gattcagaac acaaagaaac 960
 aaactcgttt acctttgagt atttcccccg tatgggtaat ttatctagag ctttcccaac 1020
 aattaatc 1028

<210> 52
 <211> 541
 <212> DNA
 <213> Homo sapien

<400> 52
 acagattggg aaggtgacat tgtatcaca agctagtctt tgagtccaaa gttttgtgg 60
 tttatgttat gatatacttt tatcatggaa ttgtcttatt aaatgttttg ccagtgggtc 120
 ttaaagtgtg tttctgacac cagtagcatt gacttcactt agaaacctgt tagaaataca 180
 aattatttgg cccaccccaa cacttgagtc acaaaacttg cagatggggc tcaatctgtt 240
 ttaacaagcg cttcatgtaa ttttgatgca ggcctaagtt tttgagccgc tgcagtatgc 300

40

atttctatTT ttaagcaaag atcttgggtct ttcttttttg acattgtaga aataacatga 360
 acttgtcttt tgtttgtttt ggttttgttt tgttttaagc tcctgatctt tgttggttat 420
 gttgcaaaag attgtatcag gagaagcctc agcatggaca ttggcatcct gacataacct 480
 ccattaatTT agtattcttt ctgaaactca aatggattct caagtccaag agactatgga 540
 a 541

<210> 53
 <211> 261
 <212> DNA
 <213> Homo sapien

<400> 53
 atgccatcag tggcacaggg ccctgtgccc tggcatctgg gttcacgctc tgctgttgct 60
 gtcttcgaat tcctagtgat gtttgaacaa aggcctatg tttgcatTTT gcactggggc 120
 ccacaaatca catggcccat cctgagaaga ggagtctcac acctccagtc tcctaaatca 180
 cctctggaag tttttctcaa cgaaagaact gaagctttcc tcaaaagtTC cgtaggggag 240
 acagttcatc accataccca a 261

<210> 54
 <211> 325
 <212> DNA
 <213> Homo sapien

<400> 54
 gctctgtttt gtgttttggt tggattgtgc tggttgtgtt ttgtgtttgt ggaagggtgtg 60
 tgtgtggggt tggcgagtac atgtcgcccg ggaccgctat ggctctgggt gcgccacgc 120
 tttttttttt tttttttttt tttttttttt ataatcaacc tataagggat ttatcaataa 180
 ataaaccctt atttattata aggaattggc ttacacaata atggaggccg agaaggcccc 240
 aagtctgctg tccgaaggtc tgagaaccag gagcactgat ggtgtcagtc ccagttcaag 300
 ggcaggagaa gatgggtgtc ccagc 325

<210> 55
 <211> 2461
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (356)..(393)
 <223> a, c, g or t

<400> 55

41

gcctgaatag agctgtgcag cccaaggggt ggactgagcc agcagtggat atgcaccact	60
gagatctctt gctgtggaac gtaattgact ggggggggtcc cgcctactgc tctctgaatc	120
cattgataca gtcataccaa ggctacattt cccatgggtt gtttccataa gaataacaat	180
aactgaatga agaagggtata ctaataatgc aggcctattc ctgtgaggta ggggggtcct	240
ccaatgggag actttgggtt gagtggtctt catcagctga ccttaaactt tattggaatt	300
gtgctacagc ctaagctttc tgctactcaa cccgccttcc ttccctctct ccttcnnnnn	360
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnaaaccta tggctctatc aatcaattaa	420
taaggattta taatcaacct ataaggattt atcaataaat aaacccttat ttattataag	480
gaattggctt acacaataat ggaggccgag aaggcccca gttctgctgc cgaagggtctg	540
agaaccagga gcaactgatg tgtcagtcac agttcaaggg caggagaaga tgggtgtccc	600
agcgccacag tcaggcagaa aattcaagct tctccacctt attttatttg ggtccttaga	660
agactggatc aagcccatcc acactgggga ctgcaatctg ctttattcag tccatcaatt	720
caaatgcgaa tttcctccag aaaaagcttc atgaacacaa ccagaaataa tgttcgatca	780
tatatggggc atcctgtggc ccagcgaagt tgacatgcat aaaattaacc atcacacctc	840
catggaggcc agaaatttta tgtattctga ggactctgtc tctctggctt cctctccatt	900
tcaacctca ggcatctttt ttttcccaa ataaatgtct tgtaaactca tttttttttt	960
acatgtgttt ttttggagt actggaacta ataaatttgg actttgttct gcaggtagtt	1020
tagttactta cagatcagct ttatactatt gaggtctgtt ttttaagctt ttgtgggggt	1080
gaggagcaag tgtagtgtag tttttagtca ggtagttta gccctacgta tgtaacacac	1140
aacctttctg ggatcttttag cgaatgcctg gttttcagtc aggactctcc actgtggctg	1200
gatggaaatt agatatttcc caatctcag ctaattttga gaattgttag gcttagtggt	1260
ccgcaatgta cacaatgggg tctctacata gatttctgga tttttttgtc taccttcttc	1320
cttggtgata ctttgtcctg aaaattcaag ctatctcagt atcaactcca atcttctct	1380
cctcaactca gcaagactct gatctcctgc gatgggatcc agagtgtca cctcagaaaag	1440
gcaggcgcat cggagggtct actttgttcc cctgcctcag cgatcaaatt gtataaactt	1500
tttccctggc ttctggaaac actgatagcc aacctttcgg taaaatttct aacatatgta	1560
cttagagctt taatatgcta agtatataaa tgctaagtat tttcttttaa attcatttca	1620
aaatattttt gcaattttgc cgtgatttat ttttggctc atgggtcatg aggtgtatgt	1680
tccttaaatt aatgcatttt ggaaattttt tgttaccttt atgtacttga tttctggttt	1740
aattcatact ctatatgatt tcaatctttt gaaatttctt gagacttgat ttgtgatcca	1800

42

```

gcctaacatg cgccccagaa cacatggtaa atgttttggg gtatacttta aaagaacatg 1860
tattctgatg tttttgaatg taatatctta tgtcttattc atatttatag taccaataca 1920
cagcacatag tagaaactta acatatattg agttaaataa ttcaaagggt ttatccgatt 1980
gggtggcaatt caagaccaa taagagagga tgatgatgac atcactattt ctgttaagac 2040
agggcctcat acaacatata ggaatgtcca gttgtcaagt catgcagttt ctcccctatt 2100
ctaaccaatg ttaatgcaa tactttgtga tgaaaattat ccagttattt ttcctcctat 2160
gtttccacca gttttccctt cattgattgt taagatttat atcactagag ctatttgaca 2220
gtaggaaaca attaccttag gaaaagttgg tgacattggc ctataaaggc cacggagaca 2280
taagaaatgg ttattttttc atttttcacc aaacaattca cgattgtttc taagattaca 2340
aaagattaga cgatagctaa tttttctatg caatgggtcaa atttttcaag tagaatcatt 2400
tttaaatttt ccaagttcca atgtcacttt ctcttgaac acgactcaag gtcaaaaactt 2460
a 2461

```

```

<210> 56
<211> 643
<212> DNA
<213> Homo sapien

```

```

<400> 56
ccgcccgggc aggtacacat gaggcggtgt atgccccag gctgggtcag ctcttctgtg 60
gattgcatgg cgtgtgatta aaagcccatg tgttcccaca catccacatc atgggaaggc 120
taatgtgtgc ctcttgga cgtgggtgtg gtgtccatgg aacttcctct ctgtatctca 180
ggtcagtagg cgcagaaacg cctcatgatg aagattcttg agccccattt ccaagacccc 240
tcacatccaa tcctgtcctg taacatccat caaggatttc cataggggtg actggtgccc 300
accaagact gcaccagtgc ctgctcattg aggagagtaa ctgctggcca ggcagaaaga 360
atatgggctc tgcaatgaga cagacctgga ggggactctc ccgttgagca ctacagctg 420
gaggagttgg gagttcatgg ctatcatggt tgtgttcaat cgattgtggg gatgacatgt 480
catttgttat ggaaggcggg gctcatggct gattggccaa taaaatggcg gctgccgttg 540
tcattgaaaa aacacaccac accacaacca aaaccgctgg ggcacaccg ggcacaaggc 600
ccccgggga aacgggttcc ccgcccaat tctccaaatt aga 643

```

```

<210> 57
<211> 1611
<212> DNA
<213> Homo sapien

```

```

<400> 57
ctcctcccga ggaaccagtg gtgacagctg aggccatgtg agtaggatcc tgaatgaggc 60
tttatctctg gctgttctgc ccatcgtcca ccgtggcacc agctccctca gccagccggg 120
atgggaccag cgactgagag agccagaggc agagaggtga ggggtgaccat atcctggact 180
gtgagaggaa tgggactctg ggcctgtagc tgccaagcag gtggcagggtg ctccaggctg 240
tgatctgcac cctctgaccc ctgacattga cctcctaccc tgaccctgc ctgaccaagc 300
catgtctgaa caggaggctc aagccccagg gggccggggg ctgcccccg acatgctggc 360
agagcagggtg gagctgtggt ggtcccagca gccggggcgc tcggcgctct gcttcgtcgt 420
ggccgtgggc ctctggcag gctgtggcgc gggcgggcgtg gcaactgctgt caaccaccag 480
cagccgctca ggtgaatggc ggctagcaac gggcactgtg ctctgtttgc tggctctgct 540
ggttctgggtg aaacagctga tgagctcggc tgtgcaggac atgaactgca tccgccaggc 600
ccaccatgtg gccctgctgc gcagtgggtg agggggccgac gccctcgtgg tgctgctcag 660
tggcctcgtg ctgctgggtc ccggcctgac cctggccggg ctggccgccc cccctgcccc 720
tgctcgcccg ctggccgcca tgctgtctgt gggcattgct ctggctgctt tgggtctgct 780
tttctgctg ggcctgctgc tgtatcaagt ggggtgtgag ggacactgcc cctccatctg 840
tatggccact cctccacccc acagtggcca tggcgcccat ggcagcatct tcagcatctc 900
aggacagttg tctgctggcc ggcgtcacga gaccacatcc agcattgcca gcctcatctg 960
acggagccag agccgtcctt cttctcacag cggcctcagc gtccccagag ccgagccagg 1020
gtgtgagtgc atgtgaacgt tgagtacaca tgagtgcgtg tatgccccca ggctgggtca 1080
gctcttctgt ggattgcatg gcgtgtgatt aaaagcccat gtgttccac acatccacat 1140
catgggaagg ttaatgtgtg cctccttggc actgggtgtt ggtgtccatg gaacttcctc 1200
tctgtatctc aggtcagtag gcgcagaaac gcctcatgat gaagattctt gagccccatt 1260
tccaagaccc ctcacatcca atcctgtcct gtaacatcca tcaaggattt ccataggggt 1320
gactggtgcc caccgaagac tgcaccagtg cctgctcatt gaggagagta actgctggcc 1380
aggcagaaag aatatgggct ctgcaatgag acagacctgg aggggactct cccgttgagc 1440
actagcagct ggaggagttg ggagtcatg gctatcatgg ttgtgttaat cgattgtggg 1500
gatgaaatgt cattgtgtat ggaaggcggg gctcatggct gattggcaat aaaatggcgg 1560
ctgccgttgt cattgtctcc aaaaaaaaaa aaaaaaaaaa aaaccgcgga c 1611

```

<210> 58

<211> 617

44

<212> DNA
 <213> Homo sapien

<400> 58
 actgtgaagt cttcaggctc ttagaaggct ccagcctgag agagcccttt attattgcc 60
 ttctgtcctt tcttcaaggc ctggtgacct gtgacctttc gctctgggca gggcccaggt 120
 agatgggccc tcatccgggc ctgtaagccg tactatgatt tctgcattga tttacatatt 180
 ttttactgtg atcttgggtc caaacacaga atcgtcacc ctttctccct tgaatgtgcc 240
 ggatccttgt aaattctcat tcacctactt gttcttaggt gtgtatgtgt gtgcgaaact 300
 ctatgttcaa gaaagaaatc atacaaagag taacgaacca tggttctgtt ggccattgga 360
 cgaaacttgg tttttggact ttcttacota acattaattt tgctcttgcc tcggtttaca 420
 cacacacaca cactacaaca aacacaacac aaacaacgtt ctgggccaac accacgcggc 480
 gccagcgcgc gctccctggg ttgaaacttg gatctcttcc cgcgccacaa ttctcccaac 540
 aactataatg agcacaagga ccacaacat acacaagaac aacacaaacc agcgacacaa 600
 cagagacaac acacaac 617

<210> 59
 <211> 913
 <212> DNA
 <213> Homo sapien

<400> 59
 caaaaccaca cccatgcaca cacataccct cagccccac acacaccccg ttgaaccctg 60
 gagtctatca gggcatccta aaactccgtg agttgacatt tcagtaattt caggggaagg 120
 tgttttccag ggatggggtc tcccagggtc agatagtgcc tttggctgca aatgctcctt 180
 tagctaaact tttcctcagg aagaattcat tattctagac attatgtgat atatctgtta 240
 ggaataaaag gtgcttaacc ttcctccctg ggatgtggga gaagggtctg gaggttgtag 300
 tgtgaagtct tcaggctctt agaaggctcc agcctgagag agccctttat tattgacatt 360
 cctgtccttc ctcaaggcct ggtgacctgt gacctttcgc tctgggcagg gccaggtag 420
 atgggcccgc atccgggcct gtaagccgta cttgatttct gcattgattt acatattttt 480
 tactgtgatc ttggttccaa acacagaatc gtcaccccat tctcccttga atgtgccgga 540
 tccttgtaaa ttctcattta cctacttggt cttagtgtgt atgtgtgtgc gaaactctat 600
 gttcaagaaa gaaatcatac aaagagtaac gaaccatggg tctgttggcc attggacgaa 660
 acttggtttt tggactttct tacctaacat taattttgct cttgcctcgg tttacacaca 720
 cacacacact acaacaaaca caacacaaac aacgttcttg gccaacacca cgcggcgcca 780

45

gcgcgggctc cctgggttga aacttggatc tcttcccgcg ccacaattct cccaacaact 840
 ataatgagca caaggaccac aaccatacac aagaacaaca caaaccagcg acacaacaga 900
 gacaacacac aac 913

<210> 60
 <211> 554
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (304)..(430)
 <223> a, c, g or t

<400> 60
 tggaaaataa agtttaaaac cagattgccc agagcaagac tctaattgtc ccaacgggtga 60
 tgacatctag ggcagaatgc tgccattttg aggggcaggg ggtcagctga tttctcatca 120
 agataataat gtatggtttt tacactaagc aactgataaa tggacaattt atcactggac 180
 aatctccctc tgcttcttta atggggccag ctttgcagcc ctgcagcctg ggtagtcgca 240
 cacatttcca tgcaccaag gccccgtgc ttgggagaat gatctgctag tgccatttta 300
 aatnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420
 nnnnnnnnnn tcaactgtgc cggcataaag tagaacattc ttacaagaaa taaatatttc 480
 gtagtcatgg agaagaacgc gaaaaaaaaa aaaacaaaaa aaaggctggg ggtaaccagg 540
 gcccaagcgg ttcc 554

<210> 61
 <211> 1401
 <212> DNA
 <213> Homo sapien

<220>
 <221> misc_feature
 <222> (803)..(929)
 <223> a, c, g or t

<400> 61
 aattattttg ggtctctgtt caaatgagtt tggagaatgc ttgacttggt ggtctgtgtg 60
 aatgtgtata tatatatata cctgaataca ggaacatcgg agacctattc actcccacac 120
 actctgctat agtttgctgt cttttgtgga caccctcat gaacaggctg gcgctctagg 180
 acgctctgtg ttactgatg atgaagaac ctagaactcc aagcctgttt gtaaacacac 240

46

```

taaacacagt ggcctagata gaaactgtat cgtagtttaa aatctgcctc gcgggatgtt 300
actaaactcg ctaatagttt aaaggttact tacaatagag caagttggac aattttgtgg 360
tggtggggaa atgttagggc aaggcctaga ggttcatttt gaatcttggg ttgtgacttt 420
agggtagtta gaaactttct acttaatgta cctttaaaat agtccatttt ctatgttttg 480
tataatctga aactgtacat ggaaaataaa gtttaaaacc agattgcca gagcaagact 540
ctaattgtcc caacggtgat gacatctagg gcagaatgct gccattttga ggggcagggg 600
gtcagctgat ttctcatcaa gataataatg tatggttttt acactaagca actgataaat 660
ggacaattta tcaactggaca atctccctct gcttctttaa tggggccagc ttgcagccc 720
tgcagcctgg gtagtcgcac acatttccat gcattccaag ccccatgct tgggagaatg 780
atctgctagt gccattttaa atnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 840
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 900
nnnnnnnnnn nnnnnnnnnn nnnnnnnnt cactgtgtcc ggcataaagt agaacattct 960
tacaagaaat aaatatttcg tagtcatgga gaagaacgct cctaaaatga tgaacgcacg 1020
acggaaaaga gtagggaaca ttttgcttga tgagaaaatc cgccagcaag gatgttgggc 1080
tctaagcaga actgaagctc tggaattaag aacacagcca aggaagagct ctggactctg 1140
agtttaaaga agctgactga cttgtaaggc aattccaggt aagattggtg aatcaagtta 1200
agaatcaaaa gcaactgaga tcaactgga ggctggaag gtaagggcca tattttacct 1260
agatactagc ttagagactt gctacattgg cactgtattt taagtatgtt atttagtagt 1320
attgtgaaat caactggttt caacattgaa aaggataaaa atagcttatg aaaacaaaac 1380
ggtttttttt tttttttaa a 1401

```

```

<210> 62
<211> 568
<212> DNA
<213> Homo sapien

```

```

<400> 62
agatgctgcc gagcggcgca gtgtgatgga tagtccaaaa aaaaaaagta ttaaaatgtg 60
attgatgtaa ttaccatgt ttactttatg catgcatttt attggggagg ggacgtgtca 120
gaataataca ccaaactcta gtggtctaatt ttcatagtgc taatctggtt tatattggca 180
ttaaacgata ctgcaagga gctagatcat tttaacagag ttgtaggttt gtcttatgtt 240
ggaaaagcag tcctctatta atatcatgtg tgaagagtat ctgttcacaa gatttatgag 300
attatgacgt gtttcagaga atgtctacta gtatatcttt acagtatttg cctgttgaa 360

```

47

tcacctgcaca aactggaatt actttccaga agacttaggg aatgcaaata tgttactcat 420
 aagatgcatt ggagtatggg aaataaaaca aaccattttg gattgggtta aattggctcg 480
 ttacagttct cttgtgggga gggactttgt cagtcatttt ggcatcttaa gctagactaa 540
 actttttggt gttgttttcc taaaacca 568

<210> 63
 <211> 791
 <212> DNA
 <213> Homo sapien

<400> 63
 tggctctatgg taatttttta tagcagtcac agccaagaca gtgcgctcat ttactacata 60
 ccatttatat tattatatag gctcctttca gaaacccatg ttcaaataag agataagata 120
 ctgaaacaca taacaccttc actagttttt agtatacaaa tattgagaaa tagttgttat 180
 taactatctc atccaagaaa tgcagattca tgttgtttct aaatttttta tatatatattga 240
 ccaaaatgaa gaaacttaac accatcctag attttagctg cccaaagaat gaaaagaatg 300
 aaaaaaaat cttgtgaaaa ccacaaagtg atatggatct aatttatggg taaatagata 360
 tagataacaa acagaatacg cctgtttaaa actgttaaaa tgacattggg tctaattata 420
 cttttattta aattgaaaga caaggcattt atatggatc tctaaccatc acaactttgg 480
 tgtgacaaaa agaaattatc accaaaatac acctccttaa gtaagtgtct gatttcacac 540
 ttccagaaaa agtgctcttt ctgggtcaagg ccagcaagaa ttgagaaaga ttaagaaagt 600
 gcttcaaaga tgtttattac aaagtgtgca taaaaactgt gaagtagatg tagacatcaa 660
 gcataccaaa taaagtaaaa actgtctctc ggcaaaacaa caacccaaaa aaaaaagcgg 720
 gggggggacc ggggccaaaa cgggtcccg ggggaatggg tccgccaatc accccaacaa 780
 aaaaaaagg a 791

<210> 64
 <211> 1523
 <212> DNA
 <213> Homo sapien

<400> 64
 gggagatgct gccacctagg ttactttagt gacctatac ggcaacctcc tttgccagga 60
 actatttata aacatcctgc aggaaaatgc agtgaagtag aagagacagg gatatcccag 120
 aaggttatgc aaaacatcaa gagaagatga gaggagtcta tatgtcagaa tacacatttc 180
 ccaccttgcc caacagtaga aaaacataag aagagaaaaa cattaaaaaa tgacaaggaa 240

48

```

gttaatggaa gtcagcaatg tgatgggtgtt tggagggtgga gccttcagaa ggtaattaat   300
gcccttgtaa gaagaggcca gagagcttgc gcaccttctt cctgccatgt gaggagccaa   360
gaagccggct gtctgcaacc tgcaagagga ccctcactag aagctagcca tactggcatc   420
ctcatcttgg ctttccaact tccagaactg tgagaagtat atgttggtgt ttagtcaatg   480
gtctatggta atttttttat agcagtccca gccaaagacag tgcctcattt actacatacc   540
atttatatta ttatataggc tcctttcaga aacccatggt caaataagag ataagatact   600
gaaacacata acaccttcac tagtttttag tatacaaata ttgagaaata gtttgttatt   660
aactatctca tccaagaaat gcagattcat gttgtttcta attttttata tataattgac   720
aaaatgaaga aacttaacac catcctagat tttagctgcc caaagaatga aaagaatgaa   780
aaaaaaatct ttgaaaaccc acaagtata tggatctaata ttatgggttaa atagatatag   840
ataacaaaca gaatacgctt gtttaaaact gttaaaatga cattgggtctt aattatactt   900
ttattttaat tgaaagacaa ggcatattata tggatatctt aaccatcaca acttttgtgt   960
gacaaaaaga aattatcacc aaaatacacc tccttaagta agtgtctgat ttcacacttc  1020
cagaaaaagt gctctttctg gtcaagccag caagaattga gaaagattaa gaaagtgctt  1080
caaagatggt tattaaaaag ttgtcataaa aatgtgaagt agatgtagca tcaagcatat  1140
caaataaagt aaaactgtca tcaagaagat tcaacagcta tgaaaagagt tcttcaaaat  1200
atgatatggt tttctagatg ataataaaat ttatcaattc caaatgtcca cattagtctt  1260
tcataaagac accaatgagt cacaggaaaa aaattaaaaa taaaaaaacc ctatctcagg  1320
gaatcatgct aacaacctga tgtgttttct tccacatatt tatgtctgct tataagtatt  1380
tacaacata tattegcata tatgcatttt gaattttttc tgttgctgca cttaaatttt  1440
tttcataata aaacaagact cctgcaattt gcttttttag gtagactatg tatccctgac  1500
aaccatccag gtcagcttga tga                                     1523

```

```

<210> 65
<211> 377
<212> DNA
<213> Homo sapien

```

```

<400> 65
ggtcgcggcc gaggtacaaa agtgcaaaca aggttagtga ttaacaactt accatcaata   60
taccacttca acatacttta cattcagcca aatactgaag gtttcaccgt ggaaaaacac   120
ttttatcact tttaaagtaa cttgactatg ttcaccctga gtgctcttgc ctgagtatgg   180
caactgatta tgagttcagg ttaagagcaa caccagggaa tacagaaacc cacgttaagt   240

```


49

tggccattct gacatgaatc tatacttgaa aatgaaaaca atcccaaaga aaacctgtat 300
 gtcaaaaaca gaactgttcc tgcctttcac cccaaaatat ttaaaactaa atctaagcca 360
 cttttaaaat gcatgct 377

<210> 66
 <211> 1703
 <212> DNA
 <213> Homo sapien

<400> 66
 ccaggctgga gtgcagtggg gtgatctcca ctactgcaa cctccacctc ccagcttcaa 60
 gtgattctcc tgcctcaacc ttccaagtag cttggattac aggcgtgctc caccacagct 120
 ggctaataatt tgtattgtta gtagagacag ggtttcacca gtgtgttcca ggcttgcga 180
 acttctgacc tcacgtgatc cacctgcctc agcctcccaa agtgctagat tataggcgtg 240
 aaccactgctg cccggccagc atgcatttta aaagtggctt agatttagtt ttaaataattt 300
 tggggtgaaa ggcaggaaca gttctgtttt tgaatacag gttttctttg ggattgtttt 360
 ctttttcaag tatagattca tgtcagaatg gccaaactta cgtgggtttc tgtattccct 420
 ggtgttgctc ttaactgaa ctcataatca gttgccatac tgaggcaaga gcactcaggg 480
 tgaacatagt caagttactt taaaagtgat aaaagtgttt ttccatgggtg aaaccttcag 540
 tatttggtctg aatgtaaagt atgttgaagt ggtatattga tggtaagttg ttaatcacta 600
 acctgttttg cacttttgta caccactgct tgcactagga tcttggtgtg aattttcaat 660
 tgttttacag tgtatacaga ttattaagga taatttatat aaagatgttt ctgtttaact 720
 ttgtgtgttt tacaacaaag agctataata gatgggttaa cgtttttgaa ttgtgtttat 780
 atgttagttt gattagtatt ttatttttcc ctctctaaca ctcaaattca tggcaggtga 840
 aaagataata gaacataatc aaactaacat ataaacacaa ttcaaaaacg tttaaccatc 900
 tattatagct ctttgttgta aaacacacag agttaaacag aaacatcttt atataaatta 960
 tccttaataa tctagtatac actgtaaaac aattgaaaat tcacaccaag atcctagtgc 1020
 aagcagtggg gtacaaaagt gcaaacaagg ttagtgatta acaacttacc atcaatatac 1080
 cacttcaaca tactttacat tcagccaaat actgaagggt tcaccatgga aaaacacttt 1140
 tatcactttt aaagtaactt gactatgttc accctgagtg ctcttgctc agtatggcaa 1200
 ctgattatga gttcagggtta agagcaacac cagggaaatc agaaaccac gttaagttgg 1260
 ccattctgac atgaatctat acttgaaaat gaaacaatc ccaaagaaaa cctgtatgtc 1320
 aaaaacagaa ctgttcctgc ctttcacccc aaaatattta aaactaaatc taagccactt 1380

50

ttaaaatgca tgctggccgg gcgcagtggg tcacgcctat aatctagcac tttgggaggg 1440
 tgaggcaggt ggatcacgtg aggtcagaag ttcgacaagc ctggacaaca tggtgaaacc 1500
 ctgtctctac taacaataca aatattagcc agctgtgggt gcgcagcctg taatccaagc 1560
 tacttggaag gttgggtgagg cagcagaatc gcttgaacct gggaagcaga ggttgacgtg 1620
 agtggagatc acaccactgc actccagcct gggtgacaaa gcaagactcc atctcaaaaa 1680
 aaaaaaaaaa aaatgagcgg tcg 1703

<210> 67
 <211> 456
 <212> DNA
 <213> Homo sapien

<400> 67
 atctcttttaa ataattagca agaagggaga caagatgcag gagttcactt ggctctttga 60
 aaaggaaaac tttaaagtca gtggttgac tgagtcccat gaagccagat cacttctgac 120
 tgcaaggagc ttggaaaagc aagtatctgg atcttttacc agctaaattg ggaggaacta 180
 taaaatgaga aaagattgat gaatattaag tagaagagt agatggcat ctttgcattt 240
 aaaaaagatc atttgctgta gttgtatgga aaatgaattg gagcaggcga tgaggcttcc 300
 tctttgaaga tcacaggtga gaagattagg tgctttctca gaagcccagc aacctgatgg 360
 gagtgtggag tgagcaagac ccaaactcga gcttcatccc tgcattggtt attttgctta 420
 tttggcaaac ttgccctgca gaatctactc aagctt 456

<210> 68
 <211> 380
 <212> DNA
 <213> Homo sapien

<400> 68
 ccgcccgggc aggtagaggt tgtagtgcgc cgggatcacg ccaactgcact ctaggcctgg 60
 gcaacagaga gagagactgt ctaaaaaagg aaaagaaaaa aatttatacg ccaaaaaaga 120
 tattctgaga taacctgtag ttaccactaa ctttgtgaca aaattataaa aatccacagc 180
 catctatgaa tctgtaggca gacctgaagt ttgaacgact ggtgaagaca tctgcatttt 240
 ctttatagcc aagttaggat aacaaaaatg caaacaagtc attaatattt actatatgca 300
 agatacagaa acgatgaacg gaaggagtaa gaagttatcc ttcgtggaac tattttaaagc 360
 aaaaatgcaa aataccaggg 380

<210> 69
 <211> 2177

51

<212> DNA

<213> Homo sapien

<400> 69

```
ttccaacatc tcatttctcc catgaactat ttggaaaaag ctgcaggcgt aatattggat      60
ccctaaatac tttattctcc ttataccatt atcagaccca agtatcatct aatagtccat      120
aatcaaaactg cctaaacagt ttctacactg tctttttaac tatttcaaac tatcaaggtc      180
cgcattttct tccttagaac ttttagtctt tttcttcccc aaaatatttg agtccatgcc      240
agttgccttt agttgtaccc aaataatggt ttgtctatct cctaaaagta gtactcttaa      300
atttaaattt agtggtatct ttgttgcat cgttccttct tctcatgtg gttgtgcagg      360
cagagcttga gcatccagat ttcaaaatta aaaaaataaa gataatctag tttaatatat      420
agtagttgaa tcaccttaag tctagactgc tgtatgagca cccattatct ttcactatat      480
tccatcatcc ccctcccca tgaactatct ggaaaaagct gcaggcgtaa tattggatcc      540
ctaaatactt tattctcctt ataccattat cagacccaag tatcatctaa tagtcataa      600
tcaaactgcc taagcagttt ctacactgtc tttttaacta tttcaaacta tcaagggtcg      660
cattttcttc cttagaactt ttagtctttt tcttcccaa aatatttgag tccatgccag      720
ttgcctttag ttgtacccaa ataatggtt gtctatttcc taaaagtagt actcttaaact      780
ttaaatntag tgttatcttt gttgtcattg ttccttcttc ctcatgtggt tgtgcaggca      840
gagcttgagc atccagattt caaaattaaa aaataaaaga taatctagtt taatatatag      900
tagttgaatc accttaagtc tagactgctg tatgagcacc cattatcttt cactatatct      960
catcatcccc caacatatcc acagtagatg aagggcagtt tgctcaaaca ttgttttgat     1020
cctgtcatgt ctgttcagaa atgcctgtct attcagaaac ccacgtctaa taacaaaatc     1080
ttggactggt tactatcaaa acccaacaac atacagactc ctcagctagg cctaggggat     1140
atctttctac cttgatttcc aaatgttcat tgaaagaatg cttaattcta atttggaaaa     1200
aagttttttg ctccccactt ctgctttaca cgttcatctt tcttgaaatc aaatccaatc     1260
caatctatat tctaagaacc tgctcaaatc ttgggttcttc aaagcttttc ctggtatttt     1320
gcatttttgc tttgaatagt tccacgaagg ataacttctt actccttcct tcatctttct     1380
gtatcttgca tatagtaaatt attaatgact tgtttgcat ttgttatcct aacttggcta     1440
taaagaaaat cagatgtctt caccagtcgt tcaaacttca ggtctgccta cagattcata     1500
gatggctgtg gatttttata attttgtcac aaagttagtg gtaactacag gttatctcag     1560
aatatctttt ttggcgtata aatcttttct ttttcccttt ttagacagtc tctctctctg     1620
tcgcccaggc tagagtgcag tggcgtgac ccggctcact acaacctctg cctcctgggt     1680
```

52

```

tcaagagatt cttaggcctc agcctcccga gtagctaggg ttacaggcgc gcaccacctc 1740
catgcccagc tcttttgtat ttttaagtag agacaggggtt tcaccatgtt ggtcaggctg 1800
gtctcgaact tctgacttca ggcaatccgg ccgcctcggc ctcccaaagt gctgggatta 1860
caggcacaag ccactgcacc cagccttatt accataaatc atcttgatgc tggtaacctga 1920
taagattcta tttgcttttc tttattcata gagaccacaa acagatcgca gatccagggt 1980
tctcaaactg gagcatctgc ttaattttcc cataaaatca gtcttattct tctgacagc 2040
tctgagactc ctccggccac gactagggtgc tgcctggag gaaacggtgg aggacggccg 2100
cacaaaaacc aatctacctg atgaaaactc cgttcccttc tcgccagaaa cataaatgc 2160
gatggagacg ctctgtgc 2177

```

```

<210> 70
<211> 226
<212> DNA
<213> Homo sapien

```

```

<400> 70
tctcatgccc attcaatatg gaatgttctt cgcttgctga atttaagcct gtattttaag 60
gttttgtggt tcctcgcca caatgggtga tgcactgat agaacgaagc tgagtttcta 120
agggtttggg gctgtgcaag agtaaacact agagcttgag ttgttatcca gctggcaagc 180
acggaagtct ttgaagaatg taatgtaaaa agggaacaag aatgta 226

```

```

<210> 71
<211> 2554
<212> DNA
<213> Homo sapien

```

```

<400> 71
gcgggagagc cctgtcctta aacacattag gacaagtagt taaaacaggg ccaagaagta 60
tggctgtgta gtgatcactg tacaagcaca cctggctgaa taaaccagtg ggggataaaa 120
tccagctcac ctgccgctgg ctatgctttg tgcctcagga caaggggtg ctctcttgct 180
aattgacagg aaccatcttc ctgcccaact gcattccac tgcgtaggca ccttatctgc 240
ccaatggggc tgtgaaccct aattggaagc tttgcaattc ttaacactat atcttcttga 300
gctgggtttg agtccctatc caatcaagat gaaggcctga gaggactact caagttctaa 360
catgatgtgg gggcaaggca tagtagtcca gatccgggac atgaggcagc ttttggtcta 420
gtatgacaat ctaatagttc ctaaaataga attatcccag gatggagctc cgtatgacag 480
aagggctctt cataggtagt tggtaggggg aattgtgtat catgtaagaa gtaggaccag 540

```

53

atgtctttaa aaagaccttc caactctaata gctacatgag tctgtctagt tgttatgttc	600
caacagggac agctctttaa atagtgtggc aaagcaagag atgagatttc cagtgtctgac	660
tgggtgtgtg aatgacttta gggcaggtat ttaacctcca cttccccaag tacacaagtt	720
atttcacaac tcttggcaaa aacagtgtctg taaaaatcgt aagtttattt gttaaaaaaa	780
atactgtatt tgaaaagtac cttccttctg ggattttcaa ataatttgta cactacattt	840
tattcatcta cacattggaa atgagtaaac tggatgaacat atagcttttt atacatttaa	900
cacaaccagt gcaaattctc ctgcctctga gaaggcagag aagcccttta ctgagaaggt	960
cttcaattct agcattactc caactcctag ggaaatttcg ggtgggtgcc tatggctgta	1020
tgaccatctg attcctcagg gacaggacag gaattcagca agggagctta aaatatatta	1080
agtaattgtc aacattccat ggtgactctc cccaaaaatc tagtggtagg aaaataatct	1140
gtacttattc ctctttctgc acacaaagcc ctcatTTaaa tttgtgagcc tgcttgggat	1200
ccattaccta gccattcaga gatcctgtca aatgcacagc agattggata ctccaccatcc	1260
caaaggggtt cctccacact ggatggggcc aatctctagt tgacagtgcc cctcagagt	1320
caccatggag atggaatgtc ccttcagag agacttttac acagggaaaa gcatttgttg	1380
gctgggtccc aactctcatt tggtaaaaa agctttacat tcttttccct ttttacatta	1440
cattcttcaa agacttccgt gcttgccagc tggataacaa ctcaagctct agtgtttact	1500
cttgcacagc cccaaaccct tggaaactca gcttcttct atcagtgaca tcaccattg	1560
tggccgagga accacaaaac cttaaaatac aggtctaaat tcagcaagcg aagaacattc	1620
catattgaat gggcatgaga tatgcctatc agatttgtgtg tgtgtgcgcg ttttttaaag	1680
acagccaatt acatcgtatc tagtcaaata agcggattct aaagcagcct gctgggatgt	1740
tccacttagt ctaatgctgt tggcactgta cgccacagca ccggacagtg ttctttggga	1800
catctctggg aaatgctctg gaacatgctc cttgatggaa aacactaatt tttgaaagaa	1860
gtagatgtct ggaggcaggt ctggtgaata aactgaatag tactgccttg gacccagct	1920
gaggggtggc agtaagcaat gaggatgggc tataaagctg ttaactggct aagggccatc	1980
cttgggcagg catttcagac acatctgtag agaggcagc agcatctccg ataggccagc	2040
tctgaaggaa gcttaatgct taatacagtc aactgcata aattagctta gaatgctctc	2100
ttgggtaaaa aatattaata gtgtatatgc acttgaaaag caaaattcct caagaaaaaa	2160
agtttaatag caaggagttt ccatcagtc cggtctttgt gaggattacc acaacaaaca	2220
cttaaaagga tacaacaggt acttattaaa tgctgccttg ccttttacct ctctctttt	2280
tttttttttt tgagatggag tctcgtctg ctgccagcc tgaagtgcag tgggtgtgatc	2340

54

tcggctcact gcaacctccg ccttccaggt ttaggtgatt ctcttgctc ggctcccga 2400
 gtagctggga tggactacag gcacatgtca ccatgccag ctaatTTTTT gtatttttag 2460
 tagagacggg gtttctgtgt tagccaggac ggtctggatc tcctgatttc atgatccgc 2520
 cgcctcggcc tccctaccct cgtgccgaat tctt 2554

<210> 72
 <211> 583
 <212> DNA
 <213> Homo sapien

<400> 72
 cagatcatga agcaattatc ttcctggaag ggTTTTtagc tatgctctcc agttgcctca 60
 gcagctttgg ctctgatgcc acagtgagcc caaggTgga ggTgatggaa cagcatcaca 120
 tctgcaggct cagtgtgtcg taaggTgagg gtaaggggag ggcaagtgt gacggatgaa 180
 gaagatttct ccctattgct tccattttga tatttcttta acttcacatt tcatccatca 240
 ttcctagaca gttgcctagt tatagaggat ttcttttata ttttttatca gaggcattgcc 300
 aggtggaagt gaggctgctg ctggcctaca actccagtgc tcgcattcca aaatgccct 360
 ggatggaggg tggTgagatg tcaacacagg tggaaaacag atccgagggc accataccca 420
 tacagacaac ctgtaaaagt cataataaag cccacactg cacggagcta aggcacaaac 480
 aacgcttccc aaccgatggc taagggccaa ctaggcgga gatgagcaag ccgaagcatc 540
 accgaaatga agcagctcag aagaggacct aagccccggg aca 583

<210> 73
 <211> 981
 <212> DNA
 <213> Homo sapien

<400> 73
 gaaagaatga gatgttttca gacatttttag gtccctgaga catgttcctg ttcattggcc 60
 agaaaactttt tggcgaacca cttcctattc aaaggcttcc tctccactaa taaagtagtc 120
 tgtggtacat gcagccctga ggcttgagat ggaactgcgc aggaagagcc caactgggta 180
 tcagaataag ccacatgcac cttctgaaac tgcccaaata cacacctgca taagaatttg 240
 agcccagttc ataaagcaga tcatgaagca attatcttcc tggaagggtt tttagcttgc 300
 tctccagttg cctcagcagc tttggctctg tgccacagtg agcccaaggg gaaggTgatg 360
 gaacagcatc acatctgcag gctcagtggt ttgtttggTg agggtaaggg gagggaaTgt 420
 agacggatga agaaatttct ccctactgct tccattttga tatttcttta acttcacatt 480

55

```

tcctcctcat tcctagcagt tgcctagtta tagaggattt cttttatctt tttttcagag 540
gcatgccagg tggaagtgag gctgctgctg gcctacaact ccagtgctcg cattccaaaa 600
tgcccctgga tggaggggtg tgagatgtca ccacaggtgg aaaccagcat cgagggcacc 660
attcccttca gcaagcctgt aaaagtttat ataatgcca aacctgcacg gcgctaaggc 720
aaaaacagtc ttcccaaccg tggcctagag ggcccttctt aggtgtcaga atgagccaag 780
cctgaagcac ttcacctgga attgatgtgt aggcttaagg agtatgtgac ccttacagtc 840
tcctctggtg tcaaacacag gataaattgt ttcttcatta aaaaataaaa aaccttcaag 900
tctacttacc cttctcctgt ccacaataaa gttgagaaaa caaaaaaaaa aaaaaaaaaa 960
aagatcttta attaagcggc c 981

```

```

<210> 74
<211> 401
<212> DNA
<213> Homo sapien

```

```

<400> 74
gccgccggg caggtagcag gcagaggag gagcaccaag gtgggggata tttaggggac 60
ctctttcctt caggaccaca cccttctagg tgaaagcacg aaccttgat tactttgat 120
tccatctgca aaaacaaatt taggttttga atatggtgaa aaacgaagaa aggaaaatat 180
aaaactctgt attttatata cagtaaggaa taatggaggc tgataatgat cttgtgatca 240
gctaagacaa tgtcagtaag caggtaggt aggggtgctt ctatgggcaa aagggtgaat 300
atcttgaatg accagaaatg actgaagag ctgcattact atcatggtag catgcatgaa 360
gtgatacatc taaacctttg ctaacctaac attattactc t 401

```

```

<210> 75
<211> 1847
<212> DNA
<213> Homo sapien

```

```

<400> 75
gccgatcttt tttttttttt ttttttattt ataaatttat tgctgtttt attataacaa 60
cattatactg tttatggttt aatacatatg gttcaaaatg tataatacat caagtagtac 120
agtttttaaaa ttttatgctt aaaacaagtt ttgtgtaaaa aatgcagata cattttacat 180
ggcaaatcaa tttttaagtc atcctaaaga ttgatttttt tttgaaattt aaaaacacat 240
ttaatttcaa tttctctctt atataacctt tattactata gcatggtttc cactacagtt 300
taacaatgca gcaaaattcc catttcacgg taaattgggt ttaagcggc aagggttaaaa 360
tgctttgagg atcctgaata cacctttgaa cttcaaatga aggttatggt tgtaattta 420

```

accctcatgc ataagcagag gcacaagtta gctgcatgtg ctctagactg tagagcgagc 480
 caccgttgag aagcaaagga cagcagcagg aagagcaatg gaacctcctc aggacttacc 540
 aggctgctgc acaggatcta gcttctccca cctaagatgg gcacattgaa agccttggtg 600
 cagcagcacc cccatctgtg gaagcacagg ctgcctgcac ttctccagct gctctagcac 660
 ctgacttcct ggtagtcagg gtaccaggga gagggaggag caccagggtg ggggatattt 720
 aggggacctc tttccttcag gaccacaccc ttctaggtga aagcacaac acttgattac 780
 tttgcattcc atctgcaaaa acaaatttag gttttgaata tggtgaaaaa cgaagaaagg 840
 aaaatataaa actctgtatt ttatatacag taaggaataa tggaggctga taatgatctt 900
 gtgatcagct aagacaatgt cagtaagcag gtgaggtagg gtgctttcta tgggcaaaag 960
 ggccaatatac ttgaatgacc agaaatgact cgaagagctg cattactatc atggtagcat 1020
 gcatgaagtg atacatctaa acctttgcta acctaacatt attactctca agctttatta 1080
 tcctcaaggc ttaaatggct gtagctgttt aatttaaaag caaggcttaa aaaatagagg 1140
 ttactcataa ttccctttcc atatcccttt ttgacttgaa aattatttca ccaactactt 1200
 ttctggaatg ctgcttataa tacatattca cagattgccc tatgtgttat tctagtcatt 1260
 ggcccgtttt gcttataaaa aaggccatgt tttgtattcc taaaaatct gcagacattg 1320
 ttaacataat acacgtcatt atacatcata tgtatgctac atctactcac tgacatttaa 1380
 aaaatgagct attttcaaag actaacacag gatctgttac tgagacgtgt aggaaggagc 1440
 tcagtgtaaa atattttctt tggatagatc ccttcaaagg gattaaaaa caaaaatat 1500
 tatttatact aaactttctt aaatgttcta tgatatttct atttcaaaat tctcttattg 1560
 tgagaatatg tgaatatag atgtagcaaa ttcaacacat aagcttatac cccttagctt 1620
 gagtaaaaga cacatatatg gcttcccagc accaagaaga tggagaagaa tctactgcaa 1680
 ctacttcctt ttttccaagc agctcaaaat gcttttagcaa ataccttggtg attctttttt 1740
 tttttttttt ttttgagacg gagtctcgct ctgtcgccca ggccggactg cggactgcag 1800
 tggcgcaatc tcggctcact gcaagccgcc ctgctgccga attctat 1847

<210> 76
 <211> 522
 <212> DNA
 <213> Homo sapien

<400> 76
 attttactct agtattaatg tggttttata aatgattata tgccttatat tctgggggga 60
 aagaaatgtg aaaatgtgct aacgtagaca gaaacagaat atataagtcg ttttgaatgt 120

57

tattttctttt	ttaaaaaatt	tgcttggtgt	catatagcca	aaactattca	tggtgacagt	180
ttcattgcta	tactttttat	atgatttcag	cgaattgaaa	acatgtatat	aatagcaaaa	240
aactggactt	catgctgagt	atagatgata	catataaaaag	aagtcaaaat	ttggagaaaa	300
aatttaaaaa	gataagtaga	aaaatgaagt	aactgtagaa	accatactta	ctctttgata	360
tcaaagtctc	aaaaactgaa	tgaaaatgtg	aatttaggcc	gaccaggtag	tcttgtcaat	420
aaactaaaag	caaaaacagg	aaaattgaga	aatatgttac	aactataaca	acacaaaaca	480
gcatagtttt	gaaacacttg	cagttcttaa	atataaaagc	tt		522

<210> 77
 <211> 1643
 <212> DNA
 <213> Homo sapien

<400> 77	
actgtcaatc	atcaattgac
attaacatgg	tcaattaagt
aatgtttctc	acccaacttt
60	
aaatttccat	agtcataacc
atggaaacat	acaaaaaaca
aacatgcaaa	taaaatgtca
120	
aaataattga	gctgagtact
ttgcatgctt	taggaaataa
gatgtagggg	ggttctttgt
180	
gccaatatat	tcaagtaatt
ggtttatctt	cccatgtttt
gctgctctaa	acatgatcta
240	
atataactct	cattcatggt
gacatagcag	agagctgcta
ggagtaaacc	tgttttctac
300	
acattaatca	agctgttctt
tcaaagtatt	gtttgacaca
ttgaatgttt	tttattctgg
360	
aatattatca	cagcaaaacc
tcattaattg	gatgctatca
aaattatgaa	aggaaatctg
420	
agtgagcaca	cttgttttga
aaagaaattg	gtaaataactt
ctatgatgca	gttttaagtt
480	
atacaattaa	ctgctatttg
gaatttaata	agtccactat
aagcaatgtg	cctgcacacc
540	
aattaaagg	tggatctgtc
tcttcttgac	aattttttag
aagccattat	ttcgttacca
600	
aataaacctg	aagttaagaa
atatttatat	ttacatctat
ttatatctgt	tgagaaatat
660	
ttcataactc	agacttggtt
gttttacaca	gacttctccc
cattatccaa	catagtgaga
720	
tttttctata	gttctatatt
ttactctagt	attaatgtgg
ttttataaat	gatttatatgc
780	
cttatattct	gggggggaaag
aaatgtgaaa	atgtgctaag
tagacagaaa	cagaatatat
840	
aagttgtttt	gaatgttatt
tcttttttaa	aaaatttgct
tggtgtcata	tagccaaaac
900	
tattcatggg	gacagtttca
ttgcttactt	tttatatgat
ttcagcgaat	tgaaaacatg
960	
tatataatag	aaaaaactgg
acttcatgct	gagtatagat
gatacatata	aaagaagtca
1020	
aaatttggag	aaaaaattta
aaaagataag	tagaaaaatg
aagtaactgt	agaaccata
1080	
cttactcttt	gatctcaa
at	gccccaaaac
tgaatgaaaa	tgtgaattta
ggccgaccag	
1140	

58

gtagtcttgt caataaacta aaagaaaaac aggaaaattg agaaatatgt tacaactata 1200
 acaacacaaa acagcatagt tttgaaacac ttgcagttct taaatataaa agcttttatt 1260
 agttaatttt ttaaaaaggat ctcataggat tgacactgaa tcagggtggg aggtggaata 1320
 aggggtgatgg catattcttt ctgaattact tattataaca tttctagaat cattaggtca 1380
 gtgctacttt gttgtcgtca atgtacaata aaggaatcac aaattgatct tagtgataat 1440
 tttacagagg cagacattgc acataggtat gactgcaaaa atgggtggct aactctggga 1500
 agatacttgt gttaaacttt atatgacatt taataaccct tcatcataag gcaatgtttt 1560
 ttacaaaaag attgcacaaa atcatgttag tcatttactc tgcaaaaatg gcacattagt 1620
 ggggggtcca aaatccataa tga 1643

<210> 78
 <211> 755
 <212> DNA
 <213> Homo sapien

<400> 78
 cgagggtataa aaactacgtc actctaaaat gttacaaata ggatcatctac ttagtatgca 60
 tagccttgat aaaaacattg gtcaagtcgg gatgtagtcg gccaccaact agaaatgtgt 120
 taagatTTTT ttaagcagac ttgcttaata aggcaaggag tggggtcagg ttgttctagg 180
 ggccagcaga aggggtctaaa atacagggtg gtgaaaagag attacgagac tagtgagttt 240
 cctttaaatg cttaactagt cattattaag acagccacat ttcagtgggg ctgagccaaa 300
 ctgctgagct tggaatagca tatgcttgga atctgaatat gaataaggcc caggtgccac 360
 actttacacc acagatcctt tgctaaagag gcactatttt gtctaacagg caaggaccag 420
 gctggcagtc aggaaggctg ggtttcggtg ctgatcttgt caccaactat gcactcttga 480
 acaagtcact tcacttcact atcctaagcc tggttatctca tctgaacaaa taacaggggt 540
 tagacttagc cttttacaat gacattttgt atatatctac tgagctctaa caattattac 600
 aacatatcta tgtctgacag ataggatagt cctacatatt caggaaactc cacgtatagc 660
 tctcctaaaa ctgattgttg cgtgttacca cacaacacaa caacatacaa acctgggcac 720
 tggcaacacg accggtcaat tctcccaaca caacc 755

<210> 79
 <211> 1002
 <212> DNA
 <213> Homo sapien

<400> 79

59

```

tatttcatct ttatagggaa ttgctccca aggtatattc ggcacgagaa aaaacctcat      60
atttaaaaac tacgtcactc taaaatgtta caaataggtc atcttcttag tatgcatagc      120
cttgataaaa acattggtca agtcgggatg tagtcggcca ccaactagaa atgtgttaag      180
atttttttaa gcagacttgc ttaataaggc aaggagtggg gtcaggttgt tctaggggcc      240
agcagaaggg tctaaaatac agggtagtga aaagagatta cgagactagt gagtttcctt      300
taaagtctta actagtcatt attaagacag ccacatttca gtggggctga gccaaactgc      360
tgagcttgga atagcatatg cttggaatct gaatatgaat aaggcccagg tgccacactt      420
tacaccacag atcctttgct aaagaggcac tatttgtcta acaggcaagg accaggctgg      480
cagtcaggaa ggctgggttt tgggtctgat cttgtcacca actatgcact cttgaacaag      540
tcacttcact tcactatcct aagcctgttt totcatctga aaaataaagg ggtagactt      600
agccttttaa atgacatttt tgtatatttc tactggctat aaaattatta caaatatcta      660
tgtctgacgg taagatagtc taaatattca ggaaaactcc aagtatagct ctcttaaaaa      720
tgatatgttg cgtgttaaaa aaagaaaaaa aagaaaagaa gaagggggag gaaaaataa      780
aatgaaaaaa acttcaaaaa tgcacggctg agttggtagc aaagaaggaa attctttgga      840
ggcaaaaaag atctagaaag tttaaatcca atgtgcagga gctggcattg cctagctaatt      900
ccctcatgat tgagaacctc agattataga cactcatggg gaccaagaga taaggcctgg      960
ggcctcaaaa aggccagagc cgaggtcgga tcaaagaatc cc                        1002

```

```

<210> 80
<211> 374
<212> DNA
<213> Homo sapien

```

```

<400> 80
tcttttctaa aactttaatt tccactatgg ctcttttgaa accattttta tcaagtcaca      60
tttcttagaa aaaattcact cagggttctg aaggaattag ttattttcta caagcaactc      120
tgtcatgagt gatagagttg tagctctctt agaagttttt ttccccttcc aaagagaatg      180
agaaatatgc agagatttcc ttactgactc actaaatgta aagattaaga ggacataata      240
aaatttgga ctacagtagc atataggttt tcagtttatt tactactaac tagctataac      300
ttagacaagt catttaacat gctgtgcttt agtttcatct ttgaaaccaa agagattcga      360
accagaaatc tctt                        374

```

```

<210> 81
<211> 399
<212> DNA

```

60

<213> Homo sapien

<400> 81

```

atggggaatt ccattgacac agtcagatat ggcaaagaat cagatntaggt ggatgttagt      60
gaagaacatg gtgaatggaa taaggaaagc tcaaataacg agcaggacaa tagtctgctt      120
gaacagtatt taacttcagt tcaacagctg gaagatgctg atgagaggac caattttgat      180
acagagacaa gagatagcaa acttcacatt gcttgtttcc cagtacagtt agatacattg      240
tctgacgggtg cttctgtaga tgagagtcac ggcatatctc ctccctttgca aggtgaaatt      300
agccagacac aagagaattc taaattaaat gcagaagttc aagggcagca gccagaatgt      360
gattctacat ttcagctatt gcatgttggt gttactgtg                               399

```

<210> 82

<211> 517

<212> DNA

<213> Homo sapien

<400> 82

```

gaaagtatat tgacgtaggt agtggagacg ccatgagttc ataactctgc cagagtcgca      60
gtatgatgta tccggcaccc gacaggtcaa gaaagaacta cttgtttcta ggaagaacat      120
atgaagtgct taatttataa gcgggctgtc gaattattac caatatagtt tcttctgaaa      180
agtgaaaggg gatcatctat tgttagatta gggggctctc gaaacttttt gaaaattcga      240
atcagtggaac caatgtacat gtgaaaacta aagagggcag ggggttaaat agggcttgaa      300
tttctcattc tgtatagacc agcaaaacttc cctgtgcaag gcaagtttac atcacaaatc      360
caagaatggt tgcatcctaa atgctagttt gcttcagccc ctagttaacc tcaggacttg      420
gtttgcatat aaaaggtaga cagctgatat gttttcatga ataaatattg tcagccagaa      480
aaggttgggt tcaggtaatg catatttttt taagctt                               517

```

<210> 83

<211> 619

<212> DNA

<213> Homo sapien

<400> 83

```

acacaatgat acccattttt gcatgttaat gtattattaa atatcagtgg gaatagtctg      60
catgctattt cacatctcag gcacacttaa ggaagacctt gtgatgtgca tggtgtcat      120
ttaatctaga aaggatacca agattcattt agaacttctt tatgcacagt ttttttttga      180
gtatgttatg tcctgaggca ttaagggtat tactaaagca agcagcggga cttctcagag      240
aaattaaagg tttcatatca accacacggt gtcaaaatct tcactttgaa taggattaaa      300

```

61

tgatgtttca tcagtattct tggcacacat gacattgttt ttaaaataac agttttatta	360
ctctgggctg tgacagtttc tcagactttc cttaatatca tacaattctc caattttaac	420
tggtatagtc agttttacaa tattttaatt accctgtatt cattagcact ttcctcattt	480
tctactacct cctccccagc tgcccctacc ctaggcaatg ccaaattctac tttctgtcta	540
tatatttgcc tattcttgaa atttcaaata aatggaatcg tataatacaa acaaaaaaca	600
ggaaaaaaaa aaaaaaag	619

<210> 84
 <211> 646
 <212> DNA
 <213> Homo sapien

<400> 84	
aatgatccat ataggcgaat ggtcatctaa atcatgctcg agcggcgag tgtgatggat	60
cggcgccggg caggtaactc acccccagg atagagaagt gtttgtagg gagagaagag	120
ggagaggcag gagccggccc aagcccaggg tccctgcttg ggcccagaa agcacttaac	180
caggcccaa gccttcaagg gaaaccaagg cctcaaccag acaatcttga ggaaggaaa	240
agccagactt tgggtttgtt ttttgggga attattggtt tttttttttt tatgtttctt	300
ttggaatttt gtttggtggc aaattctgtg tgatcttttt tcataaaaaa aaagacaaag	360
aatttacatt ggacaaaatt aaaaaaac aaaaaaaca acaaaaaca acaggcgtgg	420
gcggtctacc tcagggtggc atatgccgtt ggtgccggg ggtggtgaaa catgtggtgt	480
tatctccggc ctcaacaaat tctccccac acaattccg tccaccgac caagccgat	540
ctaacaacag gacatcatat agcaacctat atacgagcac ctcaacagca ccaacgacag	600
ccaagcgaga cgaacgacca acagacacac cactcacaac caaagc	646

<210> 85
 <211> 419
 <212> DNA
 <213> Homo sapien

<400> 85	
cggcgccgg gcaggctactt tgggtgatac aggcgtggaa gaccttgagt tccctgtgg	60
ctaccccatc atagttcctc ctaaggctat accagataag ccatacggag cagatgacca	120
gcaagaacct ttccagaatt attattctaa ctagaatctt agccaagaga atggaatcac	180
cacaaatggt atcatgaaaa tcattctcaag taaatttctt attccattca taccgttaag	240
ttgaggctcg atgatatacg aaaactttaa ctgaattgac ttcataaagg cttaatggtc	300
ttcaaaatta tgctgggttat atgaattctt aaattcaagc tcttttccaa ataataaatg	360

ataaaacaac attttaatta gtattttacg taaaaatata tattaataaag taaatcaag 419

<210> 86
 <211> 2133
 <212> DNA
 <213> Homo sapien

<400> 86
 ggaagtacag gataatatta aagtcaaata gagtacagtt cttcagcatc ataaatcaaa 60
 attcaattgc taaaaaatc aaaacttgtc agactttttg ctttaataca aatagttgga 120
 atttctgagc aatcagggtt atctttaaat atgttttttt ctgagctttt ttacttcaaa 180
 aacgatgaga attatcaatt tttcagtact actgacttgt tcotttgtgga aggagggaac 240
 attaagtatt taaatcaatt tcttaagtct tcgagtatca aatttatatt gtttaattctt 300
 tgatttaatg tttacatgg gcacttttta tattctctta cctgagttag ttttgaattc 360
 ctagaacatg tccattttaa cagtgggtgt gatattatct agttaatact actgtctgga 420
 ttattttaaa atcttggtac aatttgata aaacaacata acacttgta acttgccagt 480
 cctctaggaa cttgtttcct ttccttactc tgaatagact agtggtagct gtccattatc 540
 ttttacctta attacgattg tttgaaccac atttaaatc caaatctat attattgggt 600
 taaaagcttc aacttgaca gatattatta acagtctaca tgaaatctc aaattatata 660
 tgaattttca aacattgata tcagctcctt gatttacttt ttaatatata tttttacgta 720
 aaatacta ataaatgttg ttttatcatt tattatttgg aaaagagctt gaatttaaga 780
 attcatataa ccagcataat tttgaagacc attaagcctt tatgaagtca attcagttaa 840
 agttttcgtat tatcatcgag cctcaactta acggtatgaa tggaatagga aatttacttg 900
 agatgatttt catgataaca tttgtggtga ttccattctc ttggctaaga ttctagttag 960
 aataataatt ctggaaaggc tcttgctggt catctgctcc gtatggctta tctggtatag 1020
 ccttaggagg aactatgatg gggtagccaa aggggaactc aaggctctcc acccctgtat 1080
 caacgaaagt actctaattg ctgttttaca tactgggatt atttgtaaga tttcatttga 1140
 aaggaagggt ctttagacca agaaagaaaa ggaaaaaggc tgaaaccaat gacctgctcc 1200
 aatctcttag aaactgaatc tcagagaagt taacttcaag gtaaaagcat ttgttagtgc 1260
 tagaggtaag atgaaaatc aagttttttt attccttgctc ttcataataa tataattatt 1320
 gtgatgtctt ttgtacaatt tgcataatac tatgtatata ttcacatgta gtatttaagt 1380
 tacataagt atgggtacta tgaaattact attgatcaag aatgactatt agattttaat 1440
 taagattaca ctttatttct tgtaaaaggc gatttaaaat gcacattcct taccaatcta 1500

```

.atttgaatca tgattagcct cagtttaatt atccttacia aaatatatttt gagtggttgg 1560
gatcagtttt aagttgagct cctagatttg ttgaatagga aaggatacta ataactgttc 1620
taggggaaat gattttgtaa tatttcacct tgaatttttg aactgaacct tataaactag 1680
tcttcagaat gactaagcag gttaaatgtt ttagcattta aatgtcaa atagagaaatca 1740
atctgacttt tggaaaaaag aaagatgttt aatttaaaat atgtaaagca aacttccaaa 1800
tttcttccat cagtaagagt aactaactgt ctgaatgtag ttattattat tgtgtcaagt 1860
taaagtattg tacatacttt cctttacaga tttggataag tgaagacagt aataacattg 1920
aagcagtga cagtggaag gagacagtaa taaatccaga aaagggttgtt atcaggtggc 1980
acaaattaaa tccatcttga agacttcaca cattaatttg gtgaagaact tgacattctt 2040
ttagaagact tatgatttca atttgctacc aatgagaaga ggcaaataca caaatttgtc 2100
aatttatggg ggctataatt atggtatata atg 2133

```

```

<210> 87
<211> 493
<212> DNA
<213> Homo sapien

```

```

<400> 87
gcggccgccc ggcaggtctt cgatctcccg ggggtgctggg attacaggtg tgagccacag 60
cacctagcct taccttcaaa ttctaaacca agctatttaa atagccactg tttgattatt 120
tgaattaaca tggagcatct tctgggatat tgttcagggg aatatgagta gatcaaggta 180
ttttggggat gtaaaccctc atgtttgata aaataaatga tattttgagc tactgtttgc 240
tggggaacaga aagtaagaag ggaaaaggag cgaccataca ggaaagtaaa aataataaaa 300
gaaaatttag aaaactagag gaaaagggtat gaaaggataa atcctccatc ccatactgat 360
aatggccttt gagcatcact aagccccttt gcttctccca ttaagcaaag gatgatgact 420
gaggaggaac aaacaaaaat agacatcatt ataaaaaata cccaagactt ttagatgttt 480
ctctaacatt tgg 493

```

```

<210> 88
<211> 1412
<212> DNA
<213> Homo sapien

```

```

<400> 88
tgaattagcc atacaaaaaa aataaaaaat tactgttagt caccctacag tgcaaggtaa 60
cactagaatt tatctttcca tctagtaacc actgtttttt aaagagacag agtatctccc 120

```

64

```

tggtgcccc gctggagtgc agtggcacaa tcatagttca ccacaccctg gaactcctgg 180
gctaagggat cctccttagc ctcagcctcc caagtagcta ggtatacagg catgtgctac 240
catgcctggc taattaaaaa agatTTTTTT agagatgagg tcttgctgtg ttgccaggc 300
tggtctcaaa ctctggggt caaacaatcc tcccaccttg gcctcccaa gtgctgggat 360
tacagggtgtg agccacagca cctagcctta ccttcaaatt ctaaaccaag ctatttaa 420
agccactgtt tgattatttg aattaacatg gagcatcttc tgggatattg ttcaggga 480
tatgagtaga tcaaggtatt ttggggatgt aaaccctcat gtttgataaa ataatgata 540
ttttgagcta gtgtttgctg ggaacagaaa gtaagaaggg aaaaggagcg accatacagg 600
aaagtaaaaa taataaaaga aaatttagaa aactagagga aaaggatga aaggataaat 660
cctccatccc atactgataa tggcctttga gcatcactaa gcccctttgc ttctccatt 720
aagcaaagga tgatgactga ggaggaacaa acaaaaatag acatcattag aaaaaatacc 780
caagactttt agatgtttct ctaacatttt ggggtcattt tcagattacc agtgttcatt 840
tgctgaggta tattaacgga tatttgact taatttgaaa aatagcagga tccaaaccag 900
aggctctgat aagagcaggc ggcatgctg tctggagagc tgctgcctcc acaagtattc 960
tgacagcact gggctgctag tgagacctgg atggccccc tcccattgtc atggccatgg 1020
gttttcggga accgtttcct ccttttactg catcacagtt gcaaactcgt ctatttattt 1080
ttctcttgat taacaactgc actctgacat tgcagcagtg ttgatgaaga caatttaact 1140
catgtttttg ttaacataat aattgtctgt cgtaactaaa atataagttt cttgaaagct 1200
ataatcaggt atagagaaaa tctttgttat gcacaatacc agggcaggta atatctgtaa 1260
tatgtattaa cagcaattca ctaaacttg aatgtctctg tatgctggca cctgtgctaa 1320
agatttgctg tataaagata aataggaaat tgcctcttct cccacgaaac tcaaaacatt 1380
tattgaatga ataaataata ggtgaattaa ta 1412

```

<210> 89
<211> 624
<212> DNA
<213> Homo sapien

```

<400> 89
ggtacttgag gtgtttctca ggtccagaa catcctgtc atcttaccag atccttcaag 60
gattcagctt aaagatcagc tccaccagga agccttcttg gatttccct cttagtttcc 120
aacaagaatc cggctcttcc gttctctgcc caccttgag tagcagtagc gttcagctgt 180
gagactctcc gtgtttttcc cgttacagtc gtttgtttagc gtgcatcctc tttcgactga 240

```


65

attagttaga tgtgagaccc taggactctc ttgttttctt cgttacagtc tttgttgctg 300
 catcctctct cactgaattg ttgaattgtg agaccctgtg agggtcggca ccctgtgata 360
 ctggccagga aagggttggt gcaaggggat catgggattg ttgaatgggt tttgatctgg 420
 attttgatgt tggaaatcaa gttcccaaatt gttttcaacc ttgggttaaag gaacatgtaa 480
 tgggtgtttt taacaaaaca aaaaattaaa aaaaaaaaa aacaaacata aaaaacaacc 540
 aacggctggg ggcacccggg ggcaaagggg gcccgggggg acattgtttt tcccggtaaa 600
 atccccaaat tgggaaaaaa aagt 624

<210> 90
 <211> 659
 <212> DNA
 <213> Homo sapien

<400> 90
 accacgcctg tagcctctgt ctagagtagt tcacacatgg atgctgtctc tctgggtactt 60
 ggggtgtttct caggttccag aacatccgtt catcttacca gtccttcaag gttcagctta 120
 aagatcagct ccaccaggaa gccttcctgg atttcccctc ttagtttcca acagaatccg 180
 tctcttccgt tctctgccc ccttgagtag cagtagcttc agctgtagac tctcctgttt 240
 ttcccttaca gtctttgttg ctgcatctc tttcactgaa ttgttgatgt gagaccctag 300
 actctcctgt tttttcgta cagtctttgt tgctgcatcc tctctcactg aattgttgaa 360
 ttgtgagacc ctgtgagggt cggcaccctg tgatactggc caggaaaggg ttgttgcaag 420
 gggatcatgg gattgttgaa tgggttttga tctggatttt gatgttgaa atcaagttcc 480
 caaatgtttt caaccttggg taaaggaa ca tgaatgggtg ttttttaaca aaacaaaaaa 540
 ttaaaaaaaa aaaaaaaca acataaaaa caaccaacgg ctggggggcac ccggggggcaa 600
 agggggcccg gggggacatt gtttttcccg gtaaaatccc caaattggga aaaaaaagt 659

<210> 91
 <211> 556
 <212> DNA
 <213> Homo sapien

<400> 91
 aattttcaac tggcccatatc tttatagtga tggaaagcgc ataactactac ttgtaaatca 60
 ttaaaatagg gtgataactg tgataatagt gtttcttgca ttctagaaaa ttattttatt 120
 aactacattc aaaaccagc atttcacagg ttccatcatt agaaacagta tagttctagt 180
 taacatgatt ggagagtctc aggggaaagg tttacatttt ctgaaactgt atttggtatg 240
 tgactcaatg tggatattca gtcttgtag tcacttacat gactgacgtt tgcaaggatt 300

66

tattgccaaag taaaatttga tcagagtgcg ctgagaatag ctacataagg ggaaattctct 360
 caaaattcct tctgttcact ttaattcgga gcatatgttt caactcattt tcacacatct 420
 gtcccacagt tgaagcatta acacacatct tcacgacaca atgaacacat acacattagc 480
 aaacataagt ctcttaatgc aaaattacta gttgactaca atatagctac cttaaaagca 540
 gagcttgcta taattc 556

<210> 92
 <211> 635
 <212> DNA
 <213> Homo sapien

<400> 92
 acaaaatata atgttataaa tgtattttaa aaaaagaaat acaaattcta tggctcttttg 60
 cattttactg cctcaaagca gaattagcaa agctgatgaa gaatgaacat tttcccttgg 120
 gcgggtggcc ctgtgtcact cccacaggca cgttaccggg ctccggcgtg tgctcccacc 180
 aaccacggca aacaaaggcg tcctcctcac ttgaagtcct ggcctgtggt tgtttcatct 240
 gtttttttgc tcagtgaaca aaacgttctg aaattagaac tcaccaaagt taaaagcagt 300
 aaaacaacat atgctactta agacattttg aagcggaaag taaagctatg tgaatgccgt 360
 ccttccttcc ttcctttttc tacagcttgg aaacctctga gaatttgctg gcgggtggca 420
 gaggagggct tcgtctagct cttgaacgga caggaaactgt ctggctagac agctctccag 480
 accacgaaag cccaggaggt gccctcttcc acacaacaga ctaagcactg caccacttt 540
 ctttgatcca gaaagcatcc ctactgacct tgtaacctac accctctctg tccaaagaac 600
 agaggccgac cagagtagcc agcctggaga ggcac 635

<210> 93
 <211> 8156
 <212> DNA
 <213> Homo sapien

<400> 93
 cggggcgtgc gcgtcctcct cccaggcccc gccgcctccc tgccaagaat ctgagagagg 60
 ccgagtggag ttcggtcctt ctctgaacag ttttagctga gagtaccagc atccaactgg 120
 gagcgttgtc attgcatttc cacattccca ggaaagccca ggtgctggct gccagctgct 180
 gcgcccccca tgtagaaggc gcacctctg ggagcaggca cgtcttttgg ctcttctgac 240
 catggagaga taggacggtc cctgcagccc gcgcgacaga aagctgtgcc gccaccaccg 300
 gccgcgtccg tccttcggat ggatcgcaac agagaggccg agatggagct gaggcgaggg 360

67

cccagcccca ccagggccgg ccggggccac gaggtggatg gggacaaggc tacctgccac	420
acctgctgca tctgcggcaa gagcttcccc ttccagagct cgctttcgca gcacatgcgc	480
aagcacacgg gcgagaagcc ctacaagtgt ccctactgcg accaccgggc ttcccagaag	540
ggcaacctga agattcacat ccggagccac cgcacgggga ctctgattca gggacacgag	600
ccggaggcgg gcgaggcgcc gctgggtgag atgcgcgcct ccgagggcct ggacgcctgc	660
gccagcccca ccaagagcgc ctctgcctgc aaccggctgc tgaacggggc ctgcgaggcc	720
gacggcgcca gggtcctgaa cggggcctcg caggccgaca gcggcagagt cctgctgcgg	780
agcagcaaga agggggcaga ggggtccgca tgcgccccgg gggaggccaa ggcagcggtc	840
cagtgtcctt tctgcaagag ccagttcgag cgtaagaagg acctggagct gcacgtgcac	900
caggcgcaca agccgttcaa gtgcaggctg tgcagctacg cgacgctgcg ggaggagtgc	960
ctgctgagcc acatcgagag ggaccacatc accgcgcagg gggccggcag cggcgaggcc	1020
tgcgtggaga acggcaagcc cgagctgagc cccggggagt tcccgtgcga ggtgtgtggc	1080
caggccttca gccagacctg gttcctgaag gcgcacatga agaagcaccc gggctccttc	1140
gaccacggct gccacatctg cggccgtagg ttcaaggagc cctggttcct caagaaccac	1200
atgaaggcgc acggccccaa gacgggcagc aagaacaggc ccaagagtga gctggacccc	1260
atcgccacca tcaacaacgt ggtccaggag gaggtgatcg tcgccggcct gagcctctac	1320
gaggtctgcg ccaagtgcgg gaacctgttt acaaacctgg acagcttgaa cgcccacaat	1380
gccatccacc gcagagtcga ggccagccgc acgcgcgccc cggccgagga gggggcgagg	1440
gggccctcgg acaccaagca gttctttctc cagtgcctga acctgaggcc gtcggcgggc	1500
ggcgactcgt gccctggcac gcaggccgga cggcggtgg ctgagctgga cccggtcaac	1560
agctaccagg cctggcagct ggccacgcgg ggtaaggagg ccgagccggc cgagtacctc	1620
aagtacgggg cctgggacga ggcgctggcc ggggacgtgg ccttcgacaa ggacaggcgc	1680
gagtacgtcc tggtagacca ggagaagcgc aagcgtgagc aggatgcacc agccgcgcag	1740
gggccccgcg ggaagcgcgc gagcgggcct ggggaccccg cgcccgccgg ccacctcgat	1800
ccccgctcgg ccgcgcgccc caaccgcagg gccgcagcca ccaccggcca gggcaagtcc	1860
tccgagtgtc tcgagtgcgg caagatcttc cgcacctatc atcagatggg gctgcactca	1920
cgcgtgcata gccgcgcgcg ccgcgagagg gacagtgacg gggacagggc ggcgcggggc	1980
cgctgcggat cactcagtga ggggtgactg gcctcccagc ccagcagccc tggctccgcc	2040
tgtgccgctg ctgactcccc gggctctggc ctggccgacg aggctgccga agacagtggg	2100
gaggagggcg cccctgaacc tgcaccaggg ggacagccgc gccgctgtg cttttccgaa	2160

gaggtgactt cgaccgagct ctccagtgga gaccagagtc acaagatggg agataacgcc 2220
tcggaaagag acaccggcga gtccaaggca gggatcgag cttctgtgtc catacttgaa 2280
aacagtagca gagagacttc tagaaggcaa gagcagcaca gattttctat ggacttaaag 2340
atgccagcat ttcaccccaa gcaggaggtg cccgtccctg gtgatgggtg ggagttccct 2400
tccagtacgg gagcggaggg ccagacgggt caccctgcag aaaagctgtc cgatttgac 2460
aacaaggaa actctggggg agggaagcgg gcgctggccc cagacctcat gccgctagat 2520
ttaagtgcga ggtcgacgcg ggatgacccc agcaataagg agacggcctc ctccctgcag 2580
gcggctttag tcgttcaccc gtgtccttac tgcagccaca agacctacta ccccgaggtc 2640
ctgtggatgc acaaacgcat ctggcaccgt gtcagctgca actccgtggc tccccctgg 2700
attcagccca atggttacia aagcatcaga agcaatttgg ttttccttcc cgggagcggg 2760
cgcacggggc ccccgctgc cctcggtggc aaagaatgcc agcctttgct ccttgctcgg 2820
ttcacccgca ctcaggtgcc aggggggatg cgggggtcca aaagtggctc ttctcccctg 2880
ggagtggta caaaagccgc tagcatgcct aagaataagg agagccattc cggaggtccc 2940
tgcgctctgt gggcgcccgg ccctgacggg tatcgacaga ccaaaccttg tcacggccag 3000
gagccacatg gcgcggccac acaggggccc ctggccaagc ccaggcagga ggtagctcc 3060
aaaccggtgc ctgccccggg tggcgggggc ttcagcagga gcgccacccc tacgcccacc 3120
gtcatcgccc gggctggcgc gcagccctcg gccaatagca agcctgtgga gaagtttggg 3180
gtccccccag cgggggctgg ctttgccccc acaataaagc acagtgcctc ggactccctg 3240
aaagccaaat tcagtgtca gcctcagggc ccacctcctg caaaggcgga agggggcgct 3300
cctcctctac ctccccgca gccccctcg aaggcagccc aggagctgag gactctggcc 3360
acctgtgctg cggggtccag gggcgacgcg gccttgacag cccagcccgg cgtggctggg 3420
gcgccccccc gtctacact ccatcaaca ggagccagtg gccgaggggc atgagaagcg 3480
cctggacatc ctcaacatct ttaagacgta cattccaaag gactttgca ccctctacca 3540
gggatggggg gtcagcggcc ctgggttggg gcacagaggg aactccgga cgcaggcccg 3600
gccaggagag ttcgtctgca tcgagtgcgg aaagagcttc caccagcccg gccacctcag 3660
ggccacatg cgggcacact cagtgtgtt tgagtccgat gggcctcggg gttctgaagt 3720
tcataccacc tccgcagacg cccccaaca agggagagac cattctaaca caggtaccgt 3780
ccagacagtg cctctgagaa agggaacctt aaggcgtgtt tccgacgcac cccaggtccc 3840
cgtaacggcc attagcagta ccctcacgat gtcccagcag cctccacact gtgacctggc 3900

69

cgctccatgg aagaacagcc ggggaactcc tgagcagaca cctcacatcc cgagccgctg 3960
 cgctggagtg gaaactgaag gcagatgcct ctccttgta aacgttcaga aataaatgaa 4020
 gatgctatat tctagaaata catgtagata ctatatacgc atttacgtgc tcatcgtcca 4080
 tagtcccata ttttcttata ataaacagta gtactggcag gcacagtagg ggcacaaggc 4140
 atctgtctta ttcaagacaa gtttgagaca ctggaaaaaa agatacttgt tgtgtgtgtt 4200
 ggacagagtg gcgaggctga gactgtcac aggggcctcc catgttaaga gggactgtgg 4260
 ggatgatgtc agaacaagac gtggtggatt tgaggttgat cgagtattaa tactactgcc 4320
 tctccttgtc ttagtgggta tttaaaatag taaataagag agaggaagga ggtgacgttc 4380
 aggtgctgtg ggaagcaggc ttggcggagg ggtatgatga tgagaccctc attgttcact 4440
 ggctccatcg cactcctccc tggggccgtg tgctgttcc attcttccca ccattcgaac 4500
 tgagcgaatc tggcaaagga gacacgtctg tgggaatgcg tagattccgc ctccgaagag 4560
 agctagcgca acactaagaa aagcaggctt cttgtttatt ctccaggacct ttttgaaca 4620
 gggctacatt ctgcaaactg cttacaaagg aagactatac gtcttaacaa attatttagc 4680
 cactgagtcc tcccgattcg gacctgtttt agtaatggca gaagaatccc tgagcagggt 4740
 cagggtgccct agatgactag ggtgctgagc tctggcgcct tctgtcccca ctctttgcct 4800
 ccccgccct tccctgagcc accccagcaa gtgggtgtct tttctccctg ggctgggtga 4860
 cctccacagg atgagtgact ttgttcataa aggggtggga tcaccagccc cttgggtggg 4920
 ggacggcttc atatacctct tcctcagtaa tgcaaagcg agtttttgtg gtgggggtta 4980
 aggcccataa caaaggatct taaaccatgc agtgtacgca attgaaatgg tattccacag 5040
 atataaatat tttcttttcc cattgccgtg acactatgtg tgatggtaat atttctgaga 5100
 gtttcagatt tttgcacata tgattttatg cattatcaaa agttactgct gccttgaatg 5160
 aaaatgttct gtgaaatfff ttgcaaaagc ttactaggt ttttttttaa ttgtgaaatt 5220
 ttgtaaaggc aggaaatgga ttaaaacgag catgctaaat atatttttca aaaaagcaat 5280
 aattttacat gtacagaaat taccctaacc ttaatactg gcgagagcaa cagtttactt 5340
 aatacggtaa tggactagtg cagtttttgt agacagtggg cttctgatac aaagtcttgt 5400
 ttaaacacag acacacacac acacaaacac acacacacac cctaaagtgt gggtttcttg 5460
 ttctaataatgat ttgttgaata ttattatatt attattatta ttattattat tattgttatt 5520
 gttatttagta atgtttgggt ctggattcta cttgttactg agtttaaat acttgacgggt 5580
 tcaggttact ttgcaacact ttcaaacgat gcaatgtaac tggctagctt atatatatat 5640
 atatatatat atatatatat attttttttt ttttttactt atttttttct gatattctta 5700

caccagatat gtacgaaaat gatctgtcct gttggtgtaa ttaggaatgt ccatgcagat 5760
acagttaaac aactgtaatt gactgttctg taaagttatt ttgggcaaag ttgaggagac 5820
acattcctct gtccacctaa gaaatcagaa gactcttctg ttgatttatg tttaatcatt 5880
tcagtagttt cccacagtg atcatttctg cattttctgg cttttgtttt cttggctgaa 5940
agtgaatggg gactgttagg aatgtcaggg actagtacc cagtcctgtt tctctgtgtt 6000
ttagttatta aaaagaaatt ctgtaccaa agtgacacga aagtgtagtc tacattttta 6060
ctgtttcaga agcggcatgg aaaagtgcag ttggcctttg gagctggaag tgtcttgctg 6120
gtgaggctcc atcctggagg ctctggtggg gagtgggctg gcgctggggc cctgccggcc 6180
gcgtgctgga tccttcctgg cttgcaggag agcaggcgtg gaggacagtc agcttgccgg 6240
gccgcgcagg gtgcacagag tgcaggagga aggttttcac ccagttaaac agactgggga 6300
gccccccaa gaacgccatc ccttgaggcc agctgtgggc aggcctggat gtgtggtccc 6360
ttccttcac ccacgtcag tattgtgttg gtttgtaat ttgttgattt ggcatagta 6420
tttaatatga tttgtgttc cttatttatt tagccaccgt tttgattgcc ttttttttc 6480
cgaatggtaa tttctgcatg atacacttct gtacgttgtc ttctgactgt tacagacttt 6540
ctactacctc tcccgatctg ctgtttcctt gtttctaac aggatttttt acagtgttgc 6600
gtctaatagt acttagacaa taaagggttt ggttgcttac actgcagctt ctcggtgtct 6660
ctccctgct ttcgctcgc tgettcgcc tctgccctg ctggggcctg gctgcaccct 6720
ggcctgcctt cctatactct cctgtttccc gctcatatct cttcctcatt tttgcgttca 6780
aataacacac agctaatagt cttctaaaaa tcttttcagg ttgttcactt gtattcctta 6840
atttgaagaa tgaatattta aattctctca aaagtcagat attgaggatc ttctctggga 6900
aattggccac tgtacctgcc cacctttctg cctggttccc tggaaggctt tattgtcatc 6960
ttagacggac agatttcatt ctcagacca tacagatttg gcttcaaagc cagggtgaatt 7020
ttgcctttga ggctctgaaa agtattaagt gttttaagag gtccccaat atttacttat 7080
ttatttttta aaccaagaaa gacactggtt cctgaaaag cagggtgctt aggaagtagc 7140
aattgggagt tgcatacagt tacttcgtca gagaaaggag cggccagtat gacaggcccc 7200
caccctgat ccggccactg tgcacaggtc gctgagggtg tgagaacacc tctgcagggg 7260
ctccggcaca tgtgggtttc atcgtctcac actccttcag gctgcagggg ttgagtgcag 7320
aaagggcaag cttcatctcc atggtgcctc tccaggctgg caactctggt cggcctctgt 7380
tctttggaca gagaggggtg aggttacagg gtcagtaggg atgctttctg gatcaaagaa 7440

71

```

agtgggtgca gtgcttagtc tgttgtgtgg aagagggcac ctcttgggct ttcgtggctg 7500
gagactgtct accaacattc cttccttcaa actagacaaa ccctcctctg ccacccccag 7560
caaattctca gaggtttcca agctgtagaa aaaggaagga aggaaggacg gcattcacat 7620
agctttactt tccgcttcaa aatgtcttaa gtagcatatg ttgttttact gcttttaact 7680
ttggtgagtt ctaatttcag aacgttttgt tcactgagca aaaaaacaga tgaaacaacc 7740
acaggccagg acttcaagtg aggaggacgc ctttgtttgc cgtgggtggg gggagcacac 7800
gccggagccc ggtaacgtgc ctgtgggagt gaccaagggc caccgcca agggaaaatg 7860
ttcattcttc atcagctttg ctaattctgc tttgaggcag taaaatgcaa aagaccatag 7920
aatttgtatt tcttttttta aaatacaatt tataacatta tattttgtac tctttatatt 7980
agaatttgta actagattga tgtatttaac tatttctgaa aaagtaattc aatgttttag 8040
ttgtgtgata aaaatattta gataaaacat attcattcta ttggaatttg aaataaataa 8100
aaacatcttg gagttctgaa aaaaaaaaaa aaaaaaagat ctttaattaa gcggca 8156

```

```

<210> 94
<211> 668
<212> DNA
<213> Homo sapien

```

```

<400> 94
tggtcgcggc cgaggtatcc cttagaaatt gacagcttct atgaaattta caatcaagaa 60
ggcataagaa caactgctgc agcttcagaa ctatgcagaa aataaaatgt caacagctgg 120
gagaaaaaat tctcagtgag caacagagcc agtgaaaaat atcaccagta gagcaggcac 180
ctgagacagg gaaatggcac ccactaagtg caggtctaca ggggctgacc ttgcagacca 240
tttatggatc ccaagttacc aaaaccctta tttgattatg aactgcatag tagataccaa 300
tacatcagag cattgtctca atgttaatat ctatctgtgc tgattgtatt gtggatcatgt 360
aacagaatga atgcccttgt tcttaagtga tacgtgggaa aatatttgag ggggtgaagtg 420
tcatgatgtt tgctacttac tctcacatgc tttggcaaaa ataaaacatc tctctctctc 480
caggcaaaat atagtaatca gtaaaatatt aacaatctgt aaaaccacac cacaacaaaa 540
caaaaaaggt tgggggacaa ccaagggcaa aagggtgttc ccggggtgaa atttgttttc 600
gggcacaaaat tccccacat ctccgcaca aagcgggagc aaaaaaacc acaaaaaaca 660
cacataca 668

```

```

<210> 95
<211> 746
<212> DNA

```

72

<213> Homo sapien

<400> 95

```

gactaagaca cctttctaga cagagaggag gccgatggca gacattctca gataggtttg      60
tagctattga cctggctgca tcaaaggaga tgaaatccct tagaaattga cagcttctat     120
gaaatttaca atcaagaagg cataagaaca actgctgcag cttcagaact atgcagaaaa     180
taaaatgtca acagctggga gaaaaaatc tcagtgagca acagagccag tgaaaaatat     240
caccagtaga gcaggcacct gagacagga aatggcaccc actaagtgca ggtctacagg     300
ggctgacctt gcagaccatt tatggatccc aagttaccaa aacccttatt tgattatgaa     360
ctgcatagta gataccaata catcagagca ttgtctcaat gttaatatct atctgtgctg     420
attgtattgt ggtcatgtaa cagaatgaat gcccttgctc ttaagtgata cgtgggaaaa     480
tatttgaggg gtgaagtgtc atgatgtttg ctacttactc tcacatgctt tggcaaaaaat     540
aaaacatctc tctctotcca ggcaaaatat agtaatcagt aaaatattaa caatctgtaa     600
aaccacacca caaccaaaca aaaaagggtg ggggacaacc aaggggcaaaa ggggtgtccc     660
ggggtgaaat ttgttttcgg gccaaaaatc ccccatctct cccgcacaaa gcgggagcaa     720
aaaaaaccac aaaaaacaca cataca                                           746

```

<210> 96

<211> 978

<212> DNA

<213> Homo sapien

<400> 96

```

cggccgaggt accctgtgcc aactagggga ggagaactgt tgccctgctaa gttgggtggca      60
ggaaccagct tcctgaagga tataaattcg ctggaagaaa gaccttggtt tatgttccag     120
tgctgttttc ccctctctag agcagtggct ggcagacatg tggctactca agaattggtc     180
ccagatgaat gaatgcagga aacagttccc tcctccaatg agattaacag ctgatccatg     240
cttataatga ctgaactctg taaagagggg aacctctctc caatggggga tcaaaatggg     300
taatgagagc cctgctgtgg agagaggtag gacagcaagc acagaagcac ctgaccccat     360
gcagaggacg ggaggcagaa gcaggggcca gactggaggg agtgatctcc atatgcccac     420
atagcatcca tctgtcttgc caagcacctc tctggggtcc tctaccttta ccagagcata     480
gtctcttgtg cagatcaatg aaacgaagcg aagctggata gactatggcg agagcacttc     540
cctctctgcc tcccccaaga tgaatggcta cttgtggaga ggagctgtgg catataaaca     600
ctttcatcct tacccaaggt ccccatctct cctcaaatgg cataacaggc agacgagcgg     660
ccaaccaact ccctctgatt ctcatacaca ggggtgtggc ttccattggc atctttgagt     720

```


73

ggccccaagt cgtacgcaga ttgtggactc agtacacagc ttgcgcaaac ctggacaatg 780
tggccatggc ccatcataca cctctacacc acctcatagc gacgttgaat atgagatcca 840
cccgtagtgc ccagctcata acatcctctc cattaagatt gaccacaggc aacttaccat 900
tgactaggac caagtccccc aaacaccaa attgagaaca gagcaacatg gtgccaaaca 960
tatcacagag aaatcaac 978

<210> 97
<211> 787
<212> DNA
<213> Homo sapien

<400> 97
acctggcaca aagcaaaca taaatattat tgttattggt gttataattg taaaatgaat 60
gacttcaaaa acatagtccc agtttggagg gattttgtga tgcagaatat ctaagtcata 120
gaaatagaag acaggtggaa taagtatatg ttcagagttt ttagatgtgt tgagtagaga 180
cggtaataat ggaagcatta aatacaaatg aaaatcacac cagatatccc tgaaattcaa 240
gcaaagaaag ttcatcatgt attcttgggc agcaagagaa aggactaggg ttatggcaat 300
gtgtggaaaa gttgaggctt gctaagggtt gagatctgtt ggtagccctg gatcacatgg 360
ggtcagcacc aggcagtgcc tctgaaagcg gagagaggtc ctggacttcc cttgtgtata 420
acagttccta gtgtccaaca atgaggaaac ggtgaagcat gggtacaaa ctgtgacaaa 480
acatatttac atctagcact gttaccactc accatgccaa acattggctg cacacgtgca 540
gcccttattt gtaattaaca tcaaaagact agatctgaag ccttcataa atgagagacc 600
attcatatgg cattcctgga acaaaacact gcacaggtag caaggctctc cactccctga 660
cgggttggtg ctgaacagtc agggattgtc ttgactagac ttctgatgct tctgcatctt 720
ctttcctctt cccggaattc caaataacca attcatacca ttgtatttat gcttcgggta 780
acctagt 787

<210> 98
<211> 3670
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (3416)..(3416)
<223> a, c, g or t

<400> 98

74

agcggacagc cgctccctcg ctctgctggg gcctccggac gcgcttccca cgcgggtctc	60
tggaacactc ggtccgaacg cacgcctgct tgcactcaca ctgcggttca cacccgagg	120
cgctctcgca ctcacactgc cgctcacgcg cgctcacact cccccacgcg cgctccgctc	180
cggctccagc cccgcgcccc gcgaaggcgc aggcactgct gccgagagcg ccgagggggc	240
ccgcggcctt cccatggcgg acctgagctt catcgaagat accgtcgctt tccccgagaa	300
ggaagaggat gaggaggaag aagaggaggg tgtggagtgg ggctacgagg aagtggttga	360
gtggggctctg gtgtttcctg atgctaattg ggaataccag tctcctatta acctaaactc	420
aagagaggct aggtatgacc cctcgctggt ggatgtccgc ctctcccaa attatgtggt	480
gtgccgagac tgtgaagtca ccaatgatgg acataccatt caggttatcc tgaagtcaaa	540
atcagttctt tcgggaggac cattgcctca agggcatgaa ttgaaactgt acgaagtga	600
atttcactgg ggaagagaaa accagcgtgg ttctgagcac acggttaatt tcaaagcttt	660
tcccatggag ctccatctga tccactggaa ctccactctg tttggcagca ttgatgaggc	720
tgtggggaag ccgcacggaa tcgccatcat tgctctgttt gtccagatag gaaaggaaca	780
tgttggtctg aaggctgtga ctgaaatcct ccaagatatt cagtataagg ggaagtccaa	840
aacaatacct tgctttaatc ctaacacttt attaccagac cctctgctgc gggattactg	900
ggtgtatgaa ggctctctca ccatcccacc ttgcagtga ggtgtcacct ggatattatt	960
ccgataccct ttaactatat cccagctaca gatagaagaa ttccgaaggc tgaggacaca	1020
tgtaagggg gcgaacttg tggaaggctg tgatgggatt ttgggagaca actttcggcc	1080
cactcagcct cttagtga ca ggtcattag agctgcattt cagtagccaa agaggacagg	1140
aacaagtctg tcttcatgag ggaggaagac aatggtccta taatgccctt ggataagaaa	1200
aggaaacttt tgagctgcac cttcagttta tcctcaaagc ctgcgttggt tgtcttcac	1260
taatccagct ttgatggaca tctgtgatgg ttgcctgtac acttgctgaa atgaaatatt	1320
agaaatggct gtatattcca aagaaacct atattatata tccacattac tgctgctagg	1380
attcatagtt gcacatactg tttattgctt atgtgtagaa ggaatgaaac tagtttccag	1440
agttgttatt aatatgaata tatatcatgt gttaatattg agaaaggaaa aatacattcc	1500
cgggtgttagt agttcttcat ttctgtctc caacagaaaa ttactcatt ttagaactag	1560
tgtaattctt gataataaaa taagagtttt gattaagaac agcatagagc ttcaaatgc	1620
aaagtgaatg attagtaaaa ttatgtctca ttttattttt tcagcaccca taccacaatt	1680
aatattaggc tggattgcc a tgggaaacat tttttggcat taatgcagca acataatact	1740
cactttagggt attactacat agttgaagga ttttaactgaa tgtatggatc aaatttattt	1800

atttgacata ttcgaagctg tggtttaata ggaatttgag aaaggtgtaa gaaataggat	1860
aaaaagaagg tcagcaccat gtaccaggaa tagctttact ttccatacat agaaatataa	1920
atttagtggg atcctatatt acttttagtg cgtacgcttt gtaagactta aatattttat	1980
tctattgatt ccactacttt ggtatgttaa gacatttctt taaagatgac caacaatatc	2040
cttatttttag gtgccactag cagatgtaag cgtatactta gttgccgtta gatgtgacag	2100
aatgagataa tttatgtaaa gcagtagagt acctggcaca aagcaaacaa taaatattat	2160
tgttattggt gttataattg taaaatgaat gacttcaaaa acatagtccc agtttggagg	2220
gatttgtgat gcagaatatac taagtcataag aaatagaaga caggtggaat aagtatatgt	2280
tcagagtttt tagatgtggt gagtagagac ggtaataatg gaagcatata atacaaatga	2340
aaatcacacc agatatccct gaaattcaag caaagaaagt tcatcatgta ttcttgggca	2400
gcaagagaaa ggactagggt tatggcaatg tgtggaaaag ttgaggcttg ctaagggttg	2460
agatctgttg gtagccctgg atcacatggg gtcagcacca ggagtgccct ctgaaagcgg	2520
agagagggtcc tggacttccc ttgtgtataa cagttcctag tgtccaacaa tgaggaaacg	2580
gtgaagcatg gttacaaaac tgtgacaaaa atatttacct ctagcactgt taccactcac	2640
atgccaaaaca ttggctgcac acgtgcagcc ttatttgtaa ttaacatcaa aagactagat	2700
ctgaagcctt ccataaatga gaggccattc atatggcatt cctggaacaa aacactgcac	2760
aggtagcagc ctctccactc ctgaccgggt tgggtgctgaa cagtcaggga ttgttcttga	2820
actagacttc tgatgcttct tgcaatcttc ttcatcttt ccctgaaata cacaaaataa	2880
acaaatacaa taacaaatag taattaatg actttcagga taacatctag ttgttcagac	2940
ttcacccttc acaggtgtgt gtgtatgtgt gtttatgtct gtatatgaa gcaatttgaa	3000
tttatttact gtatattttc tgagtaaaag actgaaatga actacttggg tcagatcatg	3060
gtgtccattg gtgacattgt ttggaggcat aatattcttt atatggaaaa tcctttaatt	3120
ccacagttag ttacctcaga ttcagaatat gaatactgtt tataatacgc tttttagga	3180
atgaattcga aaggtagttg tcagtaaaca aaagcacac aaactaatct cagagtctgc	3240
cctgatggct gtgataggga cagaaagcta aacctactg ctgacgcgcc ccgcacattg	3300
ggcgcagaat ttccaagaa aacggggcaa atcaccgcca cggtcctaac tctgaactct	3360
atacgggcca tctcgcctaa accactacaa ggcacgcacg ggaaaggact ctccgntcgc	3420
gactcgcaag cctacggccc ccgaacgaca ggcgcaccac gacaccaccg gcgcgtctac	3480
gagacatgat cagcgtcaag ggcacctgaa aaaacgatgc cccaactagt gcggcccgca	3540

76

accaggcaga cactaagctt gatagcacag cgactgcacc aagagctaata cagcacaca 3600
 accaaagaca gaaactaccc actctatcac tacacggacg acactagaaa caacctgcaa 3660
 ttgttactgc 3670

<210> 99
 <211> 938
 <212> DNA
 <213> Homo sapien

<400> 99
 cccccccga cgacgacata ttaggggaac gggccactag atggctggtc gagcggcgca 60
 gtgtgatgga tgcccgggca ggtacataat gttcagacct cctccatcct tttaaatgcc 120
 tgctgcagta aataactagt ttgagtagaa ctagatcctg tctatctatt tggcacatgt 180
 tctgctgcct ggggagtaag caagctaaag ggatgagaaa gaccacctcc ccctaccctg 240
 gaaattgcac tgcaaggcag ggcgagaatg gggtagctgg cagacctggc ctccctgttc 300
 ccagtcttag ttatttcttg cagagattca gtattcagta aagaatagca ttcaattagt 360
 caaaaaatat atatctaact tcttcccttc ccttcccatg aatcattgca cgtcattccc 420
 taagctttct tctctttcca cctcatggcc tgctcagtct tcccatccct accaatcaca 480
 gactctcagc ctatagacgc agtcacagta tctcaactca tccgcctctg cttcacacta 540
 cattaacaat acctcctcac tcacatacta cataactcca gctctagtct tccaaaattc 600
 acctttcatg atgccactca gcatctcaaa tacctttcat gggctctctg ctgccaaagg 660
 ataacaggtc aaagtcatta gcctcaacag tgggcttcaa ccagccttgg gacctcagcc 720
 catttatcca tcacagaggc tggtaactag tctcactgct caggctgtga gtgttcctga 780
 tcttctgtac attctgtgct gtgctttaca tggaacaggt ctttctctc tctggcccat 840
 tcgaatctc taatcaagcc catctgattc tgtacagaac acattttcaa gttcaattcc 900
 ctggatgcgg ttgcgcgaaa agttgcttaa tgactggg 938

<210> 100
 <211> 376
 <212> DNA
 <213> Homo sapien

<400> 100
 tactcttggg tttcttctc caagactact ccttactcat atcagcaaat agcagctctt 60
 ttcaagtgtc cagtgtaaaa acctacaatt aatccttgat ttctctttca gtcagcctat 120
 actaaatcaa tttcatttaa aatatctcgg ctactactct gcatctccac tgctaccatc 180
 ggcctctcca gtcacattct ccaagagcac tctatctcat ttaaaagaca aaatctctgc 240

77

agtggcctgt gatgctcctt aatggcctac ataatccagc cctcaagcac ctccgtgatc 300
 tctgtaaaac tttcccttgg tcaactgtgt tcagccacat taaccagctt gcatatttct 360
 cacattcacc aagctt 376

<210> 101
 <211> 3661
 <212> DNA
 <213> Homo sapien

<400> 101
 ggacacaact caaccagta acagttagtc aatggctgtg gcaggctaaa tgtggctccc 60
 aaatatgtcc atatcctaata cctacagcc tgtgaatatt accttatata gccaaagagga 120
 ttttgcagat gtgattctga gattgagaga ttatgccaga ttatccaggt agggcccaaa 180
 tgtaatcacc acagtcctta taggagaggg aagaaagtca agtgtagaag gaggcgatag 240
 aaggagagag ggatttgaag attaataaggc tgcttgcttt gaagacagag ggaagggacc 300
 atcaaccaga aataaacctc tagaagctgg aaaaggcatg gaaatagacc ctcccttaag 360
 gtctctggag ggagtgcagc tttgatttct accgagtaaa attgattttg tacttcagac 420
 ctccaaaact gtaagagaat gactgttgtt ttaaaacat tgagtttgta gtaatttggt 480
 gcagcagcca caagaaactg gtacaacatc tatatagaat ttttccagat aattgggagg 540
 aaatttgaat atggatggca tattaatatt actgaatcag cattaaattt gttagggtgta 600
 ataatgtgat ttagctatt taggagaata tcctattttt aagagacatg ccaccatatt 660
 tagggagaag tgccaacata tttgcagttt attttcaaag ggttcagagg ctgtctgtgt 720
 acatgagaag acaaagataa ggcaaatgca gcaaaattgt aataattggg gaatccaggt 780
 gaagggacta tggtctggtc ttgtactttt ttttccaact tttctgtagg tttaaaattt 840
 tcaaaaataa aaatgggaaa tactttaaaa attgtaatca aagacattag tacagaaact 900
 ttcataatgt attttatttt tacagtataa ttaatttatg taaattgata gaattttact 960
 aatttcactc ccaagttaca ttaaaaggct tacatatgtt tgataatagc atatgtaaac 1020
 tagaactctg aatgatatcc attggtcata atacgtacta ttagcggta atgggtgactt 1080
 ttgtgattgc acaagtctag agatgcccc aatgacattg acttagacat ctgggtattc 1140
 taaggctgaa actgaagttg aatagaaggc tttagtcaaa tactgagatg aaaactgagg 1200
 cagtcctggc gggggggagt gagtgtgtgt gtatatatac acacatagac atcatgcttc 1260
 taaacattta cagaaagaaa gggtagatta tctacaaaa aataagaatc agactgatat 1320
 gagatcttac aaacctaacc cccttctctt tctaaactc cagattctca ttttctgac 1380

ttcctatcttg atattttacac ttcgatattt accaggagtc ttcaacattt tgttcaaaac	1440
agtactcttg gttttcttcc tocaagacta ctccttactc atatcagcaa atagcagctc	1500
ttttcaagtg ctcagtgtaa aaacctacaa ttaatccttg atttctcttt cagtcagcct	1560
atactaaatc aatttcattt aaaatatctc ggctactact ctgcatctcc actgctacca	1620
tcggcctctc cagtcacatt ctccaagagc actctatctc atttaaaaga caaaatctct	1680
gcagtgccct gtgatgtctc ttaatggcct acataatcca gccctcaagc acctccgtga	1740
tctctgtaaa actttccctt ggctactgtg cttcagccac attaaccagc ttgcatattt	1800
ctcacattca ccaagcttgt tcttgccttg gggcctttgt acttaccatg ttctgttctg	1860
agaatactct gccctcaagat atcctacaac tatcttactg tattcagctc tctgctcaag	1920
tattaactga tgaaacctgt catccctact ccactccatg ttctgcttta cttaacagca	1980
attgcacata tggccccctg aataatatac atttagtcac ttatttttac ttatctgcta	2040
attaaaatgt agactttttc tattctgttt actgctgtat tcccagcatg ttttatccga	2100
atgtgcagtg gtttcttttc ttctccctta tcgtgggaag tgatgtgcac aaatacacat	2160
aatggagcct gaatgtcata ttgctttcat acctgtgtga attttggtta gaaaggaaaa	2220
gtagcgattg acaggtaata taattacatt aagtcactct catagttagc tgtttattgc	2280
tttctgctc ttattctcag tcccaggac caaatgttga ccactacctt cccccacata	2340
taattagggt atttaccgaa cgccatgcag gtggctgtta aaaggaagat atatacttac	2400
cttataaaact caacttttcc ctgttgtctt tctgtctcac ccctacctcc atgctttaa	2460
ttaacttttc aggcttaggc cttatctctc agtagagcca tataagggtat gtgtaaaagc	2520
aggaaaatgt ttcctgggga tgaagctttg aaaagctttt ttttttttc ttttggcaat	2580
aaaataagggt agattcagca caatacctaa taactaaaa atctgttttt aattgggtgg	2640
ggcagacagc aagtgtgtca tcctggaaga tactatttgg gattttatgt aggtacataa	2700
gagaaaaaag tgaacaaaag caaggggcta ccaggacgcc gcagtatgct taacatgtat	2760
tttctaagtt tgtattatgc ctttatcttg gtacttttat cttctgttct cacttgatct	2820
ttttgaaatg tatttttaaat cctaataaaa atatataaag tctggaatta ataaaggatt	2880
aaatgaaact tttgtatatc tcactgaaat tctcagaaaa aaggggggtg tggggagggg	2940
gaattgcctg gggtagtgag tgaaaattgt gaccaggttc ttactaagga atatggcaac	3000
tgcataatca aatgtcagtg gttaccaaac ttatgaatca cctgggtgtg tgtcatagat	3060
tgtctatcct tgccctctgc cccagtgat ttagatcagt ggaactatgt ggggtttaag	3120

79

```

aaatatacaa tatatatattg tatatatattg tgtgtctcga aagcttcagg gttaaataag 3180
ttttaactgt ttaggaaaca ctattgtttt aggtatccag tctcaaagac gaaggccttt 3240
aaaacttact taatttttca ttacatttct tgcccagaaa attgtaaaat acccaacgat 3300
aacaatgggg aattgtctat cagcacttga ctaaaaagct ttactatcca tgacagcagc 3360
ctttgcatta ctcaattctg atggcattta acgtcttgaa acccagaaat aaatacctat 3420
agactcacag tacctgaaag gaataccaaa ttgagacaag agagctatat aaacaaaaaa 3480
ttgcttcaac cacagaatgg aggtctacag gtgcggaagg aaagtttata tggtagaggct 3540
tggtcgcaaa actattagga atattttcag gttactacac aattttgcga gctcaatatg 3600
cagttaacac tttttccctc gaatctcctg agcagattta cattgaccgg acccgtagca 3660
t 3661

```

```

<210> 102
<211> 698
<212> DNA
<213> Homo sapien

```

```

<400> 102
acatttccat ttccaccggc ttggagcaga gctgtcgagg agtgctattc taggatcctg 60
atgatgacca caagggcagt ttgtattcag ctgtccctgg gaacacttcc ctgaaagcgc 120
tcagggacat tttcatcagg cacagtgtc caggctacgg cactctgtat tgttccttgg 180
tggcttttagg gggctgggca tcgtagctga aataggacaa caggagatg gctgagtgtg 240
tttcccaact gccagatgac aacaggctca tcagcataaa gtcacatat aacttagaag 300
aaaccttacc ctcggtgaaa tctcccagca gatcagcaac gaaatggact aagcaacttc 360
ggtagaaaaca catggggcta ggatataaac agttcatagg aaaggacacc tgatatcatt 420
aatgattagg gagagaaatt gggtagctaa cagcaggggt gagagagaaa ctttatagta 480
ttttcctctg tagcttttga attttaagac atatgaatgg atttttttt taattgtaat 540
taaagtataa tttttttaa agagaaattt ggagtcattt aacttgtaag acaaaggcta 600
tcttgtaata agaatactgt tcttcctatt tgctctagat ttttaagttg gatgggctac 660
atggtttctt agggcagaac cactcttata gactattt 698

```

```

<210> 103
<211> 1217
<212> DNA
<213> Homo sapien

```

```

<400> 103
acatttccat ttccaccggc ttggagcaga gctgtcgagg agtgctattc taggatcctg 60

```

80

```

atgatgacca caagggcagt ttgtattcag ctgtccctgg gaacacttcc ctgaaagcgc 120
tcagggacat tttcatcagg cacagtgctc caggctacgg cactctgtat tgttccctgg 180
tggtcttagg gggctgggca tcgtagctga aataggacaa caggagatg gtgagtgtgt 240
ttcccaactg cagatgacaa caggctctata agcataaagt catcatataa cttaaagaaa 300
ccttaccctc ggtgaaatct ccagcagat cagcaagaaa tagactaaca attcggtaga 360
aaaatggggc taggatataa acagttcata ggaaaggaca cctgatatca ttaatgatta 420
gggagagaaa ttgggtagct aacagcaggg gtgagagaga aactttatag tattttcctc 480
tgtagctttt gaattttaag acatatgaat ggattttttt tttaattgta attaaagtat 540
aattttttta aaagagaaat ttgggagtca tttaacttgt aagacaaagg ctatcttgta 600
ataagaatac tgttcttcct atttgcctc gattttaagt ttggatgggc atacatgggt 660
tttcttaggg cagaaccac tctactagac ctatttaacc ccatgacaga gcctagaagg 720
aacaggtgta atagaagatg gcatttatgg caagaagggt gatcaagttc tccattagaa 780
tttgaaccag atctaatacc ttttcttccc ttgtttaaga acggcccggt atgttgact 840
tcacgggcaa ggccaagtgg gatgcctgga atgagctgaa agggacttcc aaggaagatg 900
ccatgaaagc ttacatcaac aaagtagaag agctaaagaa aaaatacggg atatgagaga 960
ctggatttgg ttaactgtgcc atgtgtttat cctaaactga gacaatgcct tgtttttttc 1020
taataccgtg gatgggtgga attcgggaaa ataaccagtt aaaccagcta ctcaaggctg 1080
ctcaccatac ggctctaaca gattaggggc taaaacgatt actgactttc cttgagtagt 1140
ttttatctga aatcaattaa aagtgtattt gttactttaa aaaaaaaaaa aaaaaaaaaaag 1200
atctttaatt aagcgggt 1217

```

```

<210> 104
<211> 193
<212> DNA
<213> Homo sapien

```

```

<400> 104
ccgggcagggt acaatatgga tttcaaaata acgttcactg gtaatccttc ctgatgccaa 60
ttttaaaatg aagaccgtct aaatttttct gaccagttat tagttgccct gcctctcggg 120
aatgtgttta aacttttctt tcaattattt gatacctttt gcccaagaga ttactatctc 180
tctctttttt ttt 193

```

```

<210> 105
<211> 542

```


81

<212> DNA

<213> Homo sapien

<400> 105

```

ggccgcactt tttttttttt ttttttagtt atatatttaa tgaatcattt ttattgcaaa      60
gggtaaatta catgaaattg acaaaattta gtccatgtaa tatctatcaa aatacataca      120
tgtaagtgtg tgtatattta tatatgtata cagtacagtt ttcacaaaaa gtttcaacat      180
tcctaagaaa cacagacata gtcattotgg tacaatatgg atttaaaata agttcatggg      240
aatccttctt gatgccaat ttaaaatgaa gaccgtctaa atttttctga ccagttatta      300
gttgccctgc ctctcggaaa tgtgtttaaa cttttctttc aattatttga taccttttgc      360
ccaagagatt actatctctc tctttttttt ttttctttta agacagagtg ttgctctgtc      420
actcaggttg gagtgcagtg gcacaattcc tgatcactgc aacctctgcc tcccaggctc      480
aaacgatcct cccacctcag cctccccagt agctgggacc acaggcacat accaccaagc      540
tt                                                                    542

```

<210> 106

<211> 715

<212> DNA

<213> Homo sapien

<400> 106

```

ccgcccgggc aggtcctaaa tagaattcaa gattagacta aatgattttc agcagagcac      60
attcaagggtt ttacattcta tgattgaaaa aaattttttg aaaacttttt atttcattct      120
ttcctgtagg attttgctac aaataacttt gggaatgaat aaagtggaat ggtaactttc      180
cagtggttca gaattgaatt agacttcttg tgactgtgat gtttggtttc cattgaaata      240
tatgaagtga gatgtcatat cctgaatata gtttgtcttc cccaattact tgatagcatg      300
tctgtcagcc agtaaagatt aagaacagag tttctctaaa ttcctccgat tattccacta      360
aggcacatta aaatacttaa ttttgggaaa ccagacatca cagattttct catgaagtcc      420
taaatcttct ttaaagtcag aatagggtatc ttagttactg acagtattca gggttttttc      480
tcccttggtg atatgtcatt ccatcagtga aaaaatatat tctccaagg gatatagaaa      540
ggtattctgg taatacatca tcatcaatcc tttaacagta acagtctggc acttatcaca      600
aaaacgacca tttcttataa ccagaaagat atcttagatg tcttcacata tatttactat      660
gctgtagata aagatgcccg gggtatgggc tccatttcat ggctggggtt acgtg          715

```

<210> 107

<211> 1716

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1594)..(1594)

<223> a, c, g or t

<400> 107

```

agactgcaat ttctgactaa agctttttaat gccagggttaa acaggagaaa ctttttccac      60
tagaagaaaa tccttgctat ctattttttc caatagaaga aaatcctgct atttatttta      120
tttgatgaat aaacaaattt attgcagtag cttaaaaaaa tttttttttt aaacagtctc      180
actctgtcgc ccaggctgga gtgaagcaat gtgatctcag ctcaactgcaa cctccacctc      240
ccgagtagct gggattacag acatgcacca ccaccctcag ctaatttttg tatttttagt      300
ggagacgggg tttcgccatg ttggccaggc tggctctttaa ctctggcctt tacgtgatcc      360
gccccccctt ggccttccaa agtgctggga ttacagggtg gagccactgc acctggcctg      420
tagtagctta aaatttttct tgagaaaatt cctgacttta aaaataaacc ttatataagt      480
acaagtgatt gtgacaaatg acgtaaaaaat ggcattcatg atgtctgaaa caagcctaaa      540
tagaattcaa gattagacta aatgattttc acaaagcaca ttcaagggtt tacattctat      600
gattgaaaaa aattttttga aaacttttta ttcatctctt tcctgtagga ttttgctaca      660
aataactttg ggaatgaata aagtggaatg gtaactttcc agtgggtcag aattgaatta      720
gacttcttgt gactgtgatg tttgggttcc attgaaatat atgaagtgag atgtcatatc      780
ctgaatatag tttgtcttcc ccaattactt gatagcatgt ctgtcagcca gtaaagatta      840
agaacagagt ttctctaaat tcctccgatt attccactaa ggcacattaa aatacttaat      900
tttgggaaac cagacatcac agattttctc atgaagtcct aaatcttctt taaagtcaga      960
ataggatatc tagttactga cagtattcag gtttttttct cccttggtga tatgtcattc     1020
catcagtcaa aaaatatttt ctcccaggga taagaaaggc attctggtaa tacattatca     1080
tcaatcctta aacagtaaca gtcttggcac ttatcacaaa accgacccat ttcttataac     1140
cagaaagatt atcttagact gtcccttcaca ttatacttta cctactgcct tgtaagaata     1200
agagttgtct actgtgttta cttgctgtcc tccatattct ccattgcacc attgggtgat     1260
aacgttaaga gtttcattga atattatttt aagtattaca aaaggcagct tgcttcttaa     1320
tctatgcac tttgggggtt ttgaagaaat ttaattcttt gatgtaaaaa ggaactgtta     1380
aaaaagttgg aagctctgca cctgtgtata tatatatttt agcaataaag cagcatgggc     1440
tgagaatgca ctgaaaaaaaa aaaatgctag tgacttcagc aagtcataat cttcctgcgg     1500

```

83

gtggaggggtc tcaactgcgat gtggatggcc gctggggctg accaggggtgg tgggtggcaga 1560
 aggctggggc ggctgtggca gtttcttaaa atangacaac aatgacattt gccacattga 1620
 tagacttttc ttttcacaaa agaagtctct gtagcacgtg gttgctgttg gtgcacttta 1680
 cccacagtgg aacttctttc aaatagtctc aatcct 1716

<210> 108
 <211> 666
 <212> DNA
 <213> Homo sapien

<400> 108
 tcgcgccga ggtacttaat aatgactgaa tttcatgttc ctacagtcac acatattcat 60
 tagaagtttt atgttggttg tctgatctga ttcttctttg tttgtgggtg gaacggcact 120
 gagagaagta tagtttttta aacttgaaca tgttcagtag ttacattgcc ttagaaaacc 180
 cagacacata gcagtggaaa tgaaagaaat ggcatcagaa gtgacttaat ttagcaattg 240
 tgattcctct tgtaaaacaa aacaaaaaaa caatgccata ttttttggag aaaagtggc 300
 aatatagggg tttcgttgtc tgtttcacaa gaagactcat ttgttctttt gggggaacca 360
 gtgccttaca gattttgtat atactgtaat tattcaggac tagggaacaa acaattgtat 420
 tgtatttggt acagattgta tatggcttg ttttaacatt cccctaaata aaatggcttc 480
 attctcccct tggaaaaaaa catgactggt atgttataaa aaaaaaaaaa aaaaaaaaaa 540
 aaaaaagggtg ggggtaccgg ggcaaacgt gtcccggggg gaatgggttc ccggccacac 600
 aatccccac attgcgagaa aaccgtgcga acaaaaaaaa aaaaaaacg aaaaaaaaaa 660
 acaggg 666

<210> 109
 <211> 1983
 <212> DNA
 <213> Homo sapien

<400> 109
 gaatttcgta atccttgaaa ttgaaaaaaa aaaaattgtg tttttaaaga gtgaaaacag 60
 ttaggaaaca agtagaactg taatcagaac gctgcttcaa ttgatattaa aaataacctc 120
 aataataatg taaagggttc tttctcttgt gtcagttata ttcttaggga tagcctagaa 180
 ggaatatatg gttagaacta agtgtgacta atcatctgag ccttgaagag aaacttcagt 240
 gcctctaaac agatcatcta caaaacaaca ggtaaacatt tatgccagtt aagtgggtca 300
 tgtttttgtt tcttgggttt ttcttaaatt taagtgggtg tgggcttacc ttgtagataa 360
 aattatgttt tcttttttgt aaatacttga atgtggataa cgtcaaatca gaatattttg 420

84

```

tgaggaggtg atgatttgaa attaagctag atttctaggg aggtgttggg tccaatgaag 480
gatgggaaga aattaaaata gtcttcaaac ttcttcctta ttatatattgg ttgcttttga 540
aaagattggg cctatcctca atctaattta ttcactatta atatttttaa aacattcctg 600
agatacttaa aaagaccac ttagcgatta tagttgctca atgaaacaag aatttattta 660
tgcatagatt tttctctgta tcttaccaaa atccacttta cttagataac actaaattgt 720
tottaaagac tactcatttc ccaataatcc tttatgattt caaaatttct agtggctcag 780
aagtgaattt tattttattt gtctttcact tgaataaatg agaaccaga aattaataat 840
gttgtttatt gcttactgtc aggactattt caaagactaa gaagagtttc ttctaacccc 900
tcctctcaa aggaatccta aattattagt tgtagataa gttttgtatg ctaagatatt 960
caggtttata gtttatgtat gtgtgtatat atataaatat atatgtatat ataaatatta 1020
tggtcagttt ggagtctggc acaactccat tatgtggatt agagagtaag atattatgga 1080
tgataaagta ctaaataaaa cataatattt atttataaaa gtgtgtagat tgtaaataca 1140
caaaaagagt gctatgacca ttatgtatga ggaaacaggc ctttgacctc ctggaaagca 1200
ctgctcaaaa gtcattagtg cccatttttg aattcccaa acagaaagct tcttagaaaa 1260
cacgctgaga ttttatttac aggaattctt ttgacacatt tcaattgggtg tgtagtcaag 1320
tatagcaagt acttaataat gactgaattt catgttccta cagtcataca tattcattag 1380
aagttttatg ttgttggtct gatctgattc ttctttgttt gtgggtggaa cggcactgag 1440
agaagtatag ttttttaaac ttgaacatgt tcagtagtta cattgcctta gaaaaccag 1500
acacatagca gtggaaatga aagaaatggc atcagaagtg acttaattta gcaattgtga 1560
ttcctcttgt aaaacaaaac aaaaaaaca tgccatattt tttggagaaa agttggcaat 1620
ataggggttt cgttgtctgt ttcacaagaa gactcatttg ttcttttggg ggaaccagt 1680
ccttacagat tttgtatata ctgtaattat tcaggactag ggaacaaaca attgtattgt 1740
atgtgttaca gattgtatat ggctttgttt taacattccc ctaaataaaa tggcttcatt 1800
ctccccttg aaaaaaacat gactgttatg ttataaaaca aaaaaaaaaa aaaaaaaaaa 1860
aaaggtgggg gtaccggggc aaaacgtgtc ccggggggaa tggtttcccg gccacaaat 1920
ccccacatt gcgagaaaac cgtgcgaaca aaaaaaaaaa aaaaacgaaa aaaaaaaca 1980
ggg 1983

```

<210> 110

<211> 758

<212> DNA

85

<213> Homo sapien

<400> 110

```

aaaaaaaaacc acaaaacaaga gaggattgat tgataatatg gggcatgctt aatctaataca    60
tgctcgagcg gcgcagtagt gatggatcga gcggccgccg ggcaggtagc taacatatag    120
tagacagtgg agagtgggtc tctttcggtg tctcaggggc agacagatgg ggtgctggag    180
tcctctatca aagagtcaga gctctatccc agatgtgtaa tgaacgtggt cacagacata    240
ttgtcccatt accatttacc ttccctataa ccaactgtgc tccagccttg tagaatagac    300
acataggagc gcagcaatac gtctaaaaat aggagtgaga gagggcaggg catgcccgtt    360
cttgtggtag aagaaaagaa tgtcaaagaa agcagctggg actaatgaac ttacattag    420
ccatattcca ttatttcagc ttaagtcaaa tgcgggtcct catgaggcaa ctggctttga    480
caggagctac gctaattgtc cacttaccaa cctttaattt ctgggtaaaa gcagaaagag    540
aaaaactaat ggatttttca ttttcagaa gagacaagaa tcaactacac tagtagtctg    600
tcagaacaaa agaaaacctg catccaatta caagaattat tactgtctct ttaataaata    660
accacattat taaaaaaaaa aaaaacaaaa aagggttggg ggtaccgggg ccaaggggtc    720
ccgggggggaa ttgtttcggg ccatatccat acaaaaaa    758

```

<210> 111

<211> 3575

<212> DNA

<213> Homo sapien

<400> 111

```

atgaaattac aactcaggat taagagtctc actcaaaacc gcacaactac atggaaactg    60
aacaacctgc tcctgaatga ctactgggta aataagaaaa ttaaggcaga aataaataag    120
ttctttgaaa ccattgagaa caaagacaca atgtaccaga acacagctaa agcagtgttc    180
agagggaat tcatagcact aaataccac atcagaaatt gggaaatacc taaaatcaac    240
gtgctaacat cacaattaaa agaactagag aagcgagagc aaacacattc aaaacaagaa    300
ataactaaga tcatagcaga actgaaggag atagagacac aaaaagccct tcaaaaaatc    360
agtgattcca ggagctggtt ttttgaaaag attaacaaaa cagatagact gctagccaga    420
ataataaaga agaaaagaga gaagaatcag atagacacaa taaaaaatga taaaggggat    480
atcaccacta accccacaga aatacaaaact gccatcagag aatgctatca acacctctac    540
ataaataaac tagaaaatct agaagaaata ggccggggcg agtgggtcac acctgtaatc    600
ccagcatttt gggaggccaa ggtgggcgga tcacctgagg tcaggagtgc gagaccagcc    660
tagccaacat ggtgaaacct cgtctctact aaaattataa aaaattagcc ggtgtagtg    720

```

gtacacgcct gtagtcccag ttacttggga ggctgaggca tgagaattgc ttgaaccag 780
gaagtggagg tggagggtgag ccgaaattgt gccactgtac tccagcctgc aacagagtga 840
gacactgtca cacaaaaaag aaagaaatat cacaatatgt cacaataggc cgggcgcagt 900
ggctcacacc tgcagtcca gcactttggg aggccaaggc agatggatca cctgaggcca 960
ggagtgtgag accagcctgg ccaacgtgac aaaaccagct ctactaaaaa tacaaaaatt 1020
agccaggcgt gatggtgggc acctgtaate ccagctactc aggaggctga gacatgagaa 1080
tcgcttgaac ccaggagggtg gagattgcac tgagctgaga tcctgccact gggctccagc 1140
ctgggtgaca gaatgagact ctgtctttaa aaaaaaaaaa aaaaaaaaaa aatcacata 1200
agtccatagg taaagatggg ggtacagaaa acaattaaat agaacaaaaa caactgtttc 1260
cttttcctgt gattcaagaa gggcttagat cttctactca gcaccctttt actaatgccc 1320
tccattggct ctacgcccac acatttcctt ttttatagct tattttgtaa tgcctcctta 1380
attatccttt aatagaagcc accgctgata agctacctac actcatacag aagcattaat 1440
ataatgcccc agatgtactg tttcagggca aaaaggaaaa taatttccaa caaagtgggtg 1500
tgtgtctcac tgtcagatgc ttgcacttac acacggaatc gctgtgcac cagacagaggc 1560
tgattggcac atggggcacg gggattgtca gctcaaacac cgtcagcagc gttgcccttg 1620
gaaatgggat ttcccagaac agtaaactg tctgtccttg atttacagag tagctacatt 1680
cctaggaaat ccagggtaca ttaaaactca ccatgttacc caggctgggc tcgaactcca 1740
ggcctcaagc aatcctcca catcagcttc ccagaatttt gggattacag gcatgagcca 1800
ccacaccag ccagaatatt ttatttctgt tagacacaga gcgttcggtg actcgtctgg 1860
gcgttagtgt taatattctg tacttgaagc aagcccacca agcggctgaa ctgggtggat 1920
aatggaaaat gtctgtgga tttgggagt agacaaaccg gcttgagtct aacctctcag 1980
ttagtctaag gctccaagct tgaaagggtt aaatgaagta ctatatgtt tttgtttcgt 2040
tttcgttttg tttgaggctt tgctctgttg ccaggtctgg agtgtagtgg cacaatctct 2100
gctcactgca acctccatct ccaggttca ggagattctc ttgcctcagc ctccagagta 2160
gctgggatta cagggtgccg ccaccacacc cggctaagtt ttttttggtt ttttttagtag 2220
acacagggtt tcaccatgtt ggctagactg gtctcgaact cctgacctca agtgatccac 2280
ctgccttggc ctcccaaagt gctgggagta tgggtggtga gccaccacgc ctggcctaaa 2340
tgaagtacca catgaccgac cgaccgacct ggggaacata gcaagacccc atctctacaa 2400
aaatgtaaaa aataaaaaatt agccgggtgt agtggtacat gcctgtaatc ctagatactc 2460

87

```

gggaggctaa ggcagaagga tcacttgagc ccaggagtgc gaggctgcag tgagctgtga 2520
tcgtgccact gcactccatc ctgggtggca gagtgaggcc ctgtctcaaa ataaataatc 2580
cagtcccccc caagaaagga atgaagtgtc ataatgagaa aaatcctagt acctaacata 2640
tagtagacag tggagagtgg ttctctttcg tttctcaggg gcagacagat ggggtgctgg 2700
agtcctctat caaagagtca gagctctatc ccagatgtgt aatgaacgtg gtcacagaca 2760
tattgtccca ttaccattta ccttccctat aaccactgtg cctccagcct tgtagaatag 2820
acacatagga gcgcagcaat acgtctaaaa ataggagtga gagagggcag ggcatgcccc 2880
ttcttgtggg agaagaaaag aatgtcaaag aaagcagctg ggactaatga actttacatt 2940
agccatattc cattatttca gcttaagtca aatgtcggtc ctcatgaggc aactggcttt 3000
gacaggagct acgctaatta ccacttacca acctttaatt tctgggtaaa agcaaaagag 3060
aaaaactaat ggatttttca ttttccagag agacaagaat aaaataatag tagtctgtag 3120
aaaaaagaaa acctgcatca attacaagaa ttattaatgt atctttaata aataaccaca 3180
ttatttagct gttaatttct ctaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3240
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3300
aggagggggg gggggcgaga aaaagagccg agggggggagc acagagcggg ccgccgcgca 3360
catatgaaaa aagcgacca gaagaagaaa caaaaacca gcaagcgcaa acagaagaaa 3420
taagaaagag aaaaagttac gagacgaata gaaaggaaat aactacagga ccaacacggg 3480
acaacccaaa agcaataaaa caaagaaat aagacagaca caagatgcca acgagctaac 3540
gcccgacaaa tggaaacagg taaacaacat aaagc 3575

```

```

<210> 112
<211> 442
<212> DNA
<213> Homo sapien

```

```

<400> 112
actgagcagc tacggaagtg caaggcactg taggagtagg gtgagtatac tccccacaag 60
ggctcagggg caggcagggg acggtagaga taaaaacca cagaccatac acatagctgg 120
cactgtctct gaggggtttt tgaggcacac aaatgcttag gagactagac gaagtaagac 180
aatgtctttg acatgaggca gaaatcaacg gaaagcatgc gcttttagaa catgtgtggg 240
actgtttttt ggtatcagca gactgaagag gcttttttaa cgtggaggga aggcaaactg 300
aggcatagag atgccaatac caggtcttgt caggaagaac agagtccaat ttggctgcag 360
gatagggcat atgtagggga ggggataaga ctggcatggg ggcagagggg gacttgaatg 420

```

88

tcagggtgaca gagtcaaagc tt

442

<210> 113
 <211> 412
 <212> DNA
 <213> Homo sapien

<400> 113
 tgtcatacta taaggcgaac tgggcctcta gatgcaattg ctcgagcggc gcagggtgatg 60
 gatgttcgcg gcgaggatc agaagctgtg atgtctgcct tgtagtcctg tgcttggtac 120
 tgtaattttt tttttttttt tacgaagcac gtgactggac taatgtaagg cagatgacgt 180
 gatctttaag actgctatat atatcagtct cttactctat aaggttttta attagaaaaag 240
 gcttatatgg ttaactacct tagactatat ctacagcagg gtctgggttg ccagaacaag 300
 tttaaagtgg ctgtttatta agttggctat tttcagaatt gaaactataa gaccgccatt 360
 tgacactgaa acttgcgatga atcctaaatt gcacaaatta tctatttgat aa 412

<210> 114
 <211> 625
 <212> DNA
 <213> Homo sapien

<400> 114
 gcaacaacaa ctgaatggct gtaatacatt aatgtataca gatgaattga gaagtcttct 60
 agtgaaatgg ctcatatctt tgttcttggt ccagtcctgt tcagtttttg atcagtcgct 120
 tgcaatatca cttgatcgac tcacttaaca tttatacaag agtgcagagg cctcctcaga 180
 gaatggatgg tagaaatgca ttgatgagag aacggtttatc tatctatctg tctatctatc 240
 tatctatcta tctgtctcta tctaagaagt cataaaggct gagtctaata aggcaaaaaa 300
 aaaaagaaaa aaaaaaaaaa ctgtggcgat acccagggcc aaagcgtgat cccggcgcca 360
 actgcgaaat ccgctcacia tccaacaac acccccacia ccccccccc agccccaaca 420
 ccaacacctc aacaaaacct cacaacacct ccaccacctc acacagccac cccctacca 480
 cacaaccaca tcacaccacc accgccccac ccacaccaca caccacacac aactccgaa 540
 caccaccgcc cactccacac accaccaac caccagcacc aacacacca cacaccaca 600
 ccgccacccc cacaccacac gcagc 625

<210> 115
 <211> 378
 <212> DNA
 <213> Homo sapien

<400> 115

89

```

gcggcgcccg ggcagggtaca tagtgagat gcagtatata atttcaggct aggaaaatta      60
gctactagta tgtatctgac agttcctaata agctaagagg cctaagaatg cagacggggga    120
gaaaaaaaaac caaaacccaaa aaaaaagaca cctctccaat tgctgggagg gcctgggaat    180
agggtgaagat caaaccacag tgggagagga gggtaaagat gtgagcttca agcgggtaat    240
gggcaagcca cacctcccag ttcctaggag ggaatcgcca cggccgactt cagcattctc    300
gtctttacta agacttacc atagagaact acagcaggaa accgatttct tcattcattc    360
tctttaaaaa gtatgaat                                     378

```

<210> 116

<211> 8905

<212> DNA

<213> Homo sapien

<400> 116

```

atggcgcccg cgctggggcc ccagaaagt atcgctcagc tggagaacgc ggctaaagt      60
ctgatgggtga ggacgccgag cccctcagac cccgggattc gcgggcccc ggctggccct    120
gccactccag gccttgctgc tcgctgggtt ggcgactggc aagggcctgc agggagcctg    180
gaagtggagg aggaggtggc ggtggcgtgg cgcaggattc ttcagcctac tttcctcctg    240
ccgtcgtccc ctcttccag gagctgtccc ctccccctgg ctgcccagca cccagtcgg    300
gcgtgggaat atagtgggtg agcaaagaga atttcttcac cttacaccct gccccacaga    360
ctgggtcgca gagcaaggcg cggggaagga gttgggggta tccccgcagg gcttcggggc    420
tctcatatac tagtccttct gtctggaatg cttttcttcc ctgtcacttc atccttcagt    480
tctctcagta gtcagtttct cagggaagcc ttccttagcc tgcctgaaag tataccctgg    540
gtgatagatt ggattggatt ggattggatc ggatcggatc ggatcggatt ggattatatt    600
gtatttatatt ttaagagaca gggcagctgt caaaatggaa gttcagggtc actagaggtt    660
ggcacatgtc tccagggtaa acacatgagt gcttgcatte atctttggat ccctgcgttc    720
gcttctgttt tagcttttga tgattcctta atttcttctg ccacagccat aatggaagca    780
gttgctccgag agtggattct cttggaaaaa ggtagcatcg agtctctgag aacattcctt    840
ttaacctatg tcttacaag gcccaacctt caaaagtatg ttcgggaaca gattctacta    900
gcagtagcag taattgtaaa aagaggatca ttagataaat caattgactg caaaagcatt    960
tttcatgaag tcagccagtt gattagtagt ggcaatccca ctgtgcaaac tctggcctgt   1020
tctattctga ctgcgtatt gagtgaattt tcaagttcaa gtaaaactag caacattgga   1080
ttgagcatgg aattccatgg taactgcaaa aagagttttt caggaagaag accttcgtca   1140

```

90

gatcttcatg ttaactgttg aagttctgca ggagttcagc aggcgggaaa acctcaatgc 1200
tcagatgtct tcagtatttc agcgttacct tgcactcgcc aatcaagtct tgagctggaa 1260
ctttcttctt ccaaatttgg gcagacatta tatagctatg tttgaatcct cgcaaatgt 1320
gctgttgaag ccaacagagt cctgcgggag actcttctgg acagcagagt tatggagctt 1380
ttcttcacag tacatcgaaa aatccgagaa gcattcagat atggcaccaa gattctctgc 1440
agtgccttgc ccagttagct tctcttcatg gacctatctt cccagatgaa ggatcacaag 1500
ttgattatct agcacacttc attgagggat tactgaatac tatcaatgga attgaaatag 1560
aagattctga agctgtgggg atctccagca ttatcagcaa cctgataacc gtgttccac 1620
gaaatgtttt aactgccatt ccaagtgaac ttttctctc ctttggttaac tgcctcacac 1680
acctcacttg ttcttttggg cgaagtgtg cattggaaga agtgcttgat aaagatgaca 1740
tggtatacat ggaagcatat gataaattgt tggagtcctg gttaactttg gttcaagatg 1800
acaacathtt ccataaaggc ttttttacc aacatgcagt tcaagttttc aattcctata 1860
ttcagtcca cctagctgct ccagatggca caagaaattt gactgccaat ggtgtggcct 1920
ctcgtgagga ggaagaaata agtgaacttc aagaggatga tcgagaccag ttttctgac 1980
aactggccag ttaggaatg ctaggaagaa ttgctgcaga aactgtata cctcttctga 2040
caagtttatt agaagaaaga gtaacaagac tccatggtca gttacaacga catcagcaac 2100
agttacttgc ttcacgggt tcaagcactg ttgacaacaa aatgcttgat gatctctatg 2160
aagatattca ctggcttatt ttagttacag gctacctctt agctgatgat actcaggag 2220
agactcogct aatacctcca gaaataatgg aatattccat taagcattca tctgaagttg 2280
acattaatac aacacttcaa attttgggat ctccaggaga aaaggcttct tccatcccag 2340
ggtacaacag aacagattct gtgattaggg tgttgtctgc cattctcaga gtttcagaag 2400
ttgaatctcg agcaataaga gcagatctca ctcatctact aagtccccag atgggcaaag 2460
atattgtttg gtttttaaaa cgctgggcaa agacttatct cctggtggat gaaaaactgt 2520
atgatcagat aagtctgcca ttcagtacag cgttcggagc agatacagag ggttctcagt 2580
ggataattgg ctaccttta caaaaagtca tcagtaacct ctcagtctgg agtagtgagc 2640
aggaccttgc aaatgacact gtgcagctcc ttgtcacttt ggtggaaaga agagaaaggg 2700
caaacttagt aattcaatgt gagaactggg ggaatttagc taagcagttt gcaagccgaa 2760
gccacctct taatttcttg tcaagtcctg tgcagaggac attgatgaag gctctagtct 2820
taggaggttt tgcacatatg gacacagaaa ccaaacagca gtattggaca gaggttcttc 2880
agccacttca gcagcgattc ttaagagtga taaaccaaga aaacttccag cagatgtgtc 2940

agcaagagga agtcaagcag gaaatcactg ccacactaga ggccctgtgt ggcattgctg 3000
aggctacca gattgacaac gtagcaatcc tgtttaattt tttaatggac ttccttacca 3060
attgcattgg attgatggaa gtttacaaga ataccccaaga gactgtcaat ctcatatag 3120
aagtttttgt tgaagttgca cataaacaga tatgctatct tggagagtcc aaagctatga 3180
acttatatga agcctgcctt actttgttgc aagtgtattc taagaataat ttagggcggc 3240
aaagaataga tgttacagca gaagaagagc aataccaaga cctgcttctc attatggaac 3300
ttcttactaa cctgctgtca aaagaattca tagatttcag tgatacagat gaagtgttta 3360
gaggacatga gccaggtaa gcagcaaaca gatctgtgtc agcagcggat gttgtgttgt 3420
atggagtaaa cctaattctg cccttgatgt cacaggatct cttgaagttt ccaacccttt 3480
gtaatcagta ctacaaatta atcacattta tctgtgagat ttttcctgaa aaaataccac 3540
agcttctga ggatctgttt aaaagtctga tgtactccct agaattagga atgacatcaa 3600
tgagttcgga ggtttgccag ctttgcttgg aggccttgac accgttagct gaacagtgtg 3660
caaaagcaca agaaacagac tcaccacttt ttctagcaac acggcacttt cttaaactgg 3720
tttttgatat gctggttttg caaaagcaca acacagagat gaccactgag gctggcgaag 3780
ctttctacac gttggtgtgt ttgcaccagg ctgaatattc tgaactggc gaaacattac 3840
tatcaagtca gcaagacca gttatttacc agagattagc agatgccttc aacaagctca 3900
ctgcaagcag cactcctcct acgctggatc ggaagcagaa gatggccttc ttaaagagtt 3960
tagaagaatt tatggcaaat gttggtggtc tcctttgtgt aaaataaaca acagaacttt 4020
atgcttaatt tagatccttt ctgcaaagt cactgaattg ctgaaagttg acttgagtct 4080
tgtctattc ctcatatcat ttggccattt tggattttgg agagcctgaa actttgatat 4140
gtatgtaata cagtgaaca ggagaggtca acttggcatc agcttctgct gtttaagtgtt 4200
agccacaatc tgtcatatat atgtctttta gattctgaat ggtgatttaa aattttcaaa 4260
atgaaattcc atatatgtgc aaacagatat gggcaccacg aaatacatat gcagtgcctt 4320
tttccctttt aacatagggtg gctagccaaa gtttagaatt tttgtcatta aatatgaaat 4380
ggatatatgc taggcagtgt ttctcaaat ctccacagat cgctgcacac acttgaggag 4440
ctggtgaaaa ggcagattct taggccaac tgtagacctt cagagtcaga atgtctggtt 4500
gttgggcca ggagtcttca tgtaataag cttctccctt tcgtcaccac aaaagttttg 4560
aatcaatgaa agagacattg aaaactctta agaggttttg tgctttctag cttttcctcc 4620
ctttgatgat tgggttttat aattcagcag gaaggggaaa catcatcagg ggtttgttg 4680

92

ctttttctta gcttgctttc ttgcttgctt gctttcttgc ttttcttgct ttctgtctct 4740
ctctttcttt tctctctctc tctcacatca acccagtgct gcaggttttg tgtaatacaa 4800
gtcactaatc atactctgat gcctgaactt gaggaggaaa atacatgtat atttttgttc 4860
cgtaaaaaata accttaggaa ctgtagccat ttcattgcct taattttaag aggaaaatac 4920
aaaaacagct gatttgtttt agtaagaaac cacgtcttga tgcttcagag ttggtttagg 4980
gtgttagctg ctatgaacct gttgcccctt tcgatcgtgt atttatgtag gtttatcagt 5040
gaaatgaaag gcttgtttcc gtctagtcta actttttgag tgtgtttcta tccagccaca 5100
tagcccatat ctactctaaa tggcttgctt aagcaataat tattttaaag gatgtgaatc 5160
actgattcac acagactatt gcacgttggg gcattagggg caataattct tatccagaca 5220
tgaggagccag tgaatttaat ttcagagatt aaaaattcac tttagatcct ctagtttgat 5280
ctcttaatca ggatttttat acagctgccca ggctccccta attcagtggtg ccagcttaca 5340
atgtggaaat gaaagctaat ttatacacag caggcatatg aaactccact cattgcagta 5400
ctttcacagc acagtgcag gtagaggact ctggcacagg tgcactcatg aaactctgct 5460
tccaccatgt tcctgacacc tatctattaa accattctgc aaatacgggt tttctacctg 5520
attgcatata gcatatgtgt cattacatgt gatgctgtgc aaaactttgt ataattctgt 5580
gttattaaca gttaacaaaa ctggagcatc tgaattacat ccaacctgtg catgtgatgt 5640
taggtagatg tgaatgcagg gccttgggcc ataacttaca tttctctcaa tttgattagc 5700
tttgagtcac aattaagggg aagcaaaaac atcttgaaaa gactgctagg aaggaaatta 5760
atatcagtca tccagaagta cacgtttctg tattttaaaa aatactttga tgcatttatt 5820
tttaggtgtt ttttttttcc ccttaaaaaa ctgaagtga tatgcagcag taatctattt 5880
gttttgcatg gttcttggtg ttttgtgttt ccagatccc tcaagctttc tcagctgttg 5940
cgaattatgt gtatctgtgt gtgtgctaag tacagtctct ttaccaaagg gcactgaaac 6000
acacaattga ctggacaggt ccacgcgcca tgacaaaact ataatcaagt tattaaaact 6060
aaagaggagt gggaaaggaa tgccttggtg agtaaaaagg catctatatt taataacttt 6120
tatccagatg gcaacatatt tgcaaaattt gccagatcc tattacaata ctaaaaatag 6180
aaaatttcac ctccatattc ctgaggtgta atttcattag actagtttta gtttaaaaag 6240
accttcttca gattggacca aataatactt ataagatcag cagaatgttg aatattagct 6300
cactgggggtg gggagaagcc actaccattt tttaggtgat ggggatgccca ctgagttgca 6360
acggctagac cttttcaggg tgggtgtgtc catgtttgcc tgattggatg cttattcact 6420
ttgtgttttc ttttgtttta ttttgtccaa ttttgtcttt agctgtgttt attaaactct 6480

ccggctcttgt tttgttttaa tgctcttggc ccagtgggtg tcaagaacac tggcttaatt 6540
caagtcagtt gatttttttt ctattaaaac tgttgtaaa atatttttta aaacaaaaac 6600
attatttgtg ccctctttta tatatgtcaa agggacactg tcaagtattt catttttaga 6660
tttttgtttt ataaaatttc tgttgttcat atagtatcct ttaacctcta gttttccata 6720
catcctttgt ttgtttctca ttttattttc cttgacccat ttatttccca aggcaaatc 6780
actaaagact ttgtactttc acagtctgtt aatgtggtag cacctgtaac tgtgttcttg 6840
ttctgttaaa aggattgatt tgcttttata gtccttgtgc tggatgagtg gctgcctcag 6900
tagcaaaact acctgacagt atttgacagt gtcctttcca gcaccattat ttgggtcttt 6960
caggggtggc atctctgtta gaagacagta gcatgttaac atcactgcat tgagtttttg 7020
tctgggtgaa agtatgactt ttaatgtaaa caaactgcag gtttttttca aactaatttt 7080
aagaatttag tcttatttcg ttgtaaactg tgtatctaata tatattacat tactctgttc 7140
agatgggatg gttactacca cttgtccatg attttcattt gaaaagcaag tatctatatc 7200
atccccccc agtcagcatt atttaacact ccccttaact gtctttgaac tttctctttt 7260
aacaaaaatg tcaagtcttt acagttgtaa tatcaccatg tttcccatth ctgttaatac 7320
ttctatgaac ccctaaagta ttgaaggga ctagctgtca gtttcaagga ttacaagttt 7380
gagtctccta gtattcaaca tcattctgaa ccctgaaata atatttttct ctgttaaaaca 7440
atttttatct gtttgccacc tctgttgta gaggtggtt tcaattgacc ttactaagtt 7500
agctgtcttt gatgaggaat tattgttatt ggctcctgaa taaaacatta accttttaag 7560
tcagaaggaa cctcggctact tcttaagggt tgtttgtgtt ttctaaaacc agagaataag 7620
gaactgattt ggctatgagg tttaacatta taattttctg taagctttcc cacaaaaaaa 7680
cattgttgat ttgaggatat aataatgttt taatcttttt aaaatataag tggttattct 7740
ctgacttggg aactatgttc tgaaaacact gcatttaaga atttttaaaa attgggtttc 7800
taaaattaaa atgtccaaat taggcatatt gctgagctca aattgatgtg aaatgccatg 7860
gttccagttg aatttttaagc atattttcat ttagatataa aatatatgaa gtatgctttg 7920
ttgattatag tgagaaccca tgacatagtt aaccaaagaa tatgtttggg tcaaataaaa 7980
atagaagctt aatactgggc attcatactt tttaaagaga atgaatgaag aaatcggttt 8040
cctgctgtag ttctctatgg gtaagtctta gtaaagacga gaatgctgaa gtcggccgtg 8100
gcatccct cctaggaact gggaggtgtg gcttgcccat taccgcttg aagctcacat 8160
ctttaccctc ctctccact gtggtttgat cttcacctat tcccaggccc tcccagcaat 8220

94

tggagaggtg tctttttttt ttggtttttg ttttttttct ccccgctctgc attcttaggc 8280
 ctcttagcta ttaggaactg tcagatacat actagtagct aattttccta gcctgaaatt 8340
 atatactgca tctgcactat gtacctacta gggatctgac ctcaagtgtt ttctgagccc 8400
 aggcttctctg gtgtgggtgc ttttaccaca taaaattatt acaaattgca aatgttggta 8460
 ttgtgatttg attatctgta caaagaaaga agctctatgc agtgagtttg tggtttaatg 8520
 gtcacaaaaa tgtagcact gctaccactc agcacgtgta aaatttttta aatttataaa 8580
 tattaaaaatt ttaaacttac actaagactt ttcagtttta tttaaagacc cagggatgag 8640
 tgtactgttt aaatatttac ctctattaac ataactaatg aaggataaaa attgcattta 8700
 gtttttcaga agatgctgca atatgatttt aggaaataag gctatgtatt gagccagtta 8760
 taggctgaat atcaggttga taaaatttta tttgtatttt taaaattcat aaatgggagt 8820
 taaaatgtgt cttttcacta aatattttta ttacaaaaaa aaaaaaaaaa aaaaaaaaaa 8880
 aaaaaaaaaa aaaaaaactg cggcc 8905

<210> 117
 <211> 827
 <212> DNA
 <213> Homo sapien

<400> 117
 tcgcgccga ggtaccctgc atcactgcca tggttgtgct attctcatct caacatagaa 60
 ttggtgggtt ctcttaaggg tgtcaggaac ctctaaaaag atgtgattct ttgggagggg 120
 atatttgaaa ttccaacttc cattccccct agcaaaagga agcagctgct gtttaaggg 180
 tttatctgag ccactttaaa gatgaatcca tggattact ctggatacta gccattcctt 240
 aggattttta ggtcacattt tattcctgga tgctttatgt cccacctcc acctgagccc 300
 tcatcctctg ttccctacta tactccaac ttctactctt tgttttatcc acctatccct 360
 attacctgac cctttgtctt ccctgtctcc catccttggg gggacatgca gccctgtggt 420
 catggttctg atgacatcat cagggcagcc ctctgcccc ggtattatgg cctgtcagca 480
 ttccctgtgc cctccaaacc ttaggcctag aatgcggagc tgccaacata acattcaccc 540
 ttttgaacag atggagtcag gcacactaac acagccttct gtccctcaata acacagccat 600
 tattgccact tggctcagtc gtcaatgtaa accctcagag tcagctgaac tatttttaggc 660
 caaacatact gtttttgtaa agtatttttt attaataaat ctataagaca gttctattta 720
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aggctggggc gaaccggggc caacggctcc 780
 cgggggaaat tgtttccgc caaattcccc caaaaaatgg caaaacg 827

<210> 118
<211> 6470
<212> DNA
<213> Homo sapien

<400> 118
ggctccctgg tagctatagc agccgcggcg gttaagtatg cggcgccagg agctgctaaa 60
tgtgaacaat aatgtcttgg aagagaaatt atttttcagg gggtcgtggg agtgtaacaag 120
ggatgtttgc acctcgaagc tcaacctcca tagcccccag caaaggcctc agcaatgagc 180
cagggcaaaa cagctgcttc ctcaacagtg ccctgcaggt tttgtggcac ttggatatct 240
tccgacgtag cttaggcag cttacaactc acaagtgcag gggagattcc tgcactcttt 300
gcgctctcaa gggaatcttt aaccagtttc agtgtagtag tgaaaaagtg cttccatctg 360
acactctccg cagtgccttg gcaaagactt tccaggatga acaacgtttc cagctgggaa 420
ttatggatga tgctgcagag tgctttgaaa acctcctgat gagaattcac ttccacattg 480
ctgatgaaac caaagaggat atatgtactg cccaacactg catttcccat cagaaatttg 540
caatgacatt gtttgagcag tgtgtatgta ctagctgtgg tgccacttct gatccgctgc 600
ctttcatcca gatggtacat tatactctcca ccacttcctt ttgcaatcag gctatttgta 660
tgctggaaag acgagagaaa ccttcaccaa gcatgtttgg tgagctgctg cagaatgcca 720
gcaccatggg ggatctgcgg aactgtccaa gcaactgtgg agagaggatc aggattcgcc 780
gtgtgttgat gaatgctcca cagattatca cgattgggct ggtatgggac tcagaccact 840
cagacttagc agaagatgtt atccacagcc tgggaacctg ccttaagctg ggtgatctgt 900
ttttcagagt gacggatgac cgggccaagc aatctgaact gtacttagtt ggaatgatct 960
gttactatgg caaacattat tctacattct tttttcaaac aaagattcgc aaatggatgt 1020
atthttgatga tgctcatgtc aaggagattg ggcccaaatg gaaggatgtg gtgaccaa 1080
gcatcaaggg gcattatcag cccctgctgc tgctttatgc agatccccag ggtacccccag 1140
tttccacca ggacctgcct cccaagctg agttccagtc atacagcagg acatgctacg 1200
acagtgaaga ttcaggacac ctgactgata gtgaatgtaa tcagaaacac acatccaaga 1260
aagggtcact gatagagcgc aagaggagct ctggtcgggt taggaggaaa ggcgatgagc 1320
cccaggcctc gggataccac agtgaaggag aaacactgaa agagaagcag gctcctagaa 1380
atgcctccaa accatccagc agcaccaaca ggctgagaga ttttaaagag acagtcagca 1440
atatgatcca taacagacca tccctggctt ctcagaccaa tgtaggctct cactgcaggg 1500
gcagaggagg agaccagcct gacaaaaaac ctcctaggac cctgccttta cactctcgtg 1560

96

actgggaaat agagagtacc agcagtgagt caaaatccag ttcttccagc aagtatcgtc	1620
ccacatggag acccaaacga gaatctctga atattgacag tatctttagt aaggacaaaa	1680
ggaagcactg tggctatacc cagcttagcc ccttttctga ggattcagct aaagaattta	1740
taccagatga accaagcaag ccaccttctt acgacattaa atttgggtga ccaagcccc	1800
agtacaagcg ctggggccca gcacggccag gctctcacct tttagagcag ccccccgac	1860
taatccagcg aatggaatct ggctatgaaa gcagtgaag gaacagcagc agccctgtca	1920
gcttgatgc agccctgcct gagagctcaa atgtctacag ggatccaagt gctaagagat	1980
cagctgggtt ggttccttcc tggcgctata tcccaaagtc gcacagcagt agcatcctgg	2040
aggtagactc cacagcatcc atgggtggct ggacaaagag tcagccttct tctggtgagg	2100
agatatcttc taaaagtga ctggatgaat tgcaggaaga ggtggccagg agggcgagg	2160
aacaggaaact tcgaagaaaa cgggagaagg agttagaggc agcgaaaggg ttttaaccctc	2220
atcctagccg cttcatggac ttggatgaac tgcagaatca ggggaggagt gacggctttg	2280
agaggtccct gcaagaggca gagtcagtgt ttgaagagtc actacatctg gaacagaaag	2340
gagactgtgc tgcagctttg gctctctgta atgaagctat ctctaaacta agacttgccc	2400
tgcatgggtc cagctgtagc acgcacagca gagccctagt cgataagaag ttgcaaatca	2460
gtattcgaaa agcacggagc ctgcaggatc gcatgcagca gcagcaatca ccacagcagc	2520
cgtcgcagcc ctacgcctgc ctcccaacac aggcggggac tctctctcag ccaacaagtg	2580
aacagcctat cccgctccaa gtattgttaa gccaaaggc ccaactggaa tccggcatgg	2640
atacagagtt tggggccagt tctttcttcc attcacctgc ttctgccat gagtacact	2700
catcactatc tccagagtca tctgccccac agcacagctc cccagtaga tctgccttga	2760
agcttctgac ttcggttgaa gtagacaaca ttgaaccctc tgcattccac aggcaagggt	2820
tacctaaagc accagggtgg actgagaaga attctcatca tagttgggag ccattggatg	2880
ccccagaggg taagctgcaa ggctctaggt gtgacaacag cagttgcagc aagctccctc	2940
cacaagaagg aagaggcatt gctcaagaac agctgttcca agaaaagaag gatcctgcta	3000
accctcccc ggtgatgcct ggaatagcca cctctgagag gggatgatga cacagcctag	3060
gctgtagtcc ttcaaattca tcagctcagc ccagccttcc cctgtataga acctgccacc	3120
ccataatgcc tgttgcttct tcatttgtgc ttcactgtcc tgatcctgtg cagaaaaacta	3180
accaatgcct ccaaggccaa agcctcaaaa cttcattgac tttaaaagtg gacagaggca	3240
gtgaggagac ctataggcca gagtttccca gcacaaagg gcttgtccgt tctctggctg	3300
agcagttcca gaggatgcag ggtgtctcca tgagggatag tacaggtttc aaggatagaa	3360

gtttgtcagg tagtctaagg aagaactctt ccccttctga ttctaagcct cctttctcac 3420
 aggggtcaaga gaaaggccac tggccatggg caaagcaaca atcctctctg gaggggtggg 3480
 atagaccact ttcctgggaa gagtccactg aacattcttc tcttgcccta aactctgggc 3540
 tgcctaattg tgaaacttct agcggaggac agcccagggt ggcagagcca gacatatacc 3600
 aagagaagct gtccaagtg agagatgtta ggtctaagga tctgggcagc agtactgact 3660
 tggggacttc cttgcctttg gattcctggg tgaatatcac aagggtctgt gattctcagc 3720
 ttaagcatgg ggcacctagg ccaggaatga agtcctcccc tcatgattcc catacgtgtg 3780
 taacctatcc agagagaaat cacatccttt tgcattccaca ttggaaccaa gacacagagc 3840
 aggagacctc agaattggag tctctgtatc aggccagtct tcaggcttct caagctggct 3900
 gttctggatg ggggcagcag gataccgcct ggcacccact tagccaaaca ggctctgcag 3960
 atggcatggg gaggagggtg cactcagccc atgatcctgg tctctcaaag acttcaacag 4020
 cagaaatgga gcatggtctc catgaagcca gaacagtgcg tacttctcag gctacacctt 4080
 gccgaggcct cagcaggag tgtggggagg atgagcagta cagtgcagag aatttacgtc 4140
 gcatctcagc cagtctcagt ggcaccgttg tctcagagag ggaggaagct ccggtttctt 4200
 cccacagttt tgattcatca aacgtgagga agccttttga aaccgggcac cgttgttcca 4260
 gtcctcttc cctccctgtc atccatgacc cttctgtgtt tctcctcggt ccccaactct 4320
 accttcccca accacagttc ctgtccccag atgtcctgat gccaccatg gcaggggagc 4380
 ccaatagact ccaggaact tcaaggagtg tccagcagtt tctggctatg tgtgacaggg 4440
 gtgaaacttc ccaaggggccc aagtacacag gaaggacttt gaactaccag agcctcccc 4500
 atcgtccag aacagacaac tcctgggcac cctggtcaga gaccaaccag catattggga 4560
 ccagattcct gactactcca ggggtgaatc ctcaactaac ctacactgcc aactaccag 4620
 aaagaagcaa gggccttcag gttcctcaca ctcagtcctg gagtgatctt ttccattcac 4680
 cctccacccc tccattgtt catcctgtgt acccaccatc tagcagtctt catgtacccc 4740
 tgaggtcagc ttggaattca gatcctgttc cagggtcccg aacccttggc cctcgaagag 4800
 tagatatgcc ccagatgat gactggaggc aaagcagtta tgcctccac tctggacaca 4860
 ggagaacagt gggagagggg tttctgtttg ttctatcaga tgctcccaga agagagcaga 4920
 tcagggttag agtcctgcag cacagtcaat ggtaaagggt attcctttcc tttcctggag 4980
 ctacaccttt ctttgtaaaa ctgtactgtg ggcggggcgc ggtggctcac acctgtaatc 5040
 ccagcacttt gggaggctga ggcgggtgga tcacgaggtc aggagattga gaccatcctg 5100

98

gccaacatgg tgaacccccg tctctaccaa aatacaaaaa attagccagg cgtgacggtg 5160
 cgtgcctgta gtcccaacta ctcggaaggc tgaggcagga gaattgcttg aaccggggag 5220
 gcagagggtg cagtgagccg agatcgcacc actgcactcc agcttggtgaa tagagtgaga 5280
 ctccatctca aaaaacaaaa caaaacaaca aaaaaataaa ctactgtggc agcgttggtgta 5340
 ccctgcatca ctgccatggt tgtgctattc tcatctcaac atagaattgg tgggttctcc 5400
 taagggtgtc aggaacctct aaaaagatgt gattctttgg gaggggatat ttgaaattcc 5460
 aacttccatt cccctagca aaaggaagca gctgctgttt aagggtttta tctgagccac 5520
 tttaaagatg aatccatggt attactctgg atactagcca ttccttagga ttttaaggtc 5580
 acattttatt cctggatgct ttatgtcccc acctccacct gagccctcat cctctgttcc 5640
 ctactatact cccaacttct actctttggt ttatccacct atccctatta cctgaccctt 5700
 tgtcttcctt gtctcccatc cttgggggga catgtagccc tgtggtcatg gttctgatga 5760
 catcatcagg gcagccccc tgcccaggta ttatggcctg tcagcattcc ctgtgccttc 5820
 caaaccttag gcctagaatg cggagctgcc aacataacat tcaccctttt gaacagatgg 5880
 agtcaggcac actaacacag ccttctgtcc tcaataacac agccattatt gccacttget 5940
 cagtcgtcaa tgtaaacctt cagagtcagc tgaactattt taggcctaac atactgtttt 6000
 tgtaaaagtat ttttcattaa taaatctata agacagttct atttaaaaaa aaaaaaaaaa 6060
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaacaaaaaa aaaaaaaaaa aaaaaaaaaa 6120
 aaacaggtgg gggcgcgcg cgggcgcgcc cccgagagaa aatttccaca aacacccgtg 6180
 gggggcgggc gggcgcccca agtgagtgac agagaaagaa agacgaggag cacaacagga 6240
 ggtcgcgtcct ccagaagaaa acaaccgcgt ggggcacaga acaaaggagg tggcgggggg 6300
 tgcgctccac cgcgacaaat aagaaaaccc cgcggggggg ggaaaaacag cagacgagtg 6360
 tcgtgaagaa caacaacca caggagagag gcctcgtgga caaggcacac agggggtgct 6420
 cacaaaacaa gggggtacaa agaaggagac gcaagaaaac ataattgccc 6470

<210> 119

<211> 435

<212> DNA

<213> Homo sapien

<400> 119

gtataatcat ataggcgcat ggttctctaa tgctgctcga gcggcgctg tgatggatgc 60
 gtggcgcggc gaggtacctc tcaacactga gaactgtagt agttgaaacc actgttctag 120
 tgggcagtta gaacagttgt tttccccgtc ttgttcccca cagagctgcc caagttatta 180

99

tctgctcctg ggggttgacc atctgtttta tgacagttat gatattgttg tttaaaaaaa 240
 atccaaattg ttactttgat ttatatgac taactctgaa tcacggaagt attactatga 300
 tgttcaaaac tctgattgac tctacttgct ttaaaaactc tcagatccct tctgcattta 360
 tcatcagaga tcggtaaaga tgacaacaag caggtctaaa gttctgagat gtttagcacat 420
 acccttttca caatt 435

<210> 120
 <211> 1262
 <212> DNA
 <213> Homo sapien

<400> 120
 ggccgagttt tttttttttt tttttttttt tgtttttttt tttttttttt tttttttttt 60
 tgttttagat atgttgcttt tattcaaaag aataaaatgc ttgacaaact cttaaatcac 120
 aagggttgaa ccaaaccacc agtcttctac aacaactctg tgaggtaggt atctgcatag 180
 ccacaaggga tccacatagt cctttcttcc ctgtgacctc tcaaacactg agaattgtag 240
 tagttgaaac cactgttcta gtgggcagtt agaacagttg ttttccccgt ctgttcccc 300
 acagagctgc ccaagttatt atctgctcct ggggttgacc catctgtttt atgacagtta 360
 tgatattggt gtttaaaaaa aatccaaatt gttactttga tttatatgat ctaactctga 420
 atcacggaag tattactatg atgttcaaaa ctctgattga ctctacttgc tttaaaaact 480
 ctcagatccc ttctgcattt atcatcagag atcggttaaag atgacaacaa gcaggtctaa 540
 agttctgaga tgttagcaca tacccttttc acaatttagg aagctttaag atcatttagt 600
 atttttttat gttacaaaat ttggtacaat acacctcttt caggaaagtc ttagtagtaa 660
 ctccaaatat tataattatt gtaaccagaa ttgtgacact tggagcagaa tgcattgaca 720
 caaaataaaa tcctgtcaaa aaatgacatc accattcccc cacaccaaatt gtgtaattgg 780
 taggaaatgc atttccagtc tggtagatgg cagtgtgaca aactcctact cactcgcttt 840
 tcaagttggg gactgcagct gaaatgtttt tctgtgatgt atgccaccct tttacctatt 900
 tgatttggaa gtgtagaatt cggattcatg tcatctccac agacctttcc tcttaggagt 960
 gctaagctg tcttactctg atggagggtat aatgtagcac gaaagacttc caaagaacca 1020
 gtttctctct tgetgttcct cttaacaact ttcacgtcta tctaaacatt ctatgcagga 1080
 gtcctactaa gaaattttgg tgtaatgcca ctttgatcag ttatttgttg tatgacttca 1140
 ttcaaaaaca ctttcatcaa tagcatgggg attgtatcta tgaaagggaa gttgggtgtcc 1200
 tgcgttcctc acaaaattat ccaaaggata aaatgaaaag tatgtgagaa acctgcttta 1260

100

at 1262

<210> 121
<211> 562
<212> DNA
<213> Homo sapien

<400> 121
ggtaccaact tgagtgcctc ctaaaagtgt aaccttgggg gcgggggatac agaaggatga 60
tgctgacaat ggaattttaa aacaaacagc aacattttgt ggtgtctaca ggcggtggggg 120
tggaggagct gcagcgtcac catgggaaca aaagtctccc acgcatctca ggcccagagga 180
atctttaaag agggagagtg ggcatgggag gaggacttaa gctattagtc atattttatt 240
tcgaaaacta gatcttaagt aactgtagca aaatgttaac aattcttacc ttggaatacc 300
ggttacatgg gattcatgtt actctathtt ttcacatgtt gcaaatatht tcatathttg 360
acaattaaaa ctaaatagta gctttttata aaagtggcat atgcactgaa gtataatgtg 420
ctaatttggg attcgtttta ataaaacagc tttcttaca aaaaaaaaaa aaaaaaaaaa 480
aaaagggttg gggaaacaag ggcaaaaggg gttcccgggg ggaaatggtt accgggtcga 540
aatttcacaa ttggagaaaa ac 562

<210> 122
<211> 695
<212> DNA
<213> Homo sapien

<220>
<221> misc_feature
<222> (13)..(13)
<223> a, c, g or t

<400> 122
ctggagcatg gtntgcagga gtgcaagact gcaagcctcc tccacggcca ccaactccagg 60
cctggataaa gaattcgtgg catatttcag ggaacagaat gtcccctggg gcgaaagggg 120
atgaagtcac tctacttgta ccaacttgag tgccctctaa aagtgttaacc ttggggggcgg 180
ggatacagaa ggatgatgct gacaatggaa tttaaaaaaca aacagcaaca ttttgtggtg 240
tctacaggcg tgggggtgga ggagctgcag cgtcaccatg ggaacaaaag tctcccacgc 300
atctcaggcc cgaggaatct ttaaagaggg agagtgggca tgggaggagg acttaagcta 360
ttagtcatat tttatttcga aaactagatc ttaagtaact gtagcaaaat gttaacaatt 420
cttaccttgg aataccggtt acatgggatt atgttactct attttttcat catgtgaaat 480
attttatatt ttgacaatta aaactaaata gtagcttttt ataaaagtgg catatgcact 540

101

gaagtataat gtgctaattt gggattcggt taaataaaac agctttctta gaataaaaaa 600
 aaaaaaaaaa aaaaaaaggt tgggggaaac aagggcaaaa ggggttcccg gggggaaatg 660
 gttaccgggt cgaaatttca caattggaga aaaac 695

<210> 123
 <211> 386
 <212> DNA
 <213> Homo sapien

<400> 123
 aaccctggc caggccagc tgccacacc tttctgggag aagcatggcc tacagaatga 60
 agagggggac caggaacccc tgtgggagag gcttagacct gaagcagtgc ccactctggc 120
 tcctctgcc ttggctgact gggttcctgg accatgtgca tttcactggg ccattgggac 180
 tacatctcct tgcacccca gctggctga tcctgccag gggcccttcc ttcctgtcga 240
 tggctctcag gtggcctgat catggaaagt aaggagttag gcattacctt ctgggagtga 300
 accctgactc catcccccta ttgccaccct aaccaatcat gcaaacttct ccctccctgg 360
 ggtaattcaa cagttaaaag aagctt 386

<210> 124
 <211> 654
 <212> DNA
 <213> Homo sapien

<400> 124
 atgataaacc acctcagccc ccaccaagcc gccgcacccg tagaccagac cccaaggacc 60
 ctggccacca tgggccagag agcattacct tcatctctgg ctctgctgag ccggcccttg 120
 agtccccac ctgctgcctg ctctggcgac cctgggtgtg ggagtgggtg cgggctgcct 180
 tctgcttccg ccgctgccgg gattgcctcc agcgtgtgg aggcctgtg cggggatgca 240
 gccctgcct gtctactgag gactccctg aggggactgc tgaagccaac tggccaagg 300
 agcacaatgg agtgccccc agcctgac gtgcagcccc ccgccggcgg gatggccagg 360
 cgggctgcaa gtcaaccatg ggcagcagct tcagctaccc cgatgttaag ctcaaaggca 420
 tcctgtgta tcctaccga gaggccacct cccagcccc tgatgcggac tcctgtgca 480
 aggagccact ggccgatccc ccaccagcg agcacagcct gccagcacc tttgccagta 540
 gtccctgtgg ctccaggag tactattctt tccatgagtc ggacctggac ctgccggaga 600
 tgggcagtgg ctccatgtcg agccgagaaa ttgatgtgct catcttcaag aagc 654

<210> 125

102

<211> 684
 <212> DNA
 <213> Homo sapien

<400> 125
 acatgcagat gtgcatgtta cagagataaa gtgacgaga caaggactga ctgggtatag 60
 aaggaagaca gactcctgtc ttcactccta aatgcagttc tttggaatca ccctactgtg 120
 atgggcgtag tagggagcca tcagctagga agaaacgtgg gagatgtgaa ttccaagagt 180
 tgcctggaca gggcaagtca tgttagcgtg ggtcacactt ccaagatatt taaagcaaat 240
 aaaaaacaga acagaggatt caaacgcaa gtatgggaga tttaggccct gcagaggcag 300
 accattcctt agtatctcac aaagcagagt aatactggag gcagagtagg ggggtggttg 360
 agagcagtta gtaccaataa caatgaagtc tgtgtttgat ctgacgata ctttccagtc 420
 ccgaatcaaa gatatggaga agcagaagaa ggagggcatt gtttgcaaag aggacaaaaa 480
 gcagtccttg tgagaacttc ctatccaggt tccggtggag gaggaggttg ctggtgatct 540
 ctgtcctaac gatgaagact gggctattca caggcagctc tctgccctca gtggtcaggc 600
 gtgcacattt ggtctgcgcc acataacatt ctgaagcttg ggtatcatgg tcatagtgtt 660
 ccgtgtgaat gtatcgtcac atcc 684

<210> 126
 <211> 2671
 <212> DNA
 <213> Homo sapien

<400> 126
 ctgccgaaga gttcaaaaca gaagagcaag atgcctcagg gagtatagaa tttggtgtat 60
 cttttcctga tagggaatca tcatctatgg aaacatccat cgaacaaaaa gcaactgaaa 120
 cttctcacac agaggggaatt actgccattg aggagagctg ggagtctatg tttaacgatg 180
 atggtgactg cctggatcca cgtcttctac aagagttatc aggaataacc aagagcagag 240
 agagcatcca ggaacctaga tctgattact acaatcatga agttcctgat attgacctca 300
 gtgattgtga attcccacat gtcattgaaa tttatgactt tcccaagaa tttcgtactg 360
 aagaccttct acgggttttc tgcagttatc aaaagaaagg atttgatatt aaatgggtgg 420
 atgatacaca tgccctagga gtattctcca gtccaattac agctcgtgat gcgttggtgta 480
 ttaaacacac catggtgaag attcgtccct tgtcacaggc cacaagagca gccaaaggcca 540
 aagctagagc ttatgctgag ttcctccagc cagcaaagga gcgtcctgag acttcagcag 600
 ccctagccag aaggttagtc atcagtgcc ttggggttcg aagtaagcag agcaaaaccg 660
 aacgagaagc agagctcaag aaactgcaag aagccagaga gagaaagcgg ttggaagcca 720

agcaacggga agacatctgg gaaggcagag accagtctac agtttgaaca tcaactcaatg	780
aaagggataa ttccatgaat cagaaaatgt ttccatagcc ttcagataag atgataccttc	840
cagagctcta tgtacatgca gatgtgcatg ttaaagagat aaagtgatcg agacaaggac	900
tgactgggta tagaaggaag acagactcct gtcttcactc ctaaatagcag ttctttggaa	960
tcaccctact gtggtgggcg tagtagggag ccatcagcta ggaagaaacg tgggagatgt	1020
gaattccaag agttgcctgg acagggcaag tcatgttagc gtgggtcaca cttccaagat	1080
atttaaagca aatacaaac agaacagagg attcaaaccg caagtatggg agatttaggc	1140
cctgcagagg cagaccattc cttagtatct cacaagcag agtaatactg gaggcagagt	1200
aggggggtgt tggagagcag ttagtaccaa taacaatgaa gtctgtgttt gatctgatcg	1260
atactttcca gtcccgaatc aaagatatgg agaagcagaa gaaggagggc attgtttgca	1320
aagaggacaa aaagcagtcc ctgtgagaac ttctatcca gggtccggtg gaggaggagg	1380
ttgctgggtga tctctgttcc taacgatgaa gactgggcct attcacagca gctctctgcc	1440
ctcagtggtc aggcgtgcaa ttttggctct cgccacataa ccattctgaa gcttttaggc	1500
gttggagagg aagtggggg agtgtagaa ctgttccaa ttaatgggag ctctgttgtt	1560
gagcgagaag aaaaaaaga tgaagaatga gaacgcagac aagtactta agagtgaana	1620
gcaaatgaag aagtctgaga aaaagagcaa gcaagagaaa gagaagagca agaagaaaa	1680
aggaggtaaa acagaacagg atggctatca gaaacccacc acaaaacact tcacgcagag	1740
tccaagaag tcagtggccg acctgctggg gtcccttgaa ggcaaacgaa gactccttct	1800
gatcactgct cccaaggctg agaacaatat gtatgtgcaa caacgtgatg aatatctgga	1860
aagtttctgc aagatggcta ccaggaaaat ctctgtgatc accatcttcg gccctgtcaa	1920
caacagcacc atgaaaatcg accactttca gctagataat gagaagccca tgcgagtgg	1980
ggatgatgaa gacttggtag accagcgtct catcagcgag ctgaggaaaag agtacggaat	2040
gacctacaat gacttcttca tgggtctaac agatgtggat ctgagagtca agcaatacta	2100
tgaggtacca ataacaatga agtctgtgtt tgatctgatc gatactttcc agtcccgaat	2160
caaagatatg gagaagcaga agaaggagg cattgtttgc aaagaggaca aaaagcagtc	2220
cctggagaac ttctatcca gggtccggtg gaggaggagg ttgctgggtga tctctgtctc	2280
taacgatgaa gactgggcct attcacagca gctctctgcc ctcagtggtc aggcgtgcac	2340
attggtctgg gcgccttacc ttctgaagct taagcgtgag cacggactgg gggcccgttc	2400
aactggcccc attaaggagc ccagagataa cgagaaacgt acaccccatg gtgaaaaaca	2460

104

ccgcacaaat ccacggaccc ggagacaacc caggccaggc gcaaaaagca agaccacacg 2520
 gatatcacc aaggcagcga gaagggacca cacacacacc cgcacaacag gacaccaag 2580
 cggcgccaca acagtcacga caccacaagg ccacgaagca acacacagaa acatacacag 2640
 cagcacacgg ccatacaacc gccacacag c 2671

<210> 127
 <211> 420
 <212> DNA
 <213> Homo sapien

<400> 127
 acgggcccga gtgttgatgg atgcgccgag gtaactctct ctcccttaag agttatgagt 60
 tatcaagagg agacttctta aagacagcaa cgcaattctt gtaacttggtg taaatagccc 120
 catctttcag agtgatacca tttctacatt tgataatgcc tgtattcctg taggatgtat 180
 atagtttagg ggattttttt ttggttgggg ttttggtttt ttagaaggtc aatatgtctg 240
 gtttttattha tgtgcttgaa aaagatcatt tgaaaaaaat aaatacatth tcaaccacaa 300
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ggcgcggggg ggaacccggg gccagagcg 360
 ggccccgggg ggccaattgg gttctcccg cccacattcc cccaaaatat tggcacacag 420

<210> 128
 <211> 2269
 <212> DNA
 <213> Homo sapien

<400> 128
 taccgaggag ggaacaagct acatgctatt ttgtttgtag tattgtggaa cagtcttggt 60
 atggagtgcc agcttagagg ttgttgcaaa cttgtctaga agtgagagca tggttttttt 120
 tagccctttg agagtctaca tctaataaac attcttgctc acccataaat aacgtcaagc 180
 ctcaatgtca ccgtcacgtt gggatactct ttctcatctg gcacccatga caggacaagg 240
 ttggttacct ttccttccat gaaccatgaa cctgtgacgg catcattcat cctgacttca 300
 ccaagctccg cctgtgggtg aggcagagc tcccactggc aattttttaga agagccagag 360
 gctccctgct tcctctagaa ataacagttc aggggtgaagc atggagggtt tcagttccca 420
 gacaatggaa ccatttagag acaacacagt tggacatttc cactttttcc ttgattcctg 480
 gaagtccagt gggttctgca gctgaaaaag ccctgggtcc cagcagcaga gagacaggac 540
 agaggggatg cttggcgagg gagggacggt aacctgcaga acagattcca tttttataga 600
 acgagtacac gtttgctaaa acagtcctgc tttcccagac tggattccca ccacagggac 660
 agtcggaact caggactagc tccagcgaca tctttcctcc gaattcaagc cttctatcac 720

105

```

aatgtcaaaa cagctattta taaagccatt ttcattgtac ttgataacag cacgagtccc 780
aaaactttta gaaataaaat aggacattgg cttgattgaa aagagggact ttttaaaaat 840
tggtctttcg tcagaagcct tttggatgac ttacaatagc tctgatgaag ataccacccc 900
agcgtcagtc caataggtca gtgagtttca acaggcatcc atccctcca tgaagggatt 960
ctggtgatgg gaagtttctg taatgacagg aaagcattga ccctcattga ttgtcaactt 1020
tggtattagc catgaaagac aggatgctca ttgggtgttc tgtagagtga ggaatgctgc 1080
ctattccctc ccagaacgtc tgacccaggg gtgtgtgttg aggagccctg ggggaaatgg 1140
accaagtttt cccacagagc agtattaggc tgaagagcag gtgactggta ggccccagct 1200
cccatcattc cctcccaaag ccattttgtt cagttgtctca tccacgctgg attccagaga 1260
gttttccaat ttgggaagcc atgagaaagg tttttaaatc ttgggaagat ggagagaggg 1320
acataggata gttgactcca acatgacagg aagaggctgg agattgggaa ttggccatca 1380
accaagcctg tagtagtaaa gccatggtcc cgcattggaa ttacttgggg aacttataca 1440
gttctgatac ccaggctctc ctagaccagt tcaaccaatt ctaggtgggg gactcaggca 1500
tcagtgtgtt tcgtagctcc cgggtgtttt tccctgtgca gccgagcttg ggaaactgcc 1560
atgctttttg gatgtcaagg cgctgttgga ggctgggtgt gacagcacag agccaggttg 1620
tcttgtggaa accacagcca cgggtttgcc actggctcag catggcctca ctgccagtcc 1680
cagcctggct gagggacaag atggtttctc ttgggagttc ctgagtggag cacccttcca 1740
ggctttttga aagccagctg atctgtggag ccttgttaag ggactcaata cgggtgtttgg 1800
atattgatgt ttttccttga gactgtcttg tccatcaata aagatggagg atgtctcctc 1860
tttgaacccc gcttccccac cagtaactctc tctcccttag agtttatgag ttattcaagg 1920
aggagacttc ttaaagacag caacgcaatt cttgtaactt gtgtaaatag ccccatcttt 1980
cagagtgata ccatttctac atttgataat gcctgtattc ctgtaggatg tatatagttt 2040
aggggatttt ttttttgttt ggttttgttt tttagaagtc aatatgtctg gttttattta 2100
ttgcttgaaa aagatcattt gaaaaaaata aatacatttt caacccaaaa aaaaaaaaaa 2160
aaaaaaaaa aaaaaaaaaa ggcgcggggg gaacccgggg cccagagcgg gccccggggg 2220
gcgaattggg ttctcccggc ccacattccc ccaaaatatt ggcacacag 2269

```

<210> 129

<211> 750

<212> DNA

<213> Homo sapien

106

<400> 129
 gccgcccgagg caggtaccca agtttcagtt acacaggagg catgagattg atctagtcca 60
 aaaaatgatg agtataataa ataataatgc actgtatatatt ttgaaattgc taaaagtaga 120
 tttaaaattg atttacatac atattttaca tatttataaa gcacatgcaa tatgttggtta 180
 catgtataga atgtgcaacg atcgagtcag ggtatctgtg gtatccacca ctttgagcat 240
 ttatcgattc tatatgtcag gaacatttca agttatctgt tctagcaagg aaatataaaa 300
 tacatttata tgttgactat ggcctatcta catgttgcaa ctaaactacta gattttactt 360
 cctttccaac tgtgggtttg tattcattta ccaccctctt ttcattccct ttctcaccca 420
 cacactatgc cgggcctcag gcataacta ttctactgtc tgtctctgta agcgattatc 480
 agtttttagct tccacatatg agagaatgca tgcaaagtgc tgtctttcca tgccgtgtct 540
 tatttcactt aagcaaaatg acctccgctg tccatccatg ttattttatat taccctaacta 600
 gtgttcataa aactagtata tacaccacat agtataccac agaaacggac cactgcggat 660
 aaacaggatt tctgggtccac acttttgtcc catacgggac cgtggggcaa tctgattacg 720
 cgcacagcaa gagcaacca gtaagaaaca 750

<210> 130
 <211> 738
 <212> DNA
 <213> Homo sapien

<400> 130
 gcgtgggtcgc ggccgaggta ctgtgaatta cggatgctct ttgaaggaaa gaaatatcga 60
 ttctaattgtt cttcagaagt tctggcaggg ataagcagga catcgactgg aacgtatgct 120
 aaatgaaagc agacaaattt ctattttctt acctgagcaa atattttatt gaaactgctt 180
 atgtatgcca aaggagccca caacttcagc tacacaactt tttgtattga aagaactcat 240
 actttttgta gcttttattt cacatttaac ttaaagtac ttttagcact aaaatgccta 300
 gaagatttta ctccagacct ataaggaaat gtttagtttt tatgaaaaat gacaagtcca 360
 tgggttaaact tctcatgtct ttggtgcttt ggccctaata gcactggaca acaccacgac 420
 cacatggaaa catatttttg gaagcaaac ttaatttta tataacgtat gctatggaga 480
 gctaagacaa ttaaggact acttgtttct tatttttttt cttaataaaa tggaatccac 540
 tgtgttgaag actcttgata ttcattgtgt tgtctaacca ttttttgttt tataattaga 600
 ataaaaatata gttgtgataa tggatcatga atggattttg tttggaaagc tacatcttat 660
 ttgtgaaatg ttttttaaaa tcagagtaac tatcaactga ttcagctttt tgttggtttg 720
 ttcttggtat aatacttg 738

<210> 131
<211> 1875
<212> DNA
<213> Homo sapien

<400> 131
tggcaacgat ctggaccgct acaacccgct aagctccagc gccttgtgcg caacgcgctg 60
gcgcacgtgg tgccaaggag cgcgagctga gctggcgcac tcggagagtt tcgccgcctg 120
tgccgctaag gcaagcgcg gttcaagatc ggccggcgagc tgccgcatcg caagcagccc 180
taaccggctgc agattcagct gtcggcgagc cgcagccaca cgctcgagtt ccagagtcta 240
gaggacctga tcatgggaga agcgacgcaa cgaccagat cgggcgcgcg gcccggtgctg 300
caggagctcg ccacgcacct gcacccggcg gagccggagg agggcgacag caacgtggcg 360
cggactacgc cgctcccgg gcgccccctt gcgccagct ccgaggagga ggacggagag 420
gcagtggcac actgatgggc gagctgagcg cagagctgcg aaggggaact gtttgagta 480
gcagccgctg ctccctttct cctctcttct ctcctcttct tgccactgtc tgggccccat 540
ctgggattcc tgggcccttt ggaaaagagt tggtgaaatg cgcagccggc tgtggacggg 600
ggaggaggaa ggggacagag ggagcaggaa taagactgta gaactgtttt gtactgtgaa 660
ttacggatgc tctttgaagg aaagaaatat cgattctaatt gttcttcaga agttctggca 720
gggataagca ggacatcgac tggaacgtat gctaaatgaa agcagacaaa tttctatttt 780
cttacctgag caaatatttt gttgaaactg cttatgtatg tcaaaggagc ccacaacttc 840
agctacacaa ctttttgtat tgaaagaact catacttttt gtagctttta tttcacattt 900
aatttaagtg gacttttagc actaaaatgc ctagaagatt ttactccaga cctataagga 960
aatgtttagt ttttatgaaa aatgacaagt cgatgggtta acttctcatg tctttggtgc 1020
tttgcccta atagcactgg acaacaccac gaccacatgg aaacatattt ttggaagcaa 1080
aactttaatt ttatataacg tatgctatgg agagctaaga caatttaagg actactgtgt 1140
ttctattttt tttcttaata aaatggaatc cactgtgttg aagactcttg atatcatgtg 1200
cttgtctaac cattttttgt ttataaatt agaataaaat atagttgtga taatggcat 1260
cgaatggatt tgtttgaaa gctacatctt atttgtgaaa tgttttttta atcagagtaa 1320
ctatcaactg attcagcttt ttgtgtttt gttcttggct ataatacttg tgactcatga 1380
agaattatgt tgacaaacag gataaattcc acatgcattt tatttcccag tgagttgtat 1440
aaactttatt tttgttgag gttgtatgtt aaatcaatgt tacattctta taccattctt 1500
tgagaaggaa gttccgattt gaaattgtat catttccttc aaaatgaagg gcagtgttta 1560

108

gttaaataaa agattgatga tatcttttaa gccaaaaaa aaaaaaaaaa aaaaaaaaaa 1620
 aaaaaaacga accaaaccaa taaaaacaag aagcacacag accgaacacc acacacacaa 1680
 gccaccagag ctacataac gcgcgggcaa acatccacac ggccacacac agcaaccac 1740
 tatgagagcc accccgcgga aaaaagacc ccacacacaa ccagagacaa gaaacctgcg 1800
 agccacgccc tccacacca caaccacgaa tagtcacctc agtaacaaaa caaacacaga 1860
 cggaggcgcc gacaa 1875

<210> 132
 <211> 828
 <212> DNA
 <213> Homo sapien

<400> 132
 tggtcgcgcc cgagggtacaa taggtctctt gaattttatc ctctgtctta attgaaattt 60
 gtatcccttg accaaccatct tcccagtcac acccccatcc ctctggtaac catcattcta 120
 ctctagtgtg atgagttcaa tttttttaga ttccatttat aagtgtattta attaatatct 180
 ttatcctctt tccagataat tcaaggacct tagcatttta actctagtca actgtaatat 240
 tacattccat cgtattgcag tatttttagt ttcttctatt aagccttcca aattggatat 300
 tagcattatt gtggttgttt cacattagca ttattgtggt tgtttcagat agtcaatatt 360
 gatgcagatt tacctgaata ttacccatga ttaccatcat tccttcttct tacttagatt 420
 tccatcatcc ttcttcttga aatataattt taaaagggtc cattgaagaa gttctgttga 480
 tggtaaatac agttttactt tctttgaaaa tatctttatt ttgccacat cagttatttt 540
 attgttcagt attaagaaaa cctaattcct gtgttttctt cccatcattg ttgatattga 600
 gttgtgtgcc atcaggcaaa tgtcattact ttttagatat tctaaacctg ttgtttcttt 660
 aagtaagtac attgtctccc ccttaatctg ttctccttcg taatgtttta ttatttgtct 720
 cactattatg gattctggac aggtttcttc tgggtccttc ttccaggttg ctattctcta 780
 ttcaggtgtg tttatctgct atttatcctc cctccagttt tttccttg 828

<210> 133
 <211> 1023
 <212> DNA
 <213> Homo sapien

<400> 133
 tggtcgcgcc cgagggtacaa taggtctctt gaattttatc ctctgtctta attgaaattt 60
 gtatcccttg accaaccatct tcccagtcac acccccatcc ctctggtaac catcattcta 120

109

```

ctctagttgt atgagttcaa tttttttaga ttccatttat aagtgattta attaatatct 180
ttatcctctt tccagataat tcaaggacct tagcatttta actctagtca actgtaatat 240
tacattccat cgtattgcag tatttttagtc ttcttctatt aagccttcca aattggatat 300
tagcattatt gtggttggtt cacattagca ttattgtggt tgtttcagat agtcaatatt 360
gatgcagatt tacctgaata ttacccatgg attaccatgc attccttctt tctacttaga 420
tttccatcat ccttcttctt gaaatataat ttttaaaagg tccattgaag aagtgtctgt 480
tgatggtaaa tacagtttta ctttctgttg aaaatatctt tattttgccc acatcagtta 540
ttttattggt cagtgattaa gaaaacctaa ttccctgtgt ttcttcccat cattgttgat 600
attgagttgt gtgccatcag gcaaattgca ttacttttta gatattctaa actgttggtt 660
gctttaagta agtacattgt gctcccctta atctgttctc ttcgtaatgt tttatttatt 720
tgtctcacta taatgaattc tggacagggt tcttctggtc tttctttgca gtttgctaata 780
tctctattca gctgtatcta atctgtctat taattcatcc atcaagtatt ttttccctag 840
tattttgttt taataatttt atttactatt tctagatttt tttctaataca tccctggtctt 900
tgtcatagta tcttcttctt tatatacatt ttatttatgt atctgataac attaataact 960
taaacccttg taagttataa gtatgttttt agttttgggt ctgatttgggt tcaaataaac 1020
ata 1023

```

```

<210> 134
<211> 757
<212> DNA
<213> Homo sapien

```

```

<400> 134
gagcggcgcc cgggcaggta ccttcgtgcc cctcagtagt tgttttagcc taatgtagag 60
tcaatctagg acttataatt attcatcatg attttgagta gattgtaatc atcaagaatt 120
tttcatagat cgtttacttc caattgaatt tagctcagaa gtgattgctt tctctttatt 180
tgagatagga gctctcgcac tgcgccagg ctaggagtgc aagcggcat gatcgtcggc 240
tcactagcaa cctctgcctc ccgggttgaa gcagatatac ccctgacctc aagcctcctg 300
cagtagctag ggactacagg tagttcatcg ctgttcctta gcttggaac taggatgcac 360
aaacacatgg gttattatac tcgtacacgg agctgggtcac acaacggaac tagactctct 420
ctccaaatgt gataccacac agacaacact cagaactacc ttcgagcctt acttaagatc 480
atcccttcac tgatctaaca aacttacaaa cattaataca accagatact gcgtctcgac 540
tattgcacgg caaatcaaaa tacaacagg tctccactaa agaccagggtg gtgacatgtc 600

```

110

ctagagatca acagaacaat ctaatcctga ccctcacgcc aactatgatg acacgatggc 660
 cgctggccca cacaggaagg ccgacacggg ccgcgctcaa agaccaccca tgtccggacc 720
 tagcctaaaa aaaactcacg ccccgccgcc cctacct 757

<210> 135
 <211> 1513
 <212> DNA
 <213> Homo sapien

<400> 135
 gcgggagcct gggcggcgag ccgggtgtga gctgcctgaa aatgcactcg gatgccgccg 60
 ctgtcaatth tcagctgaac tctcatctct caacactggc aaatattcat aagatctacc 120
 acacccttaa taagctgaac ctaacagaag acattggcca agacgatcac caaacaggaa 180
 gtctgcggtc ttgcagttct tcagactgct ttaataaagt gatgccacca aggaaaaaga 240
 gaagacctgc ctctggagat gatttatctg ccaagaaaag tagacatgat agcatgtata 300
 gaaaatatga ttcgactaga ataaagactg aagaagaagc cttttcaagt aaaaggtgct 360
 tggaaatggtt ctatgaatat gcaggaactg atgatgttgt aggcctgaa ggcattggaga 420
 aatthttgtga agacattggt gttgaaccag aaaacgtgag tcaaacttac tgagttgggt 480
 gaatcagttg gttgtttttc atacttaaat ctttgttctt tagcaaataa atagaataat 540
 taaaaagtag tggatatgta gtttttatga agcagtctaa gaaataagtt ctaattctag 600
 tttgacttat aagcagattc tccattcttg taagtatat ggtgtaacta cagttattht 660
 ttctctcatt taatthcttg tatgtaaaag gtacagtaag ccagatgctt acaaaatggt 720
 gtggccacat gtgcctacaa tgacggatca actggaggcc acattgtacg ctgtgtacct 780
 tcgtgccct cagtagttgt tttagcctaa tgtagagtca atctaggact tataattatt 840
 catcatgatt ttgagtagat tgtaatcatc aagaattht catagatcgt ttacttccaa 900
 ttgaatthtag ctcagaagtg attgcttht tttttttgag ataggagctc tcgcactgtc 960
 gccaggctag gagtgaagc ggtcatgatc gtcggctcac tagcaacctc tgcctcccg 1020
 gttgaagcag atatacccct gacctcaagc ctctgcagt agctaggagc tacaggtagt 1080
 tcatcgcttg tccttagctt ggaaactagg atgcacaaac acatgggtta ttatactcgt 1140
 acacggagct ggtcacacaa cggaaactaga ctctctctcc aaatgtgata ccacacagac 1200
 aacctcaga actacctcg agccttactt aagatcatcc cttcactgat ctaacaaact 1260
 tacaacatt aatacaacca gatactgcgt ctcgactatt gcacggcaaa tcaaaatata 1320
 acaggttctc cactaaagac caggtggtga catgtcctag agatcaacag aacaatctaa 1380

111

tcctgaccct cacgccaact atgatgacac gatggccgct ggcccacaca ggaaggccga 1440
 cacgggccgc gctcaaagac caccatgtc cggacctagc ctacacacac ctcacgcccc 1500
 gccgccccta cct 1513

<210> 136
 <211> 738
 <212> DNA
 <213> Homo sapien

<400> 136
 gcgtggcgc gccgaggtac caacccagc acacccaac agcctttcct cggccccctc 60
 ctcaggcctc ctaattactc tttctcagcc tggagtgtgg ggccgttacc gtctcttcc 120
 cctttctcct tccatactgc acttaacctt gctggaagat ttaatgatgg agatttaggg 180
 caactgtggc tgcttgggac ccttcctctg gaccaaagga acttaaaacc caatacctga 240
 cactggaatg aaatccaagt ttttaaatat cacctttcaa tcactcacag atctcacatc 300
 tatcttaaaa tactcagcct cactccttaa ctgagtgtct gcctgagagg gagaaaagtt 360
 ccattttaaa aacgtattca ctttactgat tactgtgcaa tttgaattaa gtcacgattc 420
 tttagtcatg gaggtcgaga atctcagatt caaattgtca gagaccatga tttagaagtc 480
 taccaaacac ccagtttcct tccactgttt tagggtaaca ggaaaacatg agattggggg 540
 ggtgtccgct attaaatgga accacacatc atgaaattca attctcatgt taagacattc 600
 tgtattgtgg gatgtcaaaa gtatctccca aaactttcgt ttgacctgtc agagtgggga 660
 tggttactcc ctatacttca gtttgtttca caagcttggc gtaaccagga atagtgttcc 720
 gtgtgaatgt tcgtccac 738

<210> 137
 <211> 1350
 <212> DNA
 <213> Homo sapien

<400> 137
 atggttatgg agaagcccag tccgctgctt gtagggcggg agtttgtgag gcaatattat 60
 actttgctga ataaagctcc ggaatattta cacaggtttt atggcaggaa ttcttcctat 120
 gttcatgggtg gagtagatgc tagtggaaag cccaggaag ctgtttatgg ccaaatgat 180
 atacaccaca aagtattatc tctgaacttc agtgaatgtc atactaaaat tcgtcatgtg 240
 gatgctcatg caaccttgag tgatggagta gttgtccagg tcatgggttt gctgtctaac 300
 agtggacaac cagaaagaaa gtttatgcaa acctttgttc tggctcctga aggatctgtt 360
 ccaataaat tttatgttca caatgatatg tttcgttatg aagatgaagt gtttggtgat 420

112

```

tctgagcctg aacttgatga agaatcagaa gatgaagtag aagaggaaca agaagaaaga 480
caaccatctc ctgaacctgt gcaagaaaat gctaacagtg gttactatga agctcacctc 540
gtgactaatg gcatagagga gcctttggaa gaatcctctc atgaacctga acctgagcca 600
gaatctgaaa caaagactga agagctgaaa ccacaagtgg aggagaagaa cttagaagaa 660
ctagaggaga aatctactac tcctcctccg gcagaacctg tttctctgcc acaagaacca 720
ccaaagccaa gagtcgaagc taaaccagaa gttcaatctc agccacctcg tgtgcgtgaa 780
caacgaccta gagaacgacc tgggttttcct cctagaggac caagaccagg cagaggagat 840
atggaacaga atgactctga caaccgtaga ataattcgct atccagatag tcatcaactt 900
tttggttgga acttgccaca tgatattgat gaaaatgagc taaaggaatt cttcatgagt 960
tttggaacg ttgtggaact tcgcatcaat accaaggggtg ttgggggaaa gcttccaaat 1020
tttggttttg tgggttttga tgactctgaa ccagttcaga gaatcttaat tgcaaaaccg 1080
attatgtttc gaggggaagt acgtttaaat gtggaagaga aaaaaacaag agctgcaaga 1140
gagcgagaaa ccagaggtgg tggatgatgat cgcagggata ttaggcgcaa tgatcgaggt 1200
cccggtggtc cacgtggaat tgtgggtggt ggaatgatgc gtgatcgtga tgggaagagga 1260
cctcctccaa ggggtggcat ggcacagaaa cttggctctg gaagaggaac cgggcaaatg 1320
gagggccgct tcacaggaca gcgtcgctga 1350

```

```

<210> 138
<211> 569
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (509)..(509)
<223> a, c, g or t

```

```

<400> 138
cgccccgggca ggtcgcccat gtgctgtgat gtcagtgagc gggcggagtt caggctggtc 60
agtgccaggt gtccttctc ccacccgaga acagtggcca ggttgctcct caggcacctc 120
gggcaactgc cccttccctt ccagtggggc ctgacctggc taccgagctt ggcagctaata 180
aggcggggccc ctcagcattc acgctcctga gctgctttat caaactagga ttgttcccc 240
aggcttaaga aaaccatcca ttactgcaa agttagttat tactgcggat gggctaggag 300
ttagaggaag agagtgactc aaatcacaac acctcctgga cgaagctgga agcggattaa 360
aataccgggc ctaatttcag aacaacaaaa aaaaaagaaa aaaaaaaaaa agcgcggggc 420

```


113

ggaacccagg ggccaaaagg gtgggtcccg gggggggaaa tctggttacc gcggcccaaa 480
 attccccaaa aaatttgggg gggccaaang caccgcgctc tctgcccccc ccacgccccg 540
 cccccccccc acaacccatc gccgccccg 569

<210> 139
 <211> 739
 <212> DNA
 <213> Homo sapien

<400> 139
 tatatcacta taggggactg ggtcctctag atgctgctcg agcgggccga gtgtgatgga 60
 tccgggcagg tactgcctgg ttttacaaga attaatgcag tttcacagtg aagcatgtaa 120
 gatattgaat tttagagaca atagaccaga tacctttcta atctcatttt attcattaat 180
 gtcaaataat accattttta aaaatatggt gcttatttgt ctagcaagta acctatagaa 240
 aagtattatt ttatacaaaa agatgattag gtcacataaa ggaattggaa tcttaagttt 300
 aaaatacact tctgttttta gccagaaggg agaaacgatg gttggattta tgccattttt 360
 caattaaaaa ccatgtggta ctacttgaag cagtttctga gtaaatggag gtgtttaaag 420
 atttgtatta ttctctccca atgactagat agtagtattt tacaatggag acttaaaagt 480
 tttttgtgtt ttattctttc gcttttctat gccctcaatc caaagaacac cagaaataca 540
 cttgtagtcg gaaaacttgg gtttatcact cgcacaaagg aatgacacac accatggggc 600
 actctggagc ctctcaataa aaggatgttt caaaggaaca acaacaaaaa aaaaaaaaaa 660
 aaaacgttgg gggaaacaca gggcacaag tgtcccgagg gaaattgttt tccgccacaa 720
 tccaaaattc acaaaaacc 739

<210> 140
 <211> 1131
 <212> DNA
 <213> Homo sapien

<400> 140
 aagttgatag tatatccacc acctccagct aaggaggga tctctgttac caatgaggac 60
 ctgcactgtc taaatgaagg agaattttta aatgatgtta ttatagactt ttatttgaaa 120
 tacttggtgc ttgaaaaact gaagaaggaa gacgctgacc gaattcatat attcagttct 180
 tttttctata aacgccttaa tcagagagag aggagaaatc atgaaacaac taatctgtca 240
 atacagcaaa aacggcatgg gagagtaaaa acatggaccc ggcacgtaga tatttttgag 300
 aaggatttta tttttgtacc ccttaatgaa gcgtgagtaa gaatttcctt taaaggaaaa 360

114

```

tctttaaatc atgtaaata tgacaatttt taaataatga gtatgagggtg aagaattcat 420
tttaaaacat ctttctgaaa tctcttggtg atattcataat ttgtactgcc tgttttataa 480
gaattaatgc agtttcacag tgaagcatgt aagatattga attttagaga caatagacca 540
gatacctttc taatctcatt ttattcatta atgtcaaata ataccatttt taaaaatatg 600
gtgcttattt gtctagcaag taacctatag aaaagtatta ttttatacaa aaagatgatt 660
aggtcacata aaggaattgg aatcttaagt ttaaaatata cttctgtttt tagccagaag 720
ggagaaacga tgggtggatt tatgccattt ttcaattaaa aaccatgtgg tactacttga 780
agcagtttct gagtaaattg aggtgtttta agatttgtat tattctctcc caatgactag 840
atagtagtat ttacaatgg agacttaaaa gttttttgtg ttttattctt tcgcttttct 900
atgccctcaa tccaaagaac accagaaata cacttgtagt cggaaaactt ggggtttatca 960
cttgcatcaa ggaatgacac acaccatggg ccactctgga gcctctcaat aaaaggatgt 1020
ttcaaaggaa caacaacaaa aaaaaaaaaa aaaaaacgtt gggggaaaca cagggcacaa 1080
agtgtcccg gggaaattgt tttccgccac aatccaaaat tcacaaaaac c 1131

```

<210> 141

<211> 887

<212> DNA

<213> Homo sapien

<400> 141

```

gcgtggccgc ggccgaggta cactgaatta ttcacagtaa tcgcttggtt ggggaaagg 60
ttagtaaatg ccaaaggaaa taccacaga aatctctac acagcttaga tgttggtctg 120
gcatttaagg cccatgagt atgggccatt ctgcagcttt tcatgccatg cctttccttt 180
gtgtgggggt ccacagatca gagtctgtct gtggcatcga cttccttatg tcctcattgt 240
tcccacccat tgctgggatg tccacgttg acttctcaa agtggcccaa gaatctaagt 300
gcaaaatctg tttggatttt tacaattttt tcctaattct ttacagtctt ggtcattcct 360
atttcaactg caattttttt caatgacttg cctgggtgta atattttttt aaagcatcca 420
gtattaaaca aaaaaattta aacagctaaa aaaaaaaac aaaaaacaaa cggctgggcg 480
aaaccagggc tcaataccgg ctccccgtg tgctgaacac tggatatact cgcggttcac 540
caattcccaa ccacaacata cgggcgagac aaggctgcac gcaaccggc acgcgcatgt 600
cgcaggacac gtacaggagc caagaacggg cagcaggacc acagagaacc agacgcaggc 660
cgcgcacgtg gagcggaggg gtagaacga cagccgccg gccgtgggca gcggccatgg 720
cgcacacggg ccgacacgga agcggagccg cagcgacagc gagcagcacg cggggcgacg 780

```

115

gcgcggcgag gaggggagcg gcgcggggaa cggacgctgc agagaggcgg agggcgggcga 840

gccgcggcgc ggccgagccg aaggcgaccg caagcggcgg cggcggc 887

<210> 142

<211> 2086

<212> DNA

<213> Homo sapien

<400> 142

cgagccaaga attcggcacg aaaaacaaat acttcctgat cgatcccttg tcttgtttag 60

tatgcttcct gaccattttt taccctaaca tttgtgttct tttcccgaga aggaaaatca 120

acttctatcc tatctctacc cagcagaggc cctgccccca ctttacacac aaaaccatct 180

aactttttga tattctaaat gggggaaacc cctattttat aaccctcggt tacttttaat 240

ctttagatga ggaactagag gagccactat gtctctctca gcacatgat ttatgcctta 300

gctaaggcct tacttgggg aaggggaaga aggttgttt caagcctgtg gcctcctgtc 360

actccccacc cctggaaggc ccttcacttt tgggtgatgc ctagaggcct catggacagc 420

agtcccttct gacaccagc gagatatcat ctgggagggt cgcagccctc agttccctc 480

atggctctct ctttcacttc cctccatgac accacctcat cgagttgaag atgttattga 540

tgagtgcagt ggggtgtatag tgtcctccca aaattcatgt ccaccagaa attcagaatg 600

caaccttatac tggaaataga atctttgcaa atgtgattag ttaagatgaa atcatactga 660

gttaggatga acctgaaatc caatcactgg tgtccttgta agaggaaagg tcacaaagag 720

acagaggaga tacacagagg agcccatgta atgatgggta cggagactga cgtggcacia 780

ctataagcca aggaatgcca ggggaaggcca gctagcagaa gctagggaaa aacacagagg 840

gattctcccc tggagccttt ggaggagggt tggccctgct gacaccttggt ttctggactt 900

ctggccccca gaactgtgag aaaataaatt tctgtgggtt aagccacaca gtttgtgggtg 960

ctctgacttc gtgagctttt ctgccatct gacagcgctt gcctgccttc ctccctgccc 1020

accgtcctcc cgccccgtcc cagaccctcc togctcctca tcccactcca ctctgtgag 1080

tgctcctcca caccatggct gcaatcccca ccttaagctg gggactccca aaccccgact 1140

tccccacagg gctcaggagg cttttctcca gccagcctca catttggaact catgcttctc 1200

ccccatgcca ccctcagcta cgctgaatta ttcacagtaa tcgcttggtt ggggaaaagg 1260

ttagtaaatg ccaaaggaaa taccacaga aatctcctac acagcttaga tgttgtgctg 1320

gcatttaagg cccatgagtg atggtccatt ctgcagcttt tcatgccatg cctttccttt 1380

gtgtgggggt ccacagatca gagtctgtct gtggcatcga cttccttatg tctcattgt 1440

116

```

tcccacccat tgctgggatg tccacgttgg acttctcaaa agtggccaag aatctaagtg 1500
caaaatctgt ttggatTTTTT acaatTTTTT cctaattctt tacagtcttg gtcattccta 1560
tttcaactgc aattTTTTTt aatgacttgc ctggtgtgaa tattTTTTTt aagcatccag 1620
tattaaacaa aaaaatttaa acagctaaaa aaaaaaaca aaaaacaaac ggctgggcga 1680
aaccagggct caataccggc tccccgtggt gctgaacact ggtatactcc gcggttcacc 1740
aattcccaac cacaacatac gggcgagaca aggctgcacg caaccggca cgcgcatgtc 1800
gcaggacacg tcacggagcc aagaacgggc agcaggacca cagagaacca gacgcaggcc 1860
gcgcacgtgg agcggagggg tagaaccgac agccgccgcg ccgtgggcag cggccatggc 1920
gcacacgggc cgacacggaa gcggagccgc agcgacagcg agcagcacgc gggcgacg 1980
cgcggcgagg aggggagcgg cgcggggaac ggacgctgca gagaggcga gggcggcgag 2040
ccgcggcgcg gccgagccga aggcgaccgc aagcggcggc ggcggc 2086

```

```

<210> 143
<211> 676
<212> DNA
<213> Homo sapien

```

```

<400> 143
gccgccgggc aggtactaaa taaaatgcaa aacatgtcac atcactcttc ttcattgggtt 60
catgtcctct gtgggtcagg tottccacat gtagagtaga ggtagggat gttcacacct 120
tcaatgacaa cctacacatt tctgctccaa cagggtccaa attgttcta ggtttcaaag 180
ttgttggttg tttgtttttt toctttttct tttttttttt tttttttgga gaagtggagt 240
ttggctcttg ttggccccgg tgtggagtgt gcaaggggcg gtgatctgcg gttcaccaac 300
aaacctcgtg gtcctccgcg gtttacaagg gcgattatc cgtggcctac aggcctcgcg 360
agtatagccg tgggatataa tagggcagtg gcgcacacca gtgcccagc ttaatttgtg 420
ggatatttaa ggtagaagaa gcgggggtct ctccccctt tgtgtgggtc tcgagggcgt 480
ggactctggg aggcctcgcg tggaaccctc gaggggtgat ctcacacctg tgcgcttggg 540
ggccttccca caaaaggtgg gcctgggggg atttaccagg gcgtggcaga agcccaaact 600
atgtgggcgg gggcgcacac aggggggttt cccaaaaggg tttttttaac cgggtattaaa 660
aagagggttt cgctag 676

```

```

<210> 144
<211> 1260
<212> DNA
<213> Homo sapien

```

117

<400> 144
 taaacataca cacatcaaaa ataactcagc cacatgcaac aatacagaga atcttaaaga 60
 catagtatga gcaaaataat cagtacacac aaaattccac ttatacaaag ctcaaaaaca 120
 aaattaagca atatttttta gaaatgcaat tataaatgat gactgacca ctatcaagga 180
 aagtatttaa cattgctctg aaagtcttg aaattcttga ttttccttct tcaatttcta 240
 caccatcac cagcccaagt cttcccaac tcaactaaaca gcaccgcat ccatttagca 300
 tttcaagcca gtgagaagtc atccttaatt ctgcttttct attaatctcc ctacttctaa 360
 tctattacgt gtcttattag atctaagatc aatatatttc ctgaatatgt ctatttatgt 420
 ccatttcaa cactaccact gaagtctaag ccattgtcac ctttcttctt ggattactgc 480
 aatagcctca cagcttccac tcttgaccac atacactcca ttctgcactc agccctcata 540
 gtgatcatta taaaggataa aatgggtggt ccaggttagct cagttgggta gatcatggta 600
 ctaataaaat gcaaaacatg tcacatcact cttcttcatg ggttcatgtc ctctgtgggt 660
 caggtcttcc acatgtagag tagaggtagg gtatgttcac accttcaatg acaactacac 720
 atttctgctc caacaggtcc aaaattgttc ctaggtttca aagttgttgt ttgtttgttt 780
 ttttcctttt tctttttttt tttttttttt ggagaagtgg agttttggct ctggttggcc 840
 caggcgtgga gtgtgcaagt ggcggtgatc tgcggttcac caacaaacct cgtggctctc 900
 cgcggtttac aaggcgcat attccgtggc ctacaggcct cgcgagtata gccgtgggat 960
 ataatagggc agtggcgcac accagtgcct gagcttaatt tgtgggtatt ttaaggtaga 1020
 agaagcgggg ttctctcccc cctttgtgtg ggtctcgagg gcgtggactc tgggaggcct 1080
 cgcgtggaac cctcgagggg tgatctcaca cctgtgcgct tgggggcctt cccacaaaag 1140
 gtgggcctgg ggggatttac caggcggtgg cagaagcca aactatgtgg gccggggcgc 1200
 acacaggggg gtttcccaa aggtttttt taaccggtat taaaagagg gtttcgctag 1260

<210> 145
 <211> 433
 <212> DNA
 <213> Homo sapien

<400> 145
 cggccgccgg gcaggtactg gtggttggtt tcattagtgg atcacacaca gggttgtact 60
 tggcttgtaa aatgggtgcct cggatagggt gagtttgat aagtatgtat gtatgtatga 120
 gttatagcaa aattaagtag attgaatcaa gtccatgcaa aagcagtaaa acagttatta 180
 attgttaatt ttttaaaaat taaaacgtta ataaaacagt ttgtaatgtt ttgctagtgt 240
 cttttataaa atgatgtaag ttacagtgga agtcttcaca ggacttgtgt ctttcctgga 300

118

actattgaaa tgtaatttag gatgatttga tcttccatct caagttgtca acatggctgt 360
 gtcattctgg cttacatatg ttttatttaa caaaattcta gtcaagggat aaggccttaa 420
 tgaagacaag ctt 433

<210> 146
 <211> 1791
 <212> DNA
 <213> Homo sapien

<400> 146
 ggaatgaaca aacaacaaaa aatccttgct ctctgggtgc ttacatttta gttgggagag 60
 ggacaaacaa gataaggga atacatacct tagttaagaa caagtgccac agaggaaaaag 120
 ccaggctgag gcagtgggtg tgaacatttt atacagggat gtccagaatc agggccttga 180
 agaaagccct gaaggcagcg tgtaccgagc aggaatgccc tgtggaggct gagcatttag 240
 gaagtgggaa cagccgggtg ggaggtcctg gaggtgaggy ggtgtcaaga aggcagcat 300
 ggctggagca gaaagcaggg cggggagggtg ggggaccagc tcacagggtgc ctagagccag 360
 aatgagaagg gcttcttggc tggattacag gcgtgagcca ctggaacctg gccttgtttt 420
 gctttatttt ttctcttaca tgaagtaaag cgctttggtc aaacacacaa aaatactgcc 480
 ttgtactggt ggttggtttc attagtggat cacacacagt gttctacttg gcttgtaaaa 540
 tgggtgccttg gatagggtga gtttggataa gtatgtatgt atgtatgagt tatagcaaaa 600
 ttaagtagat tgaatcaagt ccatgcaaaa gcaataaaac agttttaatt ttttaatttt 660
 ttaaaaatta aaactttaat aaaacagttt ttaatttttt gctagggtct tttaaaaaat 720
 gatgtaactt acatggaagt cttcacagga cttttttctt tcctggaact attgaaatgt 780
 aatttaggat gatttgatct tccatctcaa gttgtcaaca tggctgtgtc attctggctt 840
 acatatgttt tatttaacaa aattctagtc aagggtataag ggcataatga agacaagctt 900
 cagttatgaa agtacaaact atttgtgtga ttaattttta aaaatgacat taagaagccc 960
 attgtaaaat aatatattgca gtcaaatggt ttttcttgct gtaagtcttg ttgtagctat 1020
 gtttagggta gtggttctca tctaccttgg agtgcataag acttacctag caggcttggt 1080
 taaaaagttc agattcctag ctttgtaccc agggattgcc tcagggtgga tgggctgtgg 1140
 tcctggagtc atcactttta taaatagtgg ttcagagacc acagagagag actgcttcat 1200
 cgaatgggaa gtaccaagga gaaagtacaa ttcagtattg tctggaggca agtggacact 1260
 ttgtacctga ggtttagaat aggtggtctc ttgccagtac aatccccagg cgttttctgt 1320
 gttcagaagt agtaagaatg cctttaattc agaggattat ctaagctctt taaagctgtt 1380

119

```

tttctccatt tgtcatagtg ctttctctga aaaatgaatg tacaggtatc ctattttcta 1440
atgtaattag gattttttta aagcaatttt gatagttttt cttttaaaaa gtaaaattca 1500
gcactgtgac ttgaaccccc aaatctttca catacagggtg aaacattaag ccacaaataa 1560
atatgacaga aagaagaaaa gatactattc ctgtcattag ggactagtac ccattaactt 1620
gaaccgactc ggcaagggtg caacatttct tggcacatcg tgcacacact atgttttgac 1680
acgaggactt cccacttata aacaccggac cggggaatat ttcacatcgt ttaagtaatg 1740
caccocgggc aaaaaggaga aaccttcatt caaaaaatct atcgccgtct a 1791

```

```

<210> 147
<211> 349
<212> DNA
<213> Homo sapien

```

```

<400> 147
ggaatgatcg atactatagg ggcattggtc atctaatagca tgctcgagcg cgcgccagtt 60
gtgatggatg cgtggtcgcg gccgaggtcc acgttttagct gagtataatt ttaaataagcc 120
ctatgtgaca agtgggtact ttattggaca gtgtagatct aagattaatt cctcaactgt 180
tttgactca acaaagacat acctctgagt tggcaaccag cagggtggat aacggggccag 240
tggtgataaa atcaaagaat aggtaatgaa acaatcatcc agttaacaat cagcaagggt 300
cttcagagcc taattaatgt ttaattctaa ataaattgca acaattaag 349

```

```

<210> 148
<211> 848
<212> DNA
<213> Homo sapien

```

```

<400> 148
agctgggatt acagacgccc accaccacac ccagctaatt tttgtatatt tagtagagat 60
gggggtttcac catgttggtc gggctggtct tgaactccta acctcgtgat cctcctgcct 120
cagcctccca aagtgcaggg attacagggtg tgagccactg cgcccgacat cccatttaac 180
tttctgtctc tgtgactctg atgactctag gaacctcata taagtggaat aatataggat 240
ttattctttt ttaaaaaatt tattttgaga tggagtctca ctctgtcact caggctggag 300
tgcaagtact cgatctcggc tcaactgcaac ctccgccttc ctggcttaag caatttttgt 360
gcctcagcct cccaagtatc tgagattaca ggcgtgtgcc accacacca gctatttttt 420
attttttatt ttagtagaa gatggggttt cgccatgttg gccggactgg tctggaactc 480
ctggcctcaa gtggtcctcc cacctcggtc tctcaaagtg ctgggattac aggcgtgagc 540

```

120

caccacgttt agctgagtat aattttaaat agccctatgt gacaagtggc tactttattg 600
 gacagtgtag atctaagatt aattcctcaa ctgttttgca ctcaacaaag acatacctct 660
 gagttggcaa ccagcagggg ggataacggg ccagtgggtga taaaatcaaa gaataggtaa 720
 tgaaacaatc atccagttaa caatcagcaa gggtcttcag agcctaatta atgtttaatt 780
 ctaaataaat tgcaacaatt aagaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 840
 actcggtc 848

<210> 149
 <211> 414
 <212> DNA
 <213> Homo sapien

<400> 149
 cagtgttacg cgcgacgcag gtaccacagc tcccagtgcc cattacctct atcatggatg 60
 ctgggtgact ttgggaagtc accacctctt cccaagcctg tttcccatat cacagatgtg 120
 gggccatggc ctcgatgatg gtctccacag gtctttccac ctctgtgagt ccaagtcagg 180
 tcaatcagca aggacccaat ctctgacctt gggtcagctc ctcagaacca acccccagca 240
 tctctaaagc aaaagcctca cctcaagggc tgctcagaag agagcacctt cagcatgagt 300
 tgttgctgga aggatctaata aagctgtgtt tcttgggaag tgggtgcttta cttagccctg 360
 tggacaactt ctctatgcat ctgtgtgagc agatgatcat tgtattacct tttta 414

<210> 150
 <211> 2088
 <212> DNA
 <213> Homo sapien

<400> 150
 ggtggcagtg atacatgttg gcaggctggg cttgatcctg actcaagtga tccgccgcct 60
 caacctccca aggtgctggg attacagggtg tgagccacca cacttgtgca gtatatcctc 120
 agtatgaaga tatTTTTatc ttctgtgtgt ctctggcttc agagtttcac ctgcccacac 180
 agggctcogtt gctggcaact ggacttcccc ataagccttg ggtatcctgt gatgggctgt 240
 gtctccctga agattgtctg gcttgccac ttctccgtgc atgactctgg gtgtgagtct 300
 gtctaggaac aggagggaaa gttggactca gacagaaatc agatgcttcc atgtattcag 360
 ggcgcgcatt gtgagcagtg gagtatgagc cttgagggcc tcatgggttc agggcaggct 420
 tccttcgaga tgggtggcag cccctggtag aatgctggat ttctctggaa tctagaagtg 480
 ccataTTTTa gtggaaaggc atcagggctg tttgacagtg tgcgtcttcc caatcccatg 540
 ttctccatt cgtgtgtctg ttataaaact gagtgaaggc tgctatgacc tgtgttcact 600

121

```

ctgggttacag ggaggtgcaa accattctgt ctcccagcct ttcttctctc tttgtgtgct 660
cccagcactt ccttcttttc taacatggcc tggagagagt ctctctctcc ttgtctctgt 720
ctcttaataa tagtttttaa cgtggacatc tcttccttgg tacagtgggt tttaaatcct 780
gagaagaacc aagtcagggt ttttaaagca gactaaaagc atgaaattgc tttcagaaga 840
atgtatatca tcgggaaaag tttgggggca gagtggggga atcaggcttt attcaaaaga 900
aacagttgaa aacatggact ttttctaccc aatgccatt tcacgactcc tctgagacta 960
attgggaaac ggggaaattc ttggaatttt tttttaaga aacttttttg tgtttttttt 1020
aattttaggt cacttattag tgaaacctca ttttagatct gacattggta gatagatgga 1080
tttaggcaaa tatgatgctt ttgtggggaa tcacgtgggt tgacgttaga acctcccttc 1140
tgcagactgt tgcctgtcat ctaagcgaat tggaaatgct gagcttccat aagtcagctg 1200
agttttaaag gtaaacgtta tggctgaagt agtaaagcac ctgaccacaa aacctcttgt 1260
aaaaacagcc ctgagtaggt atttccaggg ctccacaaag ttgcttatgg gaatcctgag 1320
ctgcttttca ccatctcaag aagcctaaga agttatatat ttaatcagggt agacaaaaca 1380
gttcaaagca taagggtccat ggtggtggaa aatggatgca agtgattcta agtttgtgga 1440
tttgtggata gcagagggat cgggacctct tggaggaacc ctgggtacca agctcccagg 1500
cccttcctct atcatggatg ctgggtgact ttgggaagtc accacctctt cccaagcctg 1560
tttcccatat cacagatgtg gggccatggc ctcgatgatg gtctccacag gtctttccac 1620
ctctgtgagt ccaagtcagg tcaatcagca aggacctatc tctgccctgg gtcagctcct 1680
cagaaccaac cccagcatc tctaaagcaa aagcctcacc tcaagggtcg ctgagaagag 1740
agcaccttca gcatgagttg ttgctggaag atctaataag ctgtgtttcc tgggaagtgg 1800
tgctttactt agccctgtgg acaacttctc tatgcatctg tgtgagcaga tgatcattgt 1860
attacctttt atcggtagta agcttggaag aataatttaa gaatacaatg gagaaatgta 1920
aataagtatc tatgtaaatt tgtttaaaat aaactgaatg tatttaattg tccatttata 1980
tgttctttta tgtaacatgt agtttaataa agttcctgtt tatgagagtc atgtttcatc 2040
tcagcttctt ccaaaaaaaaa aaaaaaaaaa agatctttta ttaagcgg 2088

```

<210> 151

<211> 509

<212> DNA

<213> Homo sapien

<400> 151

```

cggactcccc ccgcgacgc gctggcttcg cgtatcgggt tacttcttt ataaaaattt 60

```

122

ttataactta tgtggaaatg ggatctcact atgttgctca gacttgcttt gaactcctgt 120
 tatagcacca cctcttacaa gtgttgggca gctccgcttc tctcacttgt ctggaattct 180
 aaggcacttc cctgaagtgc tcctcctgag ctaatatggg atagggctgg agagagaaca 240
 gaggtggata gcatgccaga atgaggtggg aagggtggga tcagcagcct ttgggaagga 300
 aagaagtatg agtcccaggg tattaacaag gtggaggggc aataaaattt attacatatt 360
 gggattcata ctaaagtatg agatttttagc ttctcttgcc acaataaaca aaaaaaatgc 420
 cacaacacca cacaaaaaaa aaagggtggg ggaaccaggg ccaaactgcc ccgggtgaat 480
 gtttcccgcc atcaaattaa aacacacag 509

<210> 152
 <211> 560
 <212> DNA
 <213> Homo sapien

<400> 152
 ccagcctggg taacagatgt gagaccctgt ctgttaagag aatcagaaaa gagagagaaa 60
 gctagactta gctccaagtc tggagctttt ggggttttct tcctttataa aaatttttta 120
 acttatgtgg aaatgggatc tcactatggt gctcagactt gtcttgaact cctgggttagc 180
 accacctctt acaagtgttg ggcagctccg cttctctcac ttgtctggaa ttctaaggca 240
 cttccctgaa gtgctcatcc tgagctaata tgggataggg ctggagagag aacagaggtg 300
 gatagctgcc agaattgaggt gggaagggtg ggatcagcag cctttgggaa ggaaagaagt 360
 atgagtccca gggattataa aggtggaggg gcaataaaat ttattacata tgggattcat 420
 actaaatgag tagatttttag cttctcttgc cacaataaac aaaaaaatg ccacaacacc 480
 acacaaaaaa aaaagggtgcg gggaaccagg gccaaactgc cccgggtgaa tgtttccgc 540
 catcaaatta aaacacacag 560

<210> 153
 <211> 577
 <212> DNA
 <213> Homo sapien

<400> 153
 tgatgatata tggggcatgg tcctctagat gctgctcgag cggcgcagtg tgatggatgc 60
 gtggtcgcgg cgaggtacca cctgttcatt ggggaactgt gggaacgga gccaacggac 120
 ctaagtgcc tttgacagtg agtttcatac catttcagta gtgtatttct ttcttaattc 180
 gaataaacca gtatgatact ctcagacaca gaagaataaa gggagcgagt cattaacgtt 240

123

ttcttttttaa accttttatga tgacttcctt atgaattact gaacgaacac tggaatggga	300
ctcaggtatc ctgaggacat ctctcaactc tggccttagt tccccctctg taaaattagg	360
gtgccaaacta aatgatctac aaggccctt ccagcgccgc cattctgtaa ttacatcatg	420
tgtaaactgta ttaaaccatac acaagtgaact gccaggcatg ggaatgtaac ttccgagtaa	480
atgctttgggt ttgttcagaa tacactatga acttctttcc aaagacgggt tgtggtaaatt	540
agtggatatt ttgattataa gaaatagagt ttccttg	577

<210> 154
 <211> 1138
 <212> DNA
 <213> Homo sapien

<400> 154	
aagaaattcg gcacgaggaa agtgctggga ttacaagcat gagcccagcg cctgggtgta	60
tctttcattt tacccaagtc actttaccca agtaagtaat taggggaaag cctgagtctt	120
gtaccacctg ttcatttggg gaactgtggg aaacggagcc aacggaccta agtgcccttt	180
gacagtgagt ttcataccat ttcagtagtg tatttctttc ttaatctgaa taaaccagaa	240
tgatactctc agcacagaag aataaaggga gcgagtcatt aacgttttct ttttaaacct	300
ttatgatgac ttccttatga attactgaac gaacactgga atgggactca ggtatcctga	360
ggacatctct caactctggc cttagtctcc cctctgtaaa attaggggtgc caactaaatg	420
atctacaagg tcccttcag cgccgccatt ctgtaattac atcatgtgta actgtattaa	480
acatacacia gtgactgcca ggcattggaa tgtaacttcc gagtaaatgc tttggtttgt	540
tcagaataca ctatgaactt ctttccaaag acgggttgtg gtaaatagtg gatattttga	600
ttataagaaa tagagtttcc ttgaagcttt agctggagat acagcaatag tgtgggtgtc	660
ctacaaatat cacagtgtat tcaaacatat ttttctatca aaaatcattt ttgtaaaagc	720
tgtgtgtttt tatccaactt gtgataataa atgttcttta ttttagaata aaaaaaaaaa	780
aaaaaaaaaa aaagaaaaaa aaaggaaata aaaaaaaaaa acaggagaca aagacaacgg	840
cggcacgcaa caaccacatc gcggaaggcg acaagcgaac aaccagccc gagctcgtga	900
aggcgagcca acatgaagga gcgcactatc caagacaggt agctgacata acagaagaga	960
acaaaaacaa gagacaagta gaacaaaaac aaagagaaga caggacacac gagaaaagca	1020
gggtgtaatca gacgaacgac gcgacaaaca gagagacgtg caagcataaa atagcaacaa	1080
ccaagagaca gcgacggaca cacgaagcaa gacgagcgac gccgagcaca gcagggat	1138

<210> 155

124

<211> 800
 <212> DNA
 <213> Homo sapien

<400> 155
 cgtgggtcgcc ggccgagggt gccataggcc ccagacccaaa ctagaccacc agcatgttca 60
 tgtccagacc tcggcagtggt cgtgcactgc ttgtgcacct cagttcctcc agtgttggtt 120
 tgtttgtttt ttaattcagc atcctgctgg ttttactttc caagcaagat ctgttgcgac 180
 tcccaaagtgc gttttaatga gctcatcctt atttgccttt cttcttacgt attttgttgt 240
 atttaaagat tgtgcaggag atattctaga aggcattaat ggtttgcatt caaaacgatg 300
 tggtttgtcc aagtattttt ctgtctttat tactgagacg gattaatctc cttatttttt 360
 tcttgatgat ttgaagttgt aacagttgtc cagctattgc ttaataaaaat tttgcagatc 420
 aaaaaaaaaa aaaaaaaaaa aaaaaagggt gggggtaacc agggccaaga ggggtccctc 480
 ggggtcgaca attgggtcac ccgggtccat caatttcccc acaaacataa tacaggacat 540
 aggcacacac agcaaacgca cacagcacca agacagacaa ctacggcgag ctaaggacgc 600
 agagaagacg cggcaacgcg gaacgccccg agcaaggccg aggcaacaca ggagaggggc 660
 agcgcacgac ggccggagca cgagcaggaa agcaacgaag agagacaacg gacacacgcg 720
 agggcgaaga gaagagagca ggaacgacag gacaagcaca caaacgagcg gcaacagcag 780
 acccagacga aacagcgcg 800

<210> 156
 <211> 4632
 <212> DNA
 <213> Homo sapien

<400> 156
 atgtatgcag cagtgggaaca tgggcctgtg ctttgcagtg actccaacat cctgtgcctg 60
 tcctggaagg ggcgtgtccc caagagttag aaggagaagc ctgtgtgcag gagacgctac 120
 tatgaggaag gctggctggc cacgggcaac gggcgaggag tggttggggt gactttcacc 180
 tctagtact gtcgcaggga caggagtact ccacagagga taaatttcaa cctccggggc 240
 cacaatagcg aggttgtgct ggtgaggtgg aatgagccct accagaaact ggccacgtgc 300
 gatgcggacg gaggcattat cgtgtggatt cagtacgagg gcaggtggtc tgtggagctg 360
 gtcaacgacc gcggggcgca ggtgagtgat ttcacgtgga gccatgatgg aactcaagca 420
 cttatttcct atcgagatgg gtttgcctg gttgggtctg tcagtggaca aagacactgg 480
 tcatccgaaa tcaacttgg aagtcaaatt acgtgtggca tatggactcc tgacgaccaa 540
 caggtgctgt ttggcacggc cgatgggcag gtgattgtca tggattgcc aaggcagaatg 600

125

ctggcccacg	tcctcttgca	cgagtcagac	ggtgtcctcg	gcatgtcctg	gaactacccg	660
atcttcctgg	tggaggacag	cagcgagagc	gacacggact	cagatgacta	cgccccctcc	720
caagatggtc	cggcagcata	tcccatacca	gtgcagaaca	tcaagcctct	gctcaccgtc	780
agcttcacct	cgggagacat	cagcttaatg	aacaactacg	atgacttgtc	tcccacggtc	840
atccgctcag	ggctgaaaga	ggtggtagcc	cagtggtgca	cacaggggga	cttgctggca	900
gtcgctggga	tggaacggca	gacccagctt	ggtgagcttc	ccaatgggtc	ccttctgaag	960
agtgccatgg	tcaagttcta	caatgttcgt	ggggagcaca	tcttcacact	ggacactctc	1020
gtgcagcgcc	ccatcatctc	catctgctgg	ggtcaccggg	attcgaggct	gttgatggca	1080
tcaggaccag	ccctgtacgt	ggtgcgtgtg	gagcaccggg	tgtccagcct	gcagctgctg	1140
tgccagcagg	ccatcgccag	caccttgctg	gaggacaagg	acgtcagcaa	gctgactctg	1200
cccccccgcc	tctgtccta	cctctccact	gccttcatcc	ccaccatcaa	gcccccaatt	1260
ccagatccga	acaacatgag	agactttgtc	agctacccat	cagccggcaa	cgagcggctg	1320
cactgcacca	tgaagcgcac	agaggacgac	ccggagggtg	gcggcccggt	ctacacgctc	1380
tacctggagt	acctgggcgg	gcttgtgccc	atcctcaaag	ggcggcgcat	cagcaagctg	1440
cggccagagt	tcgtcatcat	ggaccgcgg	acagatagca	aaccagatga	aatctatggg	1500
aacagcttga	tttctactgt	gatcgacagc	tgcaactgct	cagactccag	tgacattgag	1560
ctgagtgatg	actgggctgc	caagaaatct	ccaaaaatct	ccagagctag	caaatacccc	1620
aaactcccaa	ggatcagcat	tgaggccgcg	aagtcaccca	agctgccccg	ggctgctcag	1680
gagctctccc	ggtcccacg	gttgcccctg	cgcaagccct	ctgtgggctc	gcccagcctg	1740
actcggagag	agtttccttt	tgaagacatc	actcagcaca	actatcttgc	tcaggctcag	1800
tctaatatct	ggggaaccaa	atttaagatt	gtgggcttgg	ctgctttcct	gccaaccaac	1860
ctcgggtcag	taatctataa	aaccagcctc	ctgcatctcc	agccgcggca	gatgaccatt	1920
tatctcccag	aagttcggaa	aatttccatg	gactatatta	atttacctgt	cttcaaccca	1980
aatgttttca	gtgaagatga	agatgattta	ccagtgcag	gagcatctgg	tgtccctgag	2040
aacagcccac	cttgtaaccg	gaacatccct	attgcaccga	tccacagctc	ggctcaggct	2100
atgtcccca	cgcagagcat	agggtctggt	cagtccttac	tggccaatca	gaatgtgcag	2160
ctagatgtcc	tgaccaacca	gacgacagct	gtagggacag	cagaacatgc	aggtgcaggg	2220
tgccacccag	taaccaggt	ctccaaccgg	tactccaatc	ctggacaggt	gattttcggga	2280
agcgtggaaa	tgggcccgc	cattcagaac	ccccctccac	tgtccctgcc	tcccccgccg	2340

126

caggggcccc	tgcagctgtc	cacggtgggc	catggagacc	gagaccacga	acacctgcag	2400
aagtacagcca	aggccctgcg	gccaacaccg	cagctggcag	ctgaggggga	cgcagtggtc	2460
tttagtgccc	cccaggaggt	ccaggtgacg	aagataaacc	ctccaccccc	gtacccagga	2520
accatccccg	ctgccccac	cacagcagca	cccccgcccc	ctctgccggc	cccacagccc	2580
ccagtggatg	tgtgcttgaa	gaagggcgac	ttctccctct	accccacgtc	agtgcactac	2640
cagaccccc	tggtctatga	gaggatcacc	accttcgaca	gcagtggcaa	cgtggaggag	2700
gtgtgccggc	cccgaccccc	gatgctgtgc	tcccagaaca	cctacaccct	ccccggcccc	2760
ggtagctctg	ccaccttgag	gtcacgggc	actgagaaga	aggtccctca	gccctgcagc	2820
agtgccaccc	tgaaccgcct	gaccgtccct	cgctactcca	tccccaccgg	ggaccacccc	2880
ccgtatcctg	aaattgccag	ccagctggcc	cagggggcgg	gggctgcccc	gaggtccgac	2940
aatagcctca	tccacgctac	cctgccggag	aacaaccgtg	aggctacgct	caagatggcc	3000
cagctggccg	acagcccgcg	ggccccctg	cagccccctg	ccaagtccaa	ggcgggggccc	3060
gggggggtgg	tgacacagct	cccagcgcg	ccccacctg	ccctgtacac	ctgcagtcag	3120
tgcagtggca	caggggcccag	ctcacagccc	ggagcctccc	tggcccatat	cgccagcgcc	3180
tccccgttgg	cctcccagtc	ctcctacagc	ctcctgagcc	cacccgacag	cgcccgcgac	3240
cgcaccgact	acgtcaactc	ggccttcacg	gaggacgagg	ccctgtccca	gcactgtcag	3300
cttgagaagc	ccttgaggca	ccctcccctg	cctgaagctg	ctgtcacccct	gaaacggcca	3360
cccccttacc	agtgggaccc	catgctgggt	gaggacgttt	gggttcctca	agaaaggaca	3420
gcacagactt	caggggccc	cccccttaaa	ctgtcctctc	tgatgtgtgag	tcagggccag	3480
cacctggacg	tgtcccgact	gccccttcac	tcccccaagt	ctcctgccag	ccccactgcc	3540
actttccaaa	caggctatgg	gatgggagtg	ccatatccag	gaagctataa	caacccccct	3600
ttgcctggag	tgcaggctcc	ctgctctccc	aaagatgccc	tgtccccaac	gcagtttgca	3660
caacaggagc	ctgctgtggt	ccttcagccg	ctgtaccac	ccagcctctc	ctattgcacc	3720
ctgcccccca	tgtaccagag	aagcagcacg	tgctctagtt	tacagctgcc	acctgtcgcc	3780
ttgcatccat	ggagtcccta	cagcgctgc	cgcccatgc	agaaccccc	gggcactctc	3840
ccccaaagc	cacacttggt	ggtggagaag	ccccttgtgt	ccccaccacc	tgccgacctc	3900
caaagccact	tgggcacaga	ggtgatggta	gagactgcag	acaacttcca	ggaagtccctc	3960
tccctgaccg	aaagcccagt	ccccagcg	acagaaaaat	ttggaaagaa	gaaccggaag	4020
cgcctggaca	gccgagcaga	agaaggcagc	gttcaggcca	tcactgaggg	caaagtgaag	4080
aaggaggcta	ggactttgag	tgactttaat	tcctaatct	ccagcccaca	cctggggaga	4140

127

gagaagaaga aagtgaagag tcagaaagac caactgaagt caaagaagtt gaataagaca 4200
 aacgagttcc aggacagctc cgagagcgag cctgagctgt tcatcagcgg ggatgagctc 4260
 atgaaccaga gccagggcag cagaaagggc tggaaaagca agcgctcccc acggggccgcc 4320
 ggcgagctgg aggaggccaa gtgccggcgg gccagtgaga aggaggacgg gcggctgggc 4380
 agccaaggct tcgtgtacgt gatggccaac aagcagccgc tgtggaacga ggccaccag 4440
 gtctaccagc tggacttcgg ggggcgggtg acccaggagt ccgccaagaa ctccagatt 4500
 gagttagagg ggcggcaggt gatgcagttt ggacggattg atggcagtgc gtacattcta 4560
 gacttccagt atccgttctc agccgtgcag gcctttgcag ttgccctggc caacgtgact 4620
 cagcgctca aa 4632

<210> 157
 <211> 998
 <212> DNA
 <213> Homo sapien

<400> 157
 tgctgctcga gcgcgcgcag tgtgatggat ccgcccgggc aggtaccttt tcctctcaca 60
 ttggcagaat agcacgcact agatgcctga ccttgagctc tagtctcccc gtttaaactc 120
 taccttgggc agtaacgaca attattcctc attcaagtaa tttcaatgct gaaactgaac 180
 tctattacta atgccttcca atcagagtcc ctgatgggga tgcctgtggg atggccact 240
 aacctggggg acctaggcta gcatggggtg agttgggtaa ggaagatgat gcgttagttc 300
 ctgatagatg ctacgagatg tagtttgga tttcagttgt tgtccagtta tgattttcac 360
 tgggggttct gcagtcacag caagctgtgt atgaactagc tgtactagtg gatgacacac 420
 tataactaat caaactagac taaagacaca ctgaaaatct gcgttataac taacaagata 480
 tcactcatct gacacataac caccattaca ccttatggta cgtcaggatt cataaatagt 540
 actgctctga atgacttatg ggaaatggtg ccaactcaaaa gcaacttcct aacttgagga 600
 ataactcctt tgtagtttac tttctggtac tggttggtgc cttgtatcgg gatacagcta 660
 tatttcttagc tcaaatgtct cttttggaga gcacagtagt taccctactg gtgagactga 720
 gaacctgagc tcatgagagg ccatttcctc ctgggtgtcg gaccagggct ctgtgtcagg 780
 aaaaaccttc tgggtgacct ttgtagactc gtttcagggt gattccctct tatcttgcga 840
 gagtagaatt cgcagtcggt ggcctttccc ttcacccgta actcggcccc tctgggcagg 900
 ggcggggtgg cggctcttaa cgctggctcc gggtttgggg ggcccggggc ccgcaacgcg 960
 ggttttgggc gggtcgcgcc cctccctcca acgggccg 998

128

<210> 158
 <211> 766
 <212> DNA
 <213> Homo sapien

<400> 158
 gggatgatcg ctactatag ggcgctggtc actagatgca tgccgagcgg cgccagggtga 60
 tggatcgagc ggccgcccgg gcaggtagat gttcatgaat ttgtgctgaa taattacttg 120
 agtgtgaaat tggtatgtta tgcgatatat agtagtcaaa tatagaagat aatgcaaaac 180
 aatttaaagt gattgtagca gttcgtgtga ttctacagca gcaggattgt aggcagatta 240
 ctgtagttct cacagcgagc agcatgtgag attggccagt ccgctcaaat tcgtgccaat 300
 acttggtata tgctatcttg tcaatttcta gacattcttg agagtgtgta gtacttggtc 360
 atcttggaca aattacactt aatagttatg tatccatttc tctaattttg ataacatttt 420
 acataagttt atcgttatga gatatgttct ttattttgaa gtgcttattg tccattttac 480
 attgggtcat ctgttattga attgtaaaca ttccctgaat atttaaataat gagtgcttgg 540
 tcagtttttg tcacaaatat cctcgttttt tcaacttttg cccttttatt attctgaaaa 600
 tgccaagtga ttaaaattaa ttttactatt gttcaataaa caaaacaaaa aaaaaaaaaa 660
 aaaaacacaa aaaaacaaaa gcgcgggggg taaccggggg cccaaggggg tccccggggg 720
 acattggtct ccccggtcac aattccccc aatcgacaa cagggc 766

<210> 159
 <211> 1400
 <212> DNA
 <213> Homo sapien

<400> 159
 ctatgattag cttattagc tttgtggtt atatgcatca gaaagagtaa gacttaattt 60
 tgtgtggaac aaataccctg gtgtagcatg ttccattaga atttgtttat agagatattg 120
 ccatagaaaa gttatttttt attagtaaag aatgctttgt atttcctttg tggcttctaa 180
 gtaccctttt ttggttatta tacctttatc cataagtatc tttaaataatt acaaaaatta 240
 catattcttt taaatatttt aaagatttat tatattcatt taggttttaa tccactttta 300
 attttttaga tgaaaagtaa gagaaaagta tataaatcat gagacaaaat tgaactaacc 360
 aaggtaacaa tcaatctgct caagaaattg agcatcacca ccacctctc ctgcactgtc 420
 caaatcagca cccagtagt ccaaagcaaa tgttactcac tacactgact tctaacacaa 480
 tagacttggt ttgtctgtt tcaactatac aaaaatgaat catagagtat gtgttggttt 540

129

```

gtatctggct cctttcacta aaattttggt ttataaaatt catccatgtg gttgaacaca      600
gttgtagatt gttcatttta attgttttac agtattttatt gtgtgactaa aacactactt      660
atttattcta taattgacag actttgggtt gcttttgctt tgggagtata aacattttta      720
tatctatgct ttaggtacat gttcatgaat ttgtgctgaa taattacttg agtgtgaaat      780
tgttatgtta tgcgatatat agtagtcaaa tatagaagat aatgcaaaac aatttaaagt      840
gattgtagca gtttgctgta ttctacagca gcagattgta gcagattact gtattctaca      900
gcagcagcat gtgagattgc cagttgctca aattcgtgcc aatacttggg attttttatac      960
ttttaatttt agacattctg gagagtgtgt agtaattttt catcttgga aattacatta     1020
aattagatc catttctcta attttgataa cattttcata agtttattgt tattagatat     1080
tttctttatt ttgaagtgtt tattgtccat ttacattgg gtcactctgtt attgaattgt     1140
aaacattcct tgaatattta aatatgagtg ctgggtcagt tttgtcaca aatatcctct     1200
tttttcaett ttgcccctt tattattctg aaaatgcaa ttgattaaaa ttaattttac     1260
tattgttcaa taaacaaaac aaaaaaaaa aaaaaaaac acaaaaaaac aaaagcgcg     1320
ggggtaaccg ggggcccaag ggggtccccg ggggacattg gtctccccgg tcacaattcc     1380
ccccaatcgc acaacagggc                                     1400

```

```

<210> 160
<211> 556
<212> DNA
<213> Homo sapien

```

```

<400> 160
acctattcac cattccaacg tgaagaagct ctgcatgtag gaaagaataa ttaacacact      60
tatagtctac tgcccatgta aggatcagct ccggctaaga ggccaaagat ggggtgacac     120
gtcatgctct gccttttatt ttttctttct taccactta gcttcctaatt tggaggaagg     180
aggcgtggta aaggatatg aagactatgg tttaattaga ccagaaaaca ctgtcataat     240
ctctgggcgt cagtcagaat gtccagtttt gtctttgggc caagataagg gcagtgggat     300
ttatgatgtg ttgtttatag tctgaaacta ctctgggtgat caccaggggc agtttcttta     360
atcgatgggt tccaagctgg cctaagtaca tttaagtaga gactgggctg ataaacatga     420
ccagacgaga cataaagacc ctgttgggaa tgacattgaa ctctcaaagt caagatttct     480
tacacaaatc tatcagctgg agaataatga gaggcagctg tggtatatgt gtgcaataa     540
ggacattatg aagctt                                     556

```

```

<210> 161

```

130

<211> 1327
 <212> DNA
 <213> Homo sapien

<400> 161
 ggaagacctg attgggaata gtcgaaagcc ttgatatgtg caaagaaaga accatttgat 60
 caaccaggtt ctttaatacag gataactaact taaaatatag actcaagtta tacgataatt 120
 caaacattta ttgtatttat actattctat atgtactttt ccaggaacca ggaatacaaa 180
 actgacatgt tctctgtaca gaggtcaga ctagtagaga acagttaggt acgccgttaa 240
 ttataaacta atatgtatca tcaattatgg gtttttatgg gggtttgga ggtggaagg 300
 accagggaga gatgatgagt gatgatggtt atgtagtctt taggaggatg caattataac 360
 attgctcttc ctttcacgca ccacatgatt tagcaagtac ttcattatgg ctccaccatt 420
 aacatgggtca atggcttctg gatactcaca gttcaggcac agtttctcct gaagattttt 480
 tacctctccc atctttaaga aattgtctgg atgtccatga aagatgctga cacttgatt 540
 aattcattaa aaaacaccac cccctccctg aaataaacta aaaagtaatg aattcataga 600
 aaaaaatttc accaagattg aaactagaga atatacctag acttgcactt tgagctttga 660
 gaaatgtgta cctattcacc attccaacgt gaagaagctc tgcagtagga aaaataatta 720
 acacacttat agtctactgc ccatgtaagg atcagctccg gctaagaggc caaagatggg 780
 tgacatcggt atgctctgcc tttatttttt ctttcttacc cacttagctt cctaattgga 840
 ggaaggaggc gtggtaaagg tatatgaaga ctatggttta attagaccag aaaacactgt 900
 cataatctct ggggtcatca gaatgtccag ttttgtcttt gggccaagat aagggcagtg 960
 ggatttatga tgtgttgttt atagtctgaa actactctgg tgatcaccag ggtcagtttc 1020
 tttaatgatg gttccaact ggcctaatac attaagtaag actggctgat aacatgacca 1080
 gacagacata aagacctgt tgggaatgac attgaactct caaagtcaag atttcttaca 1140
 caaatctatc agctggagaa aatgaaggca gtgtggtata tgtgtgcaaa taaggacatt 1200
 atgaagctta aatatggaat gtctcttgga ccccgatgt catctgtatt ctctttttct 1260
 tcttgtaacta tatcctttgc ctgtaaataa aaggtttatt tgaaaaaaaa aaaaaaaaaa 1320
 gatcggc 1327

<210> 162
 <211> 318
 <212> DNA
 <213> Homo sapien

<400> 162
 gggtctccta aatgtcttaa cccatgttta tcttggtctg ctattccatg agcaaagaga 60

131

ataaagcaca aagctgtgag agtattaaat atggacacta gatttacatt tccaacaaga 120
 aattcatctc cctccaaagt cccagaccag ggctagaatg tgggtcattt ttaacaatca 180
 aagtggcaag atctgttttg tgatcactgt aaaacaggaa acacagtaat gccttcatgt 240
 tgaggtgcta aaaggtaag cttgggtaac aatgtccata gctgttctgg tgaatgtttc 300
 gtcaatcaaa tagtgaaa 318

<210> 163
 <211> 1042
 <212> DNA
 <213> Homo sapien

<400> 163
 acagtctgtt tcctccttca cccccagaac aaaaatcgaa cttctgggtg gacagtgtca 60
 gatgtcactg aggtgacccc agcctgtttg cagttccaag tcttccgtgt aggcgtcact 120
 gctactggaa cttttagatg gaggagcctg tatgatgatg tcctgaacat ttctatcctt 180
 tcctcacaca gaggggaagct actgggaata tcagagacaa gctattatta aacaagtgtc 240
 tctagtccaa gacatctcct gtggcagggg aatgaggggg caggctgtat cagtgtatatt 300
 tttataaact ctggtttttag aaaaaattct tcagatggac gcattatctt aagactttaa 360
 cattttccaa aaccaactga atcttatccc ctccatttat cccctccag acacttctaa 420
 tcaaggtcac catctccaac tcccccata gacagtaaaa atatggctgg agaattctac 480
 tgtaatagaa aaccaaggag atatggtaat ttgacagtgt gtttctcttc catccactag 540
 acaagaatac cccctcccat tcttctctcc cctcagtcac cagaatgaag tgggctggaa 600
 aacagtttgt ctggttcctt tatagagact gattcccaca ttggatactg cctggaggcc 660
 ttggggatga atgagaagtt ctgctggttt ggatcagtag cagaagcagg taacacatca 720
 gggaaccggg cagcctaaga taggagggga cagaaaatga tgaaagagtt tctgatacat 780
 ttatcagcta aattgctatg gtcaccccca tgtctcctgt aatgtccaac actaaggaat 840
 taaactaagt aaactacaac ctttgtgtct tgctctgacc ttggaccaat ggaatatact 900
 tcttatttca tattcagtgg ataagcaaat ctgcttcac cctgccttaa ctactcaag 960
 gtctctgtga tgcactccag agttttcctc cttccctgca tagtcttctc ctccctagct 1020
 gcctttcaaa ttggtgaaaa tg 1042

<210> 164
 <211> 1120
 <212> DNA
 <213> Homo sapien

132

```

<400> 164
gccgcctttt tttttttttt ttttttagaca agaaattatt ttagtccttt agtacagtct    60
gtttcctcct tcacccccag aacaaaaatc gaacttctgg ttggacagcg tcagatgtca    120
ctgaggtgac occagcctgt ttgcagttcc aagtcttccg tgtaggcgtc actgctactg    180
gaactttgta gatgaggagc ctgtatgatg atgtcctgaa catttctatc ctttcctcac    240
acagaggggaa gctactggga atatcagaga caagctatta ttaaacaagt gtctctagtct    300
caagacatct cctgtggcag ggaaatgagg gggcaggctg tatcagtgat atttttataa    360
actctgggtt tagaaaaaat tcttcagatg gacgcattat ttaagactt taacattttc    420
caaaaccaac tgaatcttat cccctccatt tatccccctc cagacacttc taatcaagggt    480
caccatctcc aacttcccc atagacaata aaaatatggc tggagaattc tactgtaata    540
gaaaaccaag gagatatagt aatttgacag tgtgtttcct ttccatccac tagacaagaa    600
taccocctcc cattctttcc tccctcagt caccagaatg aaggggctgg aaaacgttgg    660
tctggttcct tttagagctg attccccatt ggatactgcc tggaggcctt ggggatgaat    720
gagaagttct gcagtttggg tcagtagcag aagcaggtaa cacatcaggg aaccggctcag    780
cctaagatag gaggggacag aaaatgatga aagagtttct gatacattta tcagctaaat    840
tgctatggtc acccccatgt ctctgtaat gtccaaacct aaggaattaa ctaagtaaac    900
taaaaccttt gtgttcttgc tctgacctg gacaatggaa ttcttcttat tttcattcag    960
tggatagcaa atctgcttct tccctgcctt aactcactca aggtctctgt gatgcactcc   1020
agagttttcc tccttccctg catagtcttc tcctccctag ctgcctttca aattggtgaa   1080
aatgaagctt caggattatg aaaactagta cttaatgaag                               1120

```

```

<210> 165
<211> 810
<212> DNA
<213> Homo sapien

```

```

<400> 165
agatcatgct cgagcggcgc agtgtgatgg attggtcgcg gccgagggtac ttttttatgg    60
cttacatctg tgcctggtcg gccatcaagt ctgggtgcca ctgtttgaga tttggggctg    120
tttcctgcaa ctgatctctg ctacagataa ggcttccctc ctggaggcca aagccctggt    180
taacgttaag agctctatga tgatgcaaac ttcagaggcg atcacctaac ataacaaaaa    240
cctccccaga accagaacct gttttttcac caaaacctt ccgctgcttg aataagaatg    300
tcttttcctt tcctaccaac tttgatgcca ctggccactg tgacataact tttacttagc    360

```

133

ggggtaaatc atagatggat tacttgaact gccaacacaa gactgctgga cgagggacag 420
 agctggatat gttagacaaa gatatacgaa cgacttggcg taatcactgg tcaatagctg 480
 acaccatgat gtgaaaagta gtaatcacgg ctcacaagta ccaacacaag atacagaaga 540
 caggagaaga ggaacaggaa aagaagaaac aacagagcac aaagagagaa caagcacaca 600
 acagacgaag gccacaagag cgaaggagga cgggacgcag caccagcaac agaggaaacgg 660
 cacgcacaga agaacacaga caagaaaacg agaagaaacc acacgcacaa ctagccagaa 720
 tcagagacag aaaacgcgaa gacaggagggc agaagcagaa acacaagaaa accgaacacc 780
 aaaacaggca gcacaaacac gaagagaaag 810

<210> 166
 <211> 601
 <212> DNA
 <213> Homo sapien

<400> 166
 gaagtataac tatatgggcg aatgggtcct tagatgcagg ctcgagcggc gcagtgtgat 60
 ggatccgccc gggcaggtag tcagggtgta tatgattttc tgagctgaat aagtgcgagg 120
 agcagattat taagatctgc cattctgaaa cgctgggtctt tttctccttc ctatagtga 180
 ccataaaaatt ctgttgatca gattatatta catacatttg ggggagtgga gggacatgag 240
 ttaagtagcc cttcatgtat ttataatctc ttttctactg aatcaaataa cttagccatg 300
 accctgaatg gacctgtttt acttcaagtg agatgtctgc cttttatgaa ttgtatatgt 360
 gaatagagtt cggggggtgc caaaaatgca tacatgtatg taagtaaaat tttttatgaa 420
 gtagtctgtc aaatgtatca taaagtttat ttttctttta tacgtaaata attaaaaata 480
 atcacatatt tttgaaaaaa aaaaaaaaaa aaaaaaagggt ggggggtatc tcggggccaa 540
 aaggggtccc gggggggaat tggttttccg gttcaaattt ccacaaattt gggagaaaat 600
 a 601

<210> 167
 <211> 1035
 <212> DNA
 <213> Homo sapien

<400> 167
 tggtcgcgcc gaggtactgt aaatgtgatg gaaaacattg atgagaattt attggcagtt 60
 cagattgtgt tttcccaact taggctcttt attaatgggt taaggttttc tccaaaaagg 120
 gcatttcaac aatgggaatt attttaaatt ggttaaacca gtgggcacag attacttatc 180
 ttccttctct gctttgtgac tcaccagcag taacacacac aatccacatc ttgtgcacct 240

134

```

caaatgaaca gacttggttt ccttgctttc ttgacatttc catgactgtt tcacatacaa 300
actattgggt gaggtttttc agctgttacc gacccacgtc ctgctgtctc tgtgtgggtcc 360
tacaaaaact gtccattccc acccctttgc tttgccattt gcaagagtct ggaattgtca 420
ggtctcagct tcgaaaagtc ctggttccac tgacaggaca cattcttttag tgggaattaa 480
gacctacaaa gtctagtttg tatgtaggta tgaagggaat tttttaaata aagtggaaaa 540
gctgtgaaca gcattagaac tctgtctatt tcttaatttt aaaatatgct gatatgcctt 600
aaactgtagt tgtagatcct tgtcattttg ctgtttgaaa ataaccaatg tgtttttctaa 660
aactgtcgtg taatctactt tcattgttaa tgcagaattg tcatatatgt aagccgcatg 720
ttagacattt gtctttttta aactaaagta attgtattga tgtgaagcat atcatttttt 780
caaatatgaa agtgatcact tagcaacatg cttggttaatt tggcatctgt taaggtagga 840
gagtggtgaa cagataatct atgcatatat cactagtgcc aagacataaa gcgggggaaa 900
atatattttt acccaaacat taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaggc 960
tgggggtaac cggggccaaa ggggtcccgg ggtgaattgg ttttccgctc aaattccccc 1020
atttttgggc aaacc 1035

```

<210> 168

<211> 1666

<212> DNA

<213> Homo sapien

<400> 168

```

ctgggtgatg aagtgagact ctccaaaaaa aaaaagaaat tattaatccc tgcctgtgct 60
ctacatagcc tcatgggcat cattggatag ctgagagggc ccttgattct ggcaaggcaa 120
ataaagccag aatgagaaat taccatcttc tactagagaa aaccaagaga aaaattttta 180
tgctaggatg cctttatgac cacttaattt tttaatctta gttaaattgt ctctccctgg 240
tgctaactgc tgacagtggc cacctctttt ttggggattg aggggcctac ataactagct 300
ggccttacct catatctttt gttcaaacat aataccatct ttttgcttct tctgaacttt 360
agatctccat aacacatgta ctgtagaatg tgatggaaaa gcattgatga gaatttattg 420
gcagttcaga ttgtgttttc ccaacttagg ctctttatta attggttaag gttttctcca 480
aaaagggcag ttcaacaatg ggaattattt aatgtaacag tgggcacaga ttacttatct 540
tccttctctg ctttgtgact caccagcagt aacacacaca atccacatct tgtgacctc 600
aaatgaacag acttggtttc cttgctttct tgacatttcc atgactgttt cacatacaaa 660
ctattgggtg aggtttttca gctgttaccg acccacgtcc tgctgtctct gtgtgggtcct 720

```

135

```

acaaaaactg tccattccca cccctttgct ttgccatttg caagagtctg gaattgtcag      780
gtctcagctt cgaaaagtcc tggttccact gacaggacac attctttagt gggaattaag      840
acctacaaag tctagtttgt atgtaggatg gaagggaatt ttttaaataa attgaaaagc      900
tgtgaacagc attagaactt tgtctatttc ttaattttta aatatgctga tatgccttaa      960
actgtagttg tagatccttg tcattttgct gtttgaaaat aaccaatgtg ttttctaaaa    1020
ctgtcgtgta atctactttc attgttaatg cagaattgtc atatatgtaa gctgcagtgt    1080
agacatttgt cttttttaaa ctaaagtaat tgtattgatg tgaagcatat ctttttttca    1140
aatatgaaag tgatcactta gcaacatgct tggtaatttg gcatctgtta aggtaggaga    1200
gtggtgaaca gataatctat gcatatatca ctagtgccaa gacataaagc gggggaaaat    1260
atatttttac ccaaacatta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa caactgtggt    1320
cggcgcgctt gtggccccgg aagaagagtc ttctcgtaga accatcgtgg tttgggcca    1380
gcggggcccc aggaggtagg gtgccacacg ggccaaaagc gtgtcccagg agacaccggg    1440
gggcactaga acaacttagg gtgtgtgagg aatattttcg ctcccccat gttacaaaaa    1500
caaccgcgca gagggggcaa acagcaacag ggtttctgtg aaacaacaac ccccaaatgg    1560
agggaagtcc tcgagaagga catacaggga aagcctaata caacagaggg aagatcccaa    1620
ggaaaagcac tatcatataa ataattatcg ccgccggctg tgcggg                    1666

```

```

<210> 169
<211> 633
<212> DNA
<213> Homo sapien

```

```

<400> 169
aaaacaacac ggaatgtcta cgactaacta tagggccctt ggtgtatcta gatgcatgct      60
cgagccggcc gccatgatgt gactggatgt cgcgccgag gtacagagta tgtagtgggc    120
atctgttgaa tgaatgcttt tcccagtacg cacgtgtatt catacaatat taatataatt    180
agtcccctgg gcttacagat aaaaatgaaa cgcacaaacg tgcccagctg cagtgagacc    240
cagggtgtct tcctccaccc ctagtgggcc cctgggcagg tctttttttt ttggtaaacac    300
tcaccaggtc tgttctgtag tcaatcatgt gatggactgt gtcggtgaac tgtgcaggac    360
actgtttcta tagtggtcat tagcgacaga gtaaacaatg ttgccatgca agggttattt    420
ggcatctgca tttaagtgat aatgttgaat caatgaaaag gtgttgatta agcagtagtt    480
gtagatatgc taagtttttc aaattactaa tatcaagtggt agatgggttt tactttataa    540
gggtattgct ttggtgatag cataaataat gggtttccct ttttggtaac tgtaacatta    600

```

136

attggctggc aactttggta ttcccataga ctg 633

<210> 170
 <211> 563
 <212> DNA
 <213> Homo sapien

<400> 170
 gggaaggaag acatataggg cggaatgggt cctagatgca tgtcgagcgg cgcagtgtga 60
 tggatcggcg ccgggcaggt acaaaaaata ggataaatgc ttgttttttt atttagcaat 120
 gtccaaaata atgaattgat ttcccgagta tcctctaaag gtaaccaggg atttttttta 180
 tttaattatc ttgaaccac atatttaaata atacgtagta tgctacaaac cattgcagtt 240
 aagtaccttt attgatgctt gagttgccca ctttttcttt tttttttttt ggagacagag 300
 cctcgctctg tcaccagggc tggagtgcag gggcgctcatc tttgactcac ttgcaacctt 360
 ccttccttcc gtggggtgca ggcagattct cctgtgcctt acagcctccg agtttggctg 420
 ggatttacag ggcattgttg caagtttccc acattttcag tgagaaattc ctcaattggc 480
 ctccgtgagt ggtttgaaa ttgacccag aattcttggg gtgggtgtat tagctatcta 540
 tggctggtgt aacaaattga cct 563

<210> 171
 <211> 682
 <212> DNA
 <213> Homo sapien

<400> 171
 gaaaagggtg gcagcaggtg cacgtgttat cagcctgatc atctatcacc tgatggtttt 60
 agcaatacct aaatccgtga tatcatcaga ggttgcaaaa tgatgagatt cagggtttttt 120
 ttttacataa ttattggtca gaattattct gcaaatagct tctctttaac agtattcggg 180
 taccttgaaa tacagggtgt acaaaaaata ggataaatgc ttgttttttt atttagcaat 240
 gtccaaaata atgaattgat ttcccagtat cctctaaagg taaccaggga ttttttttat 300
 ttaattatct tgaaccaca tatttaaata tacgtagtat gctacaaacc attgcagtta 360
 atacctttat tgatgcttga gttgccact tttttctttt tttttttttg gagacagagc 420
 ctcgctctgt caccaggtt ggagtgcagg ggcgctcatc ttgactcact tgcaaccttc 480
 cttccttccg tggggtgcag gcagattctc ctgtgcctta cagcctccga gtttggctgg 540
 gatttacagg gcattgttgc aagtttccca cattttcagt gagaaattcc tcaattggcc 600
 tccgtgagtg gtttggaat tgacccaga attcttggag tgggtgtatt agctatctat 660

137

ggctgggtgta acaaattgac ct

682

<210> 172
 <211> 75
 <212> PRT
 <213> Homo sapien

<400> 172

Met Gly Pro Arg Ser Arg Leu Trp Pro Ser Ser Pro Leu Trp Leu Val
 1 5 10 15

Gln Pro Leu Cys Thr Pro Gly Val Phe Thr Pro Gly Ala Asp Ser Ser
 20 25 30

His Cys Ser Ser Phe Leu Arg Glu Ile Thr Val Val Ile Ala Ala Gly
 35 40 45

Ala Asn Arg Leu Gly Leu Val Ser Cys Ala Phe Gly Gln Leu Leu Thr
 50 55 60

Arg Ser Ser Leu Lys Gln Trp Gly Gly Pro His
 65 70 75

<210> 173
 <211> 38
 <212> PRT
 <213> Homo sapien

<400> 173

Met Phe Pro Arg Leu Asp Ser Thr Ser Trp Pro Gln Gly Ile Leu Trp
 1 5 10 15

Ala Trp Thr Pro Lys Pro Leu Arg Leu Glu Val Cys Glu Pro Pro Ser
 20 25 30

Leu Pro Ser Leu Trp Ser
 35

<210> 174
 <211> 52
 <212> PRT
 <213> Homo sapien

<400> 174

Met Thr Leu Phe Ile Arg Cys Cys Thr Asn Tyr Gly Asn Leu Cys Gln
 1 5 10 15

138

Tyr Phe Asn Val Cys Trp Ile Ile Thr Asp Ile Phe Ile Ile Leu Met
 20 25 30

Ser Thr Asn Leu Phe Ile Leu Ile Ala Arg Val Ser Leu Gly Ser Lys
 35 40 45

His His Leu Gly
 50

<210> 175
 <211> 37
 <212> PRT
 <213> Homo sapien

<400> 175

Met Ala Gly Ser Gly Lys Val Pro Ile Thr Thr Thr Tyr Lys Pro Pro
 1 5 10 15

Thr Asn Ser Asn Ala Ile His Leu Pro Thr Pro Ile Ile Arg Lys Ala
 20 25 30

Gly Phe Thr Gly Ile
 35

<210> 176
 <211> 88
 <212> PRT
 <213> Homo sapien

<400> 176

Met Gly Leu Thr Leu Lys Ser Leu Cys Asp Ser Lys Met Asn Cys Gln
 1 5 10 15

Ser Asn Val Pro Leu Met Lys Asp Pro Ile Thr Leu Gln His Val Cys
 20 25 30

Ile Gln Arg Thr Tyr Leu Arg Leu Ser Phe Gly His Gly Gly Arg Leu
 35 40 45

Leu Leu Lys Thr Tyr Gln Ser Pro Leu Trp Arg Ser Ala Asp Arg Pro
 50 55 60

His Asp Leu Gly Asn Gly Leu Leu Val Ile Trp Asp Cys Leu Gly Leu
 65 70 75 80

139

Cys Asn Gly Thr Trp Gly Gln Asn
85

<210> 177
<211> 61
<212> PRT
<213> Homo sapien

<400> 177

Met Asp His Lys Ser Ala Asn His Ser Ser Ala Leu Leu Lys Met Leu
1 5 10 15

Leu Ala Gly Gly Met Ser Leu Pro Glu Val Pro Glu Gly Leu Thr Pro
20 25 30

Thr Pro Ser Ser Gln Thr His Leu Ser Lys Gly Lys Gly Arg Asn Leu
35 40 45

Glu Lys Ser Tyr Phe His Asn His Ser Leu Arg Glu Pro
50 55 60

<210> 178
<211> 198
<212> PRT
<213> Homo sapien

<400> 178

Met Thr Pro Ile His Leu Ile Cys Ser Pro Ser His Glu Leu Gln Asp
1 5 10 15

Thr Thr His Pro Gln Pro Gln Arg Glu Cys Gln Arg Phe Ser Thr His
20 25 30

Gly Ala Gln Thr Thr Gln Cys Ala Thr His His His Pro Tyr Ile Ser
35 40 45

Gly Ala Ala Thr Arg Thr Tyr Leu Arg His Val Ala Pro Asp Tyr Ser
50 55 60

Ala Pro Leu Met Ala Pro Pro Thr Asn Thr Arg Leu Ala Pro Ala Ser
65 70 75 80

Leu Gln Pro Thr His Leu Arg Pro Pro Leu Ala Arg His Pro Leu Thr
85 90 95

Ala Asp Cys Arg Thr His Gln Leu Thr Asp Thr Arg Pro Leu His Pro

140

100	105	110
Arg Pro Ile Thr Ser Arg Thr	Pro Gln Pro Leu Pro	Ser His Thr His
115	120	125
Gly Leu His His Thr Arg Pro	Pro His Thr Ala Thr	Gly Cys Pro Tyr
130	135	140
Leu Ser Thr Ser Arg Pro Leu	Pro Pro Leu His Thr Arg	Ser Ile His
145	150	155
Pro Asp Asn Pro His Cys Thr	Thr Pro His His Ser Pro	Ser Lys Pro
165	170	175
Ser Thr Thr Thr His Gln Gln	Ser Pro Ala Pro Thr Pro	Asn Lys Pro
180	185	190
His Pro Arg Arg Ala Ser		
195		

<210> 179
 <211> 20
 <212> PRT
 <213> Homo sapien

<400> 179

Met Ile Gly Ile Thr Trp Cys Phe	Glu Leu Ile His Pro Thr	Leu Glu
1	5	10
		15

Leu Thr Ala Thr
20

<210> 180
 <211> 107
 <212> PRT
 <213> Homo sapien

<400> 180

Met Gly Ala Ser Gly Pro Glu Arg	Glu Asp Arg Asn Ser Glu	Asn Gly
1	5	10
		15

Val Glu Lys Lys Asn Val Lys Glu	Leu His Glu Glu His Met Ala Glu
20	25
	30

Lys Lys Glu Leu Gln Glu Glu	Asn Gln Arg Leu Gln Gly	Leu Pro Val
35	40	45

141

Ser Gly Ser Glu Glu Gly Arg Leu Pro Val Pro Ser Ala Arg Ser Ser
 50 55 60

Thr Leu Arg Ala Ser Cys Arg Asn Glu Leu Gly Ser Leu Leu Pro Gly
 65 70 75 80

Gly Glu Thr Ser Leu Gly Leu Lys Glu Gly His Arg Thr Lys Gly Ala
 85 90 95

Arg Gly Gly His Arg Glu Asp Pro Gln Glu Lys
 100 105

<210> 181
 <211> 27
 <212> PRT
 <213> Homo sapien

<400> 181

Met Ser Thr His Ser Val His Ser Thr Gly Leu Pro Phe Tyr Lys Leu
 1 5 10 15

Ser Leu Thr Ser Leu Ser Ser Met Thr Leu Val
 20 25

<210> 182
 <211> 40
 <212> PRT
 <213> Homo sapien

<400> 182

Cys Phe Glu Lys Met Leu Asn Arg Leu Gly Ala Val Ala His Val Cys
 1 5 10 15

Asn Pro Ser Thr Leu Gly Gly Arg Gly Gly Trp Ile Met Arg Ser Gly
 20 25 30

Val Arg Asp Gln Pro Gly Gln His
 35 40

<210> 183
 <211> 26
 <212> PRT
 <213> Homo sapien

<400> 183

142

Met Arg Lys Gln Ala Phe Asp Leu Leu Glu Ser Thr Ala Gln Lys Ser
 1 5 10 15

Leu Val Pro Ile Phe Glu Phe Pro Lys Gln
 20 25

<210> 184
 <211> 39
 <212> PRT
 <213> Homo sapien

<400> 184

Met Lys Glu Glu Gly Arg Leu Leu Thr Val Ala Glu Gly Arg Gln Gly
 1 5 10 15

Pro Ser Cys Ser Ser His Ile Asn Ser Lys Lys Pro Ser Gln Gln Asn
 20 25 30

Lys Ser Ile Phe Asn Ser Ser
 35

<210> 185
 <211> 76
 <212> PRT
 <213> Homo sapien

<400> 185

Met Val Glu Pro Ala Leu Ser Gly Cys Gln Gln Arg Lys Gly Gly Tyr
 1 5 10 15

Ser Ser Glu Arg Gln Ser Gln Pro Thr Gln Gly Gly Gln Gly Val Arg
 20 25 30

Pro Gln Thr Tyr Ser Pro Ala Asp Leu Thr Val Arg Pro Ser Cys Ser
 35 40 45

Gly Thr Gly Asn Ala Gln Ala Glu Ile Ala Leu Leu His Thr Tyr Asn
 50 55 60

Thr Thr Leu Glu Asn Asn Leu Glu Trp Phe Thr Leu
 65 70 75

<210> 186
 <211> 35
 <212> PRT
 <213> Homo sapien

143

<400> 186

Met Arg Gln Pro Cys Leu Ala Ile Pro Glu Ala Ser Ala Ser Leu Ile
 1 5 10 15

Cys Arg Cys His Arg His Phe Thr Tyr Ser His Leu Met Ala Arg Phe
 20 25 30

Leu Leu Leu
 35

<210> 187

<211> 76

<212> PRT

<213> Homo sapien

<400> 187

Met Phe Phe Ala Leu Met Gly Ile Cys Pro Gly Thr Leu Pro Pro Gly
 1 5 10 15

Pro Pro Leu Pro Arg Trp Pro Pro Pro Val Phe Cys Phe Phe Phe Phe
 20 25 30

Phe Phe Gly Phe Phe Phe Cys Cys Phe Thr Val Lys Leu Phe Ile Glu
 35 40 45

Gln Ile Glu Asp Asn Asp Ile Cys Phe Tyr Tyr Arg Ser Leu Pro Ser
 50 55 60

Ser Tyr Ile Ile Asp Thr Tyr Tyr Glu Thr Cys Ile
 65 70 75

<210> 188

<211> 173

<212> PRT

<213> Homo sapien

<400> 188

Met Ile Gly Cys Ser Leu Leu Val Ala Cys Leu Cys Cys Leu Val Gln
 1 5 10 15

Ser Phe Arg Ala Met Phe Ser Cys Phe Ser Gly Leu Ser Leu Cys Leu
 20 25 30

Met Leu Pro Leu Trp Cys Val Cys Pro Thr Val Cys Ala Phe Phe Cys
 35 40 45

144

Gly Tyr Leu Leu Phe Phe Ser Leu Arg His Ala Ala Cys Gly Cys Leu
 50 55 60

Leu Val Cys Leu Ser Cys Leu Ala Leu Pro Ser Gly Pro Ile Leu Ser
 65 70 75 80

Phe Ser Phe Cys Leu Arg Val Val Ser Ser Val Arg Val Ala Cys Ala
 85 90 95

Arg Ser Ala Ala Val Leu Leu Leu Arg Gly Val Pro Pro Pro Ser Leu
 100 105 110

Arg Thr Leu Ser Leu Ile Ala Ser Thr Ala Thr Arg Leu Ser Phe Val
 115 120 125

Phe Leu Phe Ser Leu Pro Arg Gly Leu Leu Cys Val Gly Gly Ser Gly
 130 135 140

Ser Val Leu Gly Ser Leu Val Arg Arg Ala Gln Ser Val Gly Leu Arg
 145 150 155 160

Asp Phe Val Ser Val Leu Gln Val Val Leu Thr Cys Leu
 165 170

<210> 189
 <211> 29
 <212> PRT
 <213> Homo sapien

<400> 189

Met Val Leu Tyr Ser Glu Gly His Gln His Gly Pro His Leu Leu Asn
 1 5 10 15

Met Glu Asn Gln Asn Leu Asn Glu Leu Pro Leu Lys Gly
 20 25

<210> 190
 <211> 122
 <212> PRT
 <213> Homo sapien

<400> 190

Phe Phe Ala Asp Glu Val Ser Arg Leu Ser Pro Gly Leu Glu Cys Ser
 1 5 10 15

145

Gly Val Ile Ser Ala His Cys Asn Phe His Leu Leu Gly Ser Ser Ser
 20 25 30

Ser Pro Ala Ser Ala Ser Gln Val Ala Glu Ile Thr Gly Ala Cys His
 35 40 45

Pro Thr Trp Leu Ile Phe Val Ile Leu Val Glu Thr Gly Phe His His
 50 55 60

Val Gly Gln Ala Asp Ala Leu Leu Thr Ser Gly Asp Pro Pro Phe Ser
 65 70 75 80

Ala Pro Lys Val Leu Gly Ile Thr Gly Val Ser His Arg Ala Arg Pro
 85 90 95

Ala Asn Thr Phe Ala Leu Thr Thr Leu Gly Leu Leu Tyr Lys Ile Val
 100 105 110

Met Ile Ala Met Glu Val Leu Pro Val Pro
 115 120

<210> 191
 <211> 11
 <212> PRT
 <213> Homo sapien

<400> 191

Met Trp Arg Ala Lys Gln Tyr Asp Leu Gln Thr
 1 5 10

<210> 192
 <211> 28
 <212> PRT
 <213> Homo sapien

<400> 192

Met Met Phe Ser Leu Ser Gln Lys Gly Ser Ala Ala Val Gln Ser Pro
 1 5 10 15

Ser Thr Leu Ser Thr Pro Thr Phe Ser Ile Ser Tyr
 20 25

<210> 193
 <211> 48
 <212> PRT
 <213> Homo sapien

146

<400> 193

Met Asp Ser Gly Ala Arg Ala Gly Lys Pro Leu Leu Asp Pro Val Cys
 1 5 10 15

Leu Pro Ala Trp Ser Leu Cys Leu Gln Pro Cys Leu Tyr Ser Ser Leu
 20 25 30

Pro Pro His Gln Pro Pro Leu Ala Ser Pro Tyr Arg Leu Ser Lys Lys
 35 40 45

<210> 194

<211> 1138

<212> PRT

<213> Homo sapien

<400> 194

Met Gly Asp Phe Ala Ala Pro Ala Ala Ala Asn Gly Ser Ser Ile
 1 5 10 15

Cys Ile Asn Ser Ser Leu Asn Ser Ser Leu Gly Gly Ala Gly Ile Gly
 20 25 30

Val Asn Asn Thr Pro Asn Ser Thr Pro Ala Ala Pro Ser Ser Asn His
 35 40 45

Pro Ala Ala Gly Gly Cys Gly Gly Ser Gly Gly Pro Gly Gly Gly Ser
 50 55 60

Ala Ala Val Pro Lys His Ser Thr Val Val Glu Arg Leu Arg Gln Arg
 65 70 75 80

Ile Glu Gly Cys Arg Arg His His Val Asn Cys Glu Asn Arg Tyr Gln
 85 90 95

Gln Ala Gln Val Glu Gln Leu Glu Leu Glu Arg Arg Asp Thr Val Ser
 100 105 110

Leu Tyr Gln Arg Thr Leu Glu Gln Arg Ala Lys Lys Ser Gly Ala Gly
 115 120 125

Thr Gly Lys Gln Gln His Pro Ser Lys Pro Gln Gln Asp Ala Glu Ala
 130 135 140

Ala Ser Ala Glu Gln Arg Asn His Thr Leu Ile Met Leu Gln Glu Thr
 145 150 155 160

147

Val Lys Arg Lys Leu Glu Gly Ala Arg Ser Pro Leu Asn Gly Asp Gln
 165 170 175

Gln Asn Gly Ala Cys Asp Gly Asn Phe Ser Pro Thr Ser Lys Arg Ile
 180 185 190

Arg Lys Asp Ile Ser Ala Gly Met Glu Ala Ile Asn Asn Leu Pro Ser
 195 200 205

Asn Met Pro Leu Pro Ser Ala Ser Pro Leu His Gln Leu Asp Leu Lys
 210 215 220

Pro Ser Leu Pro Leu Gln Asn Ser Gly Thr His Thr Pro Gly Leu Leu
 225 230 235 240

Glu Asp Leu Ser Lys Asn Gly Arg Leu Pro Glu Ile Lys Leu Pro Val
 245 250 255

Asn Gly Cys Ser Asp Leu Glu Asp Ser Phe Thr Ile Leu Gln Ser Lys
 260 265 270

Asp Leu Lys Gln Glu Pro Leu Asp Asp Pro Thr Cys Ile Asp Thr Ser
 275 280 285

Glu Thr Ser Leu Ser Asn Gln Asn Lys Leu Phe Ser Asp Ile Asn Leu
 290 295 300

Asn Asp Gln Glu Trp Gln Glu Leu Ile Asp Glu Leu Ala Asn Thr Val
 305 310 315 320

Pro Glu Asp Asp Ile Gln Asp Leu Phe Asn Glu Asp Phe Glu Glu Lys
 325 330 335

Lys Glu Pro Glu Phe Ser Gln Pro Ala Thr Glu Thr Pro Leu Ser Gln
 340 345 350

Glu Ser Ala Ser Val Lys Ser Asp Pro Ser His Ser Pro Phe Ala His
 355 360 365

Val Ser Met Gly Ser Pro Gln Ala Arg Pro Ser Ser Ser Gly Pro Pro
 370 375 380

Phe Ser Thr Val Ser Thr Ala Thr Ser Leu Pro Ser Val Ala Ser Thr

148

385 390 395 400

 Pro Ala Ala Pro Asn Pro Ala Ser Ser Pro Ala Asn Cys Ala Val Gln
 405 410 415

 Ser Pro Gln Thr Pro Asn Gln Ala His Thr Pro Gly Gln Ala Pro Pro
 420 425 430

 Arg Pro Gly Asn Gly Tyr Leu Leu Asn Pro Ala Ala Val Thr Val Ala
 435 440 445

 Gly Ser Ala Ser Gly Pro Val Ala Val Pro Ser Ser Asp Met Ser Pro
 450 455 460

 Ala Glu Gln Leu Lys Gln Met Ala Ala Gln Gln Gln Gln Arg Ala Lys
 465 470 475 480

 Leu Met Gln Gln Lys Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
 485 490 495

 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln His Ser
 500 505 510

 Asn Gln Thr Ser Asn Trp Ser Pro Leu Gly Pro Pro Ser Ser Pro Tyr
 515 520 525

 Gly Ala Ala Phe Thr Ala Glu Lys Pro Asn Ser Pro Met Met Tyr Pro
 530 535 540

 Gln Ala Phe Asn Asn Gln Asn Pro Ile Val Pro Pro Met Ala Asn Asn
 545 550 555 560

 Leu Gln Lys Thr Thr Met Asn Asn Tyr Leu Pro Gln Asn His Met Asn
 565 570 575

 Met Ile Asn Gln Gln Pro Asn Asn Leu Gly Thr Asn Ser Leu Asn Lys
 580 585 590

 Gln His Asn Ile Leu Thr Tyr Gly Asn Thr Lys Pro Leu Thr His Phe
 595 600 605

 Asn Ala Asp Leu Ser Gln Arg Met Thr Pro Pro Val Ala Asn Pro Asn
 610 615 620

149

Lys Asn Pro Leu Met Pro Tyr Ile Gln Gln Gln Gln Gln Gln Gln
 625 630 635 640

Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Pro Pro Pro Pro Gln Leu
 645 650 655

Gln Ala Pro Arg Ala His Leu Ser Glu Asp Gln Lys Arg Leu Leu Leu
 660 665 670

Met Lys Gln Lys Gly Val Met Asn Gln Pro Met Ala Tyr Ala Ala Leu
 675 680 685

Pro Ser His Gly Gln Glu Gln His Pro Val Gly Leu Pro Arg Thr Thr
 690 695 700

Gly Pro Met Gln Ser Ser Val Pro Pro Gly Ser Gly Gly Met Val Ser
 705 710 715 720

Gly Ala Ser Pro Ala Gly Pro Gly Phe Leu Gly Ser Gln Pro Gln Ala
 725 730 735

Ala Ile Met Lys Gln Met Leu Ile Asp Gln Arg Ala Gln Leu Ile Glu
 740 745 750

Gln Gln Lys Gln Gln Phe Leu Arg Glu Gln Arg Gln Gln Gln Gln
 755 760 765

Gln Gln Gln Gln Ile Leu Ala Glu Gln Gln Leu Gln Gln Ser His Leu
 770 775 780

Pro Arg Gln His Leu Gln Pro Gln Arg Asn Pro Tyr Pro Val Gln Gln
 785 790 795 800

Val Asn Gln Phe Gln Gly Ser Pro Gln Asp Ile Ala Ala Val Arg Ser
 805 810 815

Gln Ala Ala Leu Gln Ser Met Arg Thr Ser Arg Leu Met Ala Gln Asn
 820 825 830

Ala Gly Met Met Gly Ile Gly Pro Ser Gln Asn Pro Gly Thr Met Ala
 835 840 845

Thr Ala Ala Ala Gln Ser Glu Met Gly Leu Ala Pro Tyr Ser Thr Thr
 850 855 860

150

Pro Thr Ser Gln Pro Gly Met Tyr Asn Met Ser Thr Gly Met Thr Gln
 865 870 875 880

Met Leu Gln His Pro Asn Gln Ser Gly Met Ser Ile Thr His Asn Gln
 885 890 895

Ala Gln Gly Pro Arg Gln Pro Ala Ser Gly Gln Gly Val Gly Met Val
 900 905 910

Ser Gly Phe Gly Gln Ser Met Leu Val Asn Ser Ala Ile Thr Gln Gln
 915 920 925

His Pro Gln Met Lys Gly Pro Val Gly Gln Ala Leu Pro Arg Pro Gln
 930 935 940

Ala Pro Pro Arg Leu Gln Ser Leu Met Gly Thr Val Gln Gln Gly Ala
 945 950 955 960

Gln Ser Trp Gln Gln Arg Ser Leu Gln Gly Met Pro Gly Arg Thr Ser
 965 970 975

Gly Glu Leu Gly Pro Phe Asn Asn Gly Ala Ser Tyr Pro Leu Gln Ala
 980 985 990

Gly Gln Pro Arg Leu Thr Lys Gln His Phe Pro Gln Gly Leu Ser Gln
 995 1000 1005

Ser Val Val Asp Ala Asn Thr Gly Thr Val Arg Thr Leu Asn Pro
 1010 1015 1020

Ala Ala Met Gly Arg Gln Met Met Pro Ser Leu Pro Gly Gln Gln
 1025 1030 1035

Gly Thr Ser Gln Ala Arg Pro Met Val Met Ser Gly Leu Ser Gln
 1040 1045 1050

Gly Val Pro Gly Met Pro Ala Phe Ser Gln Pro Pro Ala Gln Gln
 1055 1060 1065

Gln Ile Pro Ser Gly Ser Phe Ala Pro Ser Ser Gln Ser Gln Ala
 1070 1075 1080

Tyr Glu Arg Asn Ala Pro Gln Asp Val Ser Tyr Asn Tyr Ser Gly
 1085 1090 1095

151

Asp Gly Ala Gly Gly Ser Phe Pro Gly Leu Pro Asp Gly Ala Asp
 1100 1105 1110

Leu Val Asp Ser Ile Ile Lys Gly Gly Pro Gly Asp Glu Trp Met
 1115 1120 1125

Gln Glu Leu Asp Glu Leu Phe Gly Asn Pro
 1130 1135

<210> 195
 <211> 30
 <212> PRT
 <213> Homo sapien

<400> 195

Met Gln Leu Pro Leu Ser His Lys Arg Lys Lys Gln Tyr Ser Phe Tyr
 1 5 10 15

Val Phe Asp Thr Asn Ile Lys His Asn Ser Val Leu Val His
 20 25 30

<210> 196
 <211> 46
 <212> PRT
 <213> Homo sapien

<400> 196

Met Lys Ile Tyr Phe Lys Ile Leu Leu Met Phe Leu Lys Lys Tyr Phe
 1 5 10 15

Leu Arg Phe His Leu Met Lys Thr Met Lys Tyr Ser Val Phe Tyr Ser
 20 25 30

Thr Thr Arg Gln Met Trp Ser Ile Pro Phe Val Phe Phe Phe
 35 40 45

<210> 197
 <211> 18
 <212> PRT
 <213> Homo sapien

<400> 197

Met Leu Glu Ala Gly Ile Ser Phe Lys Val Arg Leu Gln Lys Trp Lys
 1 5 10 15

152

Gln Ile

<210> 198
 <211> 132
 <212> PRT
 <213> Homo sapien

<400> 198

Met Phe Tyr Ser Ile Leu Ala Met Leu Arg Asp Arg Gly Ala Leu Gln
 1 5 10 15

Asp Leu Met Asn Met Leu Glu Leu Asp Ser Ser Gly His Leu Asp Gly
 20 25 30

Pro Gly Gly Ala Ile Leu Lys Lys Leu Gln Gln Asp Ser Asn His Ala
 35 40 45

Trp Phe Asn Pro Lys Asp Pro Ile Leu Tyr Leu Leu Glu Ala Ile Met
 50 55 60

Val Leu Ser Asp Phe Gln His Asp Leu Leu Ala Cys Ser Met Glu Lys
 65 70 75 80

Arg Ile Leu Leu Gln Gln Gln Glu Leu Val Arg Ser Ile Leu Glu Pro
 85 90 95

Asn Phe Arg Tyr Pro Trp Ser Ile Pro Phe Thr Leu Lys Pro Glu Leu
 100 105 110

Leu Ala Pro Leu Gln Ser Glu Gly Leu Ala Ser Pro Met Ala Ala Gly
 115 120 125

Gly Val Trp Pro
 130

<210> 199
 <211> 226
 <212> PRT
 <213> Homo sapien

<400> 199

Pro Pro Lys His Leu Lys Ser Lys Phe Gly Gly Met Arg Lys Ala Asp
 1 5 10 15

Asp Asp Leu Ile Leu Leu Leu Gly Arg Ile Glu Glu Pro Phe Trp Gln

153

20

25

30

Asn Phe Lys His Leu Gln Glu Val Phe Gln Lys Ile Lys Thr Leu
 35 40 45

Ala Gln Leu Ser Lys Asp Val Gln Asp Val Met Phe Tyr Ser Ile Leu
 50 55 60

Ala Met Leu Arg Asp Arg Gly Ala Leu Gln Asp Leu Met Asn Met Leu
 65 70 75 80

Glu Leu Asp Ser Ser Gly His Leu Asp Gly Pro Gly Gly Ala Ile Leu
 85 90 95

Lys Lys Leu Gln Gln Asp Ser Asn His Ala Trp Phe Asn Pro Lys Asp
 100 105 110

Pro Ile Leu Tyr Leu Leu Glu Ala Ile Met Val Leu Ser Asp Phe Gln
 115 120 125

His Asp Leu Leu Ala Cys Ser Met Glu Lys Arg Ile Leu Leu Gln Gln
 130 135 140

Gln Glu Leu Val Arg Ser Ile Leu Glu Pro Asn Phe Arg Tyr Pro Trp
 145 150 155 160

Ser Ile Pro Phe Thr Leu Lys Pro Glu Leu Leu Ala Pro Leu Gln Ser
 165 170 175

Glu Gly Leu Ala Ile Thr Tyr Gly Leu Leu Glu Glu Cys Gly Leu Arg
 180 185 190

Thr Glu Leu Asp Asn Pro Arg Ser Thr Trp Asp Val Glu Ala Lys Met
 195 200 205

Pro Leu Ser Ala Leu Tyr Gly Thr Leu Ser Leu Leu Gln Gln Leu Ala
 210 215 220

Glu Ala
 225

<210> 200
 <211> 37
 <212> PRT
 <213> Homo sapien

154

<400> 200

Met Ala Lys His Lys Gly Gly Tyr Gly Lys Tyr Trp Val Thr Leu Ile
 1 5 10 15

Ile Gly Leu Asn Ala Thr Asn Asn Ile Ile Ile Val Leu Thr Tyr Phe
 20 25 30

Phe Arg Leu Leu Ser
 35

<210> 201

<211> 28

<212> PRT

<213> Homo sapien

<400> 201

Met Val His Lys Ser Tyr Phe Thr Thr Leu Ser Leu Val Ile Leu Gly
 1 5 10 15

Val Trp Pro Cys Lys Ala Ser Ser Gln Arg Phe Cys
 20 25

<210> 202

<211> 77

<212> PRT

<213> Homo sapien

<400> 202

Met Gly Ser Val Cys Val Cys Phe His Arg Ser Thr Thr Ser Glu Val
 1 5 10 15

Ser Leu His Leu Cys Ile Phe Thr Ser Gln Gly Gln Gly Pro Gly Asn
 20 25 30

Leu Arg Gly Ser His Ser Phe Ser Leu Pro Gln Thr Met Pro Leu Pro
 35 40 45

Pro Ile Ser Leu Gly Gln Glu Ser Gly Phe Cys Phe Pro Tyr Phe Phe
 50 55 60

Phe Pro Arg His Trp Glu Ala Ser Gly Glu Gln His Gln
 65 70 75

<210> 203

<211> 70

155

<212> PRT

<213> Homo sapien

<400> 203

Met Gly Pro Pro Leu Pro Leu Gly Gly Trp Ser Ser Asp Leu Leu Ala
 1 5 10 15

Gln Lys Val Leu Phe Phe His Leu Leu Cys Leu Asn Glu Ser Ser Trp
 20 25 30

Thr Tyr Thr Pro Leu Ser Asp Glu Arg Ala Arg Leu Arg Arg Cys Ala
 35 40 45

Gly His Leu Leu Arg Ile His Val Gly Ser Ala Ala Pro Gly Gly Gly
 50 55 60

Ser Thr Ser Ala Ala Thr
 65 70

<210> 204

<211> 37

<212> PRT

<213> Homo sapien

<400> 204

Met Ser Lys Lys Lys Asp Gln Asp Leu Cys Leu Lys Ile Glu Met His
 1 5 10 15

Thr Ala Ala Ala Gln Lys Leu Arg Pro Ala Ser Lys Leu His Glu Ala
 20 25 30

Leu Val Lys Thr Asp
 35

<210> 205

<211> 87

<212> PRT

<213> Homo sapien

<400> 205

Met Pro Ser Val Ala Gln Gly Pro Val Pro Trp His Leu Gly Ser Arg
 1 5 10 15

Ser Ala Val Ala Val Phe Glu Phe Leu Val Met Phe Glu Gln Arg Pro
 20 25 30

156

Tyr Val Cys Ile Leu His Trp Ala Pro Gln Ile Thr Trp Pro Ile Leu
 35 40 45

Arg Arg Gly Val Ser His Leu Gln Ser Pro Lys Ser Pro Leu Glu Val
 50 55 60

Phe Leu Asn Glu Arg Thr Glu Ala Phe Leu Lys Ser Ser Val Gly Glu
 65 70 75 80

Thr Val His His His Thr Gln
 85

<210> 206
 <211> 46
 <212> PRT
 <213> Homo sapien

<400> 206

Met Ser Pro Gly Thr Ala Met Ala Leu Gly Ala Pro Thr Leu Phe Phe
 1 5 10 15

Phe Phe Phe Phe Phe Phe Phe Tyr Asn Gln Pro Ile Arg Asp Leu Ser
 20 25 30

Ile Asn Lys Pro Leu Phe Ile Ile Arg Asn Trp Leu Thr Gln
 35 40 45

<210> 207
 <211> 91
 <212> PRT
 <213> Homo sapien

<400> 207

Met Ser Ser Pro Gln Ser Ile Glu His Asn His Asp Ser His Glu Leu
 1 5 10 15

Pro Thr Pro Pro Ala Ala Ser Ala Gln Arg Glu Ser Pro Leu Gln Val
 20 25 30

Cys Leu Ile Ala Glu Pro Ile Phe Phe Leu Pro Gly Gln Gln Leu Leu
 35 40 45

Ser Ser Met Ser Arg His Trp Cys Ser Leu Gly Trp Ala Pro Val Thr
 50 55 60

Pro Met Glu Ile Leu Asp Gly Cys Tyr Arg Thr Gly Leu Asp Val Arg

158

<210> 210
 <211> 58
 <212> PRT
 <213> Homo sapien

<400> 210

Met Val Ile Phe Tyr Ser Ser Pro Ser Gln Asp Ser Ala Leu Ile Tyr
 1 5 10 15

Tyr Ile Pro Phe Ile Leu Leu Tyr Arg Leu Leu Ser Glu Thr His Val
 20 25 30

Gln Ile Arg Asp Lys Ile Leu Lys His Ile Thr Pro Ser Leu Val Phe
 35 40 45

Ser Ile Gln Ile Leu Arg Asn Ser Cys Tyr
 50 55

<210> 211
 <211> 37
 <212> PRT
 <213> Homo sapien

<400> 211

Met Asn Leu Tyr Leu Lys Met Lys Thr Ile Pro Lys Lys Thr Cys Met
 1 5 10 15

Ser Lys Thr Glu Leu Phe Leu Pro Phe Thr Pro Lys Tyr Leu Lys Leu
 20 25 30

Asn Leu Ser His Phe
 35

<210> 212
 <211> 99
 <212> PRT
 <213> Homo sapien

<400> 212

Phe Phe Phe Phe Leu Arg Trp Ser Leu Ala Leu Ser Pro Arg Leu Glu
 1 5 10 15

Cys Ser Gly Val Ile Ser Thr His Cys Asn Leu Cys Phe Pro Gly Ser
 20 25 30

159

Ser Asp Ser Arg Ala Ser Pro Thr Phe Gln Val Ala Trp Ile Thr Gly
 35 40 45

Val Arg His His Ser Trp Leu Ile Phe Val Leu Leu Val Glu Thr Gly
 50 55 60

Phe His His Val Val Gln Ala Val Glu Leu Leu Thr Ser Arg Asp Pro
 65 70 75 80

Pro Ala Ser Ala Ser Gln Ser Ala Ala Ile Ile Gly Val Asn His Cys
 85 90 95

Ala Arg Pro

<210> 213
 <211> 43
 <212> PRT
 <213> Homo sapien

<400> 213

Met Gln Glu Phe Thr Trp Leu Phe Glu Lys Glu Asn Phe Lys Val Ser
 1 5 10 15

Gly Trp Thr Glu Ser His Glu Ala Arg Ser Leu Leu Thr Ala Arg Ser
 20 25 30

Leu Glu Lys Gln Val Ser Gly Ser Phe Thr Ser
 35 40

<210> 214
 <211> 61
 <212> PRT
 <213> Homo sapien

<400> 214

Met Ala Val Asp Phe Tyr Asn Phe Val Thr Lys Leu Val Val Thr Thr
 1 5 10 15

Gly Tyr Leu Arg Ile Ser Phe Leu Ala Tyr Lys Phe Phe Ser Phe Pro
 20 25 30

Phe Leu Asp Ser Leu Ser Leu Cys Cys Pro Gly Leu Glu Cys Ser Gly
 35 40 45

Val Ile Pro Ala His Tyr Asn Leu Tyr Leu Pro Gly Arg

160

50

55

60

<210> 215
 <211> 127
 <212> PRT
 <213> Homo sapien

<400> 215

Ser Gln Asn Ile Phe Phe Gly Val Ala Ile Phe Phe Phe Ser Phe Phe
 1 5 10 15

Arg Gln Ser Leu Ser Leu Val Ala Gln Ala Arg Val Gln Trp Arg Asp
 20 25 30

Pro Gly Ser Leu Gln Pro Leu Pro Pro Gly Phe Lys Arg Phe Leu Gly
 35 40 45

Leu Ser Leu Pro Ser Ser Ala Gly Tyr Arg Arg Ala Pro Pro Pro Cys
 50 55 60

Pro Ala Leu Leu Tyr Phe Ala Val Glu Thr Gly Phe His His Val Gly
 65 70 75 80

Gln Ala Gly Leu Glu Leu Leu Thr Ser Gly Asn Pro Ala Ala Ser Ala
 85 90 95

Ser Gln Ser Ala Gly Ile Thr Gly Thr Ser His Cys Thr Gln Pro Tyr
 100 105 110

Tyr His Lys Ser Ser Ala Cys Trp Tyr Leu Ile Arg Phe Tyr Leu
 115 120 125

<210> 216
 <211> 13
 <212> PRT
 <213> Homo sapien

<400> 216

Met Glu Cys Ser Ser Leu Ala Glu Phe Lys Pro Val Phe
 1 5 10

<210> 217
 <211> 100
 <212> PRT
 <213> Homo sapien

<400> 217

161

Pro Gln Gln Thr Leu Lys Arg Ile Gln Gln Val Leu Ile Lys Cys Cys
 1 5 10 15

Leu Ala Phe Tyr Leu Phe Leu Phe Phe Phe Leu Arg Trp Ser Leu
 20 25 30

Ala Leu Leu Pro Ser Leu Lys Cys Ser Gly Val Ile Ser Ala His Cys
 35 40 45

Asn Leu Arg Leu Pro Gly Leu Gly Asp Ser Leu Ala Ser Ala Ser Arg
 50 55 60

Val Ala Gly Met Thr Thr Gly Thr Cys His His Ala Gln Leu Ile Phe
 65 70 75 80

Val Phe Leu Val Glu Thr Gly Phe Cys Val Ser Gln Asp Gly Leu Asp
 85 90 95

Leu Leu Ile Ser
 100

<210> 218
 <211> 46
 <212> PRT
 <213> Homo sapien

<400> 218

Met Glu Gly Gly Glu Met Ser Thr Gln Val Glu Asn Arg Ser Glu Gly
 1 5 10 15

Thr Ile Pro Ile Gln Thr Thr Cys Lys Ser His Asn Lys Ala Pro His
 20 25 30

Cys Thr Glu Leu Arg His Lys Gln Arg Phe Pro Thr Asp Gly
 35 40 45

<210> 219
 <211> 72
 <212> PRT
 <213> Homo sapien

<400> 219

Ile Ser Phe Ile Phe Phe Ser Glu Ala Cys Gln Val Glu Val Arg Leu
 1 5 10 15

Leu Leu Ala Tyr Asn Ser Ser Ala Arg Ile Pro Lys Cys Pro Trp Met
20 25 30

Glu Gly Gly Glu Met Ser Pro Gln Val Glu Thr Ser Ile Glu Gly Thr
35 40 45

Ile Pro Phe Ser Lys Pro Val Lys Val Tyr Ile Met Pro Lys Pro Ala
50 55 60

Arg Arg Pro Lys Pro Ala Arg Arg
65 70

```
<210> 220
<211> 41
<212> PRT
<213> Homo sapien
```

<400> 220

Met Glu Cys Lys Val Ile Lys Cys Ser Cys Phe His Leu Glu Gly Cys
1 5 10 15

Gly Pro Glu Gly Lys Arg Ser Pro Lys Tyr Pro Pro Pro Trp Cys Ser
20 25 30

Ser Leu Cys Leu Val Pro Ala Arg Ala
35 40

```
<210> 221
<211> 30
<212> PRT
<213> Homo sapien
```

<400> 221

Met Asn Ser Phe Gly Tyr Met Thr Pro Ser Lys Phe Phe Lys Lys Glu
1 5 10 15

Ile Thr Phe Lys Thr Thr Tyr Ile Phe Cys Phe Cys Leu Arg
20 25 30

```
<210> 222
<211> 22
<212> PRT
<213> Homo sapien
```

<400> 222

Met Leu Gln Ile Gly His Leu Leu Ser Met His Ser Leu Asp Lys Asn
1 5 10 15

163

Ile Gly Gln Val Gly Met
20

<210> 223
<211> 18
<212> PRT
<213> Homo sapien

<400> 223

Met Ser Asp Arg Val Val Ala Leu Leu Glu Val Phe Phe Pro Phe Gln
1 5 10 15

Arg Glu

<210> 224
<211> 133
<212> PRT
<213> Homo sapien

<400> 224

Met Gly Asn Ser Ile Asp Thr Val Arg Tyr Gly Lys Glu Ser Asp Leu
1 5 10 15

Gly Asp Val Ser Glu Glu His Gly Glu Trp Asn Lys Glu Ser Ser Asn
20 25 30

Asn Glu Gln Asp Asn Ser Leu Leu Glu Gln Tyr Leu Thr Ser Val Gln
35 40 45

Gln Leu Glu Asp Ala Asp Glu Arg Thr Asn Phe Asp Thr Glu Thr Arg
50 55 60

Asp Ser Lys Leu His Ile Ala Cys Phe Pro Val Gln Leu Asp Thr Leu
65 70 75 80

Ser Asp Gly Ala Ser Val Asp Glu Ser His Gly Ile Ser Pro Pro Leu
85 90 95

Gln Gly Glu Ile Ser Gln Thr Gln Glu Asn Ser Lys Leu Asn Ala Glu
100 105 110

Val Gln Gly Gln Gln Pro Glu Cys Asp Ser Thr Phe Gln Leu Leu His
115 120 125

164

Val Gly Val Thr Val
130

<210> 225
<211> 50
<212> PRT
<213> Homo sapien

<400> 225

Met Arg Asn Ser Ser Pro Ile Leu Thr Pro Ala Leu Phe Ser Phe His
1 5 10 15

Met Tyr Ile Gly Pro Leu Ile Arg Ile Phe Lys Lys Phe Pro Arg Pro
20 25 30

Pro Asn Leu Thr Ile Asp Asp Pro Leu Ser Leu Phe Arg Arg Asn Tyr
35 40 45

Ile Gly
50

<210> 226
<211> 43
<212> PRT
<213> Homo sapien

<400> 226

Met His Ser Phe Phe Leu Ser Met Leu Cys Pro Glu Ala Leu Arg Val
1 5 10 15

Leu Leu Lys Gln Ala Ala Gly Leu Leu Arg Glu Ile Lys Gly Phe Ile
20 25 30

Ser Thr Thr Arg Cys Gln Asn Leu His Phe Glu
35 40

<210> 227
<211> 99
<212> PRT
<213> Homo sapien

<400> 227

Met Leu Glu Arg Arg Ser Val Met Asp Arg Arg Arg Ala Gly Asn Ser
1 5 10 15

Pro Pro Arg Ile Glu Lys Cys Leu Leu Gly Arg Glu Glu Gly Glu Ala

165

20

25

30

Gly Ala Gly Pro Ser Pro Gly Ser Leu Leu Gly Pro Gln Lys Ala Leu
 35 40 45

Asn Gln Ala Pro Ser Leu Gln Gly Lys Pro Arg Pro Gln Pro Asp Asn
 50 55 60

Leu Glu Gly Arg Lys Ser Gln Thr Leu Gly Leu Phe Phe Gly Gly Ile
 65 70 75 80

Ile Gly Phe Phe Phe Phe Met Phe Leu Leu Glu Phe Cys Leu Leu Ala
 85 90 95

Asn Ser Val

<210> 228
 <211> 44
 <212> PRT
 <213> Homo sapien

<400> 228

Met Lys Ser Ile Gln Leu Lys Phe Ser Tyr Ile Ile Glu Pro Gln Leu
 1 5 10 15

Asn Gly Met Asn Gly Ile Gly Asn Leu Leu Glu Met Ile Phe Met Ile
 20 25 30

Thr Phe Val Val Ile Pro Phe Ser Trp Leu Arg Phe
 35 40

<210> 229
 <211> 41
 <212> PRT
 <213> Homo sapien

<400> 229

Tyr Phe Pro Leu Gln Ile Trp Ile Ser Glu Asp Ser Asn Asn Ile Glu
 1 5 10 15

Ala Val Asn Gln Trp Lys Glu Thr Val Ile Asn Pro Glu Lys Val Val
 20 25 30

Ile Arg Trp His Lys Leu Asn Pro Ser
 35 40

166

<210> 230
 <211> 48
 <212> PRT
 <213> Homo sapien

<400> 230

Met Leu Lys Gly His Tyr Gln Tyr Gly Met Glu Asp Leu Ser Phe His
 1 5 10 15

Thr Phe Ser Ser Ser Phe Leu Asn Phe Leu Leu Leu Phe Leu Leu Ser
 20 25 30

Cys Met Val Ala Pro Phe Pro Phe Leu Leu Ser Val Pro Ser Lys Gln
 35 40 45

<210> 231
 <211> 108
 <212> PRT
 <213> Homo sapien

<400> 231

Phe Leu Lys Arg Gln Ser Ile Ser Leu Leu Pro Gln Leu Glu Cys Ser
 1 5 10 15

Gly Thr Ile Ile Val His His Thr Leu Glu Leu Leu Gly Lys Gly Ser
 20 25 30

Ser Leu Ala Ser Ala Ser Gln Val Ala Arg Tyr Thr Gly Met Cys Tyr
 35 40 45

His Ala Trp Leu Ile Lys Lys Ile Phe Leu Glu Met Arg Ser Cys Cys
 50 55 60

Val Ala Gln Ala Gly Leu Lys Leu Leu Gly Ser Asn Asn Pro Pro Thr
 65 70 75 80

Leu Ala Ser Gln Ser Ala Gly Ile Thr Gly Val Ser His Ser Thr Ala
 85 90 95

Pro Tyr Leu Gln Ile Leu Asn Gln Ala Ile Ala Ile
 100 105

<210> 232
 <211> 64
 <212> PRT

167

<213> Homo sapien

<400> 232

Met Ser Pro Arg Ala Pro Phe Ala Pro Gly Cys Pro Gln Pro Leu Val
 1 5 10 15

Val Phe Tyr Val Cys Phe Phe Phe Phe Leu Ile Phe Cys Phe Val Lys
 20 25 30

Lys His His Tyr Met Phe Leu Tyr Pro Arg Leu Lys Thr Phe Gly Asn
 35 40 45

Leu Ile Ser Asn Ile Lys Ile Gln Ile Lys Thr His Ser Thr Ile Pro
 50 55 60

<210> 233

<211> 35

<212> PRT

<213> Homo sapien

<400> 233

Met Cys Val Asn Ala Ser Thr Val Gly Gln Met Cys Glu Asn Glu Leu
 1 5 10 15

Lys His Met Leu Arg Ile Lys Val Asn Arg Arg Asn Phe Glu Arg Phe
 20 25 30

Pro Leu Met
 35

<210> 234

<211> 72

<212> PRT

<213> Homo sapien

<400> 234

Met Asn Ile Phe Pro Trp Ala Gly Gly Pro Trp Ser Leu Pro Gln Ala
 1 5 10 15

Arg Tyr Arg Ala Pro Ala Cys Ala Pro Thr Asn His Gly Lys Gln Arg
 20 25 30

Arg Pro Pro His Leu Lys Ser Trp Pro Val Val Val Ser Ser Val Phe
 35 40 45

Leu Leu Ser Glu Gln Asn Val Leu Lys Leu Glu Leu Thr Lys Val Lys

168

50

55

60

Ser Ser Lys Thr Thr Tyr Ala Thr
65 70

<210> 235
<211> 1163
<212> PRT
<213> Homo sapien

<400> 235

Met Asp Arg Asn Arg Glu Ala Glu Met Glu Leu Arg Arg Gly Pro Ser
1 5 10 15

Pro Thr Arg Ala Gly Arg Gly His Glu Val Asp Gly Asp Lys Ala Thr
20 25 30

Cys His Thr Cys Cys Ile Cys Gly Lys Ser Phe Pro Phe Gln Ser Ser
35 40 45

Leu Ser Gln His Met Arg Lys His Thr Gly Glu Lys Pro Tyr Lys Cys
50 55 60

Pro Tyr Cys Asp His Arg Ala Ser Gln Lys Gly Asn Leu Lys Ile His
65 70 75 80

Ile Arg Ser His Arg Thr Gly Thr Leu Ile Gln Gly His Glu Pro Glu
85 90 95

Ala Gly Glu Ala Pro Leu Gly Glu Met Arg Ala Ser Glu Gly Leu Asp
100 105 110

Ala Cys Ala Ser Pro Thr Lys Ser Ala Ser Ala Cys Asn Arg Leu Leu
115 120 125

Asn Gly Ala Ser Gln Ala Asp Gly Ala Arg Val Leu Asn Gly Ala Ser
130 135 140

Gln Ala Asp Ser Gly Arg Val Leu Leu Arg Ser Ser Lys Lys Gly Ala
145 150 155 160

Glu Gly Ser Ala Cys Ala Pro Gly Glu Ala Lys Ala Ala Val Gln Cys
165 170 175

Ser Phe Cys Lys Ser Gln Phe Glu Arg Lys Lys Asp Leu Glu Leu His

169

180

185

190

Val His Gln Ala His Lys Pro Phe Lys Cys Arg Leu Cys Ser Tyr Ala
 195 200 205

Thr Leu Arg Glu Glu Ser Leu Leu Ser His Ile Glu Arg Asp His Ile
 210 215 220

Thr Ala Gln Gly Pro Gly Ser Gly Glu Ala Cys Val Glu Asn Gly Lys
 225 230 235 240

Pro Glu Leu Ser Pro Gly Glu Phe Pro Cys Glu Val Cys Gly Gln Ala
 245 250 255

Phe Ser Gln Thr Trp Phe Leu Lys Ala His Met Lys Lys His Arg Gly
 260 265 270

Ser Phe Asp His Gly Cys His Ile Cys Gly Arg Arg Phe Lys Glu Pro
 275 280 285

Trp Phe Leu Lys Asn His Met Lys Ala His Gly Pro Lys Thr Gly Ser
 290 295 300

Lys Asn Arg Pro Lys Ser Glu Leu Asp Pro Ile Ala Thr Ile Asn Asn
 305 310 315 320

Val Val Gln Glu Glu Val Ile Val Ala Gly Leu Ser Leu Tyr Glu Val
 325 330 335

Cys Ala Lys Cys Gly Asn Leu Phe Thr Asn Leu Asp Ser Leu Asn Ala
 340 345 350

His Asn Ala Ile His Arg Arg Val Glu Ala Ser Arg Thr Arg Ala Pro
 355 360 365

Ala Glu Glu Gly Ala Glu Gly Pro Ser Asp Thr Lys Gln Phe Phe Leu
 370 375 380

Gln Cys Leu Asn Leu Arg Pro Ser Ala Ala Gly Asp Ser Cys Pro Gly
 385 390 395 400

Thr Gln Ala Gly Arg Arg Val Ala Glu Leu Asp Pro Val Asn Ser Tyr
 405 410 415

170

Gln Ala Trp Gln Leu Ala Thr Arg Gly Lys Val Ala Glu Pro Ala Glu
 420 425 430

Tyr Leu Lys Tyr Gly Ala Trp Asp Glu Ala Leu Ala Gly Asp Val Ala
 435 440 445

Phe Asp Lys Asp Arg Arg Glu Tyr Val Leu Val Ser Gln Glu Lys Arg
 450 455 460

Lys Arg Glu Gln Asp Ala Pro Ala Ala Gln Gly Pro Pro Arg Lys Arg
 465 470 475 480

Ala Ser Gly Pro Gly Asp Pro Ala Pro Ala Gly His Leu Asp Pro Arg
 485 490 495

Ser Ala Ala Arg Pro Asn Arg Arg Ala Ala Ala Thr Thr Gly Gln Gly
 500 505 510

Lys Ser Ser Glu Cys Phe Glu Cys Gly Lys Ile Phe Arg Thr Tyr His
 515 520 525

Gln Met Val Leu His Ser Arg Val His Arg Arg Ala Arg Arg Glu Arg
 530 535 540

Asp Ser Asp Gly Asp Arg Ala Ala Arg Ala Arg Cys Gly Ser Leu Ser
 545 550 555 560

Glu Gly Asp Ser Ala Ser Gln Pro Ser Ser Pro Gly Ser Ala Cys Ala
 565 570 575

Ala Ala Asp Ser Pro Gly Ser Gly Leu Ala Asp Glu Ala Ala Glu Asp
 580 585 590

Ser Gly Glu Glu Gly Ala Pro Glu Pro Ala Pro Gly Gly Gln Pro Arg
 595 600 605

Arg Cys Cys Phe Ser Glu Glu Val Thr Ser Thr Glu Leu Ser Ser Gly
 610 615 620

Asp Gln Ser His Lys Met Gly Asp Asn Ala Ser Glu Arg Asp Thr Gly
 625 630 635 640

Glu Ser Lys Ala Gly Ile Ala Ala Ser Val Ser Ile Leu Glu Asn Ser
 645 650 655

171

Ser Arg Glu Thr Ser Arg Arg Gln Glu Gln His Arg Phe Ser Met Asp
 660 665 670

Leu Lys Met Pro Ala Phe His Pro Lys Gln Glu Val Pro Val Pro Gly
 675 680 685

Asp Gly Val Glu Phe Pro Ser Ser Thr Gly Ala Glu Gly Gln Thr Gly
 690 695 700

His Pro Ala Glu Lys Leu Ser Asp Leu His Asn Lys Glu His Ser Gly
 705 710 715 720

Gly Gly Lys Arg Ala Leu Ala Pro Asp Leu Met Pro Leu Asp Leu Ser
 725 730 735

Ala Arg Ser Thr Arg Asp Asp Pro Ser Asn Lys Glu Thr Ala Ser Ser
 740 745 750

Leu Gln Ala Ala Leu Val Val His Pro Cys Pro Tyr Cys Ser His Lys
 755 760 765

Thr Tyr Tyr Pro Glu Val Leu Trp Met His Lys Arg Ile Trp His Arg
 770 775 780

Val Ser Cys Asn Ser Val Ala Pro Pro Trp Ile Gln Pro Asn Gly Tyr
 785 790 795 800

Lys Ser Ile Arg Ser Asn Leu Val Phe Leu Ser Arg Ser Gly Arg Thr
 805 810 815

Gly Pro Pro Pro Ala Leu Gly Gly Lys Glu Cys Gln Pro Leu Leu Leu
 820 825 830

Ala Arg Phe Thr Arg Thr Gln Val Pro Gly Gly Met Pro Gly Ser Lys
 835 840 845

Ser Gly Ser Ser Pro Leu Gly Val Val Thr Lys Ala Ala Ser Met Pro
 850 855 860

Lys Asn Lys Glu Ser His Ser Gly Gly Pro Cys Ala Leu Trp Ala Pro
 865 870 875 880

Gly Pro Asp Gly Tyr Arg Gln Thr Lys Pro Cys His Gly Gln Glu Pro
 885 890 895

172

His Gly Ala Ala Thr Gln Gly Pro Leu Ala Lys Pro Arg Gln Glu Ala
 900 905 910

Ser Ser Lys Pro Val Pro Ala Pro Gly Gly Gly Gly Phe Ser Arg Ser
 915 920 925

Ala Thr Pro Thr Pro Thr Val Ile Ala Arg Ala Gly Ala Gln Pro Ser
 930 935 940

Ala Asn Ser Lys Pro Val Glu Lys Phe Gly Val Pro Pro Ala Gly Ala
 945 950 955 960

Gly Phe Ala Pro Thr Asn Lys His Ser Ala Pro Asp Ser Leu Lys Ala
 965 970 975

Lys Phe Ser Ala Gln Pro Gln Gly Pro Pro Pro Ala Lys Gly Glu Gly
 980 985 990

Gly Ala Pro Pro Leu Pro Pro Arg Glu Pro Pro Ser Lys Ala Ala Gln
 995 1000 1005

Glu Leu Arg Thr Leu Ala Thr Cys Ala Ala Gly Ser Arg Gly Asp
 1010 1015 1020

Ala Ala Leu Gln Ala Gln Pro Gly Val Ala Gly Ala Pro Pro Val
 1025 1030 1035

Leu His Ser Ile Lys Gln Glu Pro Val Ala Glu Gly His Glu Lys
 1040 1045 1050

Arg Leu Asp Ile Leu Asn Ile Phe Lys Thr Tyr Ile Pro Lys Asp
 1055 1060 1065

Phe Ala Thr Leu Tyr Gln Gly Trp Gly Val Ser Gly Pro Gly Leu
 1070 1075 1080

Glu His Arg Gly Thr Leu Arg Thr Gln Ala Arg Pro Gly Glu Phe
 1085 1090 1095

Val Cys Ile Glu Cys Gly Lys Ser Phe His Gln Pro Gly His Leu
 1100 1105 1110

Arg Ala His Met Arg Ala His Ser Val Val Phe Glu Ser Asp Gly

173

1115

1120

1125

Pro Arg Gly Ser Glu Val His Thr Thr Ser Ala Asp Ala Pro Lys
 1130 1135 1140

Gln Gly Arg Asp His Ser Asn Thr Gly Thr Val Gln Thr Val Pro
 1145 1150 1155

Leu Arg Lys Gly Thr
 1160

<210> 236
 <211> 55
 <212> PRT
 <213> Homo sapien

<400> 236

Met Cys Val Phe Cys Gly Phe Phe Cys Ser Arg Phe Val Arg Glu Met
 1 5 10 15

Trp Gly Asn Phe Gly Pro Lys Thr Asn Phe Thr Pro Gly Thr Pro Phe
 20 25 30

Cys Pro Trp Leu Ser Pro Asn Leu Phe Cys Leu Val Val Val Trp Phe
 35 40 45

Tyr Arg Leu Leu Ile Phe Tyr
 50 55

<210> 237
 <211> 156
 <212> PRT
 <213> Homo sapien

<400> 237

Met Pro Met Glu Gly His Thr Leu Cys Met Arg Ile Arg Gly Ser Trp
 1 5 10 15

Leu Ala Ala Arg Leu Pro Val Met Pro Phe Glu Gly Asp Val Gly Pro
 20 25 30

Trp Val Arg Met Lys Val Phe Ile Cys His Ser Ser Ser Pro Gln Val
 35 40 45

Ala Ile His Leu Gly Gly Gly Arg Glu Gly Ser Ala Leu Ala Ile Val
 50 55 60

174

Tyr Pro Ala Ser Leu Arg Phe Ile Asp Leu His Lys Arg Leu Cys Ser
65 70 75 80

Gly Lys Gly Arg Gly Pro Gln Lys Gly Ala Trp Gln Asp Arg Trp Met
85 90 95

Leu Tyr Gly His Met Glu Ile Thr Pro Ser Ser Leu Ala Pro Ala Ser
100 105 110

Ala Ser Arg Pro Leu His Gly Val Arg Cys Phe Cys Ala Cys Cys Pro
115 120 125

Thr Ser Leu His Ser Arg Ala Leu Ile Asn His Phe Asp Pro Pro Leu
130 135 140

Ala Glu Gly Ser Pro Leu Tyr Arg Val Gln Ser Leu
145 150 155

<210> 238
<211> 86
<212> PRT
<213> Homo sapien

<400> 238

Met Met Asn Phe Leu Cys Leu Asn Phe Arg Asp Ile Trp Cys Asp Phe
1 5 10 15

His Leu Tyr Leu Met Leu Pro Leu Leu Pro Ser Leu Leu Asn Thr Ser
20 25 30

Lys Asn Ser Glu His Ile Leu Ile Pro Pro Val Phe Tyr Phe Tyr Asp
35 40 45

Leu Asp Ile Leu His His Lys Ile Pro Pro Asn Trp Asp Tyr Val Phe
50 55 60

Glu Val Ile His Phe Thr Ile Ile Thr Thr Ile Thr Ile Ile Phe Ile
65 70 75 80

Val Cys Phe Val Pro Gly
85

<210> 239
<211> 289

175

<212> PRT

<213> Homo sapien

<400> 239

Ala Asp Leu Ser Phe Ile Glu Asp Thr Val Ala Phe Pro Glu Lys Glu
 1 5 10 15

Glu Asp Glu Glu Glu Glu Glu Gly Val Glu Trp Gly Tyr Glu Glu
 20 25 30

Gly Val Glu Trp Gly Leu Val Phe Pro Asp Ala Asn Gly Glu Tyr Gln
 35 40 45

Ser Pro Ile Asn Leu Asn Ser Arg Glu Ala Arg Tyr Asp Pro Ser Leu
 50 55 60

Leu Asp Val Arg Leu Ser Pro Asn Tyr Val Val Cys Arg Asp Cys Glu
 65 70 75 80

Val Thr Asn Asp Gly His Thr Ile Gln Val Ile Leu Lys Ser Lys Ser
 85 90 95

Val Leu Ser Gly Gly Pro Leu Pro Gln Gly His Glu Phe Glu Leu Tyr
 100 105 110

Glu Val Arg Phe His Trp Gly Arg Glu Asn Gln Arg Gly Ser Glu His
 115 120 125

Thr Val Asn Phe Lys Ala Phe Pro Met Glu Leu His Leu Ile His Trp
 130 135 140

Asn Ser Thr Leu Phe Gly Ser Ile Asp Glu Ala Val Gly Lys Pro His
 145 150 155 160

Gly Ile Ala Ile Ile Ala Leu Phe Val Gln Ile Gly Lys Glu His Val
 165 170 175

Gly Leu Lys Ala Val Thr Glu Ile Leu Gln Asp Ile Gln Tyr Lys Gly
 180 185 190

Lys Ser Lys Thr Ile Pro Cys Phe Asn Pro Asn Thr Leu Leu Pro Asp
 195 200 205

Pro Leu Leu Arg Asp Tyr Trp Val Tyr Glu Gly Ser Leu Thr Ile Pro
 210 215 220

176

Pro Cys Ser Glu Gly Val Thr Trp Ile Leu Phe Arg Tyr Pro Leu Thr
 225 230 235 240

Ile Ser Gln Leu Gln Ile Glu Glu Phe Arg Arg Leu Arg Thr His Val
 245 250 255

Lys Gly Ala Glu Leu Val Glu Gly Cys Asp Gly Ile Leu Gly Asp Asn
 260 265 270

Phe Arg Pro Thr Gln Pro Leu Ser Asp Arg Val Ile Arg Ala Ala Phe
 275 280 285

Gln

<210> 240
 <211> 59
 <212> PRT
 <213> Homo sapien

<400> 240

Met Cys Gln Ile Asp Arg Gln Asp Leu Val Leu Leu Lys Leu Val Ile
 1 5 10 15

Tyr Cys Ser Arg His Leu Lys Gly Trp Arg Arg Ser Glu His Tyr Val
 20 25 30

Pro Ala Arg Ala Ser Ile Thr Leu Arg Arg Ser Thr Ser His Leu Val
 35 40 45

Ala Arg Ser Pro Asn Met Ser Ser Ser Gly Val
 50 55

<210> 241
 <211> 41
 <212> PRT
 <213> Homo sapien

<400> 241

Met Leu Leu Asn Gly Leu His Asn Pro Ala Leu Lys His Leu Arg Asp
 1 5 10 15

Leu Cys Lys Thr Phe Pro Trp Ser Leu Cys Phe Ser His Ile Asn Gln
 20 25 30

177

Leu Ala Tyr Phe Ser His Ser Pro Ser
 35 40

<210> 242
 <211> 80
 <212> PRT
 <213> Homo sapien

<400> 242

Met Asn Cys Leu Tyr Pro Ser Pro Met Cys Phe Tyr Arg Ser Cys Leu
 1 5 10 15

Val His Phe Val Ala Asp Leu Leu Gly Asp Phe Thr Glu Gly Lys Val
 20 25 30

Ser Ser Lys Leu Tyr Asp Asp Phe Met Leu Ile Asp Leu Leu Ser Ser
 35 40 45

Gly Ser Trp Glu Thr His Ser Ala Ile Ser Leu Leu Ser Tyr Phe Ser
 50 55 60

Tyr Asp Ala Gln Pro Pro Lys Ala Thr Arg Glu Gln Tyr Arg Val Pro
 65 70 75 80

<210> 243
 <211> 45
 <212> PRT
 <213> Homo sapien

<400> 243

Glu Arg Pro Gly Met Leu Asp Phe Thr Gly Lys Ala Lys Trp Asp Ala
 1 5 10 15

Trp Asn Glu Leu Lys Gly Thr Ser Lys Glu Asp Ala Met Lys Ala Tyr
 20 25 30

Ile Asn Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly Ile
 35 40 45

<210> 244
 <211> 24
 <212> PRT
 <213> Homo sapien

<400> 244

Met Cys Leu Asn Phe Ser Phe Asn Tyr Leu Ile Pro Phe Ala Gln Glu

178

1 5 10 15

Ile Thr Ile Ser Leu Phe Phe Phe
20

<210> 245
<211> 69
<212> PRT
<213> Homo sapien

<400> 245

Leu Phe Phe Gln Leu Phe Asp Thr Phe Cys Pro Arg Asp Tyr Tyr Leu
1 5 10 15

Ser Leu Phe Phe Phe Ser Phe Lys Thr Glu Cys Cys Ser Val Thr Gln
20 25 30

Val Gly Val Gln Trp His Asn Ser Ala Ser Leu Gln Pro Leu Pro Pro
35 40 45

Arg Leu Lys Arg Ser Ser His Leu Ser Leu Pro Ser Ser Trp Asp His
50 55 60

Arg His Ile Pro Pro
65

<210> 246
<211> 39
<212> PRT
<213> Homo sapien

<400> 246

Met Glu Thr Lys His His Ser His Lys Lys Ser Asn Ser Ile Leu Asn
1 5 10 15

His Trp Lys Val Thr Ile Pro Leu Tyr Ser Phe Pro Lys Leu Phe Val
20 25 30

Ala Lys Ser Tyr Arg Lys Glu
35

<210> 247
<211> 93
<212> PRT
<213> Homo sapien

<400> 247

179

Leu Leu Gln Ala Leu Lys Lys Ile Phe Phe Leu Asn Ser Leu Thr Leu
 1 5 10 15

Ser Pro Arg Leu Glu Ala Ser Asn Val Ile Ser Ala His Cys Asn Leu
 20 25 30

His Ser Arg Val Ala Gly Ile Thr Asp Met His His His Pro Gln Leu
 35 40 45

Ile Phe Val Phe Leu Val Glu Thr Gly Phe Arg His Val Gly Gln Ala
 50 55 60

Gly Leu Ala Leu Leu Ala Leu Arg Asp Pro Pro Pro Leu Ala Phe Gln
 65 70 75 80

Ser Ala Gly Ile Thr Gly Val Ser His Cys Thr Trp Pro
 85 90

<210> 248
 <211> 51
 <212> PRT
 <213> Homo sapien

<400> 248

Met Phe Phe Phe Phe Val Phe Phe Phe Phe Leu Phe Ala Arg Phe Ser
 1 5 10 15

Arg Asn Val Gly Asp Leu Trp Ala Gly Lys Pro Phe Pro Pro Gly His
 20 25 30

Val Leu Pro Arg Tyr Pro His Leu Phe Phe Phe Phe Phe Phe Cys
 35 40 45

Phe Ile Thr
 50

<210> 249
 <211> 62
 <212> PRT
 <213> Homo sapien

<400> 249

Met Asn Phe Thr Leu Ala Ile Phe His Tyr Phe Ser Leu Ser Gln Met
 1 5 10 15

180

Ser Val Leu Met Arg Gln Leu Ala Leu Thr Gly Ala Thr Leu Met Cys
 20 25 30

His Leu Pro Thr Phe Asn Phe Trp Val Lys Ala Glu Arg Glu Lys Leu
 35 40 45

Met Asp Phe Ser Phe Ser Arg Arg Asp Lys Asn Gln Leu His
 50 55 60

<210> 250
 <211> 190
 <212> PRT
 <213> Homo sapien

<400> 250

Met Lys Leu Gln Leu Arg Ile Lys Ser Leu Thr Gln Asn Arg Thr Thr
 1 5 10 15

Thr Trp Lys Leu Asn Asn Leu Leu Leu Asn Asp Tyr Trp Val Asn Lys
 20 25 30

Lys Ile Lys Ala Glu Ile Asn Lys Phe Phe Glu Thr Ile Glu Asn Lys
 35 40 45

Asp Thr Met Tyr Gln Asn Thr Ala Lys Ala Val Phe Arg Gly Lys Phe
 50 55 60

Ile Ala Leu Asn Thr His Ile Arg Asn Trp Glu Ile Pro Lys Ile Asn
 65 70 75 80

Val Leu Thr Ser Gln Leu Lys Glu Leu Glu Lys Arg Glu Gln Thr His
 85 90 95

Ser Lys Gln Glu Ile Thr Lys Ile Ile Ala Glu Leu Lys Glu Ile Glu
 100 105 110

Thr Gln Lys Ala Leu Gln Lys Ile Ser Asp Ser Arg Ser Trp Phe Phe
 115 120 125

Glu Lys Ile Asn Lys Thr Asp Arg Leu Leu Ala Arg Ile Ile Lys Lys
 130 135 140

Lys Arg Glu Lys Asn Gln Ile Asp Thr Ile Lys Asn Asp Lys Gly Asp
 145 150 155 160

181

Ile Thr Thr Asn Pro Thr Glu Ile Gln Thr Ala Ile Arg Glu Cys Tyr
 165 170 175

Gln His Leu Tyr Ile Asn Lys Leu Glu Asn Leu Glu Glu Ile
 180 185 190

<210> 251
 <211> 132
 <212> PRT
 <213> Homo sapien

<400> 251

Met Pro Val Leu Ser Pro Pro Leu His Met Pro Tyr Pro Ala Ala Lys
 1 5 10 15

Leu Asp Ser Val Leu Pro Asp Lys Thr Trp Tyr Trp His Leu Tyr Ala
 20 25 30

Ser Val Cys Leu Pro Ser Thr Phe Lys Lys Pro Leu Gln Ser Ala Asp
 35 40 45

Thr Lys Lys Gln Ser His Thr Cys Ser Lys Ser Ala Cys Phe Pro Leu
 50 55 60

Ile Ser Ala Ser Cys Gln Arg His Cys Leu Thr Ser Ser Ser Leu Leu
 65 70 75 80

Ser Ile Cys Val Pro His Lys Thr Leu Arg Asp Ser Ala Ser Tyr Val
 85 90 95

Tyr Gly Leu Trp Val Phe Ile Ser Thr Val Pro Cys Leu Thr Leu Ser
 100 105 110

Pro Cys Gly Glu Tyr Thr His Pro Thr Pro Thr Val Pro Cys Thr Ser
 115 120 125

Val Ala Ala Gln
 130

<210> 252
 <211> 30
 <212> PRT
 <213> Homo sapien

<400> 252

Met Gln Phe Arg Ile His Ala Ser Phe Ser Val Lys Trp Arg Ser Tyr

182

1 5 10 15

Ser Phe Asn Ser Glu Asn Ser Gln Leu Asn Lys Gln Pro Leu
20 25 30

<210> 253

<211> 49

<212> PRT

<213> Homo sapien

<400> 253

Met Arg Val Val ~~Trp~~ Gly ~~Trp~~ Arg Cys Gly Cys Val Gly Val Leu Val
1 5 10 15

Leu Val Val Gly Gly Cys Val Glu Trp Ala Val Val Phe Gly Val Cys
20 25 30

Val Gly Cys Val Val Trp Val Gly Arg Trp Trp Cys Asp Val Val Val
35 40 45

Trp

<210> 254

<211> 54

<212> PRT

<213> Homo sapien

<400> 254

Met Lys Lys Ser Val Ser Cys Cys Ser Ser Leu Trp Val Ser Leu Ser
1 5 10 15

Lys Asp Glu Asn Ala Glu Val Gly Arg Gly Asp Ser Leu Leu Gly Thr
20 25 30

Gly Arg Cys Gly Leu Pro Ile Thr Arg Leu Lys Leu Thr Ser Leu Pro
35 40 45

Ser Ser Pro Thr Val Val
50

<210> 255

<211> 1088

<212> PRT

<213> Homo sapien

<400> 255

183

Asp Asp Ser Leu Ile Ser Ser Ala Thr Ala Ile Met Glu Ala Val Val
 1 5 10 15

Arg Glu Trp Ile Leu Leu Glu Lys Gly Ser Ile Glu Ser Leu Arg Thr
 20 25 30

Phe Leu Leu Thr Tyr Val Leu Gln Arg Pro Asn Leu Gln Lys Tyr Val
 35 40 45

Arg Glu Gln Ile Leu Leu Ala Val Ala Val Ile Val Lys Arg Gly Ser
 50 55 60

Leu Asp Lys Ser Ile Asp Cys Lys Ser Ile Phe His Glu Val Ser Gln
 65 70 75 80

Leu Ile Ser Ser Gly Asn Pro Thr Val Gln Thr Leu Ala Cys Ser Ile
 85 90 95

Leu Thr Ala Leu Leu Ser Glu Phe Ser Ser Ser Lys Thr Ser Asn
 100 105 110

Ile Gly Leu Ser Met Glu Phe His Gly Asn Cys Lys Arg Val Phe Gln
 115 120 125

Glu Glu Asp Leu Arg Gln Ile Phe Met Leu Thr Val Glu Val Leu Gln
 130 135 140

Glu Phe Ser Arg Arg Glu Asn Leu Asn Ala Gln Met Ser Ser Val Phe
 145 150 155 160

Gln Arg Tyr Leu Ala Leu Ala Asn Gln Val Leu Ser Trp Asn Phe Leu
 165 170 175

Pro Pro Asn Leu Gly Arg His Tyr Ile Ala Met Phe Glu Ser Ser Gln
 180 185 190

Asn Val Leu Leu Lys Pro Thr Glu Ser Leu Arg Glu Thr Leu Leu Asp
 195 200 205

Ser Arg Val Met Glu Leu Phe Phe Thr Val His Arg Lys Ile Arg Glu
 210 215 220

His Ser Asp Met Ala Gln Asp Ser Leu Gln Cys Leu Ala Gln Leu Ala
 225 230 235 240

184

Ser Leu His Gly Pro Ile Phe Pro Asp Glu Gly Ser Gln Val Asp Tyr
 245 250 255

Leu Ala His Phe Ile Glu Gly Leu Leu Asn Thr Ile Asn Gly Ile Glu
 260 265 270

Ile Glu Asp Ser Glu Ala Val Gly Ile Ser Ser Ile Ile Ser Asn Leu
 275 280 285

Ile Thr Val Phe Pro Arg Asn Val Leu Thr Ala Ile Pro Ser Glu Leu
 290 295 300

Phe Ser Ser Phe Val Asn Cys Leu Thr His Leu Thr Cys Ser Phe Gly
 305 310 315 320

Arg Ser Ala Ala Leu Glu Glu Val Leu Asp Lys Asp Asp Met Val Tyr
 325 330 335

Met Glu Ala Tyr Asp Lys Leu Leu Glu Ser Trp Leu Thr Leu Val Gln
 340 345 350

Asp Asp Lys His Phe His Lys Gly Phe Phe Thr Gln His Ala Val Gln
 355 360 365

Val Phe Asn Ser Tyr Ile Gln Cys His Leu Ala Ala Pro Asp Gly Thr
 370 375 380

Arg Asn Leu Thr Ala Asn Gly Val Ala Ser Arg Glu Glu Glu Glu Ile
 385 390 395 400

Ser Glu Leu Gln Glu Asp Asp Arg Asp Gln Phe Ser Asp Gln Leu Ala
 405 410 415

Ser Val Gly Met Leu Gly Arg Ile Ala Ala Glu His Cys Ile Pro Leu
 420 425 430

Leu Thr Ser Leu Leu Glu Glu Arg Val Thr Arg Leu His Gly Gln Leu
 435 440 445

Gln Arg His Gln Gln Gln Leu Leu Ala Ser Pro Gly Ser Ser Thr Val
 450 455 460

Asp Asn Lys Met Leu Asp Asp Leu Tyr Glu Asp Ile His Trp Leu Ile

185

465		470		475		480
Leu Val Thr Gly Tyr Leu Leu Ala Asp Asp Thr Gln Gly Glu Thr Pro	485		490		495	
Leu Ile Pro Pro Glu Ile Met Glu Tyr Ser Ile Lys His Ser Ser Glu	500		505		510	
Val Asp Ile Asn Thr Thr Leu Gln Ile Leu Gly Ser Pro Gly Glu Lys	515		520		525	
Ala Ser Ser Ile Pro Gly Tyr Asn Arg Thr Asp Ser Val Ile Arg Leu	530		535		540	
Leu Ser Ala Ile Leu Arg Val Ser Glu Val Glu Ser Arg Ala Ile Arg	545		550		555	560
Ala Asp Leu Thr His Leu Leu Ser Pro Gln Met Gly Lys Asp Ile Val	565		570		575	
Trp Phe Leu Lys Arg Trp Ala Lys Thr Tyr Leu Leu Val Asp Glu Lys	580		585		590	
Leu Tyr Asp Gln Ile Ser Leu Pro Phe Ser Thr Ala Phe Gly Ala Asp	595		600		605	
Thr Glu Gly Ser Gln Trp Ile Ile Gly Tyr Leu Leu Gln Lys Val Ile	610		615		620	
Ser Asn Leu Ser Val Trp Ser Ser Glu Gln Asp Leu Ala Asn Asp Thr	625		630		635	640
Val Gln Leu Leu Val Thr Leu Val Glu Arg Arg Glu Arg Ala Asn Leu	645		650		655	
Val Ile Gln Cys Glu Asn Trp Trp Asn Leu Ala Lys Gln Phe Ala Ser	660		665		670	
Arg Ser Pro Pro Leu Asn Phe Leu Ser Ser Pro Val Gln Arg Thr Leu	675		680		685	
Met Lys Ala Leu Val Leu Gly Gly Phe Ala His Met Asp Thr Glu Thr	690		695		700	

186

Lys Gln Gln Tyr Trp Thr Glu Val Leu Gln Pro Leu Gln Gln Arg Phe
705 710 715 720

Leu Arg Val Ile Asn Gln Glu Asn Phe Gln Gln Met Cys Gln Gln Glu
725 730 735

Glu Val Lys Gln Glu Ile Thr Ala Thr Leu Glu Ala Leu Cys Gly Ile
740 745 750

Ala Glu Ala Thr Gln Ile Asp Asn Val Ala Ile Leu Phe Asn Phe Leu
755 760 765

Met Asp Phe Leu Thr Asn Cys Ile Gly Leu Met Glu Val Tyr Lys Asn
770 775 780

Thr Pro Glu Thr Val Asn Leu Ile Ile Glu Val Phe Val Glu Val Ala
785 790 795 800

His Lys Gln Ile Cys Tyr Leu Gly Glu Ser Lys Ala Met Asn Leu Tyr
805 810 815

Glu Ala Cys Leu Thr Leu Leu Gln Val Tyr Ser Lys Asn Asn Leu Gly
820 825 830

Arg Gln Arg Ile Asp Val Thr Ala Glu Glu Glu Gln Tyr Gln Asp Leu
835 840 845

Leu Leu Ile Met Glu Leu Leu Thr Asn Leu Leu Ser Lys Glu Phe Ile
850 855 860

Asp Phe Ser Asp Thr Asp Glu Val Phe Arg Gly His Glu Pro Gly Gln
865 870 875 880

Ala Ala Asn Arg Ser Val Ser Ala Ala Asp Val Val Leu Tyr Gly Val
885 890 895

Asn Leu Ile Leu Pro Leu Met Ser Gln Asp Leu Leu Lys Phe Pro Thr
900 905 910

Leu Cys Asn Gln Tyr Tyr Lys Leu Ile Thr Phe Ile Cys Glu Ile Phe
915 920 925

Pro Glu Lys Ile Pro Gln Leu Pro Glu Asp Leu Phe Lys Ser Leu Met
930 935 940

187

Tyr Ser Leu Glu Leu Gly Met Thr Ser Met Ser Ser Glu Val Cys Gln
 945 950 955 960

Leu Cys Leu Glu Ala Leu Thr Pro Leu Ala Glu Gln Cys Ala Lys Ala
 965 970 975

Gln Glu Thr Asp Ser Pro Leu Phe Leu Ala Thr Arg His Phe Leu Lys
 980 985 990

Leu Val Phe Asp Met Leu Val Leu Gln Lys His Asn Thr Glu Met Thr
 995 1000 1005

Thr Ala Ala Gly Glu Ala Phe Tyr Thr Leu Val Cys Leu His Gln
 1010 1015 1020

Ala Glu Tyr Ser Glu Leu Val Glu Thr Leu Leu Ser Ser Gln Gln
 1025 1030 1035

Asp Pro Val Ile Tyr Gln Arg Leu Ala Asp Ala Phe Asn Lys Leu
 1040 1045 1050

Thr Ala Ser Ser Thr Pro Pro Thr Leu Asp Arg Lys Gln Lys Met
 1055 1060 1065

Ala Phe Leu Lys Ser Leu Glu Glu Phe Met Ala Asn Val Gly Gly
 1070 1075 1080

Leu Leu Cys Val Lys
 1085

<210> 256
 <211> 78
 <212> PRT
 <213> Homo sapien

<400> 256

Met Val Leu Met Thr Ser Ser Gly Gln Pro Ser Cys Pro Gly Ile Met
 1 5 10 15

Ala Cys Gln His Ser Leu Cys Pro Pro Asn Leu Arg Pro Arg Met Arg
 20 25 30

Ser Cys Gln His Asn Ile His Pro Phe Glu Gln Met Glu Ser Gly Thr
 35 40 45

188

Leu Thr Gln Pro Ser Val Leu Asn Asn Thr Ala Ile Ile Ala Thr Trp
 50 55 60

Leu Ser Arg Gln Cys Lys Pro Ser Glu Ser Ala Glu Leu Phe
 65 70 75

<210> 257
 <211> 595
 <212> PRT
 <213> Homo sapien

<400> 257

Val Gln Lys Thr Asn Gln Cys Leu Gln Gly Gln Ser Leu Lys Thr Ser
 1 5 10 15

Leu Thr Leu Lys Val Asp Arg Gly Ser Glu Glu Thr Tyr Arg Pro Glu
 20 25 30

Phe Pro Ser Thr Lys Gly Leu Val Arg Ser Leu Ala Glu Gln Phe Gln
 35 40 45

Arg Met Gln Gly Val Ser Met Arg Asp Ser Thr Gly Phe Lys Asp Arg
 50 55 60

Ser Leu Ser Gly Ser Leu Arg Lys Asn Ser Ser Pro Ser Asp Ser Lys
 65 70 75 80

Pro Pro Phe Ser Gln Gly Gln Glu Lys Gly His Trp Pro Trp Ala Lys
 85 90 95

Gln Gln Ser Ser Leu Glu Gly Gly Asp Arg Pro Leu Ser Trp Glu Glu
 100 105 110

Ser Thr Glu His Ser Ser Leu Ala Leu Asn Ser Gly Leu Pro Asn Gly
 115 120 125

Glu Thr Ser Ser Gly Gly Gln Pro Arg Leu Ala Glu Pro Asp Ile Tyr
 130 135 140

Gln Glu Lys Leu Ser Gln Val Arg Asp Val Arg Ser Lys Asp Leu Gly
 145 150 155 160

Ser Ser Thr Asp Leu Gly Thr Ser Leu Pro Leu Asp Ser Trp Val Asn
 165 170 175

189

Ile Thr Arg Phe Cys Asp Ser Gln Leu Lys His Gly Ala Pro Arg Pro
 180 185 190

Gly Met Lys Ser Ser Pro His Asp Ser His Thr Cys Val Thr Tyr Pro
 195 200 205

Glu Arg Asn His Ile Leu Leu His Pro His Trp Asn Gln Asp Thr Glu
 210 215 220

Gln Glu Thr Ser Glu Leu Glu Ser Leu Tyr Gln Ala Ser Leu Gln Ala
 225 230 235 240

Ser Gln Ala Gly Cys Ser Gly Trp Gly Gln Gln Asp Thr Ala Trp His
 245 250 255

Pro Leu Ser Gln Thr Gly Ser Ala Asp Gly Met Gly Arg Arg Leu His
 260 265 270

Ser Ala His Asp Pro Gly Leu Ser Lys Thr Ser Thr Ala Glu Met Glu
 275 280 285

His Gly Leu His Glu Ala Arg Thr Val Arg Thr Ser Gln Ala Thr Pro
 290 295 300

Cys Arg Gly Leu Ser Arg Glu Cys Gly Glu Asp Glu Gln Tyr Ser Ala
 305 310 315 320

Glu Asn Leu Arg Arg Ile Ser Arg Ser Leu Ser Gly Thr Val Val Ser
 325 330 335

Glu Arg Glu Glu Ala Pro Val Ser Ser His Ser Phe Asp Ser Ser Asn
 340 345 350

Val Arg Lys Pro Leu Glu Thr Gly His Arg Cys Ser Ser Ser Ser
 355 360 365

Leu Pro Val Ile His Asp Pro Ser Val Phe Leu Leu Gly Pro Gln Leu
 370 375 380

Tyr Leu Pro Gln Pro Gln Phe Leu Ser Pro Asp Val Leu Met Pro Thr
 385 390 395 400

Met Ala Gly Glu Pro Asn Arg Leu Pro Gly Thr Ser Arg Ser Val Gln
 405 410 415

190

Gln Phe Leu Ala Met Cys Asp Arg Gly Glu Thr Ser Gln Gly Ala Lys
 420 425 430

Tyr Thr Gly Arg Thr Leu Asn Tyr Gln Ser Leu Pro His Arg Ser Arg
 435 440 445

Thr Asp Asn Ser Trp Ala Pro Trp Ser Glu Thr Asn Gln His Ile Gly
 450 455 460

Thr Arg Phe Leu Thr Thr Pro Gly Cys Asn Pro Gln Leu Thr Tyr Thr
 465 470 475 480

Ala Thr Leu Pro Glu Arg Ser Lys Gly Leu Gln Val Pro His Thr Gln
 485 490 495

Ser Trp Ser Asp Leu Phe His Ser Pro Ser His Pro Pro Ile Val His
 500 505 510

Pro Val Tyr Pro Pro Ser Ser Ser Leu His Val Pro Leu Arg Ser Ala
 515 520 525

Trp Asn Ser Asp Pro Val Pro Gly Ser Arg Thr Pro Gly Pro Arg Arg
 530 535 540

Val Asp Met Pro Pro Asp Asp Asp Trp Arg Gln Ser Ser Tyr Ala Ser
 545 550 555 560

His Ser Gly His Arg Arg Thr Val Gly Glu Gly Phe Leu Phe Val Leu
 565 570 575

Ser Asp Ala Pro Arg Arg Glu Gln Ile Arg Ala Arg Val Leu Gln His
 580 585 590

Ser Gln Trp
 595

<210> 258
 <211> 55
 <212> PRT
 <213> Homo sapien

<400> 258

Met Thr Val Met Ile Leu Leu Phe Lys Lys Asn Pro Asn Cys Tyr Phe
 1 5 10 15

191

Asp Leu Tyr Asp Leu Thr Leu Asn His Gly Ser Ile Thr Met Met Phe
 20 25 30

Lys Thr Leu Ile Asp Ser Thr Cys Phe Lys Asn Ser Gln Ile Pro Ser
 35 40 45

Ala Phe Ile Ile Arg Asp Arg
 50 55

<210> 259
 <211> 43
 <212> PRT
 <213> Homo sapien

<400> 259

Met Met Leu Thr Met Glu Phe Lys Asn Lys Gln Gln His Phe Val Val
 1 5 10 15

Ser Thr Gly Val Gly Val Glu Glu Leu Gln Arg His His Gly Asn Lys
 20 25 30

Ser Leu Pro Arg Ile Ser Gly Pro Arg Asn Leu
 35 40

<210> 260
 <211> 75
 <212> PRT
 <213> Homo sapien

<400> 260

Met Ala Tyr Arg Met Lys Arg Gly Thr Arg Asn Pro Cys Gly Arg Gly
 1 5 10 15

Leu Asp Leu Lys Gln Cys Pro Leu Trp Leu Leu Leu Pro Trp Leu Thr
 20 25 30

Gly Phe Leu Asp His Val His Phe Thr Gly Pro Trp Asp Leu His Leu
 35 40 45

Leu Ala Ser Pro Ala Gly Leu Ile Pro Ala Arg Ala Pro Ser Phe Leu
 50 55 60

Leu Met Val Phe Arg Trp Pro Asp His Gly Lys
 65 70 75

192

<210> 261
 <211> 218
 <212> PRT
 <213> Homo sapien

<400> 261

Met Ile Asn His Leu Ser Pro His Gln Ala Ala Ala Pro Val Asp Gln
 1 5 10 15

Thr Pro Arg Thr Leu Ala Thr Met Gly Gln Arg Ala Leu Pro Ser Ser
 20 25 30

Leu Ala Leu Leu Ser Arg Pro Leu Ser Pro Pro Pro Ala Ala Cys Ser
 35 40 45

Gly Asp Pro Gly Cys Gly Ser Gly Ala Gly Leu Pro Ser Ala Ser Ala
 50 55 60

Ala Ala Gly Ile Ala Ser Ser Ala Val Glu Ala Val Cys Gly Asp Ala
 65 70 75 80

Ala Pro Ala Cys Leu Leu Arg Thr Pro Leu Arg Gly Leu Leu Lys Pro
 85 90 95

Thr Gly Pro Arg Ser Thr Met Glu Cys Pro Pro Ala Leu Ile Val Gln
 100 105 110

Pro Pro Ala Gly Gly Met Ala Arg Arg Ala Ala Ser Gln Pro Trp Ala
 115 120 125

Ala Ala Ser Ala Thr Pro Met Leu Ser Ser Lys Ala Ser Leu Cys Ile
 130 135 140

Pro Thr Glu Arg Pro Pro Pro Gln Pro Leu Met Arg Thr Pro Ala Ala
 145 150 155 160

Arg Ser His Trp Pro Ile Pro His Pro Ala Ser Thr Ala Cys Pro Ala
 165 170 175

Pro Leu Pro Val Val Leu Val Ala Pro Arg Ser Thr Ile Leu Ser Met
 180 185 190

Ser Arg Thr Trp Thr Cys Arg Arg Trp Ala Val Ala Pro Cys Arg Ala
 195 200 205

193

Glu Lys Leu Met Cys Ser Ser Ser Arg Ser
 210 215

<210> 262
 <211> 104
 <212> PRT
 <213> Homo sapien
 <400> 262

Met Pro Ser Phe Phe Cys Phe Ser Ile Ser Leu Ile Arg Asp Trp Lys
 1 5 10 15

Val Ser Ile Arg Ser Asn Thr Asp Phe Ile Val Ile Gly Thr Asn Cys
 20 25 30

Ser Pro Thr Thr Pro Tyr Ser Ala Ser Ser Ile Thr Leu Leu Cys Glu
 35 40 45

Ile Leu Arg Asn Gly Leu Pro Leu Gln Gly Leu Asn Leu Pro Tyr Leu
 50 55 60

Arg Phe Glu Ser Ser Val Leu Phe Cys Ile Cys Phe Lys Tyr Leu Gly
 65 70 75 80

Ser Val Thr His Ala Asn Met Thr Cys Pro Val Gln Ala Thr Leu Gly
 85 90 95

Ile His Ile Ser His Val Ser Ser
 100

<210> 263
 <211> 260
 <212> PRT
 <213> Homo sapien
 <400> 263

Glu Lys Lys Lys Lys Met Lys Asn Glu Asn Ala Asp Lys Leu Leu Lys
 1 5 10 15

Ser Glu Lys Gln Met Lys Lys Ser Glu Lys Lys Ser Lys Gln Glu Lys
 20 25 30

Glu Lys Ser Lys Lys Lys Lys Gly Gly Lys Thr Glu Gln Asp Gly Tyr
 35 40 45

194

Gln Lys Pro Thr Asn Lys His Phe Thr Gln Ser Pro Lys Lys Ser Val
 50 55 60

Ala Asp Leu Leu Gly Ser Phe Glu Gly Lys Arg Arg Leu Leu Leu Ile
 65 70 75 80

Thr Ala Pro Lys Ala Glu Asn Asn Met Tyr Val Gln Gln Arg Asp Glu
 85 90 95

Tyr Leu Glu Ser Phe Cys Lys Met Ala Thr Arg Lys Ile Ser Val Ile
 100 105 110

Thr Ile Phe Gly Pro Val Asn Asn Ser Thr Met Lys Ile Asp His Phe
 115 120 125

Gln Leu Asp Asn Glu Lys Pro Met Arg Val Val Asp Asp Glu Asp Leu
 130 135 140

Val Asp Gln Arg Leu Ile Ser Glu Leu Arg Lys Glu Tyr Gly Met Thr
 145 150 155 160

Tyr Asn Asp Phe Phe Met Val Leu Thr Asp Val Asp Leu Arg Val Lys
 165 170 175

Gln Tyr Tyr Glu Val Pro Ile Thr Met Lys Ser Val Phe Asp Leu Ile
 180 185 190

Asp Thr Phe Gln Ser Arg Ile Lys Asp Met Glu Lys Gln Lys Lys Glu
 195 200 205

Gly Ile Val Cys Lys Glu Asp Lys Lys Gln Ser Leu Glu Asn Phe Leu
 210 215 220

Ser Arg Phe Arg Trp Arg Arg Arg Leu Leu Val Ile Ser Ala Pro Asn
 225 230 235 240

Asp Glu Asp Trp Ala Tyr Ser Gln Gln Leu Ser Ala Leu Ser Gly Gln
 245 250 255

Ala Cys Thr Leu
 260

<210> 264
 <211> 62
 <212> PRT

195

<213> Homo sapien

<400> 264

Met Ser Gly Phe Ile Tyr Val Leu Glu Lys Asp His Leu Lys Lys Ile
 1 5 10 15

Asn Thr Phe Ser Thr Thr Lys Lys Lys Lys Lys Lys Lys Lys Lys
 20 25 30

Arg Arg Gly Gly Glu Pro Gly Ala Gln Ser Gly Pro Arg Gly Ala Asn
 35 40 45

Trp Val Leu Pro Ala His Ile Pro Pro Lys Tyr Trp His Thr
 50 55 60

<210> 265

<211> 89

<212> PRT

<213> Homo sapien

<400> 265

Met Leu Gln Leu Asn Thr Arg Phe Tyr Phe Leu Ser Asn Cys Gly Phe
 1 5 10 15

Val Phe Ile Tyr His Pro Leu Phe Ile Pro Phe Leu Thr His Thr Leu
 20 25 30

Cys Arg Ala Ser Gly Ile Tyr Tyr Ser Thr Val Cys Leu Cys Lys Arg
 35 40 45

Leu Ser Val Leu Ala Ser Thr Tyr Glu Arg Met His Ala Lys Phe Cys
 50 55 60

Leu Ser Met Pro Gly Leu Ile Ser Leu Lys Gln Asn Asp Leu Arg Val
 65 70 75 80

Pro Ser Met Leu Phe Ile Leu Pro Asn
 85

<210> 266

<211> 38

<212> PRT

<213> Homo sapien

<400> 266

Met Thr Ser Arg Trp Leu Asn Phe Ser Cys Leu Trp Cys Phe Gly Pro

196

1 5 10 15

Asn Ser Thr Gly Gln His His Asp His Met Glu Thr Tyr Phe Trp Lys
 20 25 30

Gln Asn Phe Asn Phe Ile
 35

<210> 267
 <211> 111
 <212> PRT
 <213> Homo sapien

<400> 267

Asn Asp Leu Asp Arg Tyr Asn Pro Leu Ser Ser Gln Arg Leu Val Arg
 1 5 10 15

Asn Ala Leu Ala His Val Gly Ala Lys Glu Arg Glu Leu Ser Trp Ala
 20 25 30

His Ser Glu Ser Phe Ala Ala Leu Cys Arg Tyr Gly Lys Arg Glu Phe
 35 40 45

Lys Ile Gly Gly Glu Leu Arg Ile Gly Lys Gln Pro Tyr Arg Leu Gln
 50 55 60

Ile Gln Leu Ser Ala Gln Arg Ser His Thr Leu Glu Phe Gln Ser Leu
 65 70 75 80

Glu Asp Leu Ile Met Gly Glu Ala Thr Gln Arg Pro Arg Ser Gly Ala
 85 90 95

Arg Pro Val Leu Gln Glu Leu Ala Thr His Leu His Pro Ala Glu
 100 105 110

<210> 268
 <211> 60
 <212> PRT
 <213> Homo sapien

<400> 268

Met Val Asn Thr Val Leu Leu Ser Leu Lys Ile Ser Leu Phe Cys Pro
 1 5 10 15

His Gln Leu Phe Tyr Cys Ser Val Leu Arg Lys Pro Asn Ser Cys Val
 20 25 30

197

Phe Phe Pro Ser Leu Leu Ile Leu Ser Cys Val Pro Ser Gly Lys Cys
 35 40 45

His Tyr Phe Leu Asp Ile Leu Asn Leu Leu Phe Leu
 50 55 60

<210> 269
 <211> 72
 <212> PRT
 <213> Homo sapien

<400> 269

Met Cys Leu Cys Ile Leu Val Ser Lys Leu Arg Thr Ser Asp Glu Leu
 1 5 10 15

Pro Val Val Pro Ser Tyr Cys Arg Arg Leu Glu Val Arg Gly Ile Ser
 20 25 30

Ala Ser Thr Arg Glu Ala Glu Val Ala Ser Glu Pro Thr Ile Met Thr
 35 40 45

Ala Cys Thr Pro Ser Leu Ala Thr Val Arg Glu Leu Leu Ser Gln Ile
 50 55 60

Lys Arg Lys Gln Ser Leu Leu Ser
 65 70

<210> 270
 <211> 152
 <212> PRT
 <213> Homo sapien

<400> 270

Gly Ser Leu Gly Gly Glu Pro Gly Val Ser Cys Leu Lys Met His Ser
 1 5 10 15

Asp Ala Ala Ala Val Asn Phe Gln Leu Asn Ser His Leu Ser Thr Leu
 20 25 30

Ala Asn Ile His Lys Ile Tyr His Thr Leu Asn Lys Leu Asn Leu Thr
 35 40 45

Glu Asp Ile Gly Gln Asp Asp His Gln Thr Gly Ser Leu Arg Ser Cys
 50 55 60

198

Ser Ser Ser Asp Cys Phe Asn Lys Val Met Pro Pro Arg Lys Lys Arg
65 70 75 80

Arg Pro Ala Ser Gly Asp Asp Leu Ser Ala Lys Lys Ser Arg His Asp
85 90 95

Ser Met Tyr Arg Lys Tyr Asp Ser Thr Arg Ile Lys Thr Glu Glu Glu
100 105 110

Ala Phe Ser Ser Lys Arg Cys Leu Glu Trp Phe Tyr Glu Tyr Ala Gly
115 120 125

Thr Asp Asp Val Val Gly Pro Glu Gly Met Glu Lys Phe Cys Glu Asp
130 135 140

Ile Gly Val Glu Pro Glu Asn Val
145 150

<210> 271
<211> 52
<212> PRT
<213> Homo sapien

<400> 271

Met Glu Pro His Ile Met Lys Phe Asn Ser His Val Lys Thr Phe Cys
1 5 10 15

Ile Val Gly Cys Gln Lys Tyr Leu Pro Lys Leu Ser Phe Asp Leu Ser
20 25 30

Glu Trp Gly Trp Leu Leu Pro Ile Leu Gln Phe Val Ser Gln Ala Trp
35 40 45

Arg Asn Gln Ala
50

<210> 272
<211> 449
<212> PRT
<213> Homo sapien

<400> 272

Met Val Met Glu Lys Pro Ser Pro Leu Leu Val Gly Arg Glu Phe Val
1 5 10 15

199

Arg Gln Tyr Tyr Thr Leu Leu Asn Lys Ala Pro Glu Tyr Leu His Arg
20 25 30

Phe Tyr Gly Arg Asn Ser Ser Tyr Val His Gly Gly Val Asp Ala Ser
35 40 45

Gly Lys Pro Gln Glu Ala Val Tyr Gly Gln Asn Asp Ile His His Lys
50 55 60

Val Leu Ser Leu Asn Phe Ser Glu Cys His Thr Lys Ile Arg His Val
65 70 75 80

Asp Ala His Ala Thr Leu Ser Asp Gly Val Val Val Gln Val Met Gly
85 90 95

Leu Leu Ser Asn Ser Gly Gln Pro Glu Arg Lys Phe Met Gln Thr Phe
100 105 110

Val Leu Ala Pro Glu Gly Ser Val Pro Asn Lys Phe Tyr Val His Asn
115 120 125

Asp Met Phe Arg Tyr Glu Asp Glu Val Phe Gly Asp Ser Glu Pro Glu
130 135 140

Leu Asp Glu Glu Ser Glu Asp Glu Val Glu Glu Glu Gln Glu Glu Arg
145 150 155 160

Gln Pro Ser Pro Glu Pro Val Gln Glu Asn Ala Asn Ser Gly Tyr Tyr
165 170 175

Glu Ala His Pro Val Thr Asn Gly Ile Glu Glu Pro Leu Glu Glu Ser
180 185 190

Ser His Glu Pro Glu Pro Glu Pro Glu Ser Glu Thr Lys Thr Glu Glu
195 200 205

Leu Lys Pro Gln Val Glu Glu Lys Asn Leu Glu Glu Leu Glu Glu Lys
210 215 220

Ser Thr Thr Pro Pro Pro Ala Glu Pro Val Ser Leu Pro Gln Glu Pro
225 230 235 240

Pro Lys Pro Arg Val Glu Ala Lys Pro Glu Val Gln Ser Gln Pro Pro
245 250 255

200

Arg Val Arg Glu Gln Arg Pro Arg Glu Arg Pro Gly Phe Pro Pro Arg
 260 265 270

Gly Pro Arg Pro Gly Arg Gly Asp Met Glu Gln Asn Asp Ser Asp Asn
 275 280 285

Arg Arg Ile Ile Arg Tyr Pro Asp Ser His Gln Leu Phe Val Gly Asn
 290 295 300

Leu Pro His Asp Ile Asp Glu Asn Glu Leu Lys Glu Phe Phe Met Ser
 305 310 315 320

Phe Gly Asn Val Val Glu Leu Arg Ile Asn Thr Lys Gly Val Gly Gly
 325 330 335

Lys Leu Pro Asn Phe Gly Phe Val Val Phe Asp Asp Ser Glu Pro Val
 340 345 350

Gln Arg Ile Leu Ile Ala Lys Pro Ile Met Phe Arg Gly Glu Val Arg
 355 360 365

Leu Asn Val Glu Glu Lys Lys Thr Arg Ala Ala Arg Glu Arg Glu Thr
 370 375 380

Arg Gly Gly Gly Asp Asp Arg Arg Asp Ile Arg Arg Asn Asp Arg Gly
 385 390 395 400

Pro Gly Gly Pro Arg Gly Ile Val Gly Gly Gly Met Met Arg Asp Arg
 405 410 415

Asp Gly Arg Gly Pro Pro Pro Arg Gly Gly Met Ala Gln Lys Leu Gly
 420 425 430

Ser Gly Arg Gly Thr Gly Gln Met Glu Gly Arg Phe Thr Gly Gln Arg
 435 440 445

Arg

<210> 273
 <211> 63
 <212> PRT
 <213> Homo sapien
 <400> 273

201

Met Cys Cys Asp Val Ser Glu Arg Ala Glu Phe Arg Leu Val Ser Ala
 1 5 10 15

Arg Cys Ser Phe Ser His Pro Arg Thr Val Ala Arg Leu Leu Leu Arg
 20 25 30

His Pro Gly Gln Leu Pro Leu Pro Phe Gln Trp Gly Leu Thr Trp Leu
 35 40 45

Pro Ser Leu Ala Ala Asn Arg Arg Ala Pro Gln His Ser Arg Ser
 50 55 60

<210> 274
 <211> 60
 <212> PRT
 <213> Homo sapien
 <400> 274

Met Asp Pro Gly Arg Tyr Cys Leu Val Leu Gln Glu Leu Met Gln Phe
 1 5 10 15

His Ser Glu Ala Cys Lys Ile Leu Asn Phe Arg Asp Asn Arg Pro Asp
 20 25 30

Thr Phe Leu Ile Ser Phe Tyr Ser Leu Met Ser Asn Asn Thr Ile Phe
 35 40 45

Lys Asn Met Val Leu Ile Cys Leu Ala Ser Asn Leu
 50 55 60

<210> 275
 <211> 111
 <212> PRT
 <213> Homo sapien
 <400> 275

Lys Leu Ile Val Tyr Pro Pro Pro Pro Ala Lys Gly Gly Ile Ser Val
 1 5 10 15

Thr Asn Glu Asp Leu His Cys Leu Asn Glu Gly Glu Phe Leu Asn Asp
 20 25 30

Val Ile Ile Asp Phe Tyr Leu Lys Tyr Leu Val Leu Glu Lys Leu Lys
 35 40 45

202

Lys Glu Asp Ala Asp Arg Ile His Ile Phe Ser Ser Phe Phe Tyr Lys
 50 55 60

Arg Leu Asn Gln Arg Glu Arg Arg Asn His Glu Thr Thr Asn Leu Ser
 65 70 75 80

Ile Gln Gln Lys Arg His Gly Arg Val Lys Thr Trp Thr Arg His Val
 85 90 95

Asp Ile Phe Glu Lys Asp Phe Ile Phe Val Pro Leu Asn Glu Ala
 100 105 110

<210> 276
 <211> 97
 <212> PRT
 <213> Homo sapien

<400> 276

Met Ser Gln Asp Thr Ser Arg Ser Gln Glu Arg Ala Ala Gly Pro Gln
 1 5 10 15

Arg Thr Arg Arg Arg Pro Arg Thr Trp Ser Gly Gly Val Glu Pro Thr
 20 25 30

Ala Ala Ala Pro Trp Ala Ala Ala Met Ala His Thr Gly Arg His Gly
 35 40 45

Ser Gly Ala Ala Ala Thr Ala Ser Ser Thr Arg Gly Asp Gly Ala Ala
 50 55 60

Arg Arg Gly Ala Ala Arg Gly Thr Asp Ala Ala Glu Arg Arg Arg Ala
 65 70 75 80

Ala Ser Arg Gly Ala Ala Glu Pro Lys Ala Thr Ala Ser Gly Gly Gly
 85 90 95

Gly

<210> 277
 <211> 76
 <212> PRT
 <213> Homo sapien

<400> 277

Met Gly Ser Cys Pro Leu Trp Val Arg Ser Ser Thr Cys Arg Val Glu

203

1 5 10 15
 Val Gly Tyr Val His Thr Phe Asn Asp Asn Leu His Ile Ser Ala Pro
 20 25 30
 Thr Gly Pro Lys Leu Phe Leu Gly Phe Lys Val Val Val Cys Leu Phe
 35 40 45
 Phe Ser Phe Phe Phe Phe Phe Phe Phe Gly Glu Val Glu Phe Gly
 50 55 60
 Ser Gly Trp Pro Arg Cys Gly Val Cys Lys Gly Arg
 65 70 75

<210> 278
 <211> 20
 <212> PRT
 <213> Homo sapien

<400> 278

Met Glu Asp Gln Ile Ile Leu Asn Tyr Ile Ser Ile Val Pro Gly Lys
 1 5 10 15

Thr Gln Val Leu
 20

<210> 279
 <211> 24
 <212> PRT
 <213> Homo sapien

<400> 279

Met Val His Leu Met His Ala Arg Ala Arg Ala Ser Cys Asp Gly Cys
 1 5 10 15

Val Val Ala Ala Glu Val His Val
 20

<210> 280
 <211> 101
 <212> PRT
 <213> Homo sapien

<400> 280

Leu Phe Phe Phe Lys Lys Phe Ile Leu Arg Trp Ser Leu Thr Leu Ser
 1 5 10 15

204

Leu Arg Leu Glu Cys Ser Asp Ser Ile Ser Ala His Cys Asn Leu Arg
 20 25 30

Leu Pro Gly Leu Ser Asn Phe Cys Ala Ser Ala Ser Gln Val Ser Glu
 35 40 45

Ile Thr Gly Val Cys His His Thr Gln Leu Phe Phe Ile Phe Tyr Phe
 50 55 60

Ala Ala Lys Met Gly Phe Arg His Val Gly Arg Thr Gly Leu Glu Leu
 65 70 75 80

Leu Ala Ser Ser Gly Pro Pro Thr Ser Ala Ser Gln Ser Ala Gly Ile
 85 90 95

Thr Gly Val Ser His
 100

<210> 281
 <211> 43
 <212> PRT
 <213> Homo sapien

<400> 281

Met Trp Gly His Gly Leu Asp Asp Gly Leu His Arg Ser Phe His Leu
 1 5 10 15

Cys Glu Ser Lys Ser Gly Gln Ser Ala Arg Thr Gln Ser Leu Thr Leu
 20 25 30

Gly Gln Leu Leu Arg Thr Asn Pro Gln His Leu
 35 40

<210> 282
 <211> 46
 <212> PRT
 <213> Homo sapien

<400> 282

Met Ala Gly Asn Ile His Pro Gly Thr Phe Gly Pro Gly Ser Pro His
 1 5 10 15

Leu Phe Phe Leu Cys Gly Val Val Ala Phe Phe Leu Phe Ile Val Ala
 20 25 30

205

Arg Glu Ala Lys Ile Tyr Ser Phe Ser Met Asn Pro Asn Met
 35 40 45

<210> 283
 <211> 70
 <212> PRT
 <213> Homo sapien

<400> 283

Met Pro Gly Ser His Leu Cys Met Phe Asn Thr Val Thr His Asp Val
 1 5 10 15

Ile Thr Glu Trp Arg Arg Trp Lys Gly Pro Cys Arg Ser Phe Ser Trp
 20 25 30

His Pro Asn Phe Thr Glu Gly Glu Leu Arg Pro Glu Leu Arg Asp Val
 35 40 45

Leu Arg Ile Pro Glu Ser His Ser Ser Val Arg Ser Val Ile His Lys
 50 55 60

Glu Val Ile Ile Lys Val
 65 70

<210> 284
 <211> 49
 <212> PRT
 <213> Homo sapien

<400> 284

Met Ser Ser Ser Leu Phe Ala Phe Leu Leu Thr Tyr Phe Val Val Phe
 1 5 10 15

Lys Asp Cys Ala Gly Asp Ile Leu Glu Gly Ile Asn Gly Leu His Ser
 20 25 30

Lys Arg Cys Gly Leu Ser Lys Leu Phe Ser Val Phe Ile Thr Glu Thr
 35 40 45

Asp

<210> 285
 <211> 1544
 <212> PRT
 <213> Homo sapien

206

<400> 285

```

Met Tyr Ala Ala Val Glu His Gly Pro Val Leu Cys Ser Asp Ser Asn
1          5          10          15

Ile Leu Cys Leu Ser Trp Lys Gly Arg Val Pro Lys Ser Glu Lys Glu
          20          25          30

Lys Pro Val Cys Arg Arg Arg Tyr Tyr Glu Glu Gly Trp Leu Ala Thr
          35          40          45

Gly Asn Gly Arg Gly Val Val Gly Val Thr Phe Thr Ser Ser His Cys
          50          55          60

Arg Arg Asp Arg Ser Thr Pro Gln Arg Ile Asn Phe Asn Leu Arg Gly
65          70          75          80

His Asn Ser Glu Val Val Leu Val Arg Trp Asn Glu Pro Tyr Gln Lys
          85          90          95

Leu Ala Thr Cys Asp Ala Asp Gly Gly Ile Phe Val Trp Ile Gln Tyr
          100          105          110

Glu Gly Arg Trp Ser Val Glu Leu Val Asn Asp Arg Gly Ala Gln Val
          115          120          125

Ser Asp Phe Thr Trp Ser His Asp Gly Thr Gln Ala Leu Ile Ser Tyr
          130          135          140

Arg Asp Gly Phe Val Leu Val Gly Ser Val Ser Gly Gln Arg His Trp
145          150          155          160

Ser Ser Glu Ile Asn Leu Glu Ser Gln Ile Thr Cys Gly Ile Trp Thr
          165          170          175

Pro Asp Asp Gln Gln Val Leu Phe Gly Thr Ala Asp Gly Gln Val Ile
          180          185          190

Val Met Asp Cys His Gly Arg Met Leu Ala His Val Leu Leu His Glu
          195          200          205

Ser Asp Gly Val Leu Gly Met Ser Trp Asn Tyr Pro Ile Phe Leu Val
          210          215          220

Glu Asp Ser Ser Glu Ser Asp Thr Asp Ser Asp Asp Tyr Ala Pro Pro

```

207

225		230		235		240
Gln Asp Gly Pro	Ala Ala Tyr Pro	Ile Pro Val	Gln Asn Ile	Lys Pro		
	245	250	255			
Leu Leu Thr Val	Ser Phe Thr Ser	Gly Asp Ile	Ser Leu Met	Asn Asn		
	260	265	270			
Tyr Asp Asp Leu	Ser Pro Thr Val	Ile Arg Ser	Gly Leu Lys	Glu Val		
	275	280	285			
Val Ala Gln Trp	Cys Thr Gln Gly	Asp Leu Leu	Ala Val Ala	Gly Met		
	290	295	300			
Glu Arg Gln Thr	Gln Leu Gly Glu	Leu Pro Asn	Gly Pro Leu	Leu Lys		
	305	310	315	320		
Ser Ala Met Val	Lys Phe Tyr Asn	Val Arg Gly	Glu His Ile	Phe Thr		
	325	330	335			
Leu Asp Thr Leu	Val Gln Arg Pro	Ile Ile Ser	Ile Cys Trp	Gly His		
	340	345	350			
Arg Asp Ser Arg	Leu Leu Met Ala	Ser Gly Pro	Ala Leu Tyr	Val Val		
	355	360	365			
Arg Val Glu His	Arg Val Ser Ser	Leu Gln Leu	Leu Cys Gln	Gln Ala		
	370	375	380			
Ile Ala Ser Thr	Leu Arg Glu Asp	Lys Asp Val	Ser Lys Leu	Thr Leu		
	385	390	395	400		
Pro Pro Arg Leu	Cys Ser Tyr Leu	Ser Thr Ala	Phe Ile Pro	Thr Ile		
	405	410	415			
Lys Pro Pro Ile	Pro Asp Pro Asn	Asn Met Arg	Asp Phe Val	Ser Tyr		
	420	425	430			
Pro Ser Ala Gly	Asn Glu Arg Leu	His Cys Thr	Met Lys Arg	Thr Glu		
	435	440	445			
Asp Asp Pro Glu	Val Gly Gly Pro	Cys Tyr Thr	Leu Tyr Leu	Glu Tyr		
	450	455	460			

208

Leu Gly Gly Leu Val Pro Ile Leu Lys Gly Arg Arg Ile Ser Lys Leu
 465 470 475 480

Arg Pro Glu Phe Val Ile Met Asp Pro Arg Thr Asp Ser Lys Pro Asp
 485 490 495

Glu Ile Tyr Gly Asn Ser Leu Ile Ser Thr Val Ile Asp Ser Cys Asn
 500 505 510

Cys Ser Asp Ser Ser Asp Ile Glu Leu Ser Asp Asp Trp Ala Ala Lys
 515 520 525

Lys Ser Pro Lys Ile Ser Arg Ala Ser Lys Ser Pro Lys Leu Pro Arg
 530 535 540

Ile Ser Ile Glu Ala Arg Lys Ser Pro Lys Leu Pro Arg Ala Ala Gln
 545 550 555 560

Glu Leu Ser Arg Ser Pro Arg Leu Pro Leu Arg Lys Pro Ser Val Gly
 565 570 575

Ser Pro Ser Leu Thr Arg Arg Glu Phe Pro Phe Glu Asp Ile Thr Gln
 580 585 590

His Asn Tyr Leu Ala Gln Val Thr Ser Asn Ile Trp Gly Thr Lys Phe
 595 600 605

Lys Ile Val Gly Leu Ala Ala Phe Leu Pro Thr Asn Leu Gly Ala Val
 610 615 620

Ile Tyr Lys Thr Ser Leu Leu His Leu Gln Pro Arg Gln Met Thr Ile
 625 630 635 640

Tyr Leu Pro Glu Val Arg Lys Ile Ser Met Asp Tyr Ile Asn Leu Pro
 645 650 655

Val Phe Asn Pro Asn Val Phe Ser Glu Asp Glu Asp Asp Leu Pro Val
 660 665 670

Thr Gly Ala Ser Gly Val Pro Glu Asn Ser Pro Pro Cys Thr Val Asn
 675 680 685

Ile Pro Ile Ala Pro Ile His Ser Ser Ala Gln Ala Met Ser Pro Thr
 690 695 700

209

Gln Ser Ile Gly Leu Val Gln Ser Leu Leu Ala Asn Gln Asn Val Gln
 705 710 715 720

Leu Asp Val Leu Thr Asn Gln Thr Thr Ala Val Gly Thr Ala Glu His
 725 730 735

Ala Gly Asp Arg Cys His Pro Val Thr Gln Val Ser Asn Arg Tyr Ser
 740 745 750

Asn Pro Gly Gln Val Ile Phe Gly Ser Val Glu Met Gly Arg Ile Ile
 755 760 765

Gln Asn Pro Pro Pro Leu Ser Leu Pro Pro Pro Pro Gln Gly Pro Met
 770 775 780

Gln Leu Ser Thr Val Gly His Gly Asp Arg Asp His Glu His Leu Gln
 785 790 795 800

Lys Ser Ala Lys Ala Leu Arg Pro Thr Pro Gln Leu Ala Ala Glu Gly
 805 810 815

Asp Ala Val Val Phe Ser Ala Pro Gln Glu Val Gln Val Thr Lys Ile
 820 825 830

Asn Pro Pro Pro Pro Tyr Pro Gly Thr Ile Pro Ala Ala Pro Thr Thr
 835 840 845

Ala Ala Pro Pro Pro Pro Leu Pro Pro Pro Gln Pro Pro Val Asp Val
 850 855 860

Cys Leu Lys Lys Gly Asp Phe Ser Leu Tyr Pro Thr Ser Val His Tyr
 865 870 875 880

Gln Thr Pro Leu Gly Tyr Glu Arg Ile Thr Thr Phe Asp Ser Ser Gly
 885 890 895

Asn Val Glu Glu Val Cys Arg Pro Arg Thr Arg Met Leu Cys Ser Gln
 900 905 910

Asn Thr Tyr Thr Leu Pro Gly Pro Gly Ser Ser Ala Thr Leu Arg Leu
 915 920 925

Thr Ala Thr Glu Lys Lys Val Pro Gln Pro Cys Ser Ser Ala Thr Leu
 930 935 940

210

Asn Arg Leu Thr Val Pro Arg Tyr Ser Ile Pro Thr Gly Asp Pro Pro
 945 950 955 960

Pro Tyr Pro Glu Ile Ala Ser Gln Leu Ala Gln Gly Arg Gly Ala Ala
 965 970 975

Gln Arg Ser Asp Asn Ser Leu Ile His Ala Thr Leu Arg Arg Asn Asn
 980 985 990

Arg Glu Ala Thr Leu Lys Met Ala Gln Leu Ala Asp Ser Pro Arg Ala
 995 1000 1005

Pro Leu Gln Pro Leu Ala Lys Ser Lys Gly Gly Pro Gly Gly Val
 1010 1015 1020

Val Thr Gln Leu Pro Ala Arg Pro Pro Pro Ala Leu Tyr Thr Cys
 1025 1030 1035

Ser Gln Cys Ser Gly Thr Gly Pro Ser Ser Gln Pro Gly Ala Ser
 1040 1045 1050

Leu Ala His Thr Ala Ser Ala Ser Pro Leu Ala Ser Gln Ser Ser
 1055 1060 1065

Tyr Ser Leu Leu Ser Pro Pro Asp Ser Ala Arg Asp Arg Thr Asp
 1070 1075 1080

Tyr Val Asn Ser Ala Phe Thr Glu Asp Glu Ala Leu Ser Gln His
 1085 1090 1095

Cys Gln Leu Glu Lys Pro Leu Arg His Pro Pro Leu Pro Glu Ala
 1100 1105 1110

Ala Val Thr Leu Lys Arg Pro Pro Pro Tyr Gln Trp Asp Pro Met
 1115 1120 1125

Leu Gly Glu Asp Val Trp Val Pro Gln Glu Arg Thr Ala Gln Thr
 1130 1135 1140

Ser Gly Pro Asn Pro Leu Lys Leu Ser Ser Leu Met Leu Ser Gln
 1145 1150 1155

Gly Gln His Leu Asp Val Ser Arg Leu Pro Phe Ile Ser Pro Lys

211

1160	1165	1170
Ser Pro Ala Ser Pro Thr Ala Thr Phe Gln Thr Gly Tyr Gly Met		
1175	1180	1185
Gly Val Pro Tyr Pro Gly Ser Tyr Asn Asn Pro Pro Leu Pro Gly		
1190	1195	1200
Val Gln Ala Pro Cys Ser Pro Lys Asp Ala Leu Ser Pro Thr Gln		
1205	1210	1215
Phe Ala Gln Gln Glu Pro Ala Val Val Leu Gln Pro Leu Tyr Pro		
1220	1225	1230
Pro Ser Leu Ser Tyr Cys Thr Leu Pro Pro Met Tyr Pro Gly Ser		
1235	1240	1245
Ser Thr Cys Ser Ser Leu Gln Leu Pro Pro Val Ala Leu His Pro		
1250	1255	1260
Trp Ser Ser Tyr Ser Ala Cys Pro Pro Met Gln Asn Pro Gln Gly		
1265	1270	1275
Thr Leu Pro Pro Lys Pro His Leu Val Val Glu Lys Pro Leu Val		
1280	1285	1290
Ser Pro Pro Pro Ala Asp Leu Gln Ser His Leu Gly Thr Glu Val		
1295	1300	1305
Met Val Glu Thr Ala Asp Asn Phe Gln Glu Val Leu Ser Leu Thr		
1310	1315	1320
Glu Ser Pro Val Pro Gln Arg Thr Glu Lys Phe Gly Lys Lys Asn		
1325	1330	1335
Arg Lys Arg Leu Asp Ser Arg Ala Glu Glu Gly Ser Val Gln Ala		
1340	1345	1350
Ile Thr Glu Gly Lys Val Lys Lys Glu Ala Arg Thr Leu Ser Asp		
1355	1360	1365
Phe Asn Ser Leu Ile Ser Ser Pro His Leu Gly Arg Glu Lys Lys		
1370	1375	1380

212

Lys Val Lys Ser Gln Lys Asp Gln Leu Lys Ser Lys Lys Leu Asn
 1385 1390 1395

Lys Thr Asn Glu Phe Gln Asp Ser Ser Glu Ser Glu Pro Glu Leu
 1400 1405 1410

Phe Ile Ser Gly Asp Glu Leu Met Asn Gln Ser Gln Gly Ser Arg
 1415 1420 1425

Lys Gly Trp Lys Ser Lys Arg Ser Pro Arg Ala Ala Gly Glu Leu
 1430 1435 1440

Glu Glu Ala Lys Cys Arg Arg Ala Ser Glu Lys Glu Asp Gly Arg
 1445 1450 1455

Leu Gly Ser Gln Gly Phe Val Tyr Val Met Ala Asn Lys Gln Pro
 1460 1465 1470

Leu Trp Asn Glu Ala Thr Gln Val Tyr Gln Leu Asp Phe Gly Gly
 1475 1480 1485

Arg Val Thr Gln Glu Ser Ala Lys Asn Phe Gln Ile Glu Leu Glu
 1490 1495 1500

Gly Arg Gln Val Met Gln Phe Gly Arg Ile Asp Gly Ser Ala Tyr
 1505 1510 1515

Ile Leu Asp Phe Gln Tyr Pro Phe Ser Ala Val Gln Ala Phe Ala
 1520 1525 1530

Val Ala Leu Ala Asn Val Thr Gln Arg Leu Lys
 1535 1540

<210> 286

<211> 56

<212> PRT

<213> Homo sapien

<400> 286

Met Gly Asn Gly Ala Thr Gln Lys Gln Leu Pro Asn Leu Arg Asn Asn
 1 5 10 15

Ser Phe Val Val Tyr Phe Leu Val Leu Val Gly Ala Leu Tyr Arg Asp
 20 25 30

213

Thr Ala Ile Phe Leu Ala Gln Met Ser Leu Leu Glu Ser Thr Val Val
 35 40 45

Ile Leu Leu Val Arg Leu Arg Thr
 50 55

<210> 287
 <211> 77
 <212> PRT
 <213> Homo sapien

<400> 287

Met Leu Leu Ala Val Arg Thr Thr Val Ile Cys Leu Gln Ser Cys Cys
 1 5 10 15

Cys Arg Ile Gln Arg Thr Ala Thr Ile Thr Leu Asn Cys Phe Ala Leu
 20 25 30

Ser Ser Ile Phe Asp Tyr Tyr Ile Ser His Asn Ile Thr Ile Ser His
 35 40 45

Ser Ser Asn Tyr Ser Ala Gln Ile His Glu His Val Pro Ala Arg Ala
 50 55 60

Ala Ala Arg Ser Ile Thr Trp Arg Arg Ser Ala Cys Ile
 65 70 75

<210> 288
 <211> 45
 <212> PRT
 <213> Homo sapien

<400> 288

Met Tyr Leu Gly Gln Leu Gly Asn His Arg Leu Lys Lys Leu Thr Leu
 1 5 10 15

Val Ile Thr Arg Val Val Ser Asp Tyr Lys Gln His Ile Ile Asn Pro
 20 25 30

Thr Ala Leu Ile Leu Ala Gln Arg Gln Asn Trp Thr Phe
 35 40 45

<210> 289
 <211> 44
 <212> PRT
 <213> Homo sapien

214

<400> 289

Met Lys Ala Leu Leu Cys Phe Leu Phe Tyr Ser Asp His Gln Thr Asp
1 5 10 15

Leu Ala Thr Leu Ile Val Lys Asn Glu Pro His Ser Ser Pro Gly Leu
20 25 30

Gly Leu Trp Arg Glu Met Asn Phe Leu Leu Glu Met
35 40

<210> 290

<211> 50

<212> PRT

<213> Homo sapien

<400> 290

Met Phe Arg Thr Ser Ser Tyr Arg Leu Leu Ile Tyr Lys Val Pro Val
1 5 10 15

Ala Val Thr Pro Thr Arg Lys Thr Trp Asn Cys Lys Gln Ala Gly Val
20 25 30

Thr Ser Val Thr Ser Asp Thr Val Gln Pro Glu Val Arg Phe Leu Phe
35 40 45

Trp Gly
50

<210> 291

<211> 44

<212> PRT

<213> Homo sapien

<400> 291

Met Ser Gln Trp Pro Val Ala Ser Lys Leu Val Gly Lys Glu Lys Thr
1 5 10 15

Phe Leu Phe Lys Gln Arg Lys Gly Phe Gly Glu Lys Thr Gly Ser Gly
20 25 30

Ser Gly Glu Val Phe Val Met Leu Gly Asp Arg Leu
35 40

<210> 292

<211> 61

<212> PRT

215

<213> Homo sapien

<400> 292

Met Val His Tyr Arg Lys Glu Lys Lys Thr Ser Val Ser Glu Trp Gln
 1 5 10 15

Ile Leu Ile Ile Cys Ser Ser His Leu Phe Ser Ser Glu Asn His Ile
 20 25 30

Thr Pro Glu Tyr Leu Pro Gly Arg Ile His His Thr Ala Pro Leu Glu
 35 40 45

Pro Ala Ser Lys Asp Pro Phe Ala His Ile Val Ile Leu
 50 55 60

<210> 293

<211> 112

<212> PRT

<213> Homo sapien

<400> 293

Met Gly Ile Ile Leu Asn Trp Leu Asn Gln Trp Ala Gln Ile Thr Tyr
 1 5 10 15

Leu Pro Ser Leu Leu Cys Asp Ser Pro Ala Val Thr His Thr Ile His
 20 25 30

Ile Leu Cys Thr Ser Asn Glu Gln Thr Trp Phe Pro Cys Phe Leu Asp
 35 40 45

Ile Ser Met Thr Val Ser His Thr Asn Tyr Trp Val Arg Phe Phe Ser
 50 55 60

Cys Tyr Arg Pro Thr Ser Cys Cys Leu Cys Val Val Leu Gln Lys Leu
 65 70 75 80

Ser Ile Pro Thr Pro Leu Leu Cys His Leu Gln Glu Ser Gly Ile Val
 85 90 95

Arg Ser Gln Leu Arg Lys Val Leu Val Pro Leu Thr Gly His Ile Leu
 100 105 110

<210> 294

<211> 55

<212> PRT

<213> Homo sapien

216

<400> 294

Met Arg Phe Ile Phe Ile Cys Lys Pro Arg Gly Leu Ile Ile Leu Ile
 1 5 10 15

Leu Tyr Glu Tyr Thr Cys Val Leu Gly Lys Ala Phe Ile Gln Gln Met
 20 25 30

Pro Thr Thr Tyr Ser Val Pro Arg Pro Arg His Pro Val Thr Ser Trp
 35 40 45

Arg Pro Ala Arg Ala Cys Ile
 50 55

<210> 295

<211> 77

<212> PRT

<213> Homo sapien

<400> 295

Met Leu Glu Leu Pro Thr Phe Ser Phe Phe Phe Gly Asp Arg Ala
 1 5 10 15

Ser Leu Cys His Pro Gly Trp Ser Ala Gly Ala Ser Ser Leu Thr His
 20 25 30

Leu Gln Pro Ser Phe Leu Pro Trp Gly Ala Gly Arg Phe Ser Cys Ala
 35 40 45

Leu Gln Pro Pro Ser Leu Ala Gly Ile Tyr Arg Ala Leu Leu Gln Val
 50 55 60

Ser His Ile Phe Ser Glu Lys Phe Leu Asn Trp Pro Pro
 65 70 75

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/04197

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07H 21/02, 21/04

US CL :536/23.1, 24.3

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 24.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Search the USPTO's database of nucleic acid and protein sequences.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VINCENT et al. Oligonucleotides as short as 7-mers can be used for PCR amplification. DNA and Cell Biology. 1994, Vol. 13, No. 1, pages 75-82, note the octomer in the legend of Figure 5 and the heptamer in the legend of Figure 5 and compare to positions 60-67 of SEQ ID NO: 1.	1-5 and 7-8
X	SOMMER et al. Minimal homology requirements for PCR primers. Nucleic Acids Research. 1989, Vol. 17, No. 16, page 6749, note the first primer listed in Table I and compare the 3 nucleotides on its 3' end to the complementary nucleotides at positions 252-254 of SEQ ID NO: 1.	1-5 and 7-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

31 MAY 2002

Date of mailing of the international search report

28 JUN 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 505-5230

Authorized officer

ETHAN WHISENANT, PH.D.

Telephone No. (703) 508-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/04197

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5 and 7-8, SEQ ID NO: 1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/04197

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

1. This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

I. **Claim(s)** 1-5, 7-8, drawn to polynucleotides, vectors comprising the polynucleotide, methods of introducing the polynucleotide to host cells, and host cells comprising the polynucleotide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

II. **Claim(s)** 10-11, drawn to an isolated polypeptide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

III. **Claim(s)** 12, drawn to antibodies. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

IV. **Claim(s)** 9, drawn to a method of synthesizing a polypeptide, classified in class 435, subclass 69.1. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

V. **Claim(s)** 6 and 14, drawn to a diagnostic method of using the polynucleotide of Claim 1. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

VI. **Claim(s)** 13-14, drawn to a diagnostic method of using a polypeptide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

VII. **Claim(s)** 15, drawn to a kit for determining the presence of the nucleic acid molecule of claim 1 or the polypeptide of Claim 11. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

VIII. **Claim(s)** 16, drawn to a therapeutic method of using a polypeptide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

IX. **Claim(s)** 17, drawn to a vaccine comprising the polypeptide of Claim 11 or a polynucleotide encoding said polypeptide of Claim 11. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

2. Sequence Election Requirement Applicable to All Groups

In addition, each Group detailed above reads on distinct sequences. Each sequence is distinct because they are unrelated sequences, and a further restriction is applied to each Group. For an selected Group drawn to amino acid sequences, the Applicants must elect a single amino acid sequence. For an elected Group drawn to nucleotide sequences, the Applicants must elect one nucleic acid sequence.

Examination will be restricted to only the elected sequence.

3. The inventions listed as Groups I-IX do not relate to a single

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/04197

general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature(s).

The claims as drawn are related to each other because of the product i.e. the isolated nucleic acid molecule of Claim 1. However, since the isolated nucleic acid molecule of Claim 1, as claimed, is known, the claims are no longer linked by a special technical feature, because, by definition, the special technical feature must distinguish over the prior art. Without the special technical feature the claims lack unity.